activity_comment	activity_id	assay_chembl_id	assay_description	assay_type	canonical_smiles	data_validity_comment	molecule_chembl_id	relation	standard_type	standard_units	standard_value	target_chembl_id	target_organism	type	units	value
	750644	CHEMBL803666	Inhibition of IKKi (IKK epsilon) kinase activity	B	O=C(Cc1ccc2ccccc2c1)Nc1cc(C2CC2)n[nH]1		CHEMBL115220	>	IC50	nM	10000.0	CHEMBL3529	Homo sapiens	IC50	nM	10000.0
	750644	CHEMBL803666	Inhibition of IKKi (IKK epsilon) kinase activity	B	O=C(Cc1ccc2ccccc2c1)Nc1cc(C2CC2)n[nH]1		CHEMBL115220	>	IC50	nM	10000.0	CHEMBL3529	Homo sapiens	IC50	nM	10000.0
	1442246	CHEMBL828470	Inhibition of I-kappa-B-kinase 3	B	N#Cc1c(C2CCNCC2)cc(-c2c(O)cccc2OCC2CC2)nc1N		CHEMBL368427	>	IC50	nM	20000.0	CHEMBL3529	Homo sapiens	IC50	nM	20000.0
	1782052	CHEMBL913514	Inhibition of IKKi	B	CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL402548	>	IC50	nM	10000.0	CHEMBL3529	Homo sapiens	IC50	uM	10.0
	1812432	CHEMBL911347	Inhibition of human recombinant IKKepsilon by TR-FRET assay	B	COc1cc2ncn(-c3cc(OCc4ccc(S(C)(=O)=O)cc4)c(C(N)=O)s3)c2cc1OC		CHEMBL219899	<	IC50	nM	15848.93	CHEMBL3529	Homo sapiens	Log IC50		-4.8
	1812436	CHEMBL911347	Inhibition of human recombinant IKKepsilon by TR-FRET assay	B	COc1cc2ncn(-c3cc(OCC4CCCO4)c(C#N)s3)c2cc1OC		CHEMBL375787	=	IC50	nM	794.33	CHEMBL3529	Homo sapiens	Log IC50		-6.1
	1812437	CHEMBL911347	Inhibition of human recombinant IKKepsilon by TR-FRET assay	B	COc1cc2ncn(-c3cc(OCC4CCCO4)c(C(N)=O)s3)c2cc1OC		CHEMBL220032	<	IC50	nM	15848.93	CHEMBL3529	Homo sapiens	Log IC50		-4.8
	1812438	CHEMBL911347	Inhibition of human recombinant IKKepsilon by TR-FRET assay	B	COc1cc2ncn(-c3cc(OCc4ccc(S(C)(=O)=O)cc4)c(C#N)s3)c2cc1OC		CHEMBL219711	=	IC50	nM	5011.87	CHEMBL3529	Homo sapiens	Log IC50		-5.3
	1812448	CHEMBL911347	Inhibition of human recombinant IKKepsilon by TR-FRET assay	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C#N)s3)c2cc1OC		CHEMBL376262	=	IC50	nM	1584.89	CHEMBL3529	Homo sapiens	Log IC50		-5.8
	1812449	CHEMBL911347	Inhibition of human recombinant IKKepsilon by TR-FRET assay	B	COc1cc2ncn(-c3cc(OCc4ccc(C(N)=O)cc4)c(C#N)s3)c2cc1OC		CHEMBL375115	=	IC50	nM	12589.25	CHEMBL3529	Homo sapiens	Log IC50		-4.9
	1812450	CHEMBL911347	Inhibition of human recombinant IKKepsilon by TR-FRET assay	B	COc1cc2ncn(-c3cc(OCCN4CCCCC4)c(C#N)s3)c2cc1OC		CHEMBL223425	=	IC50	nM	5011.87	CHEMBL3529	Homo sapiens	Log IC50		-5.3
	1812451	CHEMBL911347	Inhibition of human recombinant IKKepsilon by TR-FRET assay	B	N#Cc1sc(-n2cnc3ccccc32)cc1OCc1ccccc1		CHEMBL221063	=	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	Log IC50		-6.0
	1812452	CHEMBL911347	Inhibition of human recombinant IKKepsilon by TR-FRET assay	B	COc1cc2ncn(-c3cc(OCC4CC4)c(C#N)s3)c2cc1OC		CHEMBL375379	=	IC50	nM	3162.28	CHEMBL3529	Homo sapiens	Log IC50		-5.5
	1812453	CHEMBL911347	Inhibition of human recombinant IKKepsilon by TR-FRET assay	B	COc1cc2ncn(-c3cc(O)c(C#N)s3)c2cc1OC		CHEMBL219992	=	IC50	nM	2511.89	CHEMBL3529	Homo sapiens	Log IC50		-5.6
	1812454	CHEMBL911347	Inhibition of human recombinant IKKepsilon by TR-FRET assay	B	COc1cc2ncn(-c3cc(OCCN4CCOCC4)c(C#N)s3)c2cc1OC		CHEMBL219845	=	IC50	nM	1584.89	CHEMBL3529	Homo sapiens	Log IC50		-5.8
	1812455	CHEMBL911347	Inhibition of human recombinant IKKepsilon by TR-FRET assay	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	IC50	nM	39.81	CHEMBL3529	Homo sapiens	Log IC50		-7.4
	1812456	CHEMBL911347	Inhibition of human recombinant IKKepsilon by TR-FRET assay	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C#N)s3)c2cc1OC		CHEMBL220145	=	IC50	nM	3981.07	CHEMBL3529	Homo sapiens	Log IC50		-5.4
	1812457	CHEMBL911347	Inhibition of human recombinant IKKepsilon by TR-FRET assay	B	COc1cc2c(cc1OCCCO)ncn2-c1cc(OCc2ccccc2C(F)(F)F)c(C#N)s1		CHEMBL220090	=	IC50	nM	25.12	CHEMBL3529	Homo sapiens	Log IC50		-7.6
	1812458	CHEMBL911347	Inhibition of human recombinant IKKepsilon by TR-FRET assay	B	COc1cc2c(cc1OCCN1CCOCC1)ncn2-c1cc(OCc2ccccc2C(F)(F)F)c(C#N)s1		CHEMBL222318	=	IC50	nM	50.12	CHEMBL3529	Homo sapiens	Log IC50		-7.3
	1812459	CHEMBL911347	Inhibition of human recombinant IKKepsilon by TR-FRET assay	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C#N)s3)c2cc1OC		CHEMBL374440	=	IC50	nM	251.19	CHEMBL3529	Homo sapiens	Log IC50		-6.6
	1812460	CHEMBL911347	Inhibition of human recombinant IKKepsilon by TR-FRET assay	B	COc1cc2ncn(-c3cc(OCc4ccccc4)c(C(=O)O)s3)c2cc1OC		CHEMBL222312	<	IC50	nM	15848.93	CHEMBL3529	Homo sapiens	Log IC50		-4.8
	1812461	CHEMBL911347	Inhibition of human recombinant IKKepsilon by TR-FRET assay	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	IC50	nM	19952.62	CHEMBL3529	Homo sapiens	Log IC50		-4.7
Not Active	1895240	CHEMBL907587	Inhibition of IKKepsilon at 50 uM	B	CNCCNc1nc2cc3ccccc3cc2n2c(C)cnc12.Cl		CHEMBL536520		Activity			CHEMBL3529	Homo sapiens	Activity		
	1900242	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	IC50	nM	39.81	CHEMBL3529	Homo sapiens	pIC50		7.4
	1900308	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	NC(=O)c1cc(-c2ccccc2)cc(-c2ccc(S(=O)(=O)NNCCN3CCCC3)cc2)c1N		CHEMBL231129	<	IC50	nM	15848.93	CHEMBL3529	Homo sapiens	pIC50		4.8
	1900309	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	NC(=O)c1cc(-c2ccccc2)cc(-c2ccc(S(=O)(=O)NNC3CC3)cc2)c1N		CHEMBL388646	<	IC50	nM	15848.93	CHEMBL3529	Homo sapiens	pIC50		4.8
	1900310	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	COCCCNNS(=O)(=O)c1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL426532	<	IC50	nM	15848.93	CHEMBL3529	Homo sapiens	pIC50		4.8
	1900311	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	NCCNNS(=O)(=O)c1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230047	<	IC50	nM	15848.93	CHEMBL3529	Homo sapiens	pIC50		4.8
	1900312	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	NC(=O)c1cc(-c2ccccc2)cc(-c2ccc(S(=O)(=O)NNCCCN3CCOCC3)cc2)c1N		CHEMBL231614	<	IC50	nM	15848.93	CHEMBL3529	Homo sapiens	pIC50		4.8
	1900313	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	CN(C)CCCNNS(=O)(=O)c1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL231512	<	IC50	nM	15848.93	CHEMBL3529	Homo sapiens	pIC50		4.8
	1900314	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	CN(C)S(=O)(=O)c1ccc(-c2cc(-c3ccncc3)cc(C(N)=O)c2O)cc1		CHEMBL231211	<	IC50	nM	15848.93	CHEMBL3529	Homo sapiens	pIC50		4.8
	1900315	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	CNS(=O)(=O)c1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2O)cc1		CHEMBL231210	<	IC50	nM	15848.93	CHEMBL3529	Homo sapiens	pIC50		4.8
	1900316	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	NC(=O)c1cc(-c2ccc(Cl)cc2)cc(-c2ccc(S(N)(=O)=O)cc2)c1O		CHEMBL231108	<	IC50	nM	15848.93	CHEMBL3529	Homo sapiens	pIC50		4.8
Not Determined	1900317	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	NC(=O)c1cc(-c2ccncc2)ccc1O		CHEMBL389086		pIC50			CHEMBL3529	Homo sapiens	pIC50		
Not Determined	1900318	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	COc1c(C(N)=O)cc(-c2ccncc2)cc1-c1ccccc1		CHEMBL231126		pIC50			CHEMBL3529	Homo sapiens	pIC50		
Not Determined	1900319	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885		pIC50			CHEMBL3529	Homo sapiens	pIC50		
Not Determined	1900320	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	COc1c(C(N)=O)cc(-c2ccccc2)cc1-c1ccncc1		CHEMBL397668		pIC50			CHEMBL3529	Homo sapiens	pIC50		
Not Determined	1900321	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013		pIC50			CHEMBL3529	Homo sapiens	pIC50		
Not Determined	1900322	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	CS(=O)(=O)c1ccc(-c2cc(C(N)=O)c(N)c(-c3ccc(S(=O)(=O)N4CCCC4)cc3)c2)cc1		CHEMBL230913		pIC50			CHEMBL3529	Homo sapiens	pIC50		
Not Determined	1900323	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	CS(=O)(=O)c1ccc(-c2cc(C(N)=O)c(N)c(-c3ccc(S(N)(=O)=O)cc3)c2)cc1		CHEMBL230912		pIC50			CHEMBL3529	Homo sapiens	pIC50		
	1900324	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccc(S(N)(=O)=O)cc2)c1N		CHEMBL397009	=	IC50	nM	1584.89	CHEMBL3529	Homo sapiens	pIC50		5.8
	1900325	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	IC50	nM	3981.07	CHEMBL3529	Homo sapiens	pIC50		5.4
	1900326	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	CN(C)c1cccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)c1		CHEMBL230810	<	IC50	nM	15848.93	CHEMBL3529	Homo sapiens	pIC50		4.8
	1900327	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	NC(=O)c1cc(-c2ccccc2)cc(-c2ccc(CS(N)(=O)=O)cc2)c1N		CHEMBL230809	<	IC50	nM	15848.93	CHEMBL3529	Homo sapiens	pIC50		4.8
	1900328	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	NC(=O)c1cc(-c2ccccc2)cc(-c2cccc(S(N)(=O)=O)c2)c1N		CHEMBL230808	<	IC50	nM	15848.93	CHEMBL3529	Homo sapiens	pIC50		4.8
	1900329	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	NC(=O)c1cc(-c2ccccc2)cc(-c2ccc(S(N)(=O)=O)cc2)c1N		CHEMBL397008	<	IC50	nM	15848.93	CHEMBL3529	Homo sapiens	pIC50		4.8
Not Determined	1900330	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	CS(=O)(=O)Nc1cccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)c1		CHEMBL230699		pIC50			CHEMBL3529	Homo sapiens	pIC50		
	1900331	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	<	IC50	nM	15848.93	CHEMBL3529	Homo sapiens	pIC50		4.8
	1900332	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccc(Cl)cc3)cc(C(N)=O)c2N)cc1		CHEMBL230595	<	IC50	nM	15848.93	CHEMBL3529	Homo sapiens	pIC50		4.8
	1900333	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	NC(=O)c1cc(-c2ccc(Cl)cc2)cc(-c2ccc(S(N)(=O)=O)cc2)c1N		CHEMBL230488	<	IC50	nM	15848.93	CHEMBL3529	Homo sapiens	pIC50		4.8
	1900334	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(N)(=O)=O)cc2)c1N		CHEMBL230276	<	IC50	nM	15848.93	CHEMBL3529	Homo sapiens	pIC50		4.8
	1900335	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230055	<	IC50	nM	15848.93	CHEMBL3529	Homo sapiens	pIC50		4.8
	1900336	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	<	IC50	nM	15848.93	CHEMBL3529	Homo sapiens	pIC50		4.8
	1900337	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	NC(=O)c1cc(-c2ccc(F)cc2)ccc1N		CHEMBL231521	<	IC50	nM	15848.93	CHEMBL3529	Homo sapiens	pIC50		4.8
	1900338	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	NC(=O)c1cc(-c2ccccc2)ccc1N		CHEMBL207940	<	IC50	nM	15848.93	CHEMBL3529	Homo sapiens	pIC50		4.8
Not Determined	1900339	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592		pIC50			CHEMBL3529	Homo sapiens	pIC50		
Not Determined	1900340	CHEMBL889184	Inhibition of human recombinant FLAG-IKKepsilon by TR-FRET assay	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(C)(=O)=O)cc2)c1N		CHEMBL388033		pIC50			CHEMBL3529	Homo sapiens	pIC50		
	1989371	CHEMBL899092	Inhibition of IKKi at 1 uM	B	CC(C)NCc1ccc(Nc2cc(-c3ccc(-c4ccc(O)cc4O)cc3)[nH]n2)cc1		CHEMBL398606	=	Inhibition	%	26.0	CHEMBL3529	Homo sapiens	Inhibition	%	26.0
Not Active	2034799	CHEMBL888337	Inhibition of IKKepsilon	B	Cc1cnc2c(NCCN)nc3cc(-c4ccccc4)sc3n12		CHEMBL249901		Activity			CHEMBL3529	Homo sapiens	Activity		
Not Active	2034808	CHEMBL888337	Inhibition of IKKepsilon	B	CNc1nc2cc(-c3cccc(CCNC(N)=O)c3)sc2n2c(C)cnc12		CHEMBL249481		Activity			CHEMBL3529	Homo sapiens	Activity		
Not Active	2034809	CHEMBL888337	Inhibition of IKKepsilon	B	CNc1nc2cc(-c3cccc(CN)c3)sc2n2c(C)cnc12		CHEMBL400077		Activity			CHEMBL3529	Homo sapiens	Activity		
Not Active	2034826	CHEMBL888337	Inhibition of IKKepsilon	B	Cc1cnc2c(NCCN3CCCCC3)nc3cc(-c4ccccc4)sc3n12		CHEMBL250336		Activity			CHEMBL3529	Homo sapiens	Activity		
Not Active	2034827	CHEMBL888337	Inhibition of IKKepsilon	B	CNc1nc2cc(-c3ccccc3)sc2n2c(C)cnc12		CHEMBL249719		Activity			CHEMBL3529	Homo sapiens	Activity		
	2250936	CHEMBL1011030	Inhibition of IKKi	B	Nc1nccc(-c2cc3c([nH]2)[C@@H](CCF)CNC3=O)n1		CHEMBL524266	>	IC50	nM	4000.0	CHEMBL3529	Homo sapiens	IC50	uM	4.0
	2280933	CHEMBL960933	Inhibition of IKKepsilon	B	CNc1nc2oc(-c3ccccc3)nc2c2c1ncn2C		CHEMBL493940	=	IC50	nM	17000.0	CHEMBL3529	Homo sapiens	IC50	uM	17.0
	2280934	CHEMBL960933	Inhibition of IKKepsilon	B	CNc1nc2c(nc(-c3ccccc3)n2C)c2c1ncn2C		CHEMBL522011	=	IC50	nM	14000.0	CHEMBL3529	Homo sapiens	IC50	uM	14.0
	2280935	CHEMBL960933	Inhibition of IKKepsilon	B	CNc1nc2sc(-c3cccc(CNC(C)=O)c3)nc2c2c1ncn2C		CHEMBL454973	=	IC50	nM	12000.0	CHEMBL3529	Homo sapiens	IC50	uM	12.0
Not Active	2302221	CHEMBL938095	Inhibition of human IKKe at 10 uM	B	Nc1ncnc2ncn(CC(=O)c3c[nH]c4ccccc34)c12		CHEMBL485246		Inhibition	%		CHEMBL3529	Homo sapiens	INH		
	2396074	CHEMBL1006313	Inhibition of IKK epsilon at 1 uM relative to control	B	COc1ccc(/C=N/Nc2[nH]nc(C)c2C(=O)Nc2cccc(NC(C)=O)c2)cc1		CHEMBL515560	=	Inhibition	%	-8.0	CHEMBL3529	Homo sapiens	INH	%	-8.0
	2470244	CHEMBL987163	Inhibition of IKK-epsilon at 3 uM	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL521179	<	Inhibition	%	10.0	CHEMBL3529	Homo sapiens	INH	%	10.0
	2661415	CHEMBL1058621	Inhibition of IKKi	B	CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2		CHEMBL564829	>	IC50	nM	10000.0	CHEMBL3529	Homo sapiens	IC50	uM	10.0
	2893619	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2893620	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2893621	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2893622	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2893623	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2893624	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2893625	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Kd	nM	480.0	CHEMBL3529	Homo sapiens	Kd	nM	480.0
	2893626	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2893627	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2893628	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2893629	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2893630	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2893631	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2893632	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2893633	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	Kd	nM	3100.0	CHEMBL3529	Homo sapiens	Kd	nM	3100.0
	2893634	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2893635	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2893636	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2893637	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2893638	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Kd	nM	8300.0	CHEMBL3529	Homo sapiens	Kd	nM	8300.0
	2893639	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2893640	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2893641	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2893642	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2893643	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2893644	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	160.0	CHEMBL3529	Homo sapiens	Kd	nM	160.0
	2893645	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2893646	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2893647	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2893648	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2893649	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2894079	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2894080	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	5.1	CHEMBL3529	Homo sapiens	Kd	nM	5.1
	2894081	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	480.0	CHEMBL3529	Homo sapiens	Kd	nM	480.0
	2894082	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	620.0	CHEMBL3529	Homo sapiens	Kd	nM	620.0
	2894083	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Kd	nM	2600.0	CHEMBL3529	Homo sapiens	Kd	nM	2600.0
	2894084	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	2894085	CHEMBL1050835	Binding constant for full-length IKK-epsilon	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
Antagonist	2904585	CHEMBL1062812	Percentage IKKepsilon activity remaining in the presence of 0.01uM inhibitor	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Activity	%	21.0	CHEMBL3529	Homo sapiens	Activity	%	21.0
Antagonist	2904586	CHEMBL1062813	Percentage IKKepsilon activity remaining in the presence of 0.1uM inhibitor	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Activity	%	0.0	CHEMBL3529	Homo sapiens	Activity	%	0.0
Antagonist	2904587	CHEMBL1060120	Percentage IKKepsilon activity remaining in the presence of 10uM inhibitor	B	CC(C)(C(N)=O)C(=O)NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1Br		CHEMBL573108	=	Activity	%	4.0	CHEMBL3529	Homo sapiens	Activity	%	4.0
	2904588	CHEMBL1060120	Percentage IKKepsilon activity remaining in the presence of 10uM inhibitor	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	=	Activity	%	93.0	CHEMBL3529	Homo sapiens	Activity	%	93.0
	2904589	CHEMBL1060120	Percentage IKKepsilon activity remaining in the presence of 10uM inhibitor	B	NC(=O)c1sc(-c2ccsc2)cc1N		CHEMBL193093	=	Activity	%	89.0	CHEMBL3529	Homo sapiens	Activity	%	89.0
	2904590	CHEMBL1060120	Percentage IKKepsilon activity remaining in the presence of 10uM inhibitor	B	O=C(Nc1cc(Cl)cc2c1[nH]c1cnccc12)c1cccnc1		CHEMBL79004	=	Activity	%	81.0	CHEMBL3529	Homo sapiens	Activity	%	81.0
	2904591	CHEMBL1060120	Percentage IKKepsilon activity remaining in the presence of 10uM inhibitor	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Activity	%	67.0	CHEMBL3529	Homo sapiens	Activity	%	67.0
Antagonist	2904592	CHEMBL1061966	Percentage IKKepsilon activity remaining in the presence of 1uM inhibitor	B	CC(C)(C(N)=O)C(=O)NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1Br		CHEMBL573108	=	Activity	%	37.0	CHEMBL3529	Homo sapiens	Activity	%	37.0
	2904593	CHEMBL1061966	Percentage IKKepsilon activity remaining in the presence of 1uM inhibitor	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL274654	=	Activity	%	51.0	CHEMBL3529	Homo sapiens	Activity	%	51.0
	2904594	CHEMBL1061966	Percentage IKKepsilon activity remaining in the presence of 1uM inhibitor	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Activity	%	51.0	CHEMBL3529	Homo sapiens	Activity	%	51.0
	2904595	CHEMBL1061966	Percentage IKKepsilon activity remaining in the presence of 1uM inhibitor	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Activity	%	87.0	CHEMBL3529	Homo sapiens	Activity	%	87.0
	2921313	CHEMBL1053752	Inhibition of IKK-epsilon assessed as enzyme activity at 1 uM relative to untreated control	B	Cc1ccc2c(Nc3ccc(Cl)cc3)nccc2c1Nc1ncccc1-c1ncnc2[nH]cnc12.Cl.Cl.Cl		CHEMBL3215582	=	Activity	%	73.0	CHEMBL3529	Homo sapiens	Activity	%	73.0
	2926262	CHEMBL1056935	Inhibition of IKKepsilon assessed as remaining enzyme activity at 3 uM relative to DMSO	B	COc1ccccc1-n1c(-c2ccccc2C)cn2c3c(=O)[nH]c(=O)n(C)c3nc12		CHEMBL574236	=	Activity	%	101.0	CHEMBL3529	Homo sapiens	Activity	%	101.0
	2928448	CHEMBL1049150	Inhibition of IKKepsilon assessed as remaining enzyme activity at 1 uM relative to DMSO	B	COc1ccccc1-n1c(-c2cc(O)ccc2C)cn2c3c(=O)[nH]c(=O)n(C)c3nc12		CHEMBL566515	=	Activity	%	85.0	CHEMBL3529	Homo sapiens	Activity	%	85.0
	2938402	CHEMBL1038689	Inhibition of IKKi	B	Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1		CHEMBL583042	>	Ki	nM	5000.0	CHEMBL3529	Homo sapiens	Ki	uM	5.0
	2999766	CHEMBL1044630	Inhibition of IKKepsilon assessed as residual activity at 10 uM by Cherenkov counting relative to control in presence of 50 uM ATP	B	CC(C)c1onc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL220227	=	Activity	%	81.0	CHEMBL3529	Homo sapiens	Activity	%	81.0
	2999844	CHEMBL1044630	Inhibition of IKKepsilon assessed as residual activity at 10 uM by Cherenkov counting relative to control in presence of 50 uM ATP	B	CC(C)c1noc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL375428	=	Activity	%	71.0	CHEMBL3529	Homo sapiens	Activity	%	71.0
	2999921	CHEMBL1041102	Inhibition of IKKepsilon assessed as residual activity at 0.1 uM by Cherenkov counting relative to control in presence of 50 uM ATP	B	COc1ccc(/C=C/C(=O)Nc2cc(-c3[nH]c(SC)nc3-c3ccc(F)cc3)ccn2)c(OC)c1		CHEMBL569114	=	Activity	%	97.0	CHEMBL3529	Homo sapiens	Activity	%	97.0
	2999997	CHEMBL1041102	Inhibition of IKKepsilon assessed as residual activity at 0.1 uM by Cherenkov counting relative to control in presence of 50 uM ATP	B	COc1ccc(/C=C/C(=O)Nc2cc(-c3[nH]c([S+](C)[O-])nc3-c3ccc(F)cc3)ccn2)c(OC)c1		CHEMBL572006	=	Activity	%	90.0	CHEMBL3529	Homo sapiens	Activity	%	90.0
	3052632	CHEMBL1041119	Residual activity of IKKepsilon at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	81.0	CHEMBL3529	Homo sapiens	Residual activity	%	81.0
	3053941	CHEMBL1046833	Residual activity of IKKepsilon at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	76.0	CHEMBL3529	Homo sapiens	Residual activity	%	76.0
	3054193	CHEMBL1040661	Residual activity of IKKepsilon at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	91.0	CHEMBL3529	Homo sapiens	Residual activity	%	91.0
	3055480	CHEMBL1041119	Residual activity of IKKepsilon at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	90.0	CHEMBL3529	Homo sapiens	Residual activity	%	90.0
	3056785	CHEMBL1046833	Residual activity of IKKepsilon at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	101.0	CHEMBL3529	Homo sapiens	Residual activity	%	101.0
	3057037	CHEMBL1040661	Residual activity of IKKepsilon at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	92.0	CHEMBL3529	Homo sapiens	Residual activity	%	92.0
	3058357	CHEMBL1041119	Residual activity of IKKepsilon at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	98.0	CHEMBL3529	Homo sapiens	Residual activity	%	98.0
	3058609	CHEMBL1046833	Residual activity of IKKepsilon at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	99.0	CHEMBL3529	Homo sapiens	Residual activity	%	99.0
	3072955	CHEMBL1040661	Residual activity of IKKepsilon at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	87.0	CHEMBL3529	Homo sapiens	Residual activity	%	87.0
	3130811	CHEMBL1073728	Inhibition of IKKE at 3 to 6 uM relative to control	B	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1OC		CHEMBL604087	>	Inhibition	%	50.0	CHEMBL3529	Homo sapiens	INH	%	50.0
Not Active	3133144	CHEMBL1066216	Inhibition of IKKI	B	CN1CCN(c2cc(C(=O)Nc3ccc4c(c3)-c3c(c(C(N)=O)nn3-c3ccc(F)cc3)CC4)c(Cl)cn2)CC1		CHEMBL592893		Inhibition	%		CHEMBL3529	Homo sapiens	INH		
	3213935	CHEMBL1114891	Inhibition of IKKepsilon at 5 uM	B	O=C(Nc1ccccc1Cl)c1cnc2ccc(C3CCNCC3)cn12.O=C(O)C(=O)O		CHEMBL1077739	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	INH	%	2.0
	3224844	CHEMBL1100362	Inhibition of IKKepsilon at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1-c1cnc(CO)cn1		CHEMBL1081678	<	Inhibition	%	50.0	CHEMBL3529	Homo sapiens	INH	%	50.0
	3225094	CHEMBL1100362	Inhibition of IKKepsilon at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1Cc1ccc(CN(C)C)cc1		CHEMBL1078665	<	Inhibition	%	50.0	CHEMBL3529	Homo sapiens	INH	%	50.0
	3261348	CHEMBL1105204	Inhibition of IKKepsilon at 10 uM assessed as residual activity by [33P]ATP radioactive filter binding assay relative to control	B	CN(C)CCCC(=O)Nc1ccc2nccc(Nc3cccc(Br)c3)c2c1		CHEMBL1089524	=	Activity	%	92.0	CHEMBL3529	Homo sapiens	Activity	%	92.0
	3261442	CHEMBL1105204	Inhibition of IKKepsilon at 10 uM assessed as residual activity by [33P]ATP radioactive filter binding assay relative to control	B	CN(C)CCCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL1088901	=	Activity	%	89.0	CHEMBL3529	Homo sapiens	Activity	%	89.0
	3327236	CHEMBL1168290	Inhibition of IKKepsilon at 10 uM by HotSpot assay	B	CC(=O)Nc1cccc(-c2ccc(-c3ccnc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)n3)cn2)c1.Cl		CHEMBL1164847	<	Inhibition	%	50.0	CHEMBL3529	Homo sapiens	INH	%	50.0
	3331975	CHEMBL1166025	Inhibition of IKK-epsilon at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(F)ccc3F)CCN4)cn2)CC1		CHEMBL1165499	<	Inhibition	%	50.0	CHEMBL3529	Homo sapiens	INH	%	50.0
	3333390	CHEMBL1166025	Inhibition of IKK-epsilon at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	<	Inhibition	%	50.0	CHEMBL3529	Homo sapiens	INH	%	50.0
	3334795	CHEMBL1166025	Inhibition of IKK-epsilon at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3Cl)CCN4)cn2)CC1		CHEMBL1164181	<	Inhibition	%	50.0	CHEMBL3529	Homo sapiens	INH	%	50.0
	3336215	CHEMBL1166025	Inhibition of IKK-epsilon at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1		CHEMBL1164265	<	Inhibition	%	50.0	CHEMBL3529	Homo sapiens	INH	%	50.0
	3340743	CHEMBL1166025	Inhibition of IKK-epsilon at 1 uM	B	FC(F)(F)c1ccc(Cl)cc1CN1CCNc2ncc(-c3ccnc(N4CCNCC4)c3)cc21		CHEMBL1163566	<	Inhibition	%	50.0	CHEMBL3529	Homo sapiens	INH	%	50.0
	3342159	CHEMBL1166025	Inhibition of IKK-epsilon at 1 uM	B	CC(=O)N1CCN(c2cc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)ccn2)CC1		CHEMBL1163565	<	Inhibition	%	50.0	CHEMBL3529	Homo sapiens	INH	%	50.0
	3358611	CHEMBL1174456	Inhibition of IKK-epsilon at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cccnc4)c3)cc2C(F)(F)F)CC1		CHEMBL1171523	=	Inhibition	%	100.0	CHEMBL3529	Homo sapiens	INH	%	100.0
	3359053	CHEMBL1174456	Inhibition of IKK-epsilon at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5[nH]ccc5c4)c3)cc2C(F)(F)F)CC1		CHEMBL1170139	=	Inhibition	%	92.0	CHEMBL3529	Homo sapiens	INH	%	92.0
	3445149	CHEMBL1244459	Binding affinity to IKK-epsilon	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	11.0	CHEMBL3529	Homo sapiens	Kd	nM	11.0
	3448460	CHEMBL1244459	Binding affinity to IKK-epsilon	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	3448954	CHEMBL1244459	Binding affinity to IKK-epsilon	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	160.0	CHEMBL3529	Homo sapiens	Kd	nM	160.0
	3449221	CHEMBL1244459	Binding affinity to IKK-epsilon	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	620.0	CHEMBL3529	Homo sapiens	Kd	nM	620.0
	3449693	CHEMBL1244459	Binding affinity to IKK-epsilon	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	3450100	CHEMBL1244459	Binding affinity to IKK-epsilon	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	uM	10.0
	3451021	CHEMBL1244459	Binding affinity to IKK-epsilon	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL1240703	=	Kd	nM	320.0	CHEMBL3529	Homo sapiens	Kd	nM	320.0
	3504304	CHEMBL1260186	Inhibition of IKKi	B	O=C(Nc1n[nH]c2cc(C(=O)N[C@H](CN3CCCC3)c3ccccc3)sc12)c1ccc(N2CCOCC2)cc1		CHEMBL1258913	>	IC50	nM	10000.0	CHEMBL3529	Homo sapiens	IC50	uM	10.0
	3526983	CHEMBL1275103	Inhibition of IKKi	B	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccccc1		CHEMBL1270230	>	IC50	nM	10000.0	CHEMBL3529	Homo sapiens	IC50	uM	10.0
	5120833	CHEMBL1646817	Inhibition of IKBKE at 10 uM	B	CC(C)(C)c1cc(C(=O)O)c(NC(=O)Nc2ccc3[nH]ncc3c2)s1		CHEMBL1641799	=	Inhibition	%	10.0	CHEMBL3529	Homo sapiens	INH	%	10.0
	5132593	CHEMBL1645817	Inhibition of IKKepsilon assessed as residual activity at 10 uM	B	CN(C)C/C=C/C(=O)Nc1ccc2c(C#N)cnc(Nc3cccc(Br)c3)c2c1		CHEMBL1641990	=	Activity	%	80.0	CHEMBL3529	Homo sapiens	Activity	%	80.0
	5133736	CHEMBL1645817	Inhibition of IKKepsilon assessed as residual activity at 10 uM	B	CN(C)CCCC(=O)Nc1ccc2c(C#N)cnc(Nc3cccc(Br)c3)c2c1		CHEMBL1641989	=	Activity	%	100.0	CHEMBL3529	Homo sapiens	Activity	%	100.0
	5133935	CHEMBL1645817	Inhibition of IKKepsilon assessed as residual activity at 10 uM	B	CN1CCN(CCC(=O)Nc2ccc3c(C#N)cnc(Nc4cccc(Br)c4)c3c2)CC1		CHEMBL1641992	=	Activity	%	91.0	CHEMBL3529	Homo sapiens	Activity	%	91.0
	5140513	CHEMBL1646774	Inhibition of IKBKE at 1 uM	B	CC(C)(C)c1cc(C(=O)O)c(NC(=O)Nc2ccc3[nH]ncc3c2)s1		CHEMBL1641799	=	Inhibition	%	10.0	CHEMBL3529	Homo sapiens	INH	%	10.0
	5191477	CHEMBL1664095	Inhibition of IKKepsilon at 1 uM	B	COc1cc2nc(-c3cc(F)ccc3O)nc(N[C@@H]3CNC[C@H]3C(C)(C)O)c2cc1OC		CHEMBL1236782	=	Inhibition	%	-4.0	CHEMBL3529	Homo sapiens	INH	%	-4.0
	5191478	CHEMBL1664095	Inhibition of IKKepsilon at 1 uM	B	CC(C)(O)[C@@H]1CNC[C@H]1Nc1nc(-c2cc(-c3cc[nH]n3)ccc2O)nc2ccccc12		CHEMBL1650131	=	Inhibition	%	18.0	CHEMBL3529	Homo sapiens	INH	%	18.0
	6161913	CHEMBL1764209	Inhibition of IKK-epsilon	B	NC(=O)c1cc(-c2ccccc2)cc2c(C3CCCNC3)c[nH]c12		CHEMBL1761510	<	IC50	nM	3162.28	CHEMBL3529	Homo sapiens	pIC50		5.5
	6161915	CHEMBL1764209	Inhibition of IKK-epsilon	B	CCCS(=O)(=O)N1CCC(c2c[nH]c3c(C(N)=O)cc(-c4ccccc4)cc23)CC1		CHEMBL1761512	<	IC50	nM	3162.28	CHEMBL3529	Homo sapiens	pIC50		5.5
Not Active	6230339	CHEMBL1785286	Inhibition of human IKKepsilon	B	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1		CHEMBL1088752		Inhibition	%		CHEMBL3529	Homo sapiens	INH		
	6273851	CHEMBL1806271	Inhibition of IKKepsilon assessed as residual enzyme activity at 10 uM	B	CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12		CHEMBL1234833	=	Activity	%	94.0	CHEMBL3529	Homo sapiens	Activity	%	94.0
	6339924	CHEMBL1826607	Activity of IKK-epsilon kinase at 1 uM	B	CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1		CHEMBL1822054	=	Activity	%	73.0	CHEMBL3529	Homo sapiens	Activity	%	73.0
	6352220	CHEMBL1825827	Inhibition of IKK-epsilon assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	B	Nc1n[nH]c(N)c1/N=N/c1ccc(O)cc1		CHEMBL215205	=	Activity	%	45.0	CHEMBL3529	Homo sapiens	Activity	%	45.0
	7567474	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7567491	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7567962	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7568430	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1		CHEMBL386051	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7568862	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	480.0	CHEMBL3529	Homo sapiens	Kd	nM	480.0
	7569465	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7569937	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7570400	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1		CHEMBL450786	=	Kd	nM	700.0	CHEMBL3529	Homo sapiens	Kd	nM	700.0
	7570827	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	620.0	CHEMBL3529	Homo sapiens	Kd	nM	620.0
	7570981	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7571438	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	=	Kd	nM	710.0	CHEMBL3529	Homo sapiens	Kd	nM	710.0
	7571914	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	=	Kd	nM	1200.0	CHEMBL3529	Homo sapiens	Kd	nM	1200.0
	7572377	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7572793	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Kd	nM	1100.0	CHEMBL3529	Homo sapiens	Kd	nM	1100.0
	7572962	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7573419	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7573895	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl		CHEMBL1908395	=	Kd	nM	1300.0	CHEMBL3529	Homo sapiens	Kd	nM	1300.0
	7574364	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	160.0	CHEMBL3529	Homo sapiens	Kd	nM	160.0
	7574940	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	=	Kd	nM	170.0	CHEMBL3529	Homo sapiens	Kd	nM	170.0
	7575401	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7575872	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1		CHEMBL1908396	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7576303	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7576914	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7577373	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	=	Kd	nM	1400.0	CHEMBL3529	Homo sapiens	Kd	nM	1400.0
	7577879	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F		CHEMBL1230020	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7578284	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	=	Kd	nM	360.0	CHEMBL3529	Homo sapiens	Kd	nM	360.0
	7578922	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7579296	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7579746	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	Kd	nM	3100.0	CHEMBL3529	Homo sapiens	Kd	nM	3100.0
	7579778	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	=	Kd	nM	340.0	CHEMBL3529	Homo sapiens	Kd	nM	340.0
	7580247	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7580650	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7581280	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7581665	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7582139	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7582603	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7583003	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Kd	nM	2600.0	CHEMBL3529	Homo sapiens	Kd	nM	2600.0
	7584026	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1		CHEMBL525191	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7584497	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7584959	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	=	Kd	nM	13.0	CHEMBL3529	Homo sapiens	Kd	nM	13.0
	7585363	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7585514	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7585922	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7586368	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7586839	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7587293	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7587475	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7587894	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7588347	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7588818	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C		CHEMBL608154	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7589269	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7589440	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7589864	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	11.0	CHEMBL3529	Homo sapiens	Kd	nM	11.0
	7590331	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL464552	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7590805	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7591413	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7591835	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Kd	nM	480.0	CHEMBL3529	Homo sapiens	Kd	nM	480.0
	7592307	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7592791	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7593380	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7593815	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7594287	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7594318	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7594770	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	=	Kd	nM	53.0	CHEMBL3529	Homo sapiens	Kd	nM	53.0
	7595348	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7595792	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7596295	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7596742	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7597320	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7597804	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7598274	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL3529	Homo sapiens	Kd	nM	10000.0
	7598716	CHEMBL1908771	Binding constant for IKK-epsilon kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	5.1	CHEMBL3529	Homo sapiens	Kd	nM	5.1
	7969732	CHEMBL1931232	Inhibition of IKKepsilon assessed as residual activity at 10 uM using [33P-ATP] by radiometric filter binding assay	B	Cc1ccc(F)cc1-c1nc2[nH]nc(N)c2c2c1CCCC2		CHEMBL1927262	=	Activity	%	96.0	CHEMBL3529	Homo sapiens	Activity	%	96.0
	7987122	CHEMBL1936075	Inhibition of IKKi	B	O=C(c1cc2cc(F)ccc2[nH]1)N1C[C@]2(CCN(C3CCCNC3)C2)c2ccccc21		CHEMBL1933538	>	IC50	nM	30000.0	CHEMBL3529	Homo sapiens	IC50	uM	30.0
	7987144	CHEMBL1936075	Inhibition of IKKi	B	O=C(c1cc2ccc(F)cc2[nH]1)N1C[C@]2(CCN(C3CCNC3)C2)c2ccccc21		CHEMBL1933550	>	IC50	nM	30000.0	CHEMBL3529	Homo sapiens	IC50	uM	30.0
	7987166	CHEMBL1936075	Inhibition of IKKi	B	C[C@@H]1CCC(N2CC[C@]3(CN(C(=O)c4cc5ccccc5[nH]4)c4ccccc43)C2)CN1		CHEMBL1933551	>	IC50	nM	30000.0	CHEMBL3529	Homo sapiens	IC50	uM	30.0
	7987198	CHEMBL1936075	Inhibition of IKKi	B	C[C@@H]1CCC(N2CC[C@]3(CN(C(=O)c4cc5ccc(F)cc5[nH]4)c4ccccc43)C2)CN1		CHEMBL1933552	>	IC50	nM	30000.0	CHEMBL3529	Homo sapiens	IC50	uM	30.0
	8003572	CHEMBL1942748	Inhibition of human IKKepsilon in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCn3cccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1940980	<	Inhibition	%	35.0	CHEMBL3529	Homo sapiens	INH	%	35.0
	8003573	CHEMBL1942748	Inhibition of human IKKepsilon in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCn3cccn3)c(F)c(N)c3c(=O)c(C#N)cn1c23		CHEMBL1940981	<	Inhibition	%	35.0	CHEMBL3529	Homo sapiens	INH	%	35.0
	8003574	CHEMBL1942748	Inhibition of human IKKepsilon in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1940987	<	Inhibition	%	35.0	CHEMBL3529	Homo sapiens	INH	%	35.0
	8003575	CHEMBL1942748	Inhibition of human IKKepsilon in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCc3ccccn3)c(F)c(N)c3c(=O)c(C#N)cn1c23		CHEMBL1940990	<	Inhibition	%	35.0	CHEMBL3529	Homo sapiens	INH	%	35.0
	8004496	CHEMBL1943928	Inhibition of IKKepsilon at 1 uM	B	O=c1c2ccccc2[se]n1-c1ccccc1		CHEMBL51085	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	INH	%	0.0
	8004540	CHEMBL1943928	Inhibition of IKKepsilon at 1 uM	B	CC(=O)OC[C@H]1O[C@@H](O[C@H]2[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](n3[se]c4ccccc4c3=O)O[C@@H]2COC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H]1OC(C)=O		CHEMBL1940993	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	INH	%	0.0
	8005204	CHEMBL1943928	Inhibition of IKKepsilon at 1 uM	B	CC(=O)OC[C@H]1O[C@@H](NC(=O)CCCn2[se]c3ccccc3c2=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O		CHEMBL1940997	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	INH	%	0.0
	8005247	CHEMBL1943928	Inhibition of IKKepsilon at 1 uM	B	O=C(CCCn1[se]c2ccccc2c1=O)N[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O		CHEMBL1940999	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	INH	%	0.0
	8061323	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	1.2	CHEMBL3529	Homo sapiens	Inhibition	%	1.2
	8061500	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	-4.1	CHEMBL3529	Homo sapiens	Inhibition	%	-4.1
	8061831	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	6.75	CHEMBL3529	Homo sapiens	Inhibition	%	6.75
	8062022	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	3.13	CHEMBL3529	Homo sapiens	Inhibition	%	3.13
	8062362	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	6.16	CHEMBL3529	Homo sapiens	Inhibition	%	6.16
	8062524	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	9.87	CHEMBL3529	Homo sapiens	Inhibition	%	9.87
	8062748	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	7.57	CHEMBL3529	Homo sapiens	Inhibition	%	7.57
	8062846	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	0.86	CHEMBL3529	Homo sapiens	Inhibition	%	0.86
	8063202	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	-0.03	CHEMBL3529	Homo sapiens	Inhibition	%	-0.03
	8063369	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	4.71	CHEMBL3529	Homo sapiens	Inhibition	%	4.71
	8063701	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	3.15	CHEMBL3529	Homo sapiens	Inhibition	%	3.15
	8063883	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21	Outside typical range	CHEMBL1516890	=	Inhibition	%	-10.6	CHEMBL3529	Homo sapiens	Inhibition	%	-10.6
	8064107	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	2.48	CHEMBL3529	Homo sapiens	Inhibition	%	2.48
	8064222	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	6.44	CHEMBL3529	Homo sapiens	Inhibition	%	6.44
	8064432	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	0.34	CHEMBL3529	Homo sapiens	Inhibition	%	0.34
	8064656	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	-2.71	CHEMBL3529	Homo sapiens	Inhibition	%	-2.71
	8064794	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	2.76	CHEMBL3529	Homo sapiens	Inhibition	%	2.76
	8064960	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	5.7	CHEMBL3529	Homo sapiens	Inhibition	%	5.7
	8065184	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	6.37	CHEMBL3529	Homo sapiens	Inhibition	%	6.37
	8065300	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	4.06	CHEMBL3529	Homo sapiens	Inhibition	%	4.06
	8065699	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	2.87	CHEMBL3529	Homo sapiens	Inhibition	%	2.87
	8065814	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	3.07	CHEMBL3529	Homo sapiens	Inhibition	%	3.07
	8066248	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	0.57	CHEMBL3529	Homo sapiens	Inhibition	%	0.57
	8066384	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	4.37	CHEMBL3529	Homo sapiens	Inhibition	%	4.37
	8066774	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	-8.46	CHEMBL3529	Homo sapiens	Inhibition	%	-8.46
	8066898	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	4.82	CHEMBL3529	Homo sapiens	Inhibition	%	4.82
	8067122	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	5.38	CHEMBL3529	Homo sapiens	Inhibition	%	5.38
	8067297	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	2.8	CHEMBL3529	Homo sapiens	Inhibition	%	2.8
	8067418	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	14.05	CHEMBL3529	Homo sapiens	Inhibition	%	14.05
	8067642	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	2.31	CHEMBL3529	Homo sapiens	Inhibition	%	2.31
	8067852	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC	Outside typical range	CHEMBL365072	=	Inhibition	%	-15.11	CHEMBL3529	Homo sapiens	Inhibition	%	-15.11
	8067987	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	5.75	CHEMBL3529	Homo sapiens	Inhibition	%	5.75
	8068211	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	28.16	CHEMBL3529	Homo sapiens	Inhibition	%	28.16
	8068375	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	5.55	CHEMBL3529	Homo sapiens	Inhibition	%	5.55
	8068724	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	2.43	CHEMBL3529	Homo sapiens	Inhibition	%	2.43
	8068898	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	4.2	CHEMBL3529	Homo sapiens	Inhibition	%	4.2
	8069247	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	0.04	CHEMBL3529	Homo sapiens	Inhibition	%	0.04
	8069542	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	9.71	CHEMBL3529	Homo sapiens	Inhibition	%	9.71
	8069703	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	6.35	CHEMBL3529	Homo sapiens	Inhibition	%	6.35
	8070053	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	3.72	CHEMBL3529	Homo sapiens	Inhibition	%	3.72
	8070225	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	4.41	CHEMBL3529	Homo sapiens	Inhibition	%	4.41
	8070574	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	1.33	CHEMBL3529	Homo sapiens	Inhibition	%	1.33
	8070872	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	48.53	CHEMBL3529	Homo sapiens	Inhibition	%	48.53
	8071029	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	6.15	CHEMBL3529	Homo sapiens	Inhibition	%	6.15
	8071253	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	6.95	CHEMBL3529	Homo sapiens	Inhibition	%	6.95
	8071379	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	0.62	CHEMBL3529	Homo sapiens	Inhibition	%	0.62
	8071552	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	4.64	CHEMBL3529	Homo sapiens	Inhibition	%	4.64
	8071776	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	3.19	CHEMBL3529	Homo sapiens	Inhibition	%	3.19
	8071901	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	1.35	CHEMBL3529	Homo sapiens	Inhibition	%	1.35
	8072215	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	1.54	CHEMBL3529	Homo sapiens	Inhibition	%	1.54
	8072596	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	5.85	CHEMBL3529	Homo sapiens	Inhibition	%	5.85
	8072721	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	2.37	CHEMBL3529	Homo sapiens	Inhibition	%	2.37
	8073112	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	3.64	CHEMBL3529	Homo sapiens	Inhibition	%	3.64
	8073237	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	-0.11	CHEMBL3529	Homo sapiens	Inhibition	%	-0.11
	8073461	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	-1.19	CHEMBL3529	Homo sapiens	Inhibition	%	-1.19
	8073580	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	-5.56	CHEMBL3529	Homo sapiens	Inhibition	%	-5.56
	8073813	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	0.25	CHEMBL3529	Homo sapiens	Inhibition	%	0.25
	8074189	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	5.8	CHEMBL3529	Homo sapiens	Inhibition	%	5.8
	8074319	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	0.86	CHEMBL3529	Homo sapiens	Inhibition	%	0.86
	8074543	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	2.1	CHEMBL3529	Homo sapiens	Inhibition	%	2.1
	8074700	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	2.28	CHEMBL3529	Homo sapiens	Inhibition	%	2.28
	8075051	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	-1.3	CHEMBL3529	Homo sapiens	Inhibition	%	-1.3
	8075162	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	-2.89	CHEMBL3529	Homo sapiens	Inhibition	%	-2.89
	8075386	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	4.58	CHEMBL3529	Homo sapiens	Inhibition	%	4.58
	8075399	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	5.75	CHEMBL3529	Homo sapiens	Inhibition	%	5.75
	8075623	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	29.99	CHEMBL3529	Homo sapiens	Inhibition	%	29.99
	8075764	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	6.56	CHEMBL3529	Homo sapiens	Inhibition	%	6.56
	8076130	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	-0.98	CHEMBL3529	Homo sapiens	Inhibition	%	-0.98
	8076278	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	0.67	CHEMBL3529	Homo sapiens	Inhibition	%	0.67
	8076636	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	0.88	CHEMBL3529	Homo sapiens	Inhibition	%	0.88
	8076962	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1	Outside typical range	CHEMBL14112	=	Inhibition	%	-15.52	CHEMBL3529	Homo sapiens	Inhibition	%	-15.52
	8077209	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	88.29	CHEMBL3529	Homo sapiens	Inhibition	%	88.29
	8077337	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	6.69	CHEMBL3529	Homo sapiens	Inhibition	%	6.69
	8077561	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	3.28	CHEMBL3529	Homo sapiens	Inhibition	%	3.28
	8077712	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	1.28	CHEMBL3529	Homo sapiens	Inhibition	%	1.28
	8077855	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	2.79	CHEMBL3529	Homo sapiens	Inhibition	%	2.79
	8078079	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	2.69	CHEMBL3529	Homo sapiens	Inhibition	%	2.69
	8078218	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	-4.53	CHEMBL3529	Homo sapiens	Inhibition	%	-4.53
	8078544	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	1.88	CHEMBL3529	Homo sapiens	Inhibition	%	1.88
	8078794	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	98.87	CHEMBL3529	Homo sapiens	Inhibition	%	98.87
	8079134	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	6.02	CHEMBL3529	Homo sapiens	Inhibition	%	6.02
	8079292	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	-2.16	CHEMBL3529	Homo sapiens	Inhibition	%	-2.16
	8079658	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	3.11	CHEMBL3529	Homo sapiens	Inhibition	%	3.11
	8079797	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	-0.51	CHEMBL3529	Homo sapiens	Inhibition	%	-0.51
	8080126	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	2.68	CHEMBL3529	Homo sapiens	Inhibition	%	2.68
	8080378	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	46.17	CHEMBL3529	Homo sapiens	Inhibition	%	46.17
	8080717	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	3.74	CHEMBL3529	Homo sapiens	Inhibition	%	3.74
	8080881	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	-0.86	CHEMBL3529	Homo sapiens	Inhibition	%	-0.86
	8081240	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	1.45	CHEMBL3529	Homo sapiens	Inhibition	%	1.45
	8081384	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	6.68	CHEMBL3529	Homo sapiens	Inhibition	%	6.68
	8081608	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	5.85	CHEMBL3529	Homo sapiens	Inhibition	%	5.85
	8081711	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	-0.3	CHEMBL3529	Homo sapiens	Inhibition	%	-0.3
	8081963	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	93.39	CHEMBL3529	Homo sapiens	Inhibition	%	93.39
	8082300	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	1.06	CHEMBL3529	Homo sapiens	Inhibition	%	1.06
	8082473	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-4.18	CHEMBL3529	Homo sapiens	Inhibition	%	-4.18
	8082697	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-3.35	CHEMBL3529	Homo sapiens	Inhibition	%	-3.35
	8082820	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	3.52	CHEMBL3529	Homo sapiens	Inhibition	%	3.52
	8083200	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	10.76	CHEMBL3529	Homo sapiens	Inhibition	%	10.76
	8083299	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	0.33	CHEMBL3529	Homo sapiens	Inhibition	%	0.33
	8083523	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	2.67	CHEMBL3529	Homo sapiens	Inhibition	%	2.67
	8083553	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	-0.73	CHEMBL3529	Homo sapiens	Inhibition	%	-0.73
	8083777	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	16.19	CHEMBL3529	Homo sapiens	Inhibition	%	16.19
	8083887	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	3.07	CHEMBL3529	Homo sapiens	Inhibition	%	3.07
	8084296	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	8.67	CHEMBL3529	Homo sapiens	Inhibition	%	8.67
	8084414	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	2.96	CHEMBL3529	Homo sapiens	Inhibition	%	2.96
	8084638	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	3.9	CHEMBL3529	Homo sapiens	Inhibition	%	3.9
	8084799	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	26.61	CHEMBL3529	Homo sapiens	Inhibition	%	26.61
	8085121	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	2.59	CHEMBL3529	Homo sapiens	Inhibition	%	2.59
	8085377	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	-4.31	CHEMBL3529	Homo sapiens	Inhibition	%	-4.31
	8085485	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	7.06	CHEMBL3529	Homo sapiens	Inhibition	%	7.06
	8085709	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	3.59	CHEMBL3529	Homo sapiens	Inhibition	%	3.59
	8085898	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	44.71	CHEMBL3529	Homo sapiens	Inhibition	%	44.71
	8086237	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	3.38	CHEMBL3529	Homo sapiens	Inhibition	%	3.38
	8086399	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	8.54	CHEMBL3529	Homo sapiens	Inhibition	%	8.54
	8086722	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	3.33	CHEMBL3529	Homo sapiens	Inhibition	%	3.33
	8086933	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	5.94	CHEMBL3529	Homo sapiens	Inhibition	%	5.94
	8087315	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	9.75	CHEMBL3529	Homo sapiens	Inhibition	%	9.75
	8087429	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	6.37	CHEMBL3529	Homo sapiens	Inhibition	%	6.37
	8087653	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	9.49	CHEMBL3529	Homo sapiens	Inhibition	%	9.49
	8087791	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	4.6	CHEMBL3529	Homo sapiens	Inhibition	%	4.6
	8088157	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	7.71	CHEMBL3529	Homo sapiens	Inhibition	%	7.71
	8088305	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	0.29	CHEMBL3529	Homo sapiens	Inhibition	%	0.29
	8088657	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	5.3	CHEMBL3529	Homo sapiens	Inhibition	%	5.3
	8088974	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	1.58	CHEMBL3529	Homo sapiens	Inhibition	%	1.58
	8089102	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	-2.26	CHEMBL3529	Homo sapiens	Inhibition	%	-2.26
	8089474	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	5.72	CHEMBL3529	Homo sapiens	Inhibition	%	5.72
	8089594	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	-0.23	CHEMBL3529	Homo sapiens	Inhibition	%	-0.23
	8089818	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	3.21	CHEMBL3529	Homo sapiens	Inhibition	%	3.21
	8089998	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	0.39	CHEMBL3529	Homo sapiens	Inhibition	%	0.39
	8090163	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	3.12	CHEMBL3529	Homo sapiens	Inhibition	%	3.12
	8090387	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	2.31	CHEMBL3529	Homo sapiens	Inhibition	%	2.31
	8090554	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	4.87	CHEMBL3529	Homo sapiens	Inhibition	%	4.87
	8090693	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	12.12	CHEMBL3529	Homo sapiens	Inhibition	%	12.12
	8090917	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	5.07	CHEMBL3529	Homo sapiens	Inhibition	%	5.07
	8091122	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	5.66	CHEMBL3529	Homo sapiens	Inhibition	%	5.66
	8091259	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	6.17	CHEMBL3529	Homo sapiens	Inhibition	%	6.17
	8091483	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	9.65	CHEMBL3529	Homo sapiens	Inhibition	%	9.65
	8091638	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	4.21	CHEMBL3529	Homo sapiens	Inhibition	%	4.21
	8091978	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	7.83	CHEMBL3529	Homo sapiens	Inhibition	%	7.83
	8092115	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	2.6	CHEMBL3529	Homo sapiens	Inhibition	%	2.6
	8092490	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	6.48	CHEMBL3529	Homo sapiens	Inhibition	%	6.48
	8092638	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	1.3	CHEMBL3529	Homo sapiens	Inhibition	%	1.3
	8092862	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	-0.11	CHEMBL3529	Homo sapiens	Inhibition	%	-0.11
	8092991	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	7.74	CHEMBL3529	Homo sapiens	Inhibition	%	7.74
	8093303	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	0.9	CHEMBL3529	Homo sapiens	Inhibition	%	0.9
	8093443	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	-1.68	CHEMBL3529	Homo sapiens	Inhibition	%	-1.68
	8093667	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	0.47	CHEMBL3529	Homo sapiens	Inhibition	%	0.47
	8093806	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	21.91	CHEMBL3529	Homo sapiens	Inhibition	%	21.91
	8094150	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	2.16	CHEMBL3529	Homo sapiens	Inhibition	%	2.16
	8094330	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	4.22	CHEMBL3529	Homo sapiens	Inhibition	%	4.22
	8094729	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	0.77	CHEMBL3529	Homo sapiens	Inhibition	%	0.77
	8094885	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	6.26	CHEMBL3529	Homo sapiens	Inhibition	%	6.26
	8095249	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	7.75	CHEMBL3529	Homo sapiens	Inhibition	%	7.75
	8095452	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	4.6	CHEMBL3529	Homo sapiens	Inhibition	%	4.6
	8095817	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	10.35	CHEMBL3529	Homo sapiens	Inhibition	%	10.35
	8095965	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	2.69	CHEMBL3529	Homo sapiens	Inhibition	%	2.69
	8096306	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	9.02	CHEMBL3529	Homo sapiens	Inhibition	%	9.02
	8096445	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	3.7	CHEMBL3529	Homo sapiens	Inhibition	%	3.7
	8096669	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	1.93	CHEMBL3529	Homo sapiens	Inhibition	%	1.93
	8096825	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	4.64	CHEMBL3529	Homo sapiens	Inhibition	%	4.64
	8097196	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	3.74	CHEMBL3529	Homo sapiens	Inhibition	%	3.74
	8097283	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	4.23	CHEMBL3529	Homo sapiens	Inhibition	%	4.23
	8097503	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	0.15	CHEMBL3529	Homo sapiens	Inhibition	%	0.15
	8097877	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	34.9	CHEMBL3529	Homo sapiens	Inhibition	%	34.9
	8098010	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	3.11	CHEMBL3529	Homo sapiens	Inhibition	%	3.11
	8098354	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	-2.28	CHEMBL3529	Homo sapiens	Inhibition	%	-2.28
	8098534	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	3.83	CHEMBL3529	Homo sapiens	Inhibition	%	3.83
	8098758	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	4.51	CHEMBL3529	Homo sapiens	Inhibition	%	4.51
	8098943	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	4.36	CHEMBL3529	Homo sapiens	Inhibition	%	4.36
	8099087	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	4.2	CHEMBL3529	Homo sapiens	Inhibition	%	4.2
	8099311	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	4.57	CHEMBL3529	Homo sapiens	Inhibition	%	4.57
	8099453	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	6.32	CHEMBL3529	Homo sapiens	Inhibition	%	6.32
	8099647	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	1.8	CHEMBL3529	Homo sapiens	Inhibition	%	1.8
	8100018	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	5.66	CHEMBL3529	Homo sapiens	Inhibition	%	5.66
	8100164	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	4.31	CHEMBL3529	Homo sapiens	Inhibition	%	4.31
	8100388	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	5.68	CHEMBL3529	Homo sapiens	Inhibition	%	5.68
	8100504	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	6.98	CHEMBL3529	Homo sapiens	Inhibition	%	6.98
	8100868	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	1.71	CHEMBL3529	Homo sapiens	Inhibition	%	1.71
	8101028	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	5.87	CHEMBL3529	Homo sapiens	Inhibition	%	5.87
	8101394	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	0.76	CHEMBL3529	Homo sapiens	Inhibition	%	0.76
	8101579	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	5.23	CHEMBL3529	Homo sapiens	Inhibition	%	5.23
	8101832	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	2.96	CHEMBL3529	Homo sapiens	Inhibition	%	2.96
	8102056	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	16.78	CHEMBL3529	Homo sapiens	Inhibition	%	16.78
	8102211	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	-3.38	CHEMBL3529	Homo sapiens	Inhibition	%	-3.38
	8102342	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	3.63	CHEMBL3529	Homo sapiens	Inhibition	%	3.63
	8102566	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	2.98	CHEMBL3529	Homo sapiens	Inhibition	%	2.98
	8102686	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	-7.06	CHEMBL3529	Homo sapiens	Inhibition	%	-7.06
	8103088	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	3.49	CHEMBL3529	Homo sapiens	Inhibition	%	3.49
	8103284	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	8.21	CHEMBL3529	Homo sapiens	Inhibition	%	8.21
	8103646	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	2.08	CHEMBL3529	Homo sapiens	Inhibition	%	2.08
	8103796	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	4.7	CHEMBL3529	Homo sapiens	Inhibition	%	4.7
	8103981	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	3.7	CHEMBL3529	Homo sapiens	Inhibition	%	3.7
	8104205	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	4.59	CHEMBL3529	Homo sapiens	Inhibition	%	4.59
	8104353	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	6.9	CHEMBL3529	Homo sapiens	Inhibition	%	6.9
	8104723	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	26.53	CHEMBL3529	Homo sapiens	Inhibition	%	26.53
	8104837	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	9.95	CHEMBL3529	Homo sapiens	Inhibition	%	9.95
	8105061	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	5.32	CHEMBL3529	Homo sapiens	Inhibition	%	5.32
	8105201	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	3.89	CHEMBL3529	Homo sapiens	Inhibition	%	3.89
	8105367	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	6.43	CHEMBL3529	Homo sapiens	Inhibition	%	6.43
	8105591	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	5.46	CHEMBL3529	Homo sapiens	Inhibition	%	5.46
	8105729	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	1.15	CHEMBL3529	Homo sapiens	Inhibition	%	1.15
	8106009	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	0.8	CHEMBL3529	Homo sapiens	Inhibition	%	0.8
	8106398	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	2.49	CHEMBL3529	Homo sapiens	Inhibition	%	2.49
	8106554	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	21.35	CHEMBL3529	Homo sapiens	Inhibition	%	21.35
	8106907	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	1.73	CHEMBL3529	Homo sapiens	Inhibition	%	1.73
	8107028	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	-4.18	CHEMBL3529	Homo sapiens	Inhibition	%	-4.18
	8107252	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	3.46	CHEMBL3529	Homo sapiens	Inhibition	%	3.46
	8107424	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	3.08	CHEMBL3529	Homo sapiens	Inhibition	%	3.08
	8107625	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	37.94	CHEMBL3529	Homo sapiens	Inhibition	%	37.94
	8107984	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	3.29	CHEMBL3529	Homo sapiens	Inhibition	%	3.29
	8108142	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	7.72	CHEMBL3529	Homo sapiens	Inhibition	%	7.72
	8108541	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	1.25	CHEMBL3529	Homo sapiens	Inhibition	%	1.25
	8108688	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	2.73	CHEMBL3529	Homo sapiens	Inhibition	%	2.73
	8109054	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	1.59	CHEMBL3529	Homo sapiens	Inhibition	%	1.59
	8109392	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	6.04	CHEMBL3529	Homo sapiens	Inhibition	%	6.04
	8109522	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	-0.24	CHEMBL3529	Homo sapiens	Inhibition	%	-0.24
	8109917	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	6.16	CHEMBL3529	Homo sapiens	Inhibition	%	6.16
	8110049	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	12.58	CHEMBL3529	Homo sapiens	Inhibition	%	12.58
	8110328	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	-0.15	CHEMBL3529	Homo sapiens	Inhibition	%	-0.15
	8110718	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	1.28	CHEMBL3529	Homo sapiens	Inhibition	%	1.28
	8110876	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	0.53	CHEMBL3529	Homo sapiens	Inhibition	%	0.53
	8111223	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	2.77	CHEMBL3529	Homo sapiens	Inhibition	%	2.77
	8111574	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	89.58	CHEMBL3529	Homo sapiens	Inhibition	%	89.58
	8111740	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	3.62	CHEMBL3529	Homo sapiens	Inhibition	%	3.62
	8111945	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	5.18	CHEMBL3529	Homo sapiens	Inhibition	%	5.18
	8112169	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	6.48	CHEMBL3529	Homo sapiens	Inhibition	%	6.48
	8112306	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	-1.8	CHEMBL3529	Homo sapiens	Inhibition	%	-1.8
	8112474	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	5.28	CHEMBL3529	Homo sapiens	Inhibition	%	5.28
	8112698	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	7.15	CHEMBL3529	Homo sapiens	Inhibition	%	7.15
	8112870	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	-0.44	CHEMBL3529	Homo sapiens	Inhibition	%	-0.44
	8113022	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	7.27	CHEMBL3529	Homo sapiens	Inhibition	%	7.27
	8113246	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	15.25	CHEMBL3529	Homo sapiens	Inhibition	%	15.25
	8113382	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	0.73	CHEMBL3529	Homo sapiens	Inhibition	%	0.73
	8113730	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	5.24	CHEMBL3529	Homo sapiens	Inhibition	%	5.24
	8113846	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	-0.48	CHEMBL3529	Homo sapiens	Inhibition	%	-0.48
	8114070	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	-2.27	CHEMBL3529	Homo sapiens	Inhibition	%	-2.27
	8114246	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	4.74	CHEMBL3529	Homo sapiens	Inhibition	%	4.74
	8114378	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	10.88	CHEMBL3529	Homo sapiens	Inhibition	%	10.88
	8114602	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	6.22	CHEMBL3529	Homo sapiens	Inhibition	%	6.22
	8114654	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	1.75	CHEMBL3529	Homo sapiens	Inhibition	%	1.75
	8114878	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	0.57	CHEMBL3529	Homo sapiens	Inhibition	%	0.57
	8115044	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	1.57	CHEMBL3529	Homo sapiens	Inhibition	%	1.57
	8115209	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	2.04	CHEMBL3529	Homo sapiens	Inhibition	%	2.04
	8115433	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	2.95	CHEMBL3529	Homo sapiens	Inhibition	%	2.95
	8115553	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	3.32	CHEMBL3529	Homo sapiens	Inhibition	%	3.32
	8115910	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	98.7	CHEMBL3529	Homo sapiens	Inhibition	%	98.7
	8116069	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	14.29	CHEMBL3529	Homo sapiens	Inhibition	%	14.29
	8116293	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	59.74	CHEMBL3529	Homo sapiens	Inhibition	%	59.74
	8116496	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	79.54	CHEMBL3529	Homo sapiens	Inhibition	%	79.54
	8116630	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	1.16	CHEMBL3529	Homo sapiens	Inhibition	%	1.16
	8117026	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	6.28	CHEMBL3529	Homo sapiens	Inhibition	%	6.28
	8117197	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	0.42	CHEMBL3529	Homo sapiens	Inhibition	%	0.42
	8117579	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	46.6	CHEMBL3529	Homo sapiens	Inhibition	%	46.6
	8117709	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	0.17	CHEMBL3529	Homo sapiens	Inhibition	%	0.17
	8117933	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	-0.15	CHEMBL3529	Homo sapiens	Inhibition	%	-0.15
	8118071	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	6.6	CHEMBL3529	Homo sapiens	Inhibition	%	6.6
	8118411	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	8.74	CHEMBL3529	Homo sapiens	Inhibition	%	8.74
	8118583	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	4.77	CHEMBL3529	Homo sapiens	Inhibition	%	4.77
	8118943	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	4.97	CHEMBL3529	Homo sapiens	Inhibition	%	4.97
	8119214	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	1.27	CHEMBL3529	Homo sapiens	Inhibition	%	1.27
	8119373	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	11.46	CHEMBL3529	Homo sapiens	Inhibition	%	11.46
	8119764	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	1.53	CHEMBL3529	Homo sapiens	Inhibition	%	1.53
	8119883	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	1.53	CHEMBL3529	Homo sapiens	Inhibition	%	1.53
	8120107	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	2.88	CHEMBL3529	Homo sapiens	Inhibition	%	2.88
	8120246	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	4.65	CHEMBL3529	Homo sapiens	Inhibition	%	4.65
	8120630	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	-7.28	CHEMBL3529	Homo sapiens	Inhibition	%	-7.28
	8120831	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	95.78	CHEMBL3529	Homo sapiens	Inhibition	%	95.78
	8120959	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	-1.18	CHEMBL3529	Homo sapiens	Inhibition	%	-1.18
	8121183	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	-1.41	CHEMBL3529	Homo sapiens	Inhibition	%	-1.41
	8121355	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	3.09	CHEMBL3529	Homo sapiens	Inhibition	%	3.09
	8121522	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	-0.26	CHEMBL3529	Homo sapiens	Inhibition	%	-0.26
	8121746	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	3.03	CHEMBL3529	Homo sapiens	Inhibition	%	3.03
	8121909	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	8.4	CHEMBL3529	Homo sapiens	Inhibition	%	8.4
	8122254	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	0.44	CHEMBL3529	Homo sapiens	Inhibition	%	0.44
	8122392	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	4.67	CHEMBL3529	Homo sapiens	Inhibition	%	4.67
	8122736	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	5.47	CHEMBL3529	Homo sapiens	Inhibition	%	5.47
	8122903	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	6.5	CHEMBL3529	Homo sapiens	Inhibition	%	6.5
	8123127	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	7.07	CHEMBL3529	Homo sapiens	Inhibition	%	7.07
	8123269	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	6.51	CHEMBL3529	Homo sapiens	Inhibition	%	6.51
	8123547	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	5.68	CHEMBL3529	Homo sapiens	Inhibition	%	5.68
	8123697	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	3.38	CHEMBL3529	Homo sapiens	Inhibition	%	3.38
	8123921	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	8.67	CHEMBL3529	Homo sapiens	Inhibition	%	8.67
	8124088	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	3.81	CHEMBL3529	Homo sapiens	Inhibition	%	3.81
	8124431	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	3.06	CHEMBL3529	Homo sapiens	Inhibition	%	3.06
	8124570	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	-0.03	CHEMBL3529	Homo sapiens	Inhibition	%	-0.03
	8124959	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	2.35	CHEMBL3529	Homo sapiens	Inhibition	%	2.35
	8125160	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	8.2	CHEMBL3529	Homo sapiens	Inhibition	%	8.2
	8125514	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	-2.46	CHEMBL3529	Homo sapiens	Inhibition	%	-2.46
	8125682	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	3.15	CHEMBL3529	Homo sapiens	Inhibition	%	3.15
	8126070	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	-2.1	CHEMBL3529	Homo sapiens	Inhibition	%	-2.1
	8126234	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	6.21	CHEMBL3529	Homo sapiens	Inhibition	%	6.21
	8126573	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	1.35	CHEMBL3529	Homo sapiens	Inhibition	%	1.35
	8126709	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	13.26	CHEMBL3529	Homo sapiens	Inhibition	%	13.26
	8126933	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	41.92	CHEMBL3529	Homo sapiens	Inhibition	%	41.92
	8127055	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	7.47	CHEMBL3529	Homo sapiens	Inhibition	%	7.47
	8127446	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	10.81	CHEMBL3529	Homo sapiens	Inhibition	%	10.81
	8127588	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	5.84	CHEMBL3529	Homo sapiens	Inhibition	%	5.84
	8127876	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	2.97	CHEMBL3529	Homo sapiens	Inhibition	%	2.97
	8128252	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	2.77	CHEMBL3529	Homo sapiens	Inhibition	%	2.77
	8128419	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	4.51	CHEMBL3529	Homo sapiens	Inhibition	%	4.51
	8128762	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	18.08	CHEMBL3529	Homo sapiens	Inhibition	%	18.08
	8128899	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	7.81	CHEMBL3529	Homo sapiens	Inhibition	%	7.81
	8129123	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	15.25	CHEMBL3529	Homo sapiens	Inhibition	%	15.25
	8129294	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	-1.86	CHEMBL3529	Homo sapiens	Inhibition	%	-1.86
	8129483	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	6.86	CHEMBL3529	Homo sapiens	Inhibition	%	6.86
	8129707	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	4.12	CHEMBL3529	Homo sapiens	Inhibition	%	4.12
	8129846	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	0.84	CHEMBL3529	Homo sapiens	Inhibition	%	0.84
	8130007	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	6.69	CHEMBL3529	Homo sapiens	Inhibition	%	6.69
	8130231	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	0.44	CHEMBL3529	Homo sapiens	Inhibition	%	0.44
	8130403	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	-0.18	CHEMBL3529	Homo sapiens	Inhibition	%	-0.18
	8130563	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	8.95	CHEMBL3529	Homo sapiens	Inhibition	%	8.95
	8130787	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	17.81	CHEMBL3529	Homo sapiens	Inhibition	%	17.81
	8130903	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	5.78	CHEMBL3529	Homo sapiens	Inhibition	%	5.78
	8131266	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	7.58	CHEMBL3529	Homo sapiens	Inhibition	%	7.58
	8131386	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	6.34	CHEMBL3529	Homo sapiens	Inhibition	%	6.34
	8131610	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	6.92	CHEMBL3529	Homo sapiens	Inhibition	%	6.92
	8131777	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	8.87	CHEMBL3529	Homo sapiens	Inhibition	%	8.87
	8131918	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	8.03	CHEMBL3529	Homo sapiens	Inhibition	%	8.03
	8132142	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	9.66	CHEMBL3529	Homo sapiens	Inhibition	%	9.66
	8132204	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	21.32	CHEMBL3529	Homo sapiens	Inhibition	%	21.32
	8132428	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	1.26	CHEMBL3529	Homo sapiens	Inhibition	%	1.26
	8132575	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	2.2	CHEMBL3529	Homo sapiens	Inhibition	%	2.2
	8132743	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	2.76	CHEMBL3529	Homo sapiens	Inhibition	%	2.76
	8132967	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	2.69	CHEMBL3529	Homo sapiens	Inhibition	%	2.69
	8133088	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	0.31	CHEMBL3529	Homo sapiens	Inhibition	%	0.31
	8133450	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	4.71	CHEMBL3529	Homo sapiens	Inhibition	%	4.71
	8133622	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	8134026	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	14.24	CHEMBL3529	Homo sapiens	Inhibition	%	14.24
	8134174	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	-2.31	CHEMBL3529	Homo sapiens	Inhibition	%	-2.31
	8134558	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	3.64	CHEMBL3529	Homo sapiens	Inhibition	%	3.64
	8134742	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	-4.27	CHEMBL3529	Homo sapiens	Inhibition	%	-4.27
	8135126	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	7.41	CHEMBL3529	Homo sapiens	Inhibition	%	7.41
	8135241	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	4.65	CHEMBL3529	Homo sapiens	Inhibition	%	4.65
	8135606	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	7.44	CHEMBL3529	Homo sapiens	Inhibition	%	7.44
	8135951	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	6.31	CHEMBL3529	Homo sapiens	Inhibition	%	6.31
	8136119	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	4.37	CHEMBL3529	Homo sapiens	Inhibition	%	4.37
	8136487	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	7.17	CHEMBL3529	Homo sapiens	Inhibition	%	7.17
	8136777	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	0.91	CHEMBL3529	Homo sapiens	Inhibition	%	0.91
	8136912	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	0.83	CHEMBL3529	Homo sapiens	Inhibition	%	0.83
	8137299	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	5.27	CHEMBL3529	Homo sapiens	Inhibition	%	5.27
	8137419	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	-0.99	CHEMBL3529	Homo sapiens	Inhibition	%	-0.99
	8137643	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	0.37	CHEMBL3529	Homo sapiens	Inhibition	%	0.37
	8137791	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	4.56	CHEMBL3529	Homo sapiens	Inhibition	%	4.56
	8137957	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	-2.08	CHEMBL3529	Homo sapiens	Inhibition	%	-2.08
	8138181	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	-0.39	CHEMBL3529	Homo sapiens	Inhibition	%	-0.39
	8138360	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	-0.33	CHEMBL3529	Homo sapiens	Inhibition	%	-0.33
	8138508	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	-1.16	CHEMBL3529	Homo sapiens	Inhibition	%	-1.16
	8138732	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-5.06	CHEMBL3529	Homo sapiens	Inhibition	%	-5.06
	8138890	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	2.47	CHEMBL3529	Homo sapiens	Inhibition	%	2.47
	8139075	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	7.71	CHEMBL3529	Homo sapiens	Inhibition	%	7.71
	8139458	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	5.98	CHEMBL3529	Homo sapiens	Inhibition	%	5.98
	8139572	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	6.52	CHEMBL3529	Homo sapiens	Inhibition	%	6.52
	8139796	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	5.28	CHEMBL3529	Homo sapiens	Inhibition	%	5.28
	8139937	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	11.31	CHEMBL3529	Homo sapiens	Inhibition	%	11.31
	8140284	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	7.26	CHEMBL3529	Homo sapiens	Inhibition	%	7.26
	8140443	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	6.73	CHEMBL3529	Homo sapiens	Inhibition	%	6.73
	8140810	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	5.91	CHEMBL3529	Homo sapiens	Inhibition	%	5.91
	8141112	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	0.88	CHEMBL3529	Homo sapiens	Inhibition	%	0.88
	8141242	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	-0.94	CHEMBL3529	Homo sapiens	Inhibition	%	-0.94
	8141466	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	-0.37	CHEMBL3529	Homo sapiens	Inhibition	%	-0.37
	8141626	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	13.41	CHEMBL3529	Homo sapiens	Inhibition	%	13.41
	8141969	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	0.54	CHEMBL3529	Homo sapiens	Inhibition	%	0.54
	8142130	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	1.54	CHEMBL3529	Homo sapiens	Inhibition	%	1.54
	8142522	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	-3.26	CHEMBL3529	Homo sapiens	Inhibition	%	-3.26
	8142698	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	2.82	CHEMBL3529	Homo sapiens	Inhibition	%	2.82
	8143071	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-4.16	CHEMBL3529	Homo sapiens	Inhibition	%	-4.16
	8143226	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	3.63	CHEMBL3529	Homo sapiens	Inhibition	%	3.63
	8143413	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	10.24	CHEMBL3529	Homo sapiens	Inhibition	%	10.24
	8143637	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	3.78	CHEMBL3529	Homo sapiens	Inhibition	%	3.78
	8143796	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	7.46	CHEMBL3529	Homo sapiens	Inhibition	%	7.46
	8144134	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	6.98	CHEMBL3529	Homo sapiens	Inhibition	%	6.98
	8144273	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	7.12	CHEMBL3529	Homo sapiens	Inhibition	%	7.12
	8144497	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	9.48	CHEMBL3529	Homo sapiens	Inhibition	%	9.48
	8144627	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	6.26	CHEMBL3529	Homo sapiens	Inhibition	%	6.26
	8144780	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	2.88	CHEMBL3529	Homo sapiens	Inhibition	%	2.88
	8145004	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	3.73	CHEMBL3529	Homo sapiens	Inhibition	%	3.73
	8145141	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	12.0	CHEMBL3529	Homo sapiens	Inhibition	%	12.0
	8145454	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	-0.46	CHEMBL3529	Homo sapiens	Inhibition	%	-0.46
	8145802	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	-0.75	CHEMBL3529	Homo sapiens	Inhibition	%	-0.75
	8145963	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	6.91	CHEMBL3529	Homo sapiens	Inhibition	%	6.91
	8146307	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	-0.58	CHEMBL3529	Homo sapiens	Inhibition	%	-0.58
	8146467	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	-0.27	CHEMBL3529	Homo sapiens	Inhibition	%	-0.27
	8146858	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	-1.35	CHEMBL3529	Homo sapiens	Inhibition	%	-1.35
	8147027	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	3.19	CHEMBL3529	Homo sapiens	Inhibition	%	3.19
	8147393	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	3.76	CHEMBL3529	Homo sapiens	Inhibition	%	3.76
	8147546	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	4.07	CHEMBL3529	Homo sapiens	Inhibition	%	4.07
	8147770	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	4.96	CHEMBL3529	Homo sapiens	Inhibition	%	4.96
	8147957	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	7.2	CHEMBL3529	Homo sapiens	Inhibition	%	7.2
	8148115	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	6.22	CHEMBL3529	Homo sapiens	Inhibition	%	6.22
	8148453	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	4.71	CHEMBL3529	Homo sapiens	Inhibition	%	4.71
	8148816	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	5.67	CHEMBL3529	Homo sapiens	Inhibition	%	5.67
	8148954	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	8.54	CHEMBL3529	Homo sapiens	Inhibition	%	8.54
	8149337	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	1.37	CHEMBL3529	Homo sapiens	Inhibition	%	1.37
	8149471	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	7.29	CHEMBL3529	Homo sapiens	Inhibition	%	7.29
	8149695	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	7.73	CHEMBL3529	Homo sapiens	Inhibition	%	7.73
	8149793	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	2.27	CHEMBL3529	Homo sapiens	Inhibition	%	2.27
	8150142	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	-0.79	CHEMBL3529	Homo sapiens	Inhibition	%	-0.79
	8150302	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	8.6	CHEMBL3529	Homo sapiens	Inhibition	%	8.6
	8150526	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	4.53	CHEMBL3529	Homo sapiens	Inhibition	%	4.53
	8150646	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	-1.36	CHEMBL3529	Homo sapiens	Inhibition	%	-1.36
	8150811	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	-5.2	CHEMBL3529	Homo sapiens	Inhibition	%	-5.2
	8151035	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	9.27	CHEMBL3529	Homo sapiens	Inhibition	%	9.27
	8151198	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	-3.17	CHEMBL3529	Homo sapiens	Inhibition	%	-3.17
	8151375	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	4.68	CHEMBL3529	Homo sapiens	Inhibition	%	4.68
	8151599	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	4.47	CHEMBL3529	Homo sapiens	Inhibition	%	4.47
	8151737	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	5.2	CHEMBL3529	Homo sapiens	Inhibition	%	5.2
	8152115	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	4.37	CHEMBL3529	Homo sapiens	Inhibition	%	4.37
	8152303	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	13.9	CHEMBL3529	Homo sapiens	Inhibition	%	13.9
	8152461	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	3.13	CHEMBL3529	Homo sapiens	Inhibition	%	3.13
	8152685	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	8.49	CHEMBL3529	Homo sapiens	Inhibition	%	8.49
	8152799	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	7.85	CHEMBL3529	Homo sapiens	Inhibition	%	7.85
	8153162	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	3.75	CHEMBL3529	Homo sapiens	Inhibition	%	3.75
	8153299	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	7.38	CHEMBL3529	Homo sapiens	Inhibition	%	7.38
	8153523	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	12.24	CHEMBL3529	Homo sapiens	Inhibition	%	12.24
	8153680	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	1.93	CHEMBL3529	Homo sapiens	Inhibition	%	1.93
	8154037	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	17.63	CHEMBL3529	Homo sapiens	Inhibition	%	17.63
	8154134	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	0.9	CHEMBL3529	Homo sapiens	Inhibition	%	0.9
	8154358	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	2.9	CHEMBL3529	Homo sapiens	Inhibition	%	2.9
	8154484	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	-0.41	CHEMBL3529	Homo sapiens	Inhibition	%	-0.41
	8154867	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	1.01	CHEMBL3529	Homo sapiens	Inhibition	%	1.01
	8154987	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	2.05	CHEMBL3529	Homo sapiens	Inhibition	%	2.05
	8155387	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	1.65	CHEMBL3529	Homo sapiens	Inhibition	%	1.65
	8155548	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	-3.47	CHEMBL3529	Homo sapiens	Inhibition	%	-3.47
	8155950	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	6.61	CHEMBL3529	Homo sapiens	Inhibition	%	6.61
	8156088	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	8.35	CHEMBL3529	Homo sapiens	Inhibition	%	8.35
	8156300	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	6.36	CHEMBL3529	Homo sapiens	Inhibition	%	6.36
	8156524	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	4.06	CHEMBL3529	Homo sapiens	Inhibition	%	4.06
	8156674	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	5.1	CHEMBL3529	Homo sapiens	Inhibition	%	5.1
	8157041	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	5.67	CHEMBL3529	Homo sapiens	Inhibition	%	5.67
	8157161	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	0.85	CHEMBL3529	Homo sapiens	Inhibition	%	0.85
	8157385	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	2.46	CHEMBL3529	Homo sapiens	Inhibition	%	2.46
	8157526	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	10.6	CHEMBL3529	Homo sapiens	Inhibition	%	10.6
	8157880	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	4.87	CHEMBL3529	Homo sapiens	Inhibition	%	4.87
	8158041	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	-2.21	CHEMBL3529	Homo sapiens	Inhibition	%	-2.21
	8158291	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	7.25	CHEMBL3529	Homo sapiens	Inhibition	%	7.25
	8158673	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	5.3	CHEMBL3529	Homo sapiens	Inhibition	%	5.3
	8158842	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	4.29	CHEMBL3529	Homo sapiens	Inhibition	%	4.29
	8159201	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	8.36	CHEMBL3529	Homo sapiens	Inhibition	%	8.36
	8159545	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	4.09	CHEMBL3529	Homo sapiens	Inhibition	%	4.09
	8159676	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	6.34	CHEMBL3529	Homo sapiens	Inhibition	%	6.34
	8160041	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	1.63	CHEMBL3529	Homo sapiens	Inhibition	%	1.63
	8160178	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	9.02	CHEMBL3529	Homo sapiens	Inhibition	%	9.02
	8160552	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	-3.9	CHEMBL3529	Homo sapiens	Inhibition	%	-3.9
	8160846	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	6.07	CHEMBL3529	Homo sapiens	Inhibition	%	6.07
	8160996	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	3.55	CHEMBL3529	Homo sapiens	Inhibition	%	3.55
	8161220	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	95.17	CHEMBL3529	Homo sapiens	Inhibition	%	95.17
	8161363	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	6.75	CHEMBL3529	Homo sapiens	Inhibition	%	6.75
	8161712	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	1.96	CHEMBL3529	Homo sapiens	Inhibition	%	1.96
	8161850	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	18.88	CHEMBL3529	Homo sapiens	Inhibition	%	18.88
	8162204	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	7.53	CHEMBL3529	Homo sapiens	Inhibition	%	7.53
	8162364	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	-0.49	CHEMBL3529	Homo sapiens	Inhibition	%	-0.49
	8162588	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	-0.63	CHEMBL3529	Homo sapiens	Inhibition	%	-0.63
	8162617	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	13.75	CHEMBL3529	Homo sapiens	Inhibition	%	13.75
	8162841	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	36.1	CHEMBL3529	Homo sapiens	Inhibition	%	36.1
	8162989	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	19.33	CHEMBL3529	Homo sapiens	Inhibition	%	19.33
	8163158	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	6.78	CHEMBL3529	Homo sapiens	Inhibition	%	6.78
	8163382	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	4.91	CHEMBL3529	Homo sapiens	Inhibition	%	4.91
	8163516	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	9.71	CHEMBL3529	Homo sapiens	Inhibition	%	9.71
	8163863	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	5.11	CHEMBL3529	Homo sapiens	Inhibition	%	5.11
	8163997	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	4.93	CHEMBL3529	Homo sapiens	Inhibition	%	4.93
	8164221	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	8.28	CHEMBL3529	Homo sapiens	Inhibition	%	8.28
	8164361	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	0.1	CHEMBL3529	Homo sapiens	Inhibition	%	0.1
	8164516	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	91.95	CHEMBL3529	Homo sapiens	Inhibition	%	91.95
	8164740	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	7.68	CHEMBL3529	Homo sapiens	Inhibition	%	7.68
	8164884	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	-2.64	CHEMBL3529	Homo sapiens	Inhibition	%	-2.64
	8165178	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	5.04	CHEMBL3529	Homo sapiens	Inhibition	%	5.04
	8165543	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	8.42	CHEMBL3529	Homo sapiens	Inhibition	%	8.42
	8165686	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	20.51	CHEMBL3529	Homo sapiens	Inhibition	%	20.51
	8166036	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	5.16	CHEMBL3529	Homo sapiens	Inhibition	%	5.16
	8166174	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	8.55	CHEMBL3529	Homo sapiens	Inhibition	%	8.55
	8166398	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	8.08	CHEMBL3529	Homo sapiens	Inhibition	%	8.08
	8166528	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	5.43	CHEMBL3529	Homo sapiens	Inhibition	%	5.43
	8166853	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	12.92	CHEMBL3529	Homo sapiens	Inhibition	%	12.92
	8167165	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	7.92	CHEMBL3529	Homo sapiens	Inhibition	%	7.92
	8167306	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	65.41	CHEMBL3529	Homo sapiens	Inhibition	%	65.41
	8167694	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	1.87	CHEMBL3529	Homo sapiens	Inhibition	%	1.87
	8167827	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	8.59	CHEMBL3529	Homo sapiens	Inhibition	%	8.59
	8168051	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	11.01	CHEMBL3529	Homo sapiens	Inhibition	%	11.01
	8168175	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	1.7	CHEMBL3529	Homo sapiens	Inhibition	%	1.7
	8168540	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	4.91	CHEMBL3529	Homo sapiens	Inhibition	%	4.91
	8168676	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	0.72	CHEMBL3529	Homo sapiens	Inhibition	%	0.72
	8169064	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	27.9	CHEMBL3529	Homo sapiens	Inhibition	%	27.9
	8169206	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	-0.23	CHEMBL3529	Homo sapiens	Inhibition	%	-0.23
	8169430	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	2.67	CHEMBL3529	Homo sapiens	Inhibition	%	2.67
	8169510	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	10.12	CHEMBL3529	Homo sapiens	Inhibition	%	10.12
	8169868	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	9.8	CHEMBL3529	Homo sapiens	Inhibition	%	9.8
	8170013	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	-2.4	CHEMBL3529	Homo sapiens	Inhibition	%	-2.4
	8170237	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	5.33	CHEMBL3529	Homo sapiens	Inhibition	%	5.33
	8170362	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	3.32	CHEMBL3529	Homo sapiens	Inhibition	%	3.32
	8170726	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	90.28	CHEMBL3529	Homo sapiens	Inhibition	%	90.28
	8170861	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	4.72	CHEMBL3529	Homo sapiens	Inhibition	%	4.72
	8171282	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	0.88	CHEMBL3529	Homo sapiens	Inhibition	%	0.88
	8171499	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	27.54	CHEMBL3529	Homo sapiens	Inhibition	%	27.54
	8171640	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	10.85	CHEMBL3529	Homo sapiens	Inhibition	%	10.85
	8171864	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	35.23	CHEMBL3529	Homo sapiens	Inhibition	%	35.23
	8172017	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	3.6	CHEMBL3529	Homo sapiens	Inhibition	%	3.6
	8172373	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	8.71	CHEMBL3529	Homo sapiens	Inhibition	%	8.71
	8172501	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	4.43	CHEMBL3529	Homo sapiens	Inhibition	%	4.43
	8172867	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	3.59	CHEMBL3529	Homo sapiens	Inhibition	%	3.59
	8173003	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	-4.07	CHEMBL3529	Homo sapiens	Inhibition	%	-4.07
	8173227	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	-3.2	CHEMBL3529	Homo sapiens	Inhibition	%	-3.2
	8173392	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	5.23	CHEMBL3529	Homo sapiens	Inhibition	%	5.23
	8173757	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	3.51	CHEMBL3529	Homo sapiens	Inhibition	%	3.51
	8173844	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	7.82	CHEMBL3529	Homo sapiens	Inhibition	%	7.82
	8174068	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	19.0	CHEMBL3529	Homo sapiens	Inhibition	%	19.0
	8174200	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	8.93	CHEMBL3529	Homo sapiens	Inhibition	%	8.93
	8174572	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	3.8	CHEMBL3529	Homo sapiens	Inhibition	%	3.8
	8174694	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	3.85	CHEMBL3529	Homo sapiens	Inhibition	%	3.85
	8175061	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	99.1	CHEMBL3529	Homo sapiens	Inhibition	%	99.1
	8175197	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	4.12	CHEMBL3529	Homo sapiens	Inhibition	%	4.12
	8175421	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	7.95	CHEMBL3529	Homo sapiens	Inhibition	%	7.95
	8175677	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	16.35	CHEMBL3529	Homo sapiens	Inhibition	%	16.35
	8175840	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	4.1	CHEMBL3529	Homo sapiens	Inhibition	%	4.1
	8176217	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	5.51	CHEMBL3529	Homo sapiens	Inhibition	%	5.51
	8176366	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	5.09	CHEMBL3529	Homo sapiens	Inhibition	%	5.09
	8176722	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	23.27	CHEMBL3529	Homo sapiens	Inhibition	%	23.27
	8176852	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	0.86	CHEMBL3529	Homo sapiens	Inhibition	%	0.86
	8177076	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	2.18	CHEMBL3529	Homo sapiens	Inhibition	%	2.18
	8177218	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	5.04	CHEMBL3529	Homo sapiens	Inhibition	%	5.04
	8177580	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	13.49	CHEMBL3529	Homo sapiens	Inhibition	%	13.49
	8177744	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	9.13	CHEMBL3529	Homo sapiens	Inhibition	%	9.13
	8178108	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	92.13	CHEMBL3529	Homo sapiens	Inhibition	%	92.13
	8178420	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	1.55	CHEMBL3529	Homo sapiens	Inhibition	%	1.55
	8178547	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	8.63	CHEMBL3529	Homo sapiens	Inhibition	%	8.63
	8178920	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1	Outside typical range	CHEMBL479038	=	Inhibition	%	-12.87	CHEMBL3529	Homo sapiens	Inhibition	%	-12.87
	8179043	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	2.87	CHEMBL3529	Homo sapiens	Inhibition	%	2.87
	8179267	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	2.76	CHEMBL3529	Homo sapiens	Inhibition	%	2.76
	8179411	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	14.42	CHEMBL3529	Homo sapiens	Inhibition	%	14.42
	8179772	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	2.17	CHEMBL3529	Homo sapiens	Inhibition	%	2.17
	8180029	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	7.37	CHEMBL3529	Homo sapiens	Inhibition	%	7.37
	8180183	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	4.76	CHEMBL3529	Homo sapiens	Inhibition	%	4.76
	8180563	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	11.4	CHEMBL3529	Homo sapiens	Inhibition	%	11.4
	8180711	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	4.67	CHEMBL3529	Homo sapiens	Inhibition	%	4.67
	8180935	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	23.1	CHEMBL3529	Homo sapiens	Inhibition	%	23.1
	8181068	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	6.64	CHEMBL3529	Homo sapiens	Inhibition	%	6.64
	8181423	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	-2.73	CHEMBL3529	Homo sapiens	Inhibition	%	-2.73
	8181563	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	4.14	CHEMBL3529	Homo sapiens	Inhibition	%	4.14
	8181926	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	36.28	CHEMBL3529	Homo sapiens	Inhibition	%	36.28
	8182089	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	6.57	CHEMBL3529	Homo sapiens	Inhibition	%	6.57
	8182313	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	7.4	CHEMBL3529	Homo sapiens	Inhibition	%	7.4
	8182453	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	2.59	CHEMBL3529	Homo sapiens	Inhibition	%	2.59
	8182769	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	4.15	CHEMBL3529	Homo sapiens	Inhibition	%	4.15
	8182891	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	14.14	CHEMBL3529	Homo sapiens	Inhibition	%	14.14
	8183115	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	8.08	CHEMBL3529	Homo sapiens	Inhibition	%	8.08
	8183264	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	0.74	CHEMBL3529	Homo sapiens	Inhibition	%	0.74
	8183617	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	1.97	CHEMBL3529	Homo sapiens	Inhibition	%	1.97
	8183759	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	49.13	CHEMBL3529	Homo sapiens	Inhibition	%	49.13
	8183983	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	7.49	CHEMBL3529	Homo sapiens	Inhibition	%	7.49
	8184119	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	1.08	CHEMBL3529	Homo sapiens	Inhibition	%	1.08
	8184385	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	6.54	CHEMBL3529	Homo sapiens	Inhibition	%	6.54
	8184532	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	2.66	CHEMBL3529	Homo sapiens	Inhibition	%	2.66
	8184756	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	3.19	CHEMBL3529	Homo sapiens	Inhibition	%	3.19
	8184913	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	5.66	CHEMBL3529	Homo sapiens	Inhibition	%	5.66
	8185286	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	0.37	CHEMBL3529	Homo sapiens	Inhibition	%	0.37
	8185417	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	6.97	CHEMBL3529	Homo sapiens	Inhibition	%	6.97
	8185772	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	2.23	CHEMBL3529	Homo sapiens	Inhibition	%	2.23
	8185911	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	4.3	CHEMBL3529	Homo sapiens	Inhibition	%	4.3
	8186135	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	4.27	CHEMBL3529	Homo sapiens	Inhibition	%	4.27
	8186276	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	9.89	CHEMBL3529	Homo sapiens	Inhibition	%	9.89
	8186664	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	13.53	CHEMBL3529	Homo sapiens	Inhibition	%	13.53
	8186803	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	4.2	CHEMBL3529	Homo sapiens	Inhibition	%	4.2
	8187125	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	1.74	CHEMBL3529	Homo sapiens	Inhibition	%	1.74
	8187473	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	9.38	CHEMBL3529	Homo sapiens	Inhibition	%	9.38
	8187621	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	4.13	CHEMBL3529	Homo sapiens	Inhibition	%	4.13
	8187974	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	-1.52	CHEMBL3529	Homo sapiens	Inhibition	%	-1.52
	8188341	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	8.2	CHEMBL3529	Homo sapiens	Inhibition	%	8.2
	8188476	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	1.8	CHEMBL3529	Homo sapiens	Inhibition	%	1.8
	8188750	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	4.88	CHEMBL3529	Homo sapiens	Inhibition	%	4.88
	8189122	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	1.71	CHEMBL3529	Homo sapiens	Inhibition	%	1.71
	8189278	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	7.06	CHEMBL3529	Homo sapiens	Inhibition	%	7.06
	8189651	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	8189783	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	7.86	CHEMBL3529	Homo sapiens	Inhibition	%	7.86
	8190007	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	9.33	CHEMBL3529	Homo sapiens	Inhibition	%	9.33
	8190139	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	10.87	CHEMBL3529	Homo sapiens	Inhibition	%	10.87
	8190503	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	6.3	CHEMBL3529	Homo sapiens	Inhibition	%	6.3
	8190640	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	88.22	CHEMBL3529	Homo sapiens	Inhibition	%	88.22
	8190864	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	7.53	CHEMBL3529	Homo sapiens	Inhibition	%	7.53
	8191028	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	19.05	CHEMBL3529	Homo sapiens	Inhibition	%	19.05
	8191166	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	3.33	CHEMBL3529	Homo sapiens	Inhibition	%	3.33
	8191390	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	6.21	CHEMBL3529	Homo sapiens	Inhibition	%	6.21
	8191486	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	91.33	CHEMBL3529	Homo sapiens	Inhibition	%	91.33
	8191832	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	26.73	CHEMBL3529	Homo sapiens	Inhibition	%	26.73
	8191981	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	1.34	CHEMBL3529	Homo sapiens	Inhibition	%	1.34
	8192205	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	3.78	CHEMBL3529	Homo sapiens	Inhibition	%	3.78
	8192334	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	5.88	CHEMBL3529	Homo sapiens	Inhibition	%	5.88
	8192702	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	5.9	CHEMBL3529	Homo sapiens	Inhibition	%	5.9
	8192838	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	8.64	CHEMBL3529	Homo sapiens	Inhibition	%	8.64
	8193062	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	2.74	CHEMBL3529	Homo sapiens	Inhibition	%	2.74
	8193110	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	4.24	CHEMBL3529	Homo sapiens	Inhibition	%	4.24
	8193334	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	6.05	CHEMBL3529	Homo sapiens	Inhibition	%	6.05
	8193479	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	1.92	CHEMBL3529	Homo sapiens	Inhibition	%	1.92
	8193636	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	6.35	CHEMBL3529	Homo sapiens	Inhibition	%	6.35
	8193860	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	14.54	CHEMBL3529	Homo sapiens	Inhibition	%	14.54
	8194009	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	-2.71	CHEMBL3529	Homo sapiens	Inhibition	%	-2.71
	8194364	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	5.22	CHEMBL3529	Homo sapiens	Inhibition	%	5.22
	8194495	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	12.5	CHEMBL3529	Homo sapiens	Inhibition	%	12.5
	8194719	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	3.79	CHEMBL3529	Homo sapiens	Inhibition	%	3.79
	8194862	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	14.92	CHEMBL3529	Homo sapiens	Inhibition	%	14.92
	8195219	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	9.51	CHEMBL3529	Homo sapiens	Inhibition	%	9.51
	8195383	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	24.92	CHEMBL3529	Homo sapiens	Inhibition	%	24.92
	8195746	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	4.91	CHEMBL3529	Homo sapiens	Inhibition	%	4.91
	8195844	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	2.04	CHEMBL3529	Homo sapiens	Inhibition	%	2.04
	8196068	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	3.45	CHEMBL3529	Homo sapiens	Inhibition	%	3.45
	8196185	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	5.38	CHEMBL3529	Homo sapiens	Inhibition	%	5.38
	8196559	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	1.25	CHEMBL3529	Homo sapiens	Inhibition	%	1.25
	8196687	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	3.56	CHEMBL3529	Homo sapiens	Inhibition	%	3.56
	8196911	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	7.67	CHEMBL3529	Homo sapiens	Inhibition	%	7.67
	8197052	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	5.71	CHEMBL3529	Homo sapiens	Inhibition	%	5.71
	8197413	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	26.52	CHEMBL3529	Homo sapiens	Inhibition	%	26.52
	8197688	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	3.16	CHEMBL3529	Homo sapiens	Inhibition	%	3.16
	8197828	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	0.65	CHEMBL3529	Homo sapiens	Inhibition	%	0.65
	8198209	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	5.03	CHEMBL3529	Homo sapiens	Inhibition	%	5.03
	8198347	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	-2.89	CHEMBL3529	Homo sapiens	Inhibition	%	-2.89
	8198571	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	8.65	CHEMBL3529	Homo sapiens	Inhibition	%	8.65
	8198701	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	6.95	CHEMBL3529	Homo sapiens	Inhibition	%	6.95
	8199056	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	3.58	CHEMBL3529	Homo sapiens	Inhibition	%	3.58
	8199204	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	17.47	CHEMBL3529	Homo sapiens	Inhibition	%	17.47
	8199562	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	7.72	CHEMBL3529	Homo sapiens	Inhibition	%	7.72
	8199725	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	52.02	CHEMBL3529	Homo sapiens	Inhibition	%	52.02
	8199949	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	4.19	CHEMBL3529	Homo sapiens	Inhibition	%	4.19
	8200087	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	5.41	CHEMBL3529	Homo sapiens	Inhibition	%	5.41
	8200415	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	1.23	CHEMBL3529	Homo sapiens	Inhibition	%	1.23
	8200530	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	4.77	CHEMBL3529	Homo sapiens	Inhibition	%	4.77
	8200754	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	0.87	CHEMBL3529	Homo sapiens	Inhibition	%	0.87
	8200904	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	3.29	CHEMBL3529	Homo sapiens	Inhibition	%	3.29
	8201258	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	7.71	CHEMBL3529	Homo sapiens	Inhibition	%	7.71
	8201393	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	5.72	CHEMBL3529	Homo sapiens	Inhibition	%	5.72
	8201750	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	-2.45	CHEMBL3529	Homo sapiens	Inhibition	%	-2.45
	8202029	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	5.42	CHEMBL3529	Homo sapiens	Inhibition	%	5.42
	8202169	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	2.71	CHEMBL3529	Homo sapiens	Inhibition	%	2.71
	8202393	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	8202560	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	4.11	CHEMBL3529	Homo sapiens	Inhibition	%	4.11
	8202909	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	7.34	CHEMBL3529	Homo sapiens	Inhibition	%	7.34
	8203039	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	7.92	CHEMBL3529	Homo sapiens	Inhibition	%	7.92
	8203394	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	4.78	CHEMBL3529	Homo sapiens	Inhibition	%	4.78
	8203540	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	16.6	CHEMBL3529	Homo sapiens	Inhibition	%	16.6
	8203764	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	9.87	CHEMBL3529	Homo sapiens	Inhibition	%	9.87
	8203898	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	8.55	CHEMBL3529	Homo sapiens	Inhibition	%	8.55
	8204288	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	91.68	CHEMBL3529	Homo sapiens	Inhibition	%	91.68
	8204425	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	5.73	CHEMBL3529	Homo sapiens	Inhibition	%	5.73
	8204754	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	-3.51	CHEMBL3529	Homo sapiens	Inhibition	%	-3.51
	8205093	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	96.34	CHEMBL3529	Homo sapiens	Inhibition	%	96.34
	8205242	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	2.67	CHEMBL3529	Homo sapiens	Inhibition	%	2.67
	8205602	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	7.17	CHEMBL3529	Homo sapiens	Inhibition	%	7.17
	8205741	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	2.21	CHEMBL3529	Homo sapiens	Inhibition	%	2.21
	8205965	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	4.09	CHEMBL3529	Homo sapiens	Inhibition	%	4.09
	8206097	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	-2.02	CHEMBL3529	Homo sapiens	Inhibition	%	-2.02
	8206373	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	2.73	CHEMBL3529	Homo sapiens	Inhibition	%	2.73
	8206740	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	-0.65	CHEMBL3529	Homo sapiens	Inhibition	%	-0.65
	8206920	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	4.73	CHEMBL3529	Homo sapiens	Inhibition	%	4.73
	8207270	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	9.04	CHEMBL3529	Homo sapiens	Inhibition	%	9.04
	8207400	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	7.73	CHEMBL3529	Homo sapiens	Inhibition	%	7.73
	8207624	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	8.95	CHEMBL3529	Homo sapiens	Inhibition	%	8.95
	8207756	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	6.19	CHEMBL3529	Homo sapiens	Inhibition	%	6.19
	8208125	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	13.44	CHEMBL3529	Homo sapiens	Inhibition	%	13.44
	8208257	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	7.81	CHEMBL3529	Homo sapiens	Inhibition	%	7.81
	8208647	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	3.14	CHEMBL3529	Homo sapiens	Inhibition	%	3.14
	8208780	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	4.69	CHEMBL3529	Homo sapiens	Inhibition	%	4.69
	8209004	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	3.18	CHEMBL3529	Homo sapiens	Inhibition	%	3.18
	8209109	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	-1.02	CHEMBL3529	Homo sapiens	Inhibition	%	-1.02
	8209449	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	3.83	CHEMBL3529	Homo sapiens	Inhibition	%	3.83
	8209599	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	5.49	CHEMBL3529	Homo sapiens	Inhibition	%	5.49
	8209823	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	-0.78	CHEMBL3529	Homo sapiens	Inhibition	%	-0.78
	8209959	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	6.4	CHEMBL3529	Homo sapiens	Inhibition	%	6.4
	8210324	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	3.27	CHEMBL3529	Homo sapiens	Inhibition	%	3.27
	8210460	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	-5.79	CHEMBL3529	Homo sapiens	Inhibition	%	-5.79
	8210719	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	5.66	CHEMBL3529	Homo sapiens	Inhibition	%	5.66
	8210943	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	5.13	CHEMBL3529	Homo sapiens	Inhibition	%	5.13
	8211087	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	3.88	CHEMBL3529	Homo sapiens	Inhibition	%	3.88
	8211257	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	4.6	CHEMBL3529	Homo sapiens	Inhibition	%	4.6
	8211481	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	6.23	CHEMBL3529	Homo sapiens	Inhibition	%	6.23
	8211604	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	8.93	CHEMBL3529	Homo sapiens	Inhibition	%	8.93
	8211957	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	12.16	CHEMBL3529	Homo sapiens	Inhibition	%	12.16
	8212089	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	4.52	CHEMBL3529	Homo sapiens	Inhibition	%	4.52
	8212454	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	4.25	CHEMBL3529	Homo sapiens	Inhibition	%	4.25
	8212587	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	9.71	CHEMBL3529	Homo sapiens	Inhibition	%	9.71
	8212811	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	7.79	CHEMBL3529	Homo sapiens	Inhibition	%	7.79
	8212981	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	3.81	CHEMBL3529	Homo sapiens	Inhibition	%	3.81
	8213334	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	11.26	CHEMBL3529	Homo sapiens	Inhibition	%	11.26
	8213438	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	0.08	CHEMBL3529	Homo sapiens	Inhibition	%	0.08
	8213662	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-4.08	CHEMBL3529	Homo sapiens	Inhibition	%	-4.08
	8213775	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	5.46	CHEMBL3529	Homo sapiens	Inhibition	%	5.46
	8214146	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	3.02	CHEMBL3529	Homo sapiens	Inhibition	%	3.02
	8214283	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	8.51	CHEMBL3529	Homo sapiens	Inhibition	%	8.51
	8214641	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	11.44	CHEMBL3529	Homo sapiens	Inhibition	%	11.44
	8214793	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	-3.61	CHEMBL3529	Homo sapiens	Inhibition	%	-3.61
	8215017	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	-5.44	CHEMBL3529	Homo sapiens	Inhibition	%	-5.44
	8215268	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	4.76	CHEMBL3529	Homo sapiens	Inhibition	%	4.76
	8215421	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	8.59	CHEMBL3529	Homo sapiens	Inhibition	%	8.59
	8215809	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	3.8	CHEMBL3529	Homo sapiens	Inhibition	%	3.8
	8215928	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	8.4	CHEMBL3529	Homo sapiens	Inhibition	%	8.4
	8216271	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	5.17	CHEMBL3529	Homo sapiens	Inhibition	%	5.17
	8216407	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	5.04	CHEMBL3529	Homo sapiens	Inhibition	%	5.04
	8216631	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	6.27	CHEMBL3529	Homo sapiens	Inhibition	%	6.27
	8216769	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	3.59	CHEMBL3529	Homo sapiens	Inhibition	%	3.59
	8217127	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	8.77	CHEMBL3529	Homo sapiens	Inhibition	%	8.77
	8217301	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	1.29	CHEMBL3529	Homo sapiens	Inhibition	%	1.29
	8217656	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	42.52	CHEMBL3529	Homo sapiens	Inhibition	%	42.52
	8217981	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-2.57	CHEMBL3529	Homo sapiens	Inhibition	%	-2.57
	8218096	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	9.22	CHEMBL3529	Homo sapiens	Inhibition	%	9.22
	8218447	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	-1.79	CHEMBL3529	Homo sapiens	Inhibition	%	-1.79
	8218590	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	6.91	CHEMBL3529	Homo sapiens	Inhibition	%	6.91
	8218814	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	8.13	CHEMBL3529	Homo sapiens	Inhibition	%	8.13
	8218945	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	19.41	CHEMBL3529	Homo sapiens	Inhibition	%	19.41
	8219329	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	-6.6	CHEMBL3529	Homo sapiens	Inhibition	%	-6.6
	8219579	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	5.9	CHEMBL3529	Homo sapiens	Inhibition	%	5.9
	8219740	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	5.67	CHEMBL3529	Homo sapiens	Inhibition	%	5.67
	8220133	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	7.41	CHEMBL3529	Homo sapiens	Inhibition	%	7.41
	8220262	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	10.35	CHEMBL3529	Homo sapiens	Inhibition	%	10.35
	8220486	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	7.9	CHEMBL3529	Homo sapiens	Inhibition	%	7.9
	8220600	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	6.28	CHEMBL3529	Homo sapiens	Inhibition	%	6.28
	8220962	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	20.31	CHEMBL3529	Homo sapiens	Inhibition	%	20.31
	8221098	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	3.84	CHEMBL3529	Homo sapiens	Inhibition	%	3.84
	8221322	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	10.25	CHEMBL3529	Homo sapiens	Inhibition	%	10.25
	8221455	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	5.22	CHEMBL3529	Homo sapiens	Inhibition	%	5.22
	8221620	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	3.43	CHEMBL3529	Homo sapiens	Inhibition	%	3.43
	8221844	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	0.25	CHEMBL3529	Homo sapiens	Inhibition	%	0.25
	8221975	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	114.68	CHEMBL3529	Homo sapiens	Inhibition	%	114.68
	8222297	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	6.89	CHEMBL3529	Homo sapiens	Inhibition	%	6.89
	8222431	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	7.42	CHEMBL3529	Homo sapiens	Inhibition	%	7.42
	8222655	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	4.43	CHEMBL3529	Homo sapiens	Inhibition	%	4.43
	8222773	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	-5.84	CHEMBL3529	Homo sapiens	Inhibition	%	-5.84
	8223141	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	9.69	CHEMBL3529	Homo sapiens	Inhibition	%	9.69
	8223270	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	3.68	CHEMBL3529	Homo sapiens	Inhibition	%	3.68
	8223494	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	3.04	CHEMBL3529	Homo sapiens	Inhibition	%	3.04
	8223655	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	-1.79	CHEMBL3529	Homo sapiens	Inhibition	%	-1.79
	8223905	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	6.25	CHEMBL3529	Homo sapiens	Inhibition	%	6.25
	8224067	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	4.6	CHEMBL3529	Homo sapiens	Inhibition	%	4.6
	8224291	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	5.82	CHEMBL3529	Homo sapiens	Inhibition	%	5.82
	8224461	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	5.71	CHEMBL3529	Homo sapiens	Inhibition	%	5.71
	8224820	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	9.83	CHEMBL3529	Homo sapiens	Inhibition	%	9.83
	8224934	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	4.64	CHEMBL3529	Homo sapiens	Inhibition	%	4.64
	8225158	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	5.11	CHEMBL3529	Homo sapiens	Inhibition	%	5.11
	8225292	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	6.1	CHEMBL3529	Homo sapiens	Inhibition	%	6.1
	8225654	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	1.33	CHEMBL3529	Homo sapiens	Inhibition	%	1.33
	8225789	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	7.25	CHEMBL3529	Homo sapiens	Inhibition	%	7.25
	8226171	CHEMBL1962085	GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	1.18	CHEMBL3529	Homo sapiens	Inhibition	%	1.18
	8226296	CHEMBL1962084	GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	4.71	CHEMBL3529	Homo sapiens	Inhibition	%	4.71
inactive	9506999	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Oc1ccc2nc(-c3ccc(Sc4ccc(-c5nc6ccc(O)cc6[nH]5)cc4)cc3)[nH]c2c1		CHEMBL2001149	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507000	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(O)c1csc2c1NCCNC2=O		CHEMBL1974875	=	Ki	nM	31622.78	CHEMBL3529	Homo sapiens	pKi		4.5
inactive	9507001	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1ccc2c(c1)c(-c1cc3nc(Br)cnc3[nH]1)cn2C		CHEMBL2005478	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507002	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1cccc(OC)c1CNc1nc(NC2CCCCC2)nc2ccc(Cl)cc12		CHEMBL1996646	=	Ki	nM	1000.0	CHEMBL3529	Homo sapiens	pKi		6.0
inactive	9507003	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CN(CCN)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1979773	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507004	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1ccnc2[nH]c3cc(C(C)C)ccc3c(=O)c12		CHEMBL1989471	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507005	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL2002099	=	Ki	nM	2511.89	CHEMBL3529	Homo sapiens	pKi		5.6
inactive	9507006	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCCCN(C)C)cc2NC3=O)ccc1O		CHEMBL1996702	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507007	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507008	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(Nc1ccc(-c2ccc(=O)[nH]n2)cc1)Nc1cccc(C(F)(F)F)c1		CHEMBL2007124	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507009	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	NC(=O)c1cc2c(-c3ccc(Br)cc3)cncc2s1		CHEMBL1978195	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507010	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507011	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Clc1cc(-c2c[nH]c3ncccc23)nc(NC2CCCCC2)n1		CHEMBL2006439	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507012	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	N#Cc1ccc2c(c1)C(c1ccc3c(n1)CCCC3O)C(=O)N2		CHEMBL1985681	=	Ki	nM	1995.26	CHEMBL3529	Homo sapiens	pKi		5.7
active	9507013	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	=	Ki	nM	100.0	CHEMBL3529	Homo sapiens	pKi		7.0
active	9507014	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL2002099	=	Ki	nM	1258.93	CHEMBL3529	Homo sapiens	pKi		5.9
inactive	9507015	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	OC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1991674	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507016	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	NC(=O)c1ccc(-c2c[nH]c3nccc(Cl)c23)cc1		CHEMBL1982711	=	Ki	nM	1000.0	CHEMBL3529	Homo sapiens	pKi		6.0
active	9507017	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Nc1ncnc2c1N=C(c1ccccc1)CCN2		CHEMBL262623	=	Ki	nM	31622.78	CHEMBL3529	Homo sapiens	pKi		4.5
inactive	9507018	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(C)COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL1984842	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507019	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2[nH]ccc12		CHEMBL2004118	=	Ki	nM	2511.89	CHEMBL3529	Homo sapiens	pKi		5.6
inactive	9507020	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCN1CCN(c2ccc(Nc3ncc(C#N)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1973516	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507021	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	N#Cc1ccc2nc(N)n(-c3nc4c(s3)CCCC4)c2c1		CHEMBL1996345	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507022	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COCOc1cccc(OCOC)c1-c1ccc(NS(C)(=O)=O)cc1C(=O)OC		CHEMBL2004025	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507023	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1ccc(-c2cc3c(NCCN)ccc(C(N)=O)c3[nH]2)cc1		CHEMBL1996048	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507024	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507025	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(C)(C)Nc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1995211	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507026	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1cc(=O)[nH]nc1-c1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2F)cc1		CHEMBL1965033	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507027	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL461876	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507028	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507029	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	NC(=O)c1ccc(NC2CCCCC2N)nc1Nc1cccc(Cl)c1		CHEMBL1982753	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507030	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL2006299	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507031	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Oc1cc(O)cc(C=Cc2ccc(O)c(O)c2)c1		CHEMBL1972346	=	Ki	nM	398.11	CHEMBL3529	Homo sapiens	pKi		6.4
active	9507032	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1ccc(C2=NNc3cccc4c(OC)ccc2c34)cc1OC		CHEMBL1997335	=	Ki	nM	501.19	CHEMBL3529	Homo sapiens	pKi		6.3
inactive	9507033	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1ccc(-c2cc3nc(Br)cnc3[nH]2)cc1		CHEMBL1965169	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507034	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1		CHEMBL1081312	=	Ki	nM	1584.89	CHEMBL3529	Homo sapiens	pKi		5.8
inactive	9507035	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(O)CO)c5)cnc(N)c34)cc2)cc1		CHEMBL1965170	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507036	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1nnc(-c2ccccc2)c(C#N)n1		CHEMBL1994808	=	Ki	nM	31622.78	CHEMBL3529	Homo sapiens	pKi		4.5
inactive	9507037	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL2005792	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507038	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Nc1n[nH]c2nc(Cl)sc12		CHEMBL1991867	=	Ki	nM	39810.72	CHEMBL3529	Homo sapiens	pKi		4.4
active	9507039	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1c(-c2nc3ccccc3[nH]2)c(O)cc2oc(C)cc(=O)c12		CHEMBL1972355	=	Ki	nM	1995.26	CHEMBL3529	Homo sapiens	pKi		5.7
inactive	9507040	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1cc(=O)[nH]nc1-c1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2F)c(Cl)c1		CHEMBL1997892	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507041	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(C)(O)c1cn(-c2ccc3[nH]ncc3c2)nn1		CHEMBL2001641	=	Ki	nM	31622.78	CHEMBL3529	Homo sapiens	pKi		4.5
inactive	9507042	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1ccc(-c2cc(-c3cc(Br)ccc3O)[nH]c(=O)c2C#N)s1		CHEMBL1997193	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507043	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2cccc(OCC(=O)O)c2)n1		CHEMBL1964902	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507044	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Oc1cnc2ccc(-c3ccncc3)cc2c1		CHEMBL1973868	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507045	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCCCC#Cc1ccc(CN2CC(C(=O)O)C2)cc1		CHEMBL1972462	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507046	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507047	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507048	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	=	Ki	nM	501.19	CHEMBL3529	Homo sapiens	pKi		6.3
active	9507049	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3)n2)s1		CHEMBL1983715	=	Ki	nM	63.1	CHEMBL3529	Homo sapiens	pKi		7.2
inactive	9507050	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C1NCc2c(Br)cccc21		CHEMBL1984500	<	Ki	nM	63095.73	CHEMBL3529	Homo sapiens	pKi		4.2
inactive	9507051	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507052	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(N)C1CCC(C(=O)Nc2ccnc3[nH]ccc23)CC1		CHEMBL2002992	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507053	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCCCNC(=O)c1cn(C(CC)CC)c(=O)c2cc(OC)c(OC)cc12		CHEMBL1982700	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507054	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507055	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(C)Cc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2[nH]ccc12		CHEMBL1980763	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507056	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2ccc(OCC(N)=O)cc2)n1		CHEMBL1977634	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507057	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(=O)c1ccccc1-c1ncnc2[nH]ccc12		CHEMBL1977931	=	Ki	nM	100000.0	CHEMBL3529	Homo sapiens	pKi		4.0
inactive	9507058	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507059	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCCCNc1nc(N)c(C(=O)c2ccccc2)s1		CHEMBL2007479	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507060	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	c1ccc(-c2c[nH]c3ncnc(N4CCCCC4)c23)cc1		CHEMBL1998953	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507061	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCCOc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3F)cc2)c1		CHEMBL1971606	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507062	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(C)C(CO)NC(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1971223	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507063	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507064	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(C)c1cc(=O)[nH]c2[nH][nH]c(=O)c12		CHEMBL1999120	=	Ki	nM	63095.73	CHEMBL3529	Homo sapiens	pKi		4.2
active	9507065	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4ccc(OC(F)F)cc4)cc3)c12		CHEMBL1972220	=	Ki	nM	63.1	CHEMBL3529	Homo sapiens	pKi		7.2
inactive	9507066	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(OC(F)F)ccc12		CHEMBL1981215	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507067	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Fc1cccc(CNc2ncnc3[nH]cnc23)c1		CHEMBL2003785	=	Ki	nM	100000.0	CHEMBL3529	Homo sapiens	pKi		4.0
active	9507068	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1973720	=	Ki	nM	2511.89	CHEMBL3529	Homo sapiens	pKi		5.6
inactive	9507069	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507070	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCN(CC)CCCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL1999414	=	Ki	nM	630.96	CHEMBL3529	Homo sapiens	pKi		6.2
inactive	9507071	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(Nc1cnccn1)Nc1ccnc2c(F)cc(F)cc12		CHEMBL1967336	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507072	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C1Nc2cc(CCOc3ccc(N4CCOCC4)cc3)ccc2Nc2cc(-c3cn(Cc4cc(F)c(F)c(F)c4)c4cnccc34)ccc21		CHEMBL2001923	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507073	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCOc1ccccc1-c1cccc(-c2n[nH]c3nc(O)cc(C)c23)c1		CHEMBL1983070	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507074	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1cccc(C(C)NC(=O)c2cnc(-c3ccncc3)nc2)c1		CHEMBL2003514	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507075	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1		CHEMBL2001019	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507076	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Nc1noc2cccc(-c3cccc(O)c3)c12		CHEMBL1970340	=	Ki	nM	39810.72	CHEMBL3529	Homo sapiens	pKi		4.4
inactive	9507077	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	N#Cc1ccc(-c2ccncc2)cc1NCc1ccccc1		CHEMBL1967992	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507078	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507079	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CN1CCN(c2ccc(Nc3nc(N)c(C(=O)c4c(Cl)cccc4Cl)s3)cc2)CC1		CHEMBL1989043	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507080	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507081	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCCCC(=O)Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL2006450	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507082	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(F)ccc(F)c12		CHEMBL2001987	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507083	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCc1c(-c2ccc(C(C)=O)cc2)[nH]c2nccnc12		CHEMBL1994555	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507084	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507085	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507086	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1975121	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507087	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3coc4c(C#CCN5CCOCC5)cnc(N)c34)cc2)c1		CHEMBL1983640	=	Ki	nM	398.11	CHEMBL3529	Homo sapiens	pKi		6.4
active	9507088	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCOC(=O)c1nc2c(=O)[nH]c3cc([N+](=O)[O-])c(NC(C)=O)cc3n2c1C		CHEMBL1997611	=	Ki	nM	1584.89	CHEMBL3529	Homo sapiens	pKi		5.8
inactive	9507089	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507090	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1973720	=	Ki	nM	2511.89	CHEMBL3529	Homo sapiens	pKi		5.6
inactive	9507091	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Brc1ccc2cnc(Nc3ccncn3)cc2c1		CHEMBL1984686	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507092	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507093	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=S(=O)(Nc1ccc2c(c1)C(=NO)c1ccccc1-2)c1cccc(Br)c1		CHEMBL1973793	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507094	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507095	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1cc(Nc2ncc(F)c(NC3C4C=CC(C4)C3C(N)=O)n2)ccc1N1CCN(C)CC1		CHEMBL1967878	=	Ki	nM	501.19	CHEMBL3529	Homo sapiens	pKi		6.3
inactive	9507096	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCC1CC(NS(=O)(=O)C2CC2)CC1c1ncc2cnc3[nH]ccc3n12		CHEMBL1992073	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507097	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	NCC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1990254	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507098	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(NC(CCO)c1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1986143	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507099	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3sccc3n2)cc1		CHEMBL2007559	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507100	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(Cc1ccc(-c2cccnc2)cc1)Nc1ccc(SC(F)F)cc1		CHEMBL1992581	=	Ki	nM	1000.0	CHEMBL3529	Homo sapiens	pKi		6.0
active	9507101	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)(C)O)c5)cnc(N)c34)cc2)cc1		CHEMBL2004290	=	Ki	nM	630.96	CHEMBL3529	Homo sapiens	pKi		6.2
active	9507102	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=c1[nH]c2cc(Br)cnc2[nH]1		CHEMBL1975921	=	Ki	nM	39810.72	CHEMBL3529	Homo sapiens	pKi		4.4
inactive	9507103	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(CCC(=O)O)(c1ccc(O)c(N)c1)c1ccc(O)c(N)c1		CHEMBL1975923	<	Ki	nM	1584.89	CHEMBL3529	Homo sapiens	pKi		5.8
active	9507104	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=c1[nH]n2ccccc2c1Br		CHEMBL2004033	=	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507105	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(=O)OCCn1nc(-c2cccc(Br)c2)c2c(C(F)(F)F)cc(=O)[nH]c21		CHEMBL1984847	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507106	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1cc(Nc2nc(Cl)cc(NCc3ccccc3)n2)n[nH]1		CHEMBL2005449	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507107	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(Cc1ccc(OC(F)(F)F)cc1)N1CCC2(CC1)NCCc1c2[nH]c2ccccc12		CHEMBL1996576	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507108	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1991678	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507109	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(O)C1CN(Cc2ccc(OCc3ccccc3)cc2Cl)C1		CHEMBL1987998	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507110	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cn1c(NCC(N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O		CHEMBL1990496	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507111	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc([N+](=O)[O-])cc2)n1		CHEMBL242865	=	Ki	nM	398.11	CHEMBL3529	Homo sapiens	pKi		6.4
inactive	9507112	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507113	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1cc2ncc3c(N)nc4c(C)c(N)ccc4c3c2cc1OC		CHEMBL235157	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507114	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Nc1nc2ncc(-c3ccccc3)cn2n1		CHEMBL2002480	=	Ki	nM	63095.73	CHEMBL3529	Homo sapiens	pKi		4.2
inactive	9507115	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507116	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1cccc(CNC(=O)c2cnc(-c3ccncc3)nc2)c1		CHEMBL2004159	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507117	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	N#CC1=C(c2ccccc2)CC(c2ccc(Cl)cc2)C(C(=O)c2ccccc2)C1=O		CHEMBL1978371	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507118	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507119	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	[2H]C([2H])([2H])Oc1cccc(C(C)NC(=O)c2sc(-c3ccncc3)nc2C)c1		CHEMBL1998110	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507120	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCCCCCCCCN)cnc(N)c34)cc2)c1		CHEMBL1978166	=	Ki	nM	398.11	CHEMBL3529	Homo sapiens	pKi		6.4
active	9507121	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(=O)n1ncc2cc(N)ccc21		CHEMBL1972454	=	Ki	nM	79432.82	CHEMBL3529	Homo sapiens	pKi		4.1
inactive	9507122	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1cc(O)nc2[nH]nc(-c3cccc(-c4ccc(Cl)cc4)c3)c12		CHEMBL1990590	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507123	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1nn(C)c2c1c(=O)c1cc(Cl)ccc1n2OCC(C)C		CHEMBL1977814	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507124	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	OCc1cc(-c2ccc3[nH]ncc3c2)on1		CHEMBL1974617	=	Ki	nM	19952.62	CHEMBL3529	Homo sapiens	pKi		4.7
active	9507125	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C1Nc2ccccc2C1=Cc1ccc[nH]1		CHEMBL1996176	=	Ki	nM	1995.26	CHEMBL3529	Homo sapiens	pKi		5.7
inactive	9507126	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507127	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1cc(Nc2ncnc(N3CCCc4cc(C)ccc43)n2)cc(OC)c1OC		CHEMBL1992125	=	Ki	nM	1995.26	CHEMBL3529	Homo sapiens	pKi		5.7
inactive	9507128	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC1CCN(C(=O)CC#N)CC1c1ncc2cnc3[nH]ccc3n12		CHEMBL1966175	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507129	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC#Cc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL2007375	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507130	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1[nH]c3ccc(O)cc3c21		CHEMBL379975	=	Ki	nM	2511.89	CHEMBL3529	Homo sapiens	pKi		5.6
inactive	9507131	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CS(=O)(=O)c1cccc(C(=O)Nc2nc3ccccc3n2CCCO)c1		CHEMBL1973016	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507132	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Nc1n[nH]c2c(OCCCn3cccc3)ccc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)c12		CHEMBL1965387	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507133	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	c1cc2c(s1)CCc1cn[nH]c1-2		CHEMBL2001539	=	Ki	nM	63095.73	CHEMBL3529	Homo sapiens	pKi		4.2
active	9507134	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CNC1CC2OC(C)(C1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL1980995	=	Ki	nM	5.012	CHEMBL3529	Homo sapiens	pKi		8.3
active	9507135	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1cc(-c2ncnc3[nH]ccc23)ccc1F		CHEMBL1997041	=	Ki	nM	25118.86	CHEMBL3529	Homo sapiens	pKi		4.6
active	9507136	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1cc(-c2ccc3c(c2)Nc2c(O)cccc2NC3=O)ccc1O		CHEMBL550418	=	Ki	nM	1258.93	CHEMBL3529	Homo sapiens	pKi		5.9
inactive	9507137	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	N#Cc1ccc2[nH]c(O)c(-c3ccc(CN4CCOCC4)cn3)c2c1		CHEMBL1969664	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507138	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCCCN4CCOCC4)cc2-3)cn1		CHEMBL398951	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507139	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCOc1ccc(C=C2SC(=N)NC2=O)c(O)c1		CHEMBL1971289	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507140	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CNC(=O)c1ccccc1Sc1ccc2c(C=Cc3ccccn3)n[nH]c2c1		CHEMBL1988437	=	Ki	nM	1995.26	CHEMBL3529	Homo sapiens	pKi		5.7
inactive	9507141	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2ccc(F)cc12		CHEMBL2007603	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507142	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(Cc1cccs1)Nc1nc2ccccc2s1		CHEMBL1421720	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507143	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1ccc2c(c1)c(-c1cc3nccnc3[nH]1)cn2C		CHEMBL1233887	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507144	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Nc1nnc2cncc(Cl)n12		CHEMBL1968130	=	Ki	nM	19952.62	CHEMBL3529	Homo sapiens	pKi		4.7
inactive	9507145	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2ccc(OCCC(=O)O)cc2)n1		CHEMBL2003689	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507146	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCN(CC)CCCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)csc12		CHEMBL1996649	=	Ki	nM	630.96	CHEMBL3529	Homo sapiens	pKi		6.2
inactive	9507147	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1		CHEMBL1986756	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507148	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507149	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=c1[nH]cnc2c(Cl)cccc12		CHEMBL1949855	=	Ki	nM	12589.25	CHEMBL3529	Homo sapiens	pKi		4.9
inactive	9507150	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C		CHEMBL1990885	<	Ki	nM	2511.89	CHEMBL3529	Homo sapiens	pKi		5.6
inactive	9507151	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1cc(OCc2ccc(Cl)c(Cl)c2)ccc1CN1CC(C(=O)O)C1		CHEMBL1990223	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507152	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Nc1c(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)ccc2nccnc12		CHEMBL2004438	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507153	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(C)(c1cc(Br)c(O)c(I)c1)c1cc(Br)c(O)c(I)c1		CHEMBL1964382	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507154	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CN(C)CC(O)COc1ccc(Nc2nccc(Nc3cc(Cl)ccc3Cl)n2)cc1		CHEMBL101311	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507155	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507156	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	NC(=O)c1ccc2nc(-c3ccc([N+](=O)[O-])o3)cn2c1		CHEMBL1973359	=	Ki	nM	125.89	CHEMBL3529	Homo sapiens	pKi		6.9
active	9507157	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1cc(=O)n2ccc(CN(C)C)c(O)c2n1		CHEMBL1988581	=	Ki	nM	50.12	CHEMBL3529	Homo sapiens	pKi		7.3
inactive	9507158	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2ccc(OCC(=O)O)cc2)n1		CHEMBL2005699	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507159	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCN(C(C)=O)c1ccc(Nc2nc(NC3CC3)c3nc[nH]c3n2)cc1		CHEMBL2006564	=	Ki	nM	158.49	CHEMBL3529	Homo sapiens	pKi		6.8
active	9507160	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	=	Ki	nM	794.33	CHEMBL3529	Homo sapiens	pKi		6.1
active	9507161	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1979690	=	Ki	nM	630.96	CHEMBL3529	Homo sapiens	pKi		6.2
inactive	9507162	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC1CCN(C(=O)CC#N)CC1N(C)c1ncnc2[nH]ccc12		CHEMBL234085	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507163	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCCCCCCCCN)cnc(N)c34)cc2)c1		CHEMBL1978166	=	Ki	nM	398.11	CHEMBL3529	Homo sapiens	pKi		6.4
inactive	9507164	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2ccccc21		CHEMBL1978167	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507165	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C(O)C1		CHEMBL422897	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507166	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Ki	nM	794.33	CHEMBL3529	Homo sapiens	pKi		6.1
inactive	9507167	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C1NCCc2[nH]c(-c3ccncc3)cc21		CHEMBL225519	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507168	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Nc1ncnc2c1c(-c1ccc(Oc3ccc(CO)cc3)cc1)cn2C1CCOC1		CHEMBL1976376	=	Ki	nM	2511.89	CHEMBL3529	Homo sapiens	pKi		5.6
active	9507169	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(NN=Cc1cc(Br)c(O)c(Br)c1)Nc1ccccc1		CHEMBL1983575	=	Ki	nM	501.19	CHEMBL3529	Homo sapiens	pKi		6.3
inactive	9507170	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	N#Cc1cccc(NC(=O)Nc2ccnc3cc(C(F)(F)F)ccc23)n1		CHEMBL1968868	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507171	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1[nH]c(C=C2C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL2007064	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507172	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COC(C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL1981047	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507173	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCCC(=O)Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1998470	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507174	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(Nc1ccc([N+](=O)[O-])cc1)N1CCc2[nH]c3c(Cl)cc(Cl)cc3c2C1		CHEMBL1976196	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507175	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1ccccc1CNC(=N)Nc1nccc(-c2cccs2)n1		CHEMBL1997197	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507176	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1ccccc1-c1ccnc(Nc2cccc(S(C)(=O)=O)c2)n1		CHEMBL1975903	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507177	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C1Cc2cc(-c3ccccc3)cnc2N1		CHEMBL1983630	=	Ki	nM	100000.0	CHEMBL3529	Homo sapiens	pKi		4.0
active	9507178	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	=	Ki	nM	316.23	CHEMBL3529	Homo sapiens	pKi		6.5
inactive	9507179	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	N#Cc1ccc2nc(N)n(-c3nccs3)c2c1		CHEMBL1988805	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507180	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	<	Ki	nM	1995.26	CHEMBL3529	Homo sapiens	pKi		5.7
inactive	9507181	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(Nc1ccc(-c2ccc3cn[nH]c3c2)cc1)Nc1cccc(F)c1		CHEMBL1969942	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507182	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1		CHEMBL1982660	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507183	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1cccc(C(C)NC(=O)c2sc(-c3ccncc3)nc2C)c1		CHEMBL1978567	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507184	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C1Nc2ccccc2C1=Cc1ccc[nH]1		CHEMBL1996176	=	Ki	nM	1584.89	CHEMBL3529	Homo sapiens	pKi		5.8
active	9507185	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Nc1cc(=O)[nH]n1-c1ccccn1		CHEMBL1995765	=	Ki	nM	15848.93	CHEMBL3529	Homo sapiens	pKi		4.8
inactive	9507186	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCCNC(=O)c1ccc(Nc2nc(CCC(F)(F)F)c3cc[nH]c3n2)cc1		CHEMBL1984760	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507187	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Clc1cc(NC2CCCCC2)nc(-c2c[nH]c3ncccc23)n1		CHEMBL1997846	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507188	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1C#N		CHEMBL424872	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507189	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507190	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CN(C)CC1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL360847	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507191	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cc(F)ccc1F		CHEMBL1995811	=	Ki	nM	1258.93	CHEMBL3529	Homo sapiens	pKi		5.9
active	9507192	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1		CHEMBL49120	=	Ki	nM	2511.89	CHEMBL3529	Homo sapiens	pKi		5.6
active	9507193	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	=	Ki	nM	39.81	CHEMBL3529	Homo sapiens	pKi		7.4
active	9507194	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCC(=O)Nc1ccc(C(=O)N2CCNCC2)c(O)c1		CHEMBL1988141	=	Ki	nM	2511.89	CHEMBL3529	Homo sapiens	pKi		5.6
inactive	9507195	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1ccc(Nc2nc3ccc([N+](=O)[O-])cc3[nH]2)nc1		CHEMBL1992937	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507196	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Nc1c(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)cnc2c(-c3ccc4c(c3)OCO4)cnn12		CHEMBL1977134	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507197	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COCC#Cc1cccc2c1Cc1c(-c3cccs3)n[nH]c1-2		CHEMBL1985206	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507198	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507199	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1ccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1OC		CHEMBL1991078	=	Ki	nM	199.53	CHEMBL3529	Homo sapiens	pKi		6.7
active	9507200	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	C=CCc1cccc2c(=NO)cc(-c3ccccc3)oc12		CHEMBL1977749	=	Ki	nM	794.33	CHEMBL3529	Homo sapiens	pKi		6.1
active	9507201	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1cccc(NC(=O)Nc2ccc(-c3nn(C)c4ncnc(N)c34)cc2)c1		CHEMBL1982837	=	Ki	nM	501.19	CHEMBL3529	Homo sapiens	pKi		6.3
active	9507202	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Nc1ncnc2scc(-c3ccccc3)c12		CHEMBL1975212	=	Ki	nM	63095.73	CHEMBL3529	Homo sapiens	pKi		4.2
active	9507203	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=c1[nH][nH]c2ccc(Br)cc12		CHEMBL2001613	=	Ki	nM	7943.28	CHEMBL3529	Homo sapiens	pKi		5.1
inactive	9507204	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507205	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(C=Cc3ccccc3)n2)n[nH]1		CHEMBL1983923	=	Ki	nM	630.96	CHEMBL3529	Homo sapiens	pKi		6.2
inactive	9507206	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507207	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507208	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	NC(=O)c1cc2c(-c3ccc(Nc4nc5ccccc5o4)cc3)cnc(N)c2s1		CHEMBL1993904	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507209	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1ccc2[nH]cc(C=C3C(=O)Nc4ccccc43)c2c1		CHEMBL1997275	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507210	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2ccc(Cl)cc12		CHEMBL1967513	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507211	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1cc(O)nc2[nH]nc(-c3cccc(-c4ccc(C#N)cc4)c3)c12		CHEMBL2000724	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507212	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1		CHEMBL1982660	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507213	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507214	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CN(Cc1cc(Cl)c(O)c2ncccc12)C1CCCCC1		CHEMBL1982413	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507215	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1cc(=O)[nH]c2[nH]n(-c3ccccc3)c(=O)c12		CHEMBL1985042	=	Ki	nM	50118.72	CHEMBL3529	Homo sapiens	pKi		4.3
inactive	9507216	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(NCCc1cccs1)N1CC=C(c2c[nH]c3ncccc23)CC1		CHEMBL1987535	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507217	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(Nc1cccc(F)c1)Nc1cccc(-c2ccc3cn[nH]c3c2)c1		CHEMBL1983393	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507218	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(F)c(F)cc12		CHEMBL1981792	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507219	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Nc1noc2c(CN3CCOCC3)ccc(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL1985006	=	Ki	nM	1000.0	CHEMBL3529	Homo sapiens	pKi		6.0
inactive	9507220	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Clc1cc(Nc2nc(NC3CC3)c3sccc3n2)ccc1N1CCOCC1		CHEMBL2002586	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507221	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCCC3CCO)nc12		CHEMBL2006674	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507222	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(Nc1cnccn1)Nc1cccc2c(O)cccc12		CHEMBL1992371	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507223	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	NC(COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1981133	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507224	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CN(C)c1ccc(Nc2cc(-c3csc(Br)c3)[nH]n2)cc1		CHEMBL1984236	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507225	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(C)Oc1cc(Nc2nc(NC(C)c3ccc(F)cn3)ncc2Cl)n[nH]1		CHEMBL2007421	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507226	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc(Nc2ccc(C(=O)N3CCOCC3)cn2)c(=O)n(C)c1		CHEMBL1973138	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507227	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(Nc1cnccn1)Nc1ccnc2ccc(N3CC4COCC4C3)cc12		CHEMBL2002599	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507228	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9507229	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CN(C)C1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1969151	=	Ki	nM	2511.89	CHEMBL3529	Homo sapiens	pKi		5.6
active	9507230	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1n[nH]c2ccc(-c3cccnc3)cc12		CHEMBL1967252	=	Ki	nM	19952.62	CHEMBL3529	Homo sapiens	pKi		4.7
inactive	9507231	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2cc(F)ccc21		CHEMBL1993335	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507232	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Nc1nc(Cl)cc(-c2c[nH]c3ncccc23)n1		CHEMBL2007574	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507233	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(C)NC1=NNC(=O)C1=Cc1cc2ccccc2[nH]1		CHEMBL1988692	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507234	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCN(CCN)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL2004637	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507235	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(C)C(C)Nc1ncc(Cl)c(Nc2nccs2)n1		CHEMBL1993374	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9507236	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(C)N(CCCN)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1994318	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9511155	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2cccc(OCC(=O)NCCO)c2)n1		CHEMBL1998680	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9511156	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	NCCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL592030	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9511157	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCCCCC(=O)O)c2)n1		CHEMBL1999506	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9511158	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1970317	=	Ki	nM	1000.0	CHEMBL3529	Homo sapiens	pKi		6.0
inactive	9511159	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(N)C1CCC(C(=O)Nc2ccncc2)CC1		CHEMBL1994526	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9511160	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Nc1ncnc2c1N=C(c1ccc(NC(=O)Nc3ccc(F)c(C(F)(F)F)c3)cc1)CCN2		CHEMBL429516	=	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9511161	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCCNC(=O)c1ccc(Nc2nc(CC)c3cc[nH]c3n2)cc1		CHEMBL1997007	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9511162	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCOC(=O)c1c(C)n(-c2ccc(I)cc2)c2c1cc(O)c1ccccc12		CHEMBL1970352	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9511163	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL1964444	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9511164	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(Nc1nc2c(O)cccc2s1)Nc1ccccc1-c1ccccc1		CHEMBL2002690	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9511165	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CN(C)c1ccc(-c2cc(-c3ccc([N+](=O)[O-])cc3)nc(NS(=O)(=O)c3ccc(N)cc3)n2)cc1		CHEMBL1980167	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9511166	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCOc1nc(C(=O)NCc2ccccc2S(N)(=O)=O)cc(N)c1C#N		CHEMBL377408	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9511167	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9511168	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9511169	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3cc[nH]c3n2)cc1		CHEMBL2006765	=	Ki	nM	794.33	CHEMBL3529	Homo sapiens	pKi		6.1
inactive	9511170	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C1Nc2ccccc2C1=Cc1c[nH]c2ccccc12		CHEMBL1986590	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9511171	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCC(N)C3)c21		CHEMBL1870106	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9511172	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc21		CHEMBL406845	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9511173	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	NCc1cc(Nc2ncnc(-c3ccccc3)n2)ccc1O		CHEMBL1980246	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9511174	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(O)C1CN(Cc2ccc(OCc3cccc(C(F)(F)F)c3)cc2F)C1		CHEMBL1998478	=	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9511175	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(Nc1nc2ccccc2s1)c1cccc2c1CN(c1nc(C(=O)O)c(-c3ccc(CO)cc3)s1)CC2		CHEMBL1983980	=	Ki	nM	2511.89	CHEMBL3529	Homo sapiens	pKi		5.6
active	9511176	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1980297	=	Ki	nM	25.12	CHEMBL3529	Homo sapiens	pKi		7.6
active	9511177	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)s1		CHEMBL1999484	=	Ki	nM	251.19	CHEMBL3529	Homo sapiens	pKi		6.6
active	9511178	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1ccc(C)c(NC(=O)c2cc(-c3ccco3)nc3ccccc23)c1		CHEMBL1984296	=	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9511179	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1ccc(NCc2ccc(-c3ccc(F)cc3)nc2)cc1		CHEMBL1986899	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9511180	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1cc(-c2ccc3c(c2)NC(=O)c2ccc(-c4ccccc4NS(C)(=O)=O)cc2N3)cc(OC)c1OC		CHEMBL1984038	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9511181	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC1=CN2CC(=O)NN=C2C=C1		CHEMBL1964718	=	Ki	nM	100000.0	CHEMBL3529	Homo sapiens	pKi		4.0
active	9511182	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1Cl		CHEMBL1993661	=	Ki	nM	125.89	CHEMBL3529	Homo sapiens	pKi		6.9
inactive	9511183	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCC4)ccc3n2)c1		CHEMBL1968705	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9511184	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1)c1c(F)cccc1F		CHEMBL1991410	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9511185	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CNCC#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL1964441	=	Ki	nM	794.33	CHEMBL3529	Homo sapiens	pKi		6.1
inactive	9511186	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2		CHEMBL1980391	<	Ki	nM	2511.89	CHEMBL3529	Homo sapiens	pKi		5.6
inactive	9511187	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	ON=C(c1nc2ccccc2[nH]1)c1nc2ccccc2[nH]1		CHEMBL546797	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569147	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCCOCCO)c2)n1		CHEMBL1978271	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569148	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3ccc(OCCCn4cccc4)c4[nH]nc(N)c34)cc2)c1		CHEMBL2007266	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569149	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1		CHEMBL202721	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569150	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(=O)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL2000568	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569151	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(CCC(=O)Nc1cc(C(F)(F)F)ccc1Cl)NN=Cc1c[nH]c2ccccc12		CHEMBL1994308	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569152	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569153	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569154	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569155	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCN1CCN(c2ccc(Nc3ncc(C#N)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1973516	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569156	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1cccc(Nc2nc(NC3CCCCC3N)cnc2C(N)=O)c1		CHEMBL1974328	<	Ki	nM	1995.26	CHEMBL3529	Homo sapiens	pKi		5.7
active	9569157	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Ki	nM	1000.0	CHEMBL3529	Homo sapiens	pKi		6.0
active	9569158	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	NC(COc1cncc(-c2ccc3c(c2)C(=Cc2ccc[nH]2)C(=O)N3)c1)Cc1ccccc1		CHEMBL1980407	=	Ki	nM	19.95	CHEMBL3529	Homo sapiens	pKi		7.7
inactive	9569159	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CN(C)CCCN(C)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1964948	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569160	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1cnc(Nc2nc(NC(C)C)ncc2Br)s1		CHEMBL1973013	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569161	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569162	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCCc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL1987430	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569163	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1)c1ccccc1		CHEMBL1993413	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569164	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	NC(Cc1c[nH]c2ccccc12)C(=O)Nc1cncc(C=Cc2ccncc2)c1		CHEMBL1983945	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9569165	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1ccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)cc1		CHEMBL1975927	=	Ki	nM	199.53	CHEMBL3529	Homo sapiens	pKi		6.7
active	9569166	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	=	Ki	nM	794.33	CHEMBL3529	Homo sapiens	pKi		6.1
active	9569167	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(Nc1cncc(-n2cnc3ccc(C#N)cc32)n1)c1ccccc1F		CHEMBL1977138	=	Ki	nM	1000.0	CHEMBL3529	Homo sapiens	pKi		6.0
inactive	9569168	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CS(=O)(=O)N(Cc1ccc2[nH]c(=O)c3cccn3c2c1)C1CC1		CHEMBL1978448	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569169	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C1Nc2cc(-c3ccc(O)cc3)ccc2C1=Cc1ccc[nH]1		CHEMBL1980329	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9569170	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	c1nc(-c2ccc3c(c2)OCO3)c2cc[nH]c2n1		CHEMBL2004515	=	Ki	nM	7943.28	CHEMBL3529	Homo sapiens	pKi		5.1
inactive	9569171	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(Nc1cccc(C2Nc3ccc4ccccc4c3C3C=CCC32)c1)c1ccc(F)cc1		CHEMBL1992042	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569172	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(O)C1CN(Cc2ccc(OCc3cccc(C(F)(F)F)c3)cc2Cl)C1		CHEMBL1986265	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9569173	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CN1c2ccc(N)cc2C(c2ccccc2)c2cc(N)ccc21		CHEMBL1991734	=	Ki	nM	1995.26	CHEMBL3529	Homo sapiens	pKi		5.7
active	9569174	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Ki	nM	100.0	CHEMBL3529	Homo sapiens	pKi		7.0
inactive	9569175	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)s2)c1		CHEMBL1994724	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9569176	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1cc(-c2csc3c(C=CC(=O)NCCN(C)C)cnc(N)c23)ccc1NC(=O)c1cc2ccccc2n1C		CHEMBL1989267	=	Ki	nM	630.96	CHEMBL3529	Homo sapiens	pKi		6.2
inactive	9569177	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569178	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C1NCc2c1cccc2-c1cccs1		CHEMBL1991782	<	Ki	nM	63095.73	CHEMBL3529	Homo sapiens	pKi		4.2
active	9569179	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Nc1n[nH]c2ncc(Br)cc12		CHEMBL2002105	=	Ki	nM	79432.82	CHEMBL3529	Homo sapiens	pKi		4.1
inactive	9569180	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9569181	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCCCN(CCC#N)C(=O)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1983348	=	Ki	nM	630.96	CHEMBL3529	Homo sapiens	pKi		6.2
inactive	9569182	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCN(CC)CCNC(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1970290	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9569183	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1		CHEMBL1976040	=	Ki	nM	1584.89	CHEMBL3529	Homo sapiens	pKi		5.8
inactive	9569184	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569185	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	C#Cc1cn(C2CCCC2)c2ncnc(N)c12		CHEMBL1993877	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569186	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL2000934	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569187	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1996500	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569188	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(Nc1cccc(Cl)c1)Nc1nc(CCNc2ncnc3ccsc23)cs1		CHEMBL1986177	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9569189	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1		CHEMBL1989708	=	Ki	nM	25.12	CHEMBL3529	Homo sapiens	pKi		7.6
inactive	9569190	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCc1c(-c2ccc(C(C)(C)O)cc2)[nH]c2nccnc12		CHEMBL1976420	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569191	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CN(C)c1ccc(N)c2ccccc12		CHEMBL1998253	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569192	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(Cl)ccc12		CHEMBL1981744	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569193	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1ccnc(Nc2cc(C)nc(-c3ccccc3)n2)c1		CHEMBL1985367	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569194	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21		CHEMBL1879463	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569195	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1nc(N2CCNCC2)nc2ccccc12		CHEMBL1996510	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9569196	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cc1ccccc1-c1c(-c2ccc3[nH]nc(N)c3c2)nnn1Cc1ccccc1		CHEMBL2000029	=	Ki	nM	251.19	CHEMBL3529	Homo sapiens	pKi		6.6
inactive	9569197	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Brc1ccc2c(c1)-c1[nH]ncc1C2		CHEMBL1995172	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569198	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cn1cc(-c2cccc(NC(=O)c3ccc(C(C)(C)C)cc3)c2CO)cc(Nc2ccc(C(=O)N3CCOCC3)cn2)c1=O		CHEMBL2001584	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569199	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	COc1cc(N2CCN(C)CC2)ccc1C(=O)Nc1n[nH]c2ccc(Cc3cc(F)cc(F)c3)cc12		CHEMBL1973961	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
active	9569200	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CCN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1967998	=	Ki	nM	1000.0	CHEMBL3529	Homo sapiens	pKi		6.0
inactive	9569201	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2cc(C#N)ccc21		CHEMBL1978562	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
inactive	9569202	CHEMBL1964108	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: IKBKE	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCCCCO)c2)n1		CHEMBL1994977	<	Ki	nM	3162.28	CHEMBL3529	Homo sapiens	pKi		5.5
	10831191	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831192	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	21.0	CHEMBL3529	Homo sapiens	Inhibition	%	21.0
	10831193	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831194	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831195	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	27.0	CHEMBL3529	Homo sapiens	Inhibition	%	27.0
	10831196	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	29.0	CHEMBL3529	Homo sapiens	Inhibition	%	29.0
	10831197	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831198	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	16.0	CHEMBL3529	Homo sapiens	Inhibition	%	16.0
	10831199	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831200	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	92.0	CHEMBL3529	Homo sapiens	Inhibition	%	92.0
	10831201	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831202	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	-4.0	CHEMBL3529	Homo sapiens	Inhibition	%	-4.0
	10831203	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831204	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831205	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831206	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831207	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831208	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831209	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831210	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	5.0	CHEMBL3529	Homo sapiens	Inhibition	%	5.0
	10831211	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831212	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	23.0	CHEMBL3529	Homo sapiens	Inhibition	%	23.0
	10831213	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831214	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	13.0	CHEMBL3529	Homo sapiens	Inhibition	%	13.0
	10831215	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831216	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831217	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	91.0	CHEMBL3529	Homo sapiens	Inhibition	%	91.0
	10831218	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831219	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831220	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831221	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831222	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831223	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831224	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	35.0	CHEMBL3529	Homo sapiens	Inhibition	%	35.0
	10831225	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	7.0	CHEMBL3529	Homo sapiens	Inhibition	%	7.0
	10831226	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831227	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831228	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831229	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831230	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831231	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	17.0	CHEMBL3529	Homo sapiens	Inhibition	%	17.0
	10831232	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831233	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831234	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	19.0	CHEMBL3529	Homo sapiens	Inhibition	%	19.0
	10831235	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831236	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831237	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831238	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831239	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	9.0	CHEMBL3529	Homo sapiens	Inhibition	%	9.0
	10831240	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831241	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831242	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831243	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831244	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831245	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831246	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831247	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831248	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831249	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831250	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	4.0	CHEMBL3529	Homo sapiens	Inhibition	%	4.0
	10831251	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831252	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831253	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	65.0	CHEMBL3529	Homo sapiens	Inhibition	%	65.0
	10831254	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	26.0	CHEMBL3529	Homo sapiens	Inhibition	%	26.0
	10831255	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831256	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	22.0	CHEMBL3529	Homo sapiens	Inhibition	%	22.0
	10831257	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831258	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831259	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	-4.0	CHEMBL3529	Homo sapiens	Inhibition	%	-4.0
	10831260	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831261	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831262	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831263	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831264	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	37.0	CHEMBL3529	Homo sapiens	Inhibition	%	37.0
	10831265	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831266	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831267	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831268	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831269	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831270	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831271	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	16.0	CHEMBL3529	Homo sapiens	Inhibition	%	16.0
	10831272	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831273	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831274	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831275	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	6.0	CHEMBL3529	Homo sapiens	Inhibition	%	6.0
	10831276	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831277	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	59.0	CHEMBL3529	Homo sapiens	Inhibition	%	59.0
	10831278	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831279	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831280	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	-5.0	CHEMBL3529	Homo sapiens	Inhibition	%	-5.0
	10831281	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831282	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	9.0	CHEMBL3529	Homo sapiens	Inhibition	%	9.0
	10831283	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831284	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	90.0	CHEMBL3529	Homo sapiens	Inhibition	%	90.0
	10831285	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	5.0	CHEMBL3529	Homo sapiens	Inhibition	%	5.0
	10831286	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831287	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	17.0	CHEMBL3529	Homo sapiens	Inhibition	%	17.0
	10831288	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	22.0	CHEMBL3529	Homo sapiens	Inhibition	%	22.0
	10831289	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831290	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	13.0	CHEMBL3529	Homo sapiens	Inhibition	%	13.0
	10831291	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	15.0	CHEMBL3529	Homo sapiens	Inhibition	%	15.0
	10831292	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831293	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	18.0	CHEMBL3529	Homo sapiens	Inhibition	%	18.0
	10831294	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831295	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831296	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831297	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831298	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	44.0	CHEMBL3529	Homo sapiens	Inhibition	%	44.0
	10831299	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	25.0	CHEMBL3529	Homo sapiens	Inhibition	%	25.0
	10831300	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831301	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831302	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831303	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831304	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	35.0	CHEMBL3529	Homo sapiens	Inhibition	%	35.0
	10831305	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	11.0	CHEMBL3529	Homo sapiens	Inhibition	%	11.0
	10831306	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831307	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	-8.0	CHEMBL3529	Homo sapiens	Inhibition	%	-8.0
	10831308	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	4.0	CHEMBL3529	Homo sapiens	Inhibition	%	4.0
	10831309	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	9.0	CHEMBL3529	Homo sapiens	Inhibition	%	9.0
	10831310	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	5.0	CHEMBL3529	Homo sapiens	Inhibition	%	5.0
	10831311	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	27.0	CHEMBL3529	Homo sapiens	Inhibition	%	27.0
	10831312	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831313	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	23.0	CHEMBL3529	Homo sapiens	Inhibition	%	23.0
	10831314	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831315	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831316	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831317	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	39.0	CHEMBL3529	Homo sapiens	Inhibition	%	39.0
	10831318	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831319	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831320	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	8.0	CHEMBL3529	Homo sapiens	Inhibition	%	8.0
	10831321	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831322	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	10.0	CHEMBL3529	Homo sapiens	Inhibition	%	10.0
	10831323	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	14.0	CHEMBL3529	Homo sapiens	Inhibition	%	14.0
	10831324	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831325	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831326	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831327	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	11.0	CHEMBL3529	Homo sapiens	Inhibition	%	11.0
	10831328	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831329	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831330	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831331	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	10.0	CHEMBL3529	Homo sapiens	Inhibition	%	10.0
	10831332	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831333	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	41.0	CHEMBL3529	Homo sapiens	Inhibition	%	41.0
	10831334	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831335	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831336	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	8.0	CHEMBL3529	Homo sapiens	Inhibition	%	8.0
	10831337	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831338	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	25.0	CHEMBL3529	Homo sapiens	Inhibition	%	25.0
	10831339	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831340	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	13.0	CHEMBL3529	Homo sapiens	Inhibition	%	13.0
	10831341	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	51.0	CHEMBL3529	Homo sapiens	Inhibition	%	51.0
	10831342	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831343	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831344	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	-9.0	CHEMBL3529	Homo sapiens	Inhibition	%	-9.0
	10831345	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831346	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831347	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	21.0	CHEMBL3529	Homo sapiens	Inhibition	%	21.0
	10831348	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831349	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831350	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831351	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	-7.0	CHEMBL3529	Homo sapiens	Inhibition	%	-7.0
	10831352	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	13.0	CHEMBL3529	Homo sapiens	Inhibition	%	13.0
	10831353	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831354	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831355	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831356	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831357	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831358	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831359	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831360	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	6.0	CHEMBL3529	Homo sapiens	Inhibition	%	6.0
	10831361	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831362	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831363	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831364	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831365	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	-4.0	CHEMBL3529	Homo sapiens	Inhibition	%	-4.0
	10831366	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831367	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831368	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831369	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831370	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	5.0	CHEMBL3529	Homo sapiens	Inhibition	%	5.0
	10831371	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831372	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831373	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	15.0	CHEMBL3529	Homo sapiens	Inhibition	%	15.0
	10831374	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831375	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831376	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831377	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	6.0	CHEMBL3529	Homo sapiens	Inhibition	%	6.0
	10831378	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831379	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831380	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831381	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831382	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	18.0	CHEMBL3529	Homo sapiens	Inhibition	%	18.0
	10831383	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831384	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831385	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831386	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831387	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831388	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	4.0	CHEMBL3529	Homo sapiens	Inhibition	%	4.0
	10831389	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	77.0	CHEMBL3529	Homo sapiens	Inhibition	%	77.0
	10831390	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831391	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	-4.0	CHEMBL3529	Homo sapiens	Inhibition	%	-4.0
	10831392	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	11.0	CHEMBL3529	Homo sapiens	Inhibition	%	11.0
	10831393	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831394	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831395	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	5.0	CHEMBL3529	Homo sapiens	Inhibition	%	5.0
	10831396	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	8.0	CHEMBL3529	Homo sapiens	Inhibition	%	8.0
	10831397	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831398	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831399	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831400	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831401	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	39.0	CHEMBL3529	Homo sapiens	Inhibition	%	39.0
	10831402	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831403	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	13.0	CHEMBL3529	Homo sapiens	Inhibition	%	13.0
	10831404	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	6.0	CHEMBL3529	Homo sapiens	Inhibition	%	6.0
	10831405	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831406	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831407	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831408	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831409	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831410	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831411	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831412	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831413	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831414	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831415	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831416	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831417	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831418	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831419	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	76.0	CHEMBL3529	Homo sapiens	Inhibition	%	76.0
	10831420	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831421	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	-4.0	CHEMBL3529	Homo sapiens	Inhibition	%	-4.0
	10831422	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	12.0	CHEMBL3529	Homo sapiens	Inhibition	%	12.0
	10831423	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831424	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831425	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831426	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831427	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	4.0	CHEMBL3529	Homo sapiens	Inhibition	%	4.0
	10831428	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831429	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831430	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831431	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831432	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	13.0	CHEMBL3529	Homo sapiens	Inhibition	%	13.0
	10831433	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	10.0	CHEMBL3529	Homo sapiens	Inhibition	%	10.0
	10831434	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831435	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	6.0	CHEMBL3529	Homo sapiens	Inhibition	%	6.0
	10831436	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831437	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	5.0	CHEMBL3529	Homo sapiens	Inhibition	%	5.0
	10831438	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831439	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831440	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	8.0	CHEMBL3529	Homo sapiens	Inhibition	%	8.0
	10831441	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	13.0	CHEMBL3529	Homo sapiens	Inhibition	%	13.0
	10831442	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831443	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831444	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831445	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831446	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	5.0	CHEMBL3529	Homo sapiens	Inhibition	%	5.0
	10831447	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	39.0	CHEMBL3529	Homo sapiens	Inhibition	%	39.0
	10831448	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	8.0	CHEMBL3529	Homo sapiens	Inhibition	%	8.0
	10831449	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	17.0	CHEMBL3529	Homo sapiens	Inhibition	%	17.0
	10831450	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831451	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	-4.0	CHEMBL3529	Homo sapiens	Inhibition	%	-4.0
	10831452	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	36.0	CHEMBL3529	Homo sapiens	Inhibition	%	36.0
	10831453	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831454	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831455	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831456	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831457	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831458	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	27.0	CHEMBL3529	Homo sapiens	Inhibition	%	27.0
	10831459	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831460	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831461	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831462	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831463	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	15.0	CHEMBL3529	Homo sapiens	Inhibition	%	15.0
	10831464	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831465	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831466	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831467	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831468	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831469	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831470	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	4.0	CHEMBL3529	Homo sapiens	Inhibition	%	4.0
	10831471	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831472	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831473	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831474	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	32.0	CHEMBL3529	Homo sapiens	Inhibition	%	32.0
	10831475	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831476	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831477	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	99.0	CHEMBL3529	Homo sapiens	Inhibition	%	99.0
	10831478	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831479	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831480	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	95.0	CHEMBL3529	Homo sapiens	Inhibition	%	95.0
	10831481	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831482	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831483	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	96.0	CHEMBL3529	Homo sapiens	Inhibition	%	96.0
	10831484	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	6.0	CHEMBL3529	Homo sapiens	Inhibition	%	6.0
	10831485	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831486	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831487	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	38.0	CHEMBL3529	Homo sapiens	Inhibition	%	38.0
	10831488	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	4.0	CHEMBL3529	Homo sapiens	Inhibition	%	4.0
	10831489	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831490	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831491	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831492	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831493	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	4.0	CHEMBL3529	Homo sapiens	Inhibition	%	4.0
	10831494	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	7.0	CHEMBL3529	Homo sapiens	Inhibition	%	7.0
	10831495	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831496	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	-6.0	CHEMBL3529	Homo sapiens	Inhibition	%	-6.0
	10831497	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831498	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831499	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	10.0	CHEMBL3529	Homo sapiens	Inhibition	%	10.0
	10831500	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	5.0	CHEMBL3529	Homo sapiens	Inhibition	%	5.0
	10831501	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831502	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831503	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	7.0	CHEMBL3529	Homo sapiens	Inhibition	%	7.0
	10831504	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831505	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	13.0	CHEMBL3529	Homo sapiens	Inhibition	%	13.0
	10831506	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	8.0	CHEMBL3529	Homo sapiens	Inhibition	%	8.0
	10831507	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831508	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831509	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	-4.0	CHEMBL3529	Homo sapiens	Inhibition	%	-4.0
	10831510	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831511	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831512	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831513	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	9.0	CHEMBL3529	Homo sapiens	Inhibition	%	9.0
	10831514	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	4.0	CHEMBL3529	Homo sapiens	Inhibition	%	4.0
	10831515	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	10.0	CHEMBL3529	Homo sapiens	Inhibition	%	10.0
	10831516	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831517	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831518	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831519	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	88.0	CHEMBL3529	Homo sapiens	Inhibition	%	88.0
	10831520	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831521	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831522	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831523	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831524	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	5.0	CHEMBL3529	Homo sapiens	Inhibition	%	5.0
	10831525	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831526	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831527	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	21.0	CHEMBL3529	Homo sapiens	Inhibition	%	21.0
	10831528	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831529	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831530	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831531	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	10.0	CHEMBL3529	Homo sapiens	Inhibition	%	10.0
	10831532	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	6.0	CHEMBL3529	Homo sapiens	Inhibition	%	6.0
	10831533	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	13.0	CHEMBL3529	Homo sapiens	Inhibition	%	13.0
	10831534	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831535	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831536	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	-4.0	CHEMBL3529	Homo sapiens	Inhibition	%	-4.0
	10831537	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831538	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831539	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	29.0	CHEMBL3529	Homo sapiens	Inhibition	%	29.0
	10831540	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831541	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831542	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831543	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831544	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	20.0	CHEMBL3529	Homo sapiens	Inhibition	%	20.0
	10831545	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	-4.0	CHEMBL3529	Homo sapiens	Inhibition	%	-4.0
	10831546	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	7.0	CHEMBL3529	Homo sapiens	Inhibition	%	7.0
	10831547	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	35.0	CHEMBL3529	Homo sapiens	Inhibition	%	35.0
	10831548	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	8.0	CHEMBL3529	Homo sapiens	Inhibition	%	8.0
	10831549	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	22.0	CHEMBL3529	Homo sapiens	Inhibition	%	22.0
	10831550	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831551	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831552	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	11.0	CHEMBL3529	Homo sapiens	Inhibition	%	11.0
	10831553	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831554	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	33.0	CHEMBL3529	Homo sapiens	Inhibition	%	33.0
	10831555	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831556	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	45.0	CHEMBL3529	Homo sapiens	Inhibition	%	45.0
	10831557	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	9.0	CHEMBL3529	Homo sapiens	Inhibition	%	9.0
	10831558	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	39.0	CHEMBL3529	Homo sapiens	Inhibition	%	39.0
	10831559	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831560	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831561	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	31.0	CHEMBL3529	Homo sapiens	Inhibition	%	31.0
	10831562	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831563	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831564	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	37.0	CHEMBL3529	Homo sapiens	Inhibition	%	37.0
	10831565	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831566	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	17.0	CHEMBL3529	Homo sapiens	Inhibition	%	17.0
	10831567	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831568	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831569	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	26.0	CHEMBL3529	Homo sapiens	Inhibition	%	26.0
	10831570	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	85.0	CHEMBL3529	Homo sapiens	Inhibition	%	85.0
	10831571	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831572	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831573	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	55.0	CHEMBL3529	Homo sapiens	Inhibition	%	55.0
	10831574	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831575	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	11.0	CHEMBL3529	Homo sapiens	Inhibition	%	11.0
	10831576	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	52.0	CHEMBL3529	Homo sapiens	Inhibition	%	52.0
	10831577	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	54.0	CHEMBL3529	Homo sapiens	Inhibition	%	54.0
	10831578	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	18.0	CHEMBL3529	Homo sapiens	Inhibition	%	18.0
	10831579	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831580	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831581	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	7.0	CHEMBL3529	Homo sapiens	Inhibition	%	7.0
	10831582	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	54.0	CHEMBL3529	Homo sapiens	Inhibition	%	54.0
	10831583	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831584	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	4.0	CHEMBL3529	Homo sapiens	Inhibition	%	4.0
	10831585	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831586	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	21.0	CHEMBL3529	Homo sapiens	Inhibition	%	21.0
	10831587	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	5.0	CHEMBL3529	Homo sapiens	Inhibition	%	5.0
	10831588	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	44.0	CHEMBL3529	Homo sapiens	Inhibition	%	44.0
	10831589	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831590	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	5.0	CHEMBL3529	Homo sapiens	Inhibition	%	5.0
	10831591	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831592	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831593	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	-4.0	CHEMBL3529	Homo sapiens	Inhibition	%	-4.0
	10831594	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831595	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831596	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	7.0	CHEMBL3529	Homo sapiens	Inhibition	%	7.0
	10831597	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831598	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831599	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	12.0	CHEMBL3529	Homo sapiens	Inhibition	%	12.0
	10831600	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831601	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	97.0	CHEMBL3529	Homo sapiens	Inhibition	%	97.0
	10831602	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	5.0	CHEMBL3529	Homo sapiens	Inhibition	%	5.0
	10831603	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	51.0	CHEMBL3529	Homo sapiens	Inhibition	%	51.0
	10831604	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	12.0	CHEMBL3529	Homo sapiens	Inhibition	%	12.0
	10831605	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831606	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831607	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831608	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	4.0	CHEMBL3529	Homo sapiens	Inhibition	%	4.0
	10831609	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831610	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831611	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831612	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831613	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	19.0	CHEMBL3529	Homo sapiens	Inhibition	%	19.0
	10831614	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831615	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831616	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831617	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831618	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831619	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831620	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	44.0	CHEMBL3529	Homo sapiens	Inhibition	%	44.0
	10831621	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	31.0	CHEMBL3529	Homo sapiens	Inhibition	%	31.0
	10831622	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831623	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831624	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	10.0	CHEMBL3529	Homo sapiens	Inhibition	%	10.0
	10831625	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	98.0	CHEMBL3529	Homo sapiens	Inhibition	%	98.0
	10831626	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831627	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	-4.0	CHEMBL3529	Homo sapiens	Inhibition	%	-4.0
	10831628	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	96.0	CHEMBL3529	Homo sapiens	Inhibition	%	96.0
	10831629	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831630	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831631	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	43.0	CHEMBL3529	Homo sapiens	Inhibition	%	43.0
	10831632	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	91.0	CHEMBL3529	Homo sapiens	Inhibition	%	91.0
	10831633	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831634	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831635	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831636	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831637	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	88.0	CHEMBL3529	Homo sapiens	Inhibition	%	88.0
	10831638	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831639	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831640	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831641	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831642	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831643	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	8.0	CHEMBL3529	Homo sapiens	Inhibition	%	8.0
	10831644	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831645	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	-4.0	CHEMBL3529	Homo sapiens	Inhibition	%	-4.0
	10831646	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831647	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831648	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	8.0	CHEMBL3529	Homo sapiens	Inhibition	%	8.0
	10831649	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	18.0	CHEMBL3529	Homo sapiens	Inhibition	%	18.0
	10831650	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831651	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	4.0	CHEMBL3529	Homo sapiens	Inhibition	%	4.0
	10831652	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831653	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	6.0	CHEMBL3529	Homo sapiens	Inhibition	%	6.0
	10831654	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831655	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831656	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831657	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831658	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	33.0	CHEMBL3529	Homo sapiens	Inhibition	%	33.0
	10831659	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831660	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831661	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831662	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	9.0	CHEMBL3529	Homo sapiens	Inhibition	%	9.0
	10831663	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831664	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831665	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831666	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831667	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831668	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	11.0	CHEMBL3529	Homo sapiens	Inhibition	%	11.0
	10831669	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831670	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	-4.0	CHEMBL3529	Homo sapiens	Inhibition	%	-4.0
	10831671	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831672	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831673	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831674	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831675	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	33.0	CHEMBL3529	Homo sapiens	Inhibition	%	33.0
	10831676	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831677	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831678	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831679	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831680	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831681	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	4.0	CHEMBL3529	Homo sapiens	Inhibition	%	4.0
	10831682	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831683	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831684	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831685	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	37.0	CHEMBL3529	Homo sapiens	Inhibition	%	37.0
	10831686	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831687	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831688	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831689	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831690	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831691	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	11.0	CHEMBL3529	Homo sapiens	Inhibition	%	11.0
	10831692	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831693	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	7.0	CHEMBL3529	Homo sapiens	Inhibition	%	7.0
	10831694	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831695	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831696	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831697	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831698	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831699	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831700	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	20.0	CHEMBL3529	Homo sapiens	Inhibition	%	20.0
	10831701	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	94.0	CHEMBL3529	Homo sapiens	Inhibition	%	94.0
	10831702	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831703	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	40.0	CHEMBL3529	Homo sapiens	Inhibition	%	40.0
	10831704	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	-4.0	CHEMBL3529	Homo sapiens	Inhibition	%	-4.0
	10831705	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831706	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	18.0	CHEMBL3529	Homo sapiens	Inhibition	%	18.0
	10831707	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	4.0	CHEMBL3529	Homo sapiens	Inhibition	%	4.0
	10831708	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	5.0	CHEMBL3529	Homo sapiens	Inhibition	%	5.0
	10831709	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831710	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	46.0	CHEMBL3529	Homo sapiens	Inhibition	%	46.0
	10831711	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	4.0	CHEMBL3529	Homo sapiens	Inhibition	%	4.0
	10831712	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	20.0	CHEMBL3529	Homo sapiens	Inhibition	%	20.0
	10831713	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831714	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831715	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831716	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831717	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	24.0	CHEMBL3529	Homo sapiens	Inhibition	%	24.0
	10831718	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831719	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831720	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	5.0	CHEMBL3529	Homo sapiens	Inhibition	%	5.0
	10831721	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831722	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831723	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831724	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	-5.0	CHEMBL3529	Homo sapiens	Inhibition	%	-5.0
	10831725	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831726	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831727	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	4.0	CHEMBL3529	Homo sapiens	Inhibition	%	4.0
	10831728	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831729	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	-6.0	CHEMBL3529	Homo sapiens	Inhibition	%	-6.0
	10831730	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	6.0	CHEMBL3529	Homo sapiens	Inhibition	%	6.0
	10831731	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831732	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	14.0	CHEMBL3529	Homo sapiens	Inhibition	%	14.0
	10831733	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	4.0	CHEMBL3529	Homo sapiens	Inhibition	%	4.0
	10831734	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831735	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831736	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	36.0	CHEMBL3529	Homo sapiens	Inhibition	%	36.0
	10831737	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	6.0	CHEMBL3529	Homo sapiens	Inhibition	%	6.0
	10831738	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	6.0	CHEMBL3529	Homo sapiens	Inhibition	%	6.0
	10831739	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	15.0	CHEMBL3529	Homo sapiens	Inhibition	%	15.0
	10831740	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831741	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831742	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831743	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	12.0	CHEMBL3529	Homo sapiens	Inhibition	%	12.0
	10831744	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831745	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	41.0	CHEMBL3529	Homo sapiens	Inhibition	%	41.0
	10831746	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831747	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831748	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831749	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831750	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831751	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831752	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	53.0	CHEMBL3529	Homo sapiens	Inhibition	%	53.0
	10831753	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831754	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831755	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	45.0	CHEMBL3529	Homo sapiens	Inhibition	%	45.0
	10831756	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831757	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831758	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831759	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	42.0	CHEMBL3529	Homo sapiens	Inhibition	%	42.0
	10831760	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831761	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	26.0	CHEMBL3529	Homo sapiens	Inhibition	%	26.0
	10831762	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831763	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831764	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	4.0	CHEMBL3529	Homo sapiens	Inhibition	%	4.0
	10831765	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831766	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831767	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	4.0	CHEMBL3529	Homo sapiens	Inhibition	%	4.0
	10831768	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831769	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831770	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831771	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831772	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	6.0	CHEMBL3529	Homo sapiens	Inhibition	%	6.0
	10831773	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831774	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831775	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831776	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831777	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831778	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831779	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831780	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	19.0	CHEMBL3529	Homo sapiens	Inhibition	%	19.0
	10831781	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831782	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	6.0	CHEMBL3529	Homo sapiens	Inhibition	%	6.0
	10831783	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831784	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831785	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831786	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	52.0	CHEMBL3529	Homo sapiens	Inhibition	%	52.0
	10831787	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831788	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831789	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831790	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831791	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831792	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831793	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831794	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831795	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831796	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831797	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	46.0	CHEMBL3529	Homo sapiens	Inhibition	%	46.0
	10831798	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831799	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831800	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	20.0	CHEMBL3529	Homo sapiens	Inhibition	%	20.0
	10831801	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	Inhibition	%	3.0
	10831802	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	-4.0	CHEMBL3529	Homo sapiens	Inhibition	%	-4.0
	10831803	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831804	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831805	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831806	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	22.0	CHEMBL3529	Homo sapiens	Inhibition	%	22.0
	10831807	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831808	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	-4.0	CHEMBL3529	Homo sapiens	Inhibition	%	-4.0
	10831809	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831810	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	8.0	CHEMBL3529	Homo sapiens	Inhibition	%	8.0
	10831811	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831812	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	53.0	CHEMBL3529	Homo sapiens	Inhibition	%	53.0
	10831813	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831814	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831815	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	4.0	CHEMBL3529	Homo sapiens	Inhibition	%	4.0
	10831816	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	Inhibition	%	-1.0
	10831817	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	5.0	CHEMBL3529	Homo sapiens	Inhibition	%	5.0
	10831818	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	6.0	CHEMBL3529	Homo sapiens	Inhibition	%	6.0
	10831819	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	Inhibition	%	1.0
	10831820	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	11.0	CHEMBL3529	Homo sapiens	Inhibition	%	11.0
	10831821	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831822	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	-3.0	CHEMBL3529	Homo sapiens	Inhibition	%	-3.0
	10831823	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	-4.0	CHEMBL3529	Homo sapiens	Inhibition	%	-4.0
	10831824	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831825	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	Inhibition	%	2.0
	10831826	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831827	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	Inhibition	%	-2.0
	10831828	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	Inhibition	%	0.0
	10831829	CHEMBL2007664	GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	6.0	CHEMBL3529	Homo sapiens	Inhibition	%	6.0
	10834132	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(OCCN4CCCCC4)cc3)nc12		CHEMBL2011895	=	IC50	nM	707.0	CHEMBL3529	Homo sapiens	IC50	uM	0.707
Not Determined	10834133	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	Brc1cnc2[nH]c(-c3ccc(OCCN4CCCCC4)cc3)nc2c1NC1CCCC1		CHEMBL2011896		IC50			CHEMBL3529	Homo sapiens	IC50		
Not Determined	10834134	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CN(C)CCCNc1c(Br)cnc2[nH]c(-c3ccc(OCCN4CCCCC4)cc3)nc12		CHEMBL2011897		IC50			CHEMBL3529	Homo sapiens	IC50		
Not Determined	10834135	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CN(C)CCNc1c(Br)cnc2[nH]c(-c3ccc(OCCN4CCCCC4)cc3)nc12		CHEMBL2011898		IC50			CHEMBL3529	Homo sapiens	IC50		
	10834136	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	Brc1cnc2[nH]c(-c3ccc(OCCN4CCCCC4)cc3)nc2c1NCC1CCNCC1		CHEMBL2011899	=	IC50	nM	523.0	CHEMBL3529	Homo sapiens	IC50	uM	0.523
	10834137	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	Brc1cnc2[nH]c(-c3ccc(OCCN4CCCCC4)cc3)nc2c1NCCC1CCNCC1		CHEMBL2011900	=	IC50	nM	4320.0	CHEMBL3529	Homo sapiens	IC50	uM	4.32
Not Determined	10834138	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CNc1c(C#N)cnc2[nH]c(-c3ccc(OCCN4CCCCC4)cc3)nc12		CHEMBL2011901		IC50			CHEMBL3529	Homo sapiens	IC50		
Not Determined	10834139	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	Clc1c(Br)cnc2[nH]c(-c3ccc(OCCN4CCCCC4)cc3)nc12		CHEMBL2011902		IC50			CHEMBL3529	Homo sapiens	IC50		
Not Determined	10834140	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(OC)cc3)nc12		CHEMBL2011903		IC50			CHEMBL3529	Homo sapiens	IC50		
Not Determined	10834141	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CCOc1ccc(-c2nc3c(NC)c(Br)cnc3[nH]2)cc1		CHEMBL2011904		IC50			CHEMBL3529	Homo sapiens	IC50		
Not Determined	10834142	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(OC(C)C)cc3)nc12		CHEMBL2011905		IC50			CHEMBL3529	Homo sapiens	IC50		
Not Determined	10834143	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(O)cc3)nc12		CHEMBL2011906		IC50			CHEMBL3529	Homo sapiens	IC50		
	10834144	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(C(=O)O)cc3)nc12		CHEMBL2011907	=	IC50	nM	590.0	CHEMBL3529	Homo sapiens	IC50	uM	0.59
Not Determined	10834145	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(S(C)(=O)=O)cc3)nc12		CHEMBL2011908		IC50			CHEMBL3529	Homo sapiens	IC50		
	10834146	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3cccc(S(C)(=O)=O)c3)nc12		CHEMBL2011909	>	IC50	nM	30000.0	CHEMBL3529	Homo sapiens	IC50	uM	30.0
	10834147	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3cccc(N)c3)nc12		CHEMBL2011910	=	IC50	nM	93.0	CHEMBL3529	Homo sapiens	IC50	uM	0.093
	10834148	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(N)cc3)nc12		CHEMBL2011911	=	IC50	nM	425.0	CHEMBL3529	Homo sapiens	IC50	uM	0.425
	10834149	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccnc(N)c3)nc12		CHEMBL2011912	=	IC50	nM	120.0	CHEMBL3529	Homo sapiens	IC50	uM	0.12
Not Determined	10834150	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(OC)c(OC)c3)nc12		CHEMBL2011913		IC50			CHEMBL3529	Homo sapiens	IC50		
	10834151	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(N4CCCC4)cc3)nc12		CHEMBL2011914	=	IC50	nM	5960.0	CHEMBL3529	Homo sapiens	IC50	uM	5.96
Not Determined	10834152	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(N4CCOCC4)cc3)nc12		CHEMBL2011915		IC50			CHEMBL3529	Homo sapiens	IC50		
Not Determined	10834153	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(OCCCN4CCOCC4)cc3)nc12		CHEMBL2011916		IC50			CHEMBL3529	Homo sapiens	IC50		
Not Determined	10834154	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(OCCN4CCOCC4)cc3)nc12		CHEMBL2011917		IC50			CHEMBL3529	Homo sapiens	IC50		
Not Determined	10834155	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(OCCN4CCN(C)CC4)cc3)nc12		CHEMBL2011918		IC50			CHEMBL3529	Homo sapiens	IC50		
	10834156	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(C(=O)NCCN4CCN(C)CC4)cc3)nc12		CHEMBL2011919	=	IC50	nM	627.0	CHEMBL3529	Homo sapiens	IC50	uM	0.627
	10834157	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3cnn(C4CCN(C)CC4)c3)nc12		CHEMBL2011920	=	IC50	nM	510.0	CHEMBL3529	Homo sapiens	IC50	uM	0.51
Not Determined	10834158	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc4[nH]ncc4c3)nc12		CHEMBL2011921		IC50			CHEMBL3529	Homo sapiens	IC50		
	10834159	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3cnn(C)c3)nc12		CHEMBL2011922	=	IC50	nM	2460.0	CHEMBL3529	Homo sapiens	IC50	uM	2.46
Not Determined	10834160	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CNc1c(C(N)=O)cnc2[nH]c(-c3ccc(OCCN4CCOCC4)cc3)nc12		CHEMBL2011923		IC50			CHEMBL3529	Homo sapiens	IC50		
	10834161	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CNc1c(Cl)cnc2[nH]c(-c3ccc(OCCN4CCOCC4)cc3)nc12		CHEMBL2011924	=	IC50	nM	16100.0	CHEMBL3529	Homo sapiens	IC50	uM	16.1
Not Determined	10834162	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CNc1ccnc2[nH]c(-c3ccc(OCCN4CCOCC4)cc3)nc12		CHEMBL2011925		IC50			CHEMBL3529	Homo sapiens	IC50		
	10834163	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCC4CCNCC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011926	=	IC50	nM	265.0	CHEMBL3529	Homo sapiens	IC50	uM	0.265
	10834164	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(OCC4CCNCC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011927	=	IC50	nM	172.0	CHEMBL3529	Homo sapiens	IC50	uM	0.172
	10834165	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(C)=O)c(Br)cnc3[nH]2)cc1		CHEMBL2011928	=	IC50	nM	543.0	CHEMBL3529	Homo sapiens	IC50	uM	0.543
	10834166	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C(C)C)c(Br)cnc3[nH]2)cc1		CHEMBL2011929	=	IC50	nM	84.0	CHEMBL3529	Homo sapiens	IC50	uM	0.084
	10834167	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C(C)(C)C)c(Br)cnc3[nH]2)cc1		CHEMBL2011930	=	IC50	nM	60.0	CHEMBL3529	Homo sapiens	IC50	uM	0.06
	10834168	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011931	=	IC50	nM	115.0	CHEMBL3529	Homo sapiens	IC50	uM	0.115
	10834169	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4(CN)CC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011932	=	IC50	nM	5.0	CHEMBL3529	Homo sapiens	IC50	uM	0.005
	10834170	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011933	=	IC50	nM	21.0	CHEMBL3529	Homo sapiens	IC50	uM	0.021
	10834171	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCN(C)C(=O)C4CCC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011934	=	IC50	nM	20.0	CHEMBL3529	Homo sapiens	IC50	uM	0.02
	10834172	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CC(O)C4)c(Br)cnc3[nH]2)cc1		CHEMBL2011935	=	IC50	nM	46.0	CHEMBL3529	Homo sapiens	IC50	uM	0.046
	10834173	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011936	=	IC50	nM	76.0	CHEMBL3529	Homo sapiens	IC50	uM	0.076
	10834174	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)c4ccccc4)c(Br)cnc3[nH]2)cc1		CHEMBL2011937	=	IC50	nM	14900.0	CHEMBL3529	Homo sapiens	IC50	uM	14.9
	10834175	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)c4cccnc4)c(Br)cnc3[nH]2)cc1		CHEMBL2011938	=	IC50	nM	278.0	CHEMBL3529	Homo sapiens	IC50	uM	0.278
	10834176	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)c4cccs4)c(Br)cnc3[nH]2)cc1		CHEMBL2011939	=	IC50	nM	541.0	CHEMBL3529	Homo sapiens	IC50	uM	0.541
	10834177	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	Nc1cccc(-c2nc3c(NCCCNC(=O)C4CCC4)c(Br)cnc3[nH]2)c1		CHEMBL2011940	=	IC50	nM	4.0	CHEMBL3529	Homo sapiens	IC50	uM	0.004
	10834178	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	O=C(NCCCNc1c(Br)cnc2[nH]c(-c3ccc(OCCN4CCCCC4)cc3)nc12)C1CCC1		CHEMBL2011941	=	IC50	nM	17.0	CHEMBL3529	Homo sapiens	IC50	uM	0.017
	10834179	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	NC(=O)c1cnc2[nH]c(-c3ccc(OCCN4CCCCC4)cc3)nc2c1NCCCNC(=O)C1CCC1		CHEMBL2011942	=	IC50	nM	9.0	CHEMBL3529	Homo sapiens	IC50	uM	0.009
	10834180	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(C(N)=O)cnc3[nH]2)cc1		CHEMBL2011943	=	IC50	nM	46.0	CHEMBL3529	Homo sapiens	IC50	uM	0.046
	10834181	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccccc1-c1nc2c(NCC(O)CNC(=O)C3CCC3)c(Br)cnc2[nH]1		CHEMBL2011944	=	IC50	nM	102.0	CHEMBL3529	Homo sapiens	IC50	uM	0.102
	10834182	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(F)cc1-c1nc2c(NCCCNC(=O)C3CCC3)c(Br)cnc2[nH]1		CHEMBL2011945	=	IC50	nM	122.0	CHEMBL3529	Homo sapiens	IC50	uM	0.122
	10834183	CHEMBL2013354	Inhibition of Ikkepsilon using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1cc(F)ccc1-c1nc2c(NCCCNC(=O)C3CCC3)c(Br)cnc2[nH]1		CHEMBL2010815	=	IC50	nM	204.0	CHEMBL3529	Homo sapiens	IC50	uM	0.204
	10838710	CHEMBL2014936	Inhibition of IKKe at 10 uM	B	COc1ccc2c3ccnc(C(F)(F)F)c3n(CCCCN)c2c1		CHEMBL2012574	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	INH	%	0.0
	10839662	CHEMBL2016270	Inhibition of IKKepsilon assessed as residual activity at 1 uM relative to control	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Activity	%	89.0	CHEMBL3529	Homo sapiens	Activity	%	89.0
	10840388	CHEMBL2015138	Inhibition of IKKepsilon assessed as residual activity at 10 uM relative to control	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Activity	%	86.0	CHEMBL3529	Homo sapiens	Activity	%	86.0
	12046332	CHEMBL2156662	Inhibition of IKKepsilon at 1 uM	B	CC(C)(O)C1CCN(Cc2ccc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3n2)CC1		CHEMBL2152768	=	Inhibition	%	1.1	CHEMBL3529	Homo sapiens	INH	%	1.1
	12116237	CHEMBL2172941	Inhibition of IKBKE	B	Cn1cc(-c2ccc3c(c2)CCN3C(=O)Cc2cccc(C(F)(F)F)c2)c2c(N)ncnc21		CHEMBL2171124	=	IC50	nM	1064.0	CHEMBL3529	Homo sapiens	IC50	nM	1064.0
	12170800	CHEMBL2209926	Inhibition of IKKe assessed as residual activity at 1 uM	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	106.0	CHEMBL3529	Homo sapiens	Activity	%	106.0
	12172101	CHEMBL2213927	Inhibition of IKKe assessed as residual activity at 10 uM	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	102.0	CHEMBL3529	Homo sapiens	Activity	%	102.0
	12173577	CHEMBL2211075	Inhibition of IKK-epsilon assessed as residual activity at 10 uM relative to control	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	100.0	CHEMBL3529	Homo sapiens	Activity	%	100.0
	12183879	CHEMBL2211508	Inhibition of IKBKE	B	CC(C)(C)NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1		CHEMBL2205766	<	IC50	nM	10000.0	CHEMBL3529	Homo sapiens	pIC50		5.0
	12190838	CHEMBL2212356	Inhibition of IKKepsilon	B	Cn1cc(Nc2ncc(C3CC3)c(NCCCNC(=O)C3CCC3)n2)cn1		CHEMBL2207208	=	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	uM	0.1
	12190839	CHEMBL2212356	Inhibition of IKKepsilon	B	O=C(NCCCNc1nc(Nc2ccc(N3CCOCC3)cc2)ncc1C1CC1)C1CCC1		CHEMBL2207198	=	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	uM	0.03
	12626728	CHEMBL2317000	Inhibition of IKKepsilon (unknown origin) at 1 uM	B	COc1cc(Nc2cc(-c3cccc(C#N)c3)ccn2)ccc1N1CCN(C)CC1		CHEMBL2312142	>=	Inhibition	%	80.0	CHEMBL3529	Homo sapiens	INH	%	80.0
	12626729	CHEMBL2317000	Inhibition of IKKepsilon (unknown origin) at 1 uM	B	COc1cc(Nc2ncc(Cl)c(-c3cccc(CC#N)c3)n2)ccc1N1CCN(C)CC1		CHEMBL2312140	>	Inhibition	%	95.0	CHEMBL3529	Homo sapiens	INH	%	95.0
	12628457	CHEMBL2321408	Inhibition of IKK-epsilon (unknown origin) at 10 uM	B	N#Cc1c(N)nc2sc(C(=O)c3cccc(Cl)c3)c(N)c2c1-c1ccccc1Cl		CHEMBL2313853	>	Inhibition	%	50.0	CHEMBL3529	Homo sapiens	INH	%	50.0
	12629521	CHEMBL2319128	Inhibition of IKKi (unknown origin)	B	O=C(NCCCN1CCOC1=O)c1cnc(NCc2cc(Cl)ccc2Cl)nc1NC1CCCC1		CHEMBL2312304	>	IC50	nM	30000.0	CHEMBL3529	Homo sapiens	IC50	uM	30.0
	12629522	CHEMBL2319128	Inhibition of IKKi (unknown origin)	B	O=C(NCCCN1CCCC1=O)c1cnc(NCc2cc(Cl)ccc2Cl)nc1NC1CCCC1		CHEMBL2312303	>	IC50	nM	30000.0	CHEMBL3529	Homo sapiens	IC50	uM	30.0
	12629523	CHEMBL2319128	Inhibition of IKKi (unknown origin)	B	COc1ccccc1CNc1ncc(C(=O)NCCCN2CCCC2=O)c(NC2CCCC2)n1		CHEMBL2312301	>	IC50	nM	30000.0	CHEMBL3529	Homo sapiens	IC50	uM	30.0
	12629524	CHEMBL2319128	Inhibition of IKKi (unknown origin)	B	COc1ccc(CCNc2ncc(C(=O)NCCCN3CCCC3=O)c(NC3CCCC3)n2)cc1OC		CHEMBL2312290	>	IC50	nM	30000.0	CHEMBL3529	Homo sapiens	IC50	uM	30.0
	12631677	CHEMBL2317771	Inhibition of IKKi (unknown origin) in presence of ATP	B	Cc1cc(-c2cnc(Nc3cc(Cl)cc(Cl)c3)nc2NC2CCC(N(C)C)CC2)on1		CHEMBL2312654	=	IC50	nM	30000.0	CHEMBL3529	Homo sapiens	IC50	uM	30.0
	12631678	CHEMBL2317771	Inhibition of IKKi (unknown origin) in presence of ATP	B	CN1CCC(NC(=O)c2cnc(Nc3cc(Cl)cc(Cl)c3)nc2N[C@@H]2COC[C@H]2O)CC1		CHEMBL2312652	=	IC50	nM	30000.0	CHEMBL3529	Homo sapiens	IC50	uM	30.0
	12631679	CHEMBL2317771	Inhibition of IKKi (unknown origin) in presence of ATP	B	CN1CCC(NC(=O)c2cnc(Nc3cc(Cl)cc(Cl)c3)nc2NC2CCC(N(C)C)CC2)CC1		CHEMBL2312649	=	IC50	nM	30000.0	CHEMBL3529	Homo sapiens	IC50	uM	30.0
	12631680	CHEMBL2317771	Inhibition of IKKi (unknown origin) in presence of ATP	B	CN1CCC(NC(=O)c2cnc(NCc3cc(Cl)ccc3Cl)nc2NC2CCCC2)CC1		CHEMBL2312646	=	IC50	nM	30000.0	CHEMBL3529	Homo sapiens	IC50	uM	30.0
	12631681	CHEMBL2317771	Inhibition of IKKi (unknown origin) in presence of ATP	B	COc1ccccc1CNc1ncc(C(=O)NC2CCN(C)CC2)c(NC2CCCC2)n1		CHEMBL2312645	=	IC50	nM	30000.0	CHEMBL3529	Homo sapiens	IC50	uM	30.0
	12673021	CHEMBL2339737	Inhibition of recombinant IKKepsilon (unknown origin) assessed as residual activity using [gamma-33P]ATP as substrate at 1 uM	B	CC[C@@H](CO)Nc1nc(NC(=N)N)c2ncn(C(C)C)c2n1		CHEMBL2336379	=	Activity	%	52.0	CHEMBL3529	Homo sapiens	Activity	%	52.0
	12673022	CHEMBL2339737	Inhibition of recombinant IKKepsilon (unknown origin) assessed as residual activity using [gamma-33P]ATP as substrate at 1 uM	B	CC[C@H](CO)Nc1nc(NC(=N)N)c2ncn(C(C)C)c2n1		CHEMBL2336377	=	Activity	%	66.0	CHEMBL3529	Homo sapiens	Activity	%	66.0
	12700127	CHEMBL2344139	Inhibition of recombinant IKBKE (unknown origin) at 5 uM by FRET-based Z'-LYTE assay	B	O=C1/C(=C/c2ccccn2)CNC/C1=C\c1ccccn1		CHEMBL574646	=	Inhibition	%	15.0	CHEMBL3529	Homo sapiens	INH	%	15.0
	12727617	CHEMBL2352553	Inhibition of IKBKE (unknown origin) assessed as remaining activity at 10 uM relative to control	B	O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CCC1CCOCC1		CHEMBL2348865	=	Activity	%	89.0	CHEMBL3529	Homo sapiens	Activity	%	89.0
	12729052	CHEMBL2351958	Inhibition of IKKepsilon (unknown origin) assessed as remaining activity at 1 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	103.0	CHEMBL3529	Homo sapiens	Activity	%	103.0
	12730195	CHEMBL2352880	Inhibition of IKKepsilon (unknown origin) assessed as remaining activity at 10 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	101.0	CHEMBL3529	Homo sapiens	Activity	%	101.0
	13327666	CHEMBL2389828	Inhibition of IKBKE (unknown origin) at 1 uM	B	CC(C)(C)c1cc(NC(=O)NCc2ccc(-c3cc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)[nH]n3)cc2)no1		CHEMBL2386802	=	Inhibition	%	-5.0	CHEMBL3529	Homo sapiens	INH	%	-5.0
	13327667	CHEMBL2389828	Inhibition of IKBKE (unknown origin) at 1 uM	B	Cc1cc(-c2cc(NC(=O)c3ccc(CN4CCN(C)CC4)cc3)[nH]n2)ccc1NC(=O)Nc1cc(C(C)(C)C)on1		CHEMBL2386796	=	Inhibition	%	12.0	CHEMBL3529	Homo sapiens	INH	%	12.0
	13375839	CHEMBL2404352	Inhibition of IKKepsilon (unknown origin) at 10 uM relative to control	B	CC[C@@H]1C(=O)N(C)c2cnc(-n3ccnc3-c3ccc(F)cc3)nc2N1c1ccn(C)n1		CHEMBL2402081	=	Inhibition	%	2.0	CHEMBL3529	Homo sapiens	INH	%	2.0
	13439837	CHEMBL2426982	Competitive binding affinity to IKKepsilon (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ccc4ccccc43)n2)CC1		CHEMBL2425646	<	Inhibition	%	50.0	CHEMBL3529	Homo sapiens	INH	%	50.0
	13445670	CHEMBL2426982	Competitive binding affinity to IKKepsilon (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ncc4ccccc43)n2)CC1		CHEMBL2425645	<	Inhibition	%	50.0	CHEMBL3529	Homo sapiens	INH	%	50.0
	13451657	CHEMBL2426982	Competitive binding affinity to IKKepsilon (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1		CHEMBL2425654	<	Inhibition	%	50.0	CHEMBL3529	Homo sapiens	INH	%	50.0
	13464332	CHEMBL2433465	Inhibition of human IKKepsilon assessed as residual activity at 1 uM relative to control	B	CCCC(=O)Nc1n[nH]c2ncc(-c3cccnc3)cc12		CHEMBL407002	=	Activity	%	113.0	CHEMBL3529	Homo sapiens	Activity	%	113.0
	13465277	CHEMBL2434023	Inhibition of human IKKepsilon assessed as residual activity at 10 uM relative to control	B	CCCC(=O)Nc1n[nH]c2ncc(-c3cccnc3)cc12		CHEMBL407002	=	Activity	%	89.0	CHEMBL3529	Homo sapiens	Activity	%	89.0
	13465355	CHEMBL2433465	Inhibition of human IKKepsilon assessed as residual activity at 1 uM relative to control	B	CC(=O)Nc1nccc(-c2c(-c3ccccc3)noc2C)n1		CHEMBL2430324	=	Activity	%	85.11	CHEMBL3529	Homo sapiens	Activity	%	85.11
	13465386	CHEMBL2434023	Inhibition of human IKKepsilon assessed as residual activity at 10 uM relative to control	B	CC(=O)Nc1nccc(-c2c(-c3ccccc3)noc2C)n1		CHEMBL2430324	=	Activity	%	82.42	CHEMBL3529	Homo sapiens	Activity	%	82.42
	13465417	CHEMBL2433465	Inhibition of human IKKepsilon assessed as residual activity at 1 uM relative to control	B	CC(=O)Nc1cccc(-c2cnc3[nH]nc(C)c3c2)c1		CHEMBL2430323	=	Activity	%	93.82	CHEMBL3529	Homo sapiens	Activity	%	93.82
	13465448	CHEMBL2434023	Inhibition of human IKKepsilon assessed as residual activity at 10 uM relative to control	B	CC(=O)Nc1cccc(-c2cnc3[nH]nc(C)c3c2)c1		CHEMBL2430323	=	Activity	%	51.98	CHEMBL3529	Homo sapiens	Activity	%	51.98
Not Active	13508493	CHEMBL2447366	Inhibition of IKKepsilon (unknown origin) at 30 uM	B	O=C(Nc1ccc2c(c1)B(O)OC2)c1c(C(F)(F)F)ccc(Cl)c1F		CHEMBL2441375		Inhibition	%		CHEMBL3529	Homo sapiens	INH		
	13911791	CHEMBL3118441	Inhibition of recombinant IKKepsilon (unknown origin) using ulight-rpS6 as substrate at 20 uM after 1 hr by LANCE ultra TR-FRET assay relative to control	B	COCCOCOc1ccc(-c2ncc(-c3ccc(C(=O)O)cc3)nc2OC)cc1C12CC3CC(CC(C3)C1)C2		CHEMBL3114305	=	Inhibition	%	18.8	CHEMBL3529	Homo sapiens	INH	%	18.8
	13911792	CHEMBL3118441	Inhibition of recombinant IKKepsilon (unknown origin) using ulight-rpS6 as substrate at 20 uM after 1 hr by LANCE ultra TR-FRET assay relative to control	B	COc1nc(-c2ccc(C(=O)O)cc2)cnc1-c1ccc(O)c(C23CC4CC(CC(C4)C2)C3)c1		CHEMBL3114304	=	Inhibition	%	26.1	CHEMBL3529	Homo sapiens	INH	%	26.1
	13911793	CHEMBL3118441	Inhibition of recombinant IKKepsilon (unknown origin) using ulight-rpS6 as substrate at 20 uM after 1 hr by LANCE ultra TR-FRET assay relative to control	B	COCCOCOc1cc(C)c(-c2ncc(/C=C/C(=O)O)nc2OC)cc1C12CC3CC(CC(C3)C1)C2		CHEMBL3114303	=	Inhibition	%	5.9	CHEMBL3529	Homo sapiens	INH	%	5.9
	13911794	CHEMBL3118441	Inhibition of recombinant IKKepsilon (unknown origin) using ulight-rpS6 as substrate at 20 uM after 1 hr by LANCE ultra TR-FRET assay relative to control	B	COCCOCOc1ccc(-c2ncc(/C=C/C(=O)O)nc2OC)cc1C12CC3CC(CC(C3)C1)C2		CHEMBL3114302	=	Inhibition	%	9.4	CHEMBL3529	Homo sapiens	INH	%	9.4
	13911795	CHEMBL3118441	Inhibition of recombinant IKKepsilon (unknown origin) using ulight-rpS6 as substrate at 20 uM after 1 hr by LANCE ultra TR-FRET assay relative to control	B	COc1nc(/C=C/C(=O)O)cnc1-c1cc(C23CC4CC(CC(C4)C2)C3)c(O)cc1C		CHEMBL3114301	=	Inhibition	%	6.7	CHEMBL3529	Homo sapiens	INH	%	6.7
	13911796	CHEMBL3118441	Inhibition of recombinant IKKepsilon (unknown origin) using ulight-rpS6 as substrate at 20 uM after 1 hr by LANCE ultra TR-FRET assay relative to control	B	COc1nc(/C=C/C(=O)O)cnc1-c1ccc(O)c(C23CC4CC(CC(C4)C2)C3)c1		CHEMBL3114300	=	Inhibition	%	7.8	CHEMBL3529	Homo sapiens	INH	%	7.8
	13911797	CHEMBL3118441	Inhibition of recombinant IKKepsilon (unknown origin) using ulight-rpS6 as substrate at 20 uM after 1 hr by LANCE ultra TR-FRET assay relative to control	B	COCCOCOc1cc(C)c(-c2ncc(-c3ccc(C(=O)O)cc3)s2)cc1C12CC3CC(CC(C3)C1)C2		CHEMBL3114299	=	Inhibition	%	17.0	CHEMBL3529	Homo sapiens	INH	%	17.0
	13911798	CHEMBL3118441	Inhibition of recombinant IKKepsilon (unknown origin) using ulight-rpS6 as substrate at 20 uM after 1 hr by LANCE ultra TR-FRET assay relative to control	B	COCCOCOc1ccc(-c2ncc(-c3ccc(C(=O)O)cc3)s2)cc1C12CC3CC(CC(C3)C1)C2		CHEMBL3114298	=	Inhibition	%	25.3	CHEMBL3529	Homo sapiens	INH	%	25.3
	13911799	CHEMBL3118441	Inhibition of recombinant IKKepsilon (unknown origin) using ulight-rpS6 as substrate at 20 uM after 1 hr by LANCE ultra TR-FRET assay relative to control	B	Cc1cc(O)c(C23CC4CC(CC(C4)C2)C3)cc1-c1ncc(-c2ccc(C(=O)O)cc2)s1		CHEMBL3114297	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	INH	%	0.0
	13911800	CHEMBL3118441	Inhibition of recombinant IKKepsilon (unknown origin) using ulight-rpS6 as substrate at 20 uM after 1 hr by LANCE ultra TR-FRET assay relative to control	B	O=C(O)c1ccc(-c2cnc(-c3ccc(O)c(C45CC6CC(CC(C6)C4)C5)c3)s2)cc1		CHEMBL3114296	=	Inhibition	%	11.6	CHEMBL3529	Homo sapiens	INH	%	11.6
	13911801	CHEMBL3118441	Inhibition of recombinant IKKepsilon (unknown origin) using ulight-rpS6 as substrate at 20 uM after 1 hr by LANCE ultra TR-FRET assay relative to control	B	COCCOCOc1cc(C)c(-c2ncc(/C=C/C(=O)O)s2)cc1C12CC3CC(CC(C3)C1)C2		CHEMBL3114295	=	Inhibition	%	11.1	CHEMBL3529	Homo sapiens	INH	%	11.1
	13911802	CHEMBL3118441	Inhibition of recombinant IKKepsilon (unknown origin) using ulight-rpS6 as substrate at 20 uM after 1 hr by LANCE ultra TR-FRET assay relative to control	B	COCCOCOc1ccc(-c2ncc(/C=C/C(=O)O)s2)cc1C12CC3CC(CC(C3)C1)C2		CHEMBL3114294	=	Inhibition	%	14.3	CHEMBL3529	Homo sapiens	INH	%	14.3
	13911803	CHEMBL3118441	Inhibition of recombinant IKKepsilon (unknown origin) using ulight-rpS6 as substrate at 20 uM after 1 hr by LANCE ultra TR-FRET assay relative to control	B	Cc1cc(O)c(C23CC4CC(CC(C4)C2)C3)cc1-c1ncc(/C=C/C(=O)O)s1		CHEMBL3114293	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	INH	%	0.0
	13911804	CHEMBL3118441	Inhibition of recombinant IKKepsilon (unknown origin) using ulight-rpS6 as substrate at 20 uM after 1 hr by LANCE ultra TR-FRET assay relative to control	B	O=C(O)/C=C/c1cnc(-c2ccc(O)c(C34CC5CC(CC(C5)C3)C4)c2)s1		CHEMBL3114292	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	INH	%	0.0
	13911805	CHEMBL3118441	Inhibition of recombinant IKKepsilon (unknown origin) using ulight-rpS6 as substrate at 20 uM after 1 hr by LANCE ultra TR-FRET assay relative to control	B	COCCOCOc1cc(C)c(-c2ccc(CC(=O)O)cc2Cl)cc1C12CC3CC(CC(C3)C1)C2		CHEMBL560351	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	INH	%	0.0
	13911806	CHEMBL3118441	Inhibition of recombinant IKKepsilon (unknown origin) using ulight-rpS6 as substrate at 20 uM after 1 hr by LANCE ultra TR-FRET assay relative to control	B	Cc1cc(O)c(C23CC4CC(CC(C4)C2)C3)cc1-c1ccc(CC(=O)O)cc1Cl		CHEMBL564037	=	Inhibition	%	8.5	CHEMBL3529	Homo sapiens	INH	%	8.5
	13911807	CHEMBL3118441	Inhibition of recombinant IKKepsilon (unknown origin) using ulight-rpS6 as substrate at 20 uM after 1 hr by LANCE ultra TR-FRET assay relative to control	B	CC(=O)NCCCOc1cc(/C=C/C(=O)O)ccc1-c1cc(C23CC4CC(CC(C4)C2)C3)c(O)cc1C		CHEMBL3114291	=	Inhibition	%	5.2	CHEMBL3529	Homo sapiens	INH	%	5.2
	13911808	CHEMBL3118441	Inhibition of recombinant IKKepsilon (unknown origin) using ulight-rpS6 as substrate at 20 uM after 1 hr by LANCE ultra TR-FRET assay relative to control	B	COCCOCOc1cc(C)c(-c2ccc(/C=C/C(=O)O)cc2Cl)cc1C12CC3CC(CC(C3)C1)C2		CHEMBL564563	=	Inhibition	%	2.9	CHEMBL3529	Homo sapiens	INH	%	2.9
	13911809	CHEMBL3118441	Inhibition of recombinant IKKepsilon (unknown origin) using ulight-rpS6 as substrate at 20 uM after 1 hr by LANCE ultra TR-FRET assay relative to control	B	Cc1cc(O)c(C23CC4CC(CC(C4)C2)C3)cc1-c1ccc(/C=C/C(=O)O)cc1Cl		CHEMBL554740	=	Inhibition	%	11.9	CHEMBL3529	Homo sapiens	INH	%	11.9
	13911810	CHEMBL3118441	Inhibition of recombinant IKKepsilon (unknown origin) using ulight-rpS6 as substrate at 20 uM after 1 hr by LANCE ultra TR-FRET assay relative to control	B	COCCOCOc1cc(C)c(-c2ccc3cc(C(=O)O)ccc3c2Cl)cc1C12CC3CC(CC(C3)C1)C2		CHEMBL563805	=	Inhibition	%	13.7	CHEMBL3529	Homo sapiens	INH	%	13.7
	13911811	CHEMBL3118441	Inhibition of recombinant IKKepsilon (unknown origin) using ulight-rpS6 as substrate at 20 uM after 1 hr by LANCE ultra TR-FRET assay relative to control	B	Cc1cc(O)c(C23CC4CC(CC(C4)C2)C3)cc1-c1ccc2cc(C(=O)O)ccc2c1Cl		CHEMBL565088	=	Inhibition	%	41.5	CHEMBL3529	Homo sapiens	INH	%	41.5
	13911812	CHEMBL3118441	Inhibition of recombinant IKKepsilon (unknown origin) using ulight-rpS6 as substrate at 20 uM after 1 hr by LANCE ultra TR-FRET assay relative to control	B	COCCOCOc1ccc(C(=O)/C=C/c2ccc(C(=O)O)cc2)cc1C12CC3CC(CC(C3)C1)C2		CHEMBL462134	=	Inhibition	%	15.8	CHEMBL3529	Homo sapiens	INH	%	15.8
	13911813	CHEMBL3118441	Inhibition of recombinant IKKepsilon (unknown origin) using ulight-rpS6 as substrate at 20 uM after 1 hr by LANCE ultra TR-FRET assay relative to control	B	CC(=O)NCCCOc1cc(/C=C/C(=O)O)ccc1-c1ccc(O)c(C23CC4CC(CC(C4)C2)C3)c1		CHEMBL331534	=	Inhibition	%	14.4	CHEMBL3529	Homo sapiens	INH	%	14.4
	13911814	CHEMBL3118441	Inhibition of recombinant IKKepsilon (unknown origin) using ulight-rpS6 as substrate at 20 uM after 1 hr by LANCE ultra TR-FRET assay relative to control	B	O=C(O)/C=C/c1ccc(-c2ccc(O)c(C34CC5CC(CC(C5)C3)C4)c2)c(Cl)c1		CHEMBL176252	=	Inhibition	%	24.1	CHEMBL3529	Homo sapiens	INH	%	24.1
	13953200	CHEMBL3132513	Inhibition of IKK-epsilon (unknown origin) using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(OCCCNC(=O)C4CCCC4)c(Br)cnc3[nH]2)cc1		CHEMBL3125725	>	IC50	nM	30000.0	CHEMBL3529	Homo sapiens	IC50	uM	30.0
	13953201	CHEMBL3132513	Inhibition of IKK-epsilon (unknown origin) using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3cc(-c4csc(C#N)c4)cnc3[nH]2)cc1		CHEMBL3125742	>	IC50	nM	30000.0	CHEMBL3529	Homo sapiens	IC50	uM	30.0
	13954584	CHEMBL3132513	Inhibition of IKK-epsilon (unknown origin) using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3cc(-c4cc(C(=O)O)co4)cnc3[nH]2)cc1		CHEMBL3125740	=	IC50	nM	11600.0	CHEMBL3529	Homo sapiens	IC50	uM	11.6
	13954592	CHEMBL3132513	Inhibition of IKK-epsilon (unknown origin) using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CNc1c(-c2ccc(C(=O)O)s2)cnc2[nH]c(-c3ccc(OC)cc3)nc12		CHEMBL3125737	=	IC50	nM	3300.0	CHEMBL3529	Homo sapiens	IC50	uM	3.3
	13954593	CHEMBL3132513	Inhibition of IKK-epsilon (unknown origin) using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(-c4nc(C(=O)NCC(C)C)cs4)cnc3[nH]2)cc1		CHEMBL3125720	=	IC50	nM	3230.0	CHEMBL3529	Homo sapiens	IC50	uM	3.23
	13954601	CHEMBL3132513	Inhibition of IKK-epsilon (unknown origin) using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCCC(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125728	=	IC50	nM	1750.0	CHEMBL3529	Homo sapiens	IC50	uM	1.75
	13954605	CHEMBL3132513	Inhibition of IKK-epsilon (unknown origin) using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(OCCCNC(=O)C4CCCC4)c(-c4csc(C(=O)O)c4)cnc3[nH]2)cc1		CHEMBL3125724	=	IC50	nM	1100.0	CHEMBL3529	Homo sapiens	IC50	uM	1.1
	13954614	CHEMBL3132513	Inhibition of IKK-epsilon (unknown origin) using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3cc(-c4ccc(C(=O)O)s4)cnc3[nH]2)cc1		CHEMBL3125738	=	IC50	nM	867.0	CHEMBL3529	Homo sapiens	IC50	uM	0.867
	13954618	CHEMBL3132513	Inhibition of IKK-epsilon (unknown origin) using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125726	=	IC50	nM	497.0	CHEMBL3529	Homo sapiens	IC50	uM	0.497
	13954620	CHEMBL3132513	Inhibition of IKK-epsilon (unknown origin) using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	IC50	nM	469.0	CHEMBL3529	Homo sapiens	IC50	uM	0.469
	13954624	CHEMBL3132513	Inhibition of IKK-epsilon (unknown origin) using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(C(N)=S)cnc3[nH]2)cc1		CHEMBL3125723	=	IC50	nM	448.0	CHEMBL3529	Homo sapiens	IC50	uM	0.448
	13954627	CHEMBL3132513	Inhibition of IKK-epsilon (unknown origin) using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3cc(-c4cc(C(=O)O)cs4)cnc3[nH]2)cc1		CHEMBL3125739	=	IC50	nM	395.0	CHEMBL3529	Homo sapiens	IC50	uM	0.395
	13954636	CHEMBL3132513	Inhibition of IKK-epsilon (unknown origin) using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3cc(-c4csc(C(N)=O)c4)cnc3[nH]2)cc1		CHEMBL3125732	=	IC50	nM	205.0	CHEMBL3529	Homo sapiens	IC50	uM	0.205
	13954641	CHEMBL3132513	Inhibition of IKK-epsilon (unknown origin) using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(-c4nc(C(=O)O)cs4)cnc3[nH]2)cc1		CHEMBL3125722	=	IC50	nM	158.0	CHEMBL3529	Homo sapiens	IC50	uM	0.158
	13954649	CHEMBL3132513	Inhibition of IKK-epsilon (unknown origin) using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)O)c4)cnc3[nH]2)cc1		CHEMBL3125741	=	IC50	nM	114.0	CHEMBL3529	Homo sapiens	IC50	uM	0.114
	13954657	CHEMBL3132513	Inhibition of IKK-epsilon (unknown origin) using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011936	=	IC50	nM	76.0	CHEMBL3529	Homo sapiens	IC50	uM	0.076
	13954663	CHEMBL3132513	Inhibition of IKK-epsilon (unknown origin) using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(-c4nc(C(N)=O)cs4)cnc3[nH]2)cc1		CHEMBL3125721	=	IC50	nM	42.0	CHEMBL3529	Homo sapiens	IC50	uM	0.042
	13954673	CHEMBL3132513	Inhibition of IKK-epsilon (unknown origin) using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011933	=	IC50	nM	21.0	CHEMBL3529	Homo sapiens	IC50	uM	0.021
	13954812	CHEMBL3132513	Inhibition of IKK-epsilon (unknown origin) using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3cc(-c4csc(C(C)=O)c4)cnc3[nH]2)cc1		CHEMBL3125734	=	IC50	nM	6750.0	CHEMBL3529	Homo sapiens	IC50	uM	6.75
	13954822	CHEMBL3132513	Inhibition of IKK-epsilon (unknown origin) using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CNC(=O)c1cc(-c2cnc3[nH]c(-c4ccc(OC)cc4)nc3c2)cs1		CHEMBL3125733	=	IC50	nM	2560.0	CHEMBL3529	Homo sapiens	IC50	uM	2.56
	13954827	CHEMBL3132513	Inhibition of IKK-epsilon (unknown origin) using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	CCC(C)CNC(=O)c1cc(-c2cnc3[nH]c(-c4ccc(OC)cc4)nc3c2)cs1		CHEMBL3125729	=	IC50	nM	1090.0	CHEMBL3529	Homo sapiens	IC50	uM	1.09
	13954829	CHEMBL3132513	Inhibition of IKK-epsilon (unknown origin) using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COCCNC(=O)c1cc(-c2cnc3[nH]c(-c4ccc(OC)cc4)nc3c2)cs1		CHEMBL3125731	=	IC50	nM	412.0	CHEMBL3529	Homo sapiens	IC50	uM	0.412
	13954832	CHEMBL3132513	Inhibition of IKK-epsilon (unknown origin) using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125727	=	IC50	nM	273.0	CHEMBL3529	Homo sapiens	IC50	uM	0.273
	13954833	CHEMBL3132513	Inhibition of IKK-epsilon (unknown origin) using 5FAM-AKELDQGSLCTpSFVGTLQ-NH2 as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)(C)CO)c4)cnc3[nH]2)cc1		CHEMBL3125730	=	IC50	nM	330.0	CHEMBL3529	Homo sapiens	IC50	uM	0.33
	14545794	CHEMBL3224464	Inhibition of IKKepsilon (unknown origin) assessed as residual activity at 1 uM	B	CS(=O)(=O)O.O=C(NCc1cccc(O)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218297	=	Activity	%	108.0	CHEMBL3529	Homo sapiens	Activity	%	108.0
	14545817	CHEMBL3224484	Inhibition of IKKepsilon (unknown origin)	B	CS(=O)(=O)O.O=C(NCc1cccc(O)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218297	<	IC50	nM	1.0	CHEMBL3529	Homo sapiens	IC50	nM	1.0
	15072424	CHEMBL3388069	Inhibition of IKKepsilon (unknown origin) assessed as remaining enzyme activity at 10 uM by radioactive [33P]-ATP filter binding assay	B	Cc1ccc(-c2cc(C(=O)Nc3ccnc(Cl)c3)nn2-c2ccc3ccccc3n2)cc1		CHEMBL3338802	=	Activity	%	112.0	CHEMBL3529	Homo sapiens	Activity	%	112.0
	15251871	CHEMBL3427937	Inhibition of IKKepsilon (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL443738	=	Activity	%	52.0	CHEMBL3529	Homo sapiens	Activity	%	52.0
	15251926	CHEMBL3427937	Inhibition of IKKepsilon (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL3427170	=	Activity	%	41.0	CHEMBL3529	Homo sapiens	Activity	%	41.0
	15252028	CHEMBL3427937	Inhibition of IKKepsilon (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL3427171	=	Activity	%	74.0	CHEMBL3529	Homo sapiens	Activity	%	74.0
	15252673	CHEMBL3427937	Inhibition of IKKepsilon (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL3427172	=	Activity	%	81.0	CHEMBL3529	Homo sapiens	Activity	%	81.0
	15252775	CHEMBL3427937	Inhibition of IKKepsilon (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@@H](C(=O)O)CS3)sc2c1		CHEMBL3427173	=	Activity	%	45.0	CHEMBL3529	Homo sapiens	Activity	%	45.0
	15252877	CHEMBL3427937	Inhibition of IKKepsilon (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@H](C(=O)O)CS3)sc2c1		CHEMBL3427174	=	Activity	%	58.0	CHEMBL3529	Homo sapiens	Activity	%	58.0
	15253551	CHEMBL3427937	Inhibition of IKKepsilon (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@H]1CSC(c2nc3ccc(OC)cc3s2)=N1		CHEMBL3427175	=	Activity	%	55.0	CHEMBL3529	Homo sapiens	Activity	%	55.0
	15253653	CHEMBL3427937	Inhibition of IKKepsilon (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@@H]1CSC(c2nc3ccc(OC)cc3s2)=N1		CHEMBL3427176	=	Activity	%	76.0	CHEMBL3529	Homo sapiens	Activity	%	76.0
	15253755	CHEMBL3427937	Inhibition of IKKepsilon (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@@H](C(=O)O)C(C)(C)S3)sc2c1		CHEMBL3427177	=	Activity	%	52.0	CHEMBL3529	Homo sapiens	Activity	%	52.0
	15254421	CHEMBL3427937	Inhibition of IKKepsilon (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@H](C(=O)O)C(C)(C)S3)sc2c1		CHEMBL3427178	=	Activity	%	65.0	CHEMBL3529	Homo sapiens	Activity	%	65.0
	15254523	CHEMBL3427937	Inhibition of IKKepsilon (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	CC1(C)SC(c2nc3ccc(O)cc3s2)=N[C@H]1C(=O)O		CHEMBL3427179	=	Activity	%	51.0	CHEMBL3529	Homo sapiens	Activity	%	51.0
	15254625	CHEMBL3427937	Inhibition of IKKepsilon (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	CC1(C)SC(c2nc3ccc(O)cc3s2)=N[C@@H]1C(=O)O		CHEMBL3427180	=	Activity	%	59.0	CHEMBL3529	Homo sapiens	Activity	%	59.0
	15255316	CHEMBL3427937	Inhibition of IKKepsilon (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@H]1CSC(c2ccc3cc(O)ccc3n2)=N1		CHEMBL3427181	=	Activity	%	38.0	CHEMBL3529	Homo sapiens	Activity	%	38.0
	15255418	CHEMBL3427937	Inhibition of IKKepsilon (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@@H]1CSC(c2ccc3cc(O)ccc3n2)=N1		CHEMBL3427182	=	Activity	%	70.0	CHEMBL3529	Homo sapiens	Activity	%	70.0
	15255521	CHEMBL3427937	Inhibition of IKKepsilon (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@H]1CSC(c2ccc3cccc(O)c3n2)=N1		CHEMBL3427183	=	Activity	%	88.0	CHEMBL3529	Homo sapiens	Activity	%	88.0
	15256252	CHEMBL3427937	Inhibition of IKKepsilon (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@@H]1CSC(c2ccc3cccc(O)c3n2)=N1		CHEMBL3427184	=	Activity	%	88.0	CHEMBL3529	Homo sapiens	Activity	%	88.0
	15650157	CHEMBL3595423	Inhibition of human IKKepsilon at 0.1 uM relative to control	B	CCc1cc(NC(=O)Nc2ccc(-c3cnc(Nc4cc(N5CCN(CC)CC5)nc(C)n4)s3)cc2)no1		CHEMBL3593290	=	Inhibition	%	18.0	CHEMBL3529	Homo sapiens	INH	%	18.0
	15665867	CHEMBL3602863	Inhibition of recombinant IKBKE (unknown origin) at 1 uM after 3 hrs	B	CS(=O)(=O)NCc1ccc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nn12		CHEMBL3601472	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	INH	%	1.0
	15747320	CHEMBL3624071	Inhibition of IKKepsilon (unknown origin) assessed as residual enzyme activity at 10 uM by kinaseprolier assay	B	NCCn1c(C2CCNCC2)nc2cc(C(N)=O)ccc21		CHEMBL3622826	>	Activity	%	65.0	CHEMBL3529	Homo sapiens	Activity	%	65.0
	15756954	CHEMBL3631256	Inhibition of IKKepsilon (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccncc3)cc2)no1		CHEMBL166031	=	Inhibition	%	1.8	CHEMBL3529	Homo sapiens	INH	%	1.8
	15757769	CHEMBL3631256	Inhibition of IKKepsilon (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CS(=O)(=O)c1cccc(Nc2nccc(-c3sc(N4CCOCC4)nc3-c3cccc(NS(=O)(=O)c4c(F)cccc4F)c3)n2)c1		CHEMBL3628627	=	Inhibition	%	67.71	CHEMBL3529	Homo sapiens	INH	%	67.71
	15758748	CHEMBL3631256	Inhibition of IKKepsilon (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	COCCNC(=O)c1ccc2c(c1)nc(-c1cnc(-c3ccc(Cl)cc3)[nH]1)n2CCOC		CHEMBL3628628	=	Inhibition	%	-0.19	CHEMBL3529	Homo sapiens	INH	%	-0.19
280472	16259231	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(=O)[nH]n3)n2)ccc1OC1CCOCC1		CHEMBL3682425	=	IC50	nM	650.0	CHEMBL3529	Homo sapiens	IC50	nM	650.0
286019	16261515	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cn1nccc1Nc1nccc(-c2ccc(N3CCCC3)c(C#N)c2)n1		CHEMBL3650711	<	IC50	nM	300.0	CHEMBL3529	Homo sapiens	IC50	nM	300.0
280485	16263779	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cc(N4CCOCC4)ccn3)c2)ccc1OC1CCOCC1		CHEMBL3687112	=	IC50	nM	150.0	CHEMBL3529	Homo sapiens	IC50	nM	150.0
286015	16263822	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	N#Cc1cc(-c2ccnc(Nc3ccn(CC(N)=O)n3)n2)ccc1N1CCCC1		CHEMBL3650707	<	IC50	nM	300.0	CHEMBL3529	Homo sapiens	IC50	nM	300.0
286037	16264051	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CC(=O)Nc1ccc(Nc2nccc(-c3ccc(N4CCN(C)CC4)c(C#N)c3)n2)cn1		CHEMBL3650729	<	IC50	nM	300.0	CHEMBL3529	Homo sapiens	IC50	nM	300.0
280454	16265219	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	Cn1ccc(Nc2nccc(-c3ccc(OC4CCOCC4)c(C#N)c3)n2)n1		CHEMBL3687174	=	IC50	nM	58.0	CHEMBL3529	Homo sapiens	IC50	nM	58.0
286007	16266402	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	N#Cc1cc(-c2ccnc(Nc3ccc4c(c3)NC(=O)CC4)n2)ccc1N1CCCC1		CHEMBL3650699	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280521	16266472	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)cn3)c2)ccc1OC1CCOCC1		CHEMBL3687133	=	IC50	nM	25.0	CHEMBL3529	Homo sapiens	IC50	nM	25.0
280440	16266499	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cc(CO)ccn3)c2)ccc1OC1CCOCC1		CHEMBL3687160	=	IC50	nM	13.0	CHEMBL3529	Homo sapiens	IC50	nM	13.0
286026	16266821	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CC(=O)N(C)c1ccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)cc1		CHEMBL3650718	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280488	16267089	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cncc(N4CCOCC4)n3)c2)ccc1OC1CCOCC1		CHEMBL3687115	=	IC50	nM	390.0	CHEMBL3529	Homo sapiens	IC50	nM	390.0
286002	16267917	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	N#Cc1cc(-c2ccnc(Nc3ccncc3)n2)ccc1N1CCCC1		CHEMBL3650695	<	IC50	nM	9000.0	CHEMBL3529	Homo sapiens	IC50	nM	9000.0
280504	16268471	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn([C@H]4CC[C@H](O)CC4)c3)n2)ccc1OC1CCOCC1		CHEMBL3639859	=	IC50	nM	5.0	CHEMBL3529	Homo sapiens	IC50	nM	5.0
280486	16268968	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCN4CCCC4)c3)n2)ccc1OC1CCOCC1		CHEMBL3687113	=	IC50	nM	88.0	CHEMBL3529	Homo sapiens	IC50	nM	88.0
286043	16271003	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN1CCN(c2ccc(Nc3nccc(-c4ccc(N5CC[C@H](O)C5)c(C#N)c4)n3)cn2)CC1		CHEMBL3650735	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280468	16272170	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cc(C(=O)O)ccn3)c2)ccc1OC1CCOCC1		CHEMBL3682421	=	IC50	nM	120.0	CHEMBL3529	Homo sapiens	IC50	nM	120.0
280500	16273259	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn([C@H]4CC[C@@H](O)CC4)c3)n2)ccc1OCC1CCC1		CHEMBL3687127	=	IC50	nM	39.0	CHEMBL3529	Homo sapiens	IC50	nM	39.0
280450	16273471	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(C4CCNC4)c3)c2)ccc1OC1CCOCC1		CHEMBL3687170	=	IC50	nM	74.0	CHEMBL3529	Homo sapiens	IC50	nM	74.0
280520	16273704	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	[C-]#[N+]c1cc(-c2ccnc(Nc3ccc(N4CCOCC4)cn3)c2)ccc1OCC1CCN(C(C)=O)CC1		CHEMBL3687147	=	IC50	nM	610.0	CHEMBL3529	Homo sapiens	IC50	nM	610.0
286005	16274545	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CC(=O)Nc1ccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)cn1		CHEMBL3650698	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
286039	16274769	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN(C)CC(=O)Nc1ccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)cn1		CHEMBL3650731	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
286041	16275379	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cn1nccc1Nc1nccc(-c2ccc(N3CC[C@H](O)C3)c(C#N)c2)n1		CHEMBL3650733	<	IC50	nM	300.0	CHEMBL3529	Homo sapiens	IC50	nM	300.0
280464	16275500	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCn4cccn4)c3)n2)ccc1OC1CCOCC1		CHEMBL3687184	=	IC50	nM	65.0	CHEMBL3529	Homo sapiens	IC50	nM	65.0
280476	16275825	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn([C@H]4CC[C@@H](O)CC4)c3)n2)ccc1OC1CCOCC1		CHEMBL3682429	=	IC50	nM	10.0	CHEMBL3529	Homo sapiens	IC50	nM	10.0
280491	16275971	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CC5(COC5)C4)cn3)c2)ccc1OC1CCOCC1		CHEMBL3687118	=	IC50	nM	45.0	CHEMBL3529	Homo sapiens	IC50	nM	45.0
286040	16276384	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CC(=O)Nc1ccc(Nc2nccc(-c3ccc(N4CCC[C@@H]4C(N)=O)c(C#N)c3)n2)cn1		CHEMBL3650732	<	IC50	nM	300.0	CHEMBL3529	Homo sapiens	IC50	nM	300.0
286062	16276864	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN1CCC(Nc2ccc(Nc3nccc(-c4ccc(N5CC[C@H](O)C5)c(C#N)c4)n3)cn2)CC1		CHEMBL3650754	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280432	16278826	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(-c4cn[nH]c4)cn3)c2)ccc1OC1CCOCC1		CHEMBL3687152	=	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
285999	16278881	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CC(=O)Nc1ccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)cc1		CHEMBL3650692	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
286003	16278893	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	N#Cc1cc(-c2ccnc(Nc3ccccn3)n2)ccc1N1CCCC1		CHEMBL3650696	<	IC50	nM	9000.0	CHEMBL3529	Homo sapiens	IC50	nM	9000.0
286038	16279077	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CC(=O)Nc1ccc(Nc2nccc(-c3ccc(N4CC[C@H](O)C4)c(C#N)c3)n2)cn1		CHEMBL3650730	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280490	16279324	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3nc(C4CC4)cs3)n2)ccc1OC1CCOCC1		CHEMBL3687117	=	IC50	nM	300.0	CHEMBL3529	Homo sapiens	IC50	nM	300.0
286057	16279541	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cn1cc(Nc2nccc(-c3ccc(N4CC[C@H](O)C4)c(C#N)c3)n2)cn1		CHEMBL3650749	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280449	16280096	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CC4CCOC4)c3)c2)ccc1OC1CCOCC1		CHEMBL3687169	=	IC50	nM	77.0	CHEMBL3529	Homo sapiens	IC50	nM	77.0
280471	16280329	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	Cn1nc(Nc2nccc(-c3ccc(OC4CCOCC4)c(C#N)c3)n2)ccc1=O		CHEMBL3682424	=	IC50	nM	200.0	CHEMBL3529	Homo sapiens	IC50	nM	200.0
280510	16280394	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	[C-]#[N+]c1cc(-c2ccnc(Nc3ccn(C4CCNCC4)n3)c2)ccc1OCC1CC1		CHEMBL3687137	=	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280444	16280772	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCN4CCOCC4)c3)c2)ccc1OC1CCOCC1		CHEMBL3687164	=	IC50	nM	150.0	CHEMBL3529	Homo sapiens	IC50	nM	150.0
280505	16280909	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3nccnc3CO)c2)ccc1OC1CCOCC1		CHEMBL3687131	=	IC50	nM	430.0	CHEMBL3529	Homo sapiens	IC50	nM	430.0
280475	16281317	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnc(C4CCNCC4)cn3)c2)ccc1OC1CCOCC1		CHEMBL3682428	=	IC50	nM	7.0	CHEMBL3529	Homo sapiens	IC50	nM	7.0
280457	16281974	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ncc4c(n3)CCNC4)c2)ccc1OC1CCOCC1		CHEMBL3687177	=	IC50	nM	140.0	CHEMBL3529	Homo sapiens	IC50	nM	140.0
286004	16283160	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	N#Cc1cc(-c2ccnc(Nc3ccc4c(c3)CC(=O)N4)n2)ccc1N1CCCC1		CHEMBL3650697	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
286060	16283452	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN1CCC(Nc2ccc(Nc3nccc(-c4ccc(N5CC[C@@H](F)C5)c(C#N)c4)n3)cn2)CC1		CHEMBL3650752	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280452	16283751	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCC4CCN(C(=O)CN)CC4)c3)c2)ccc1OC1CCOCC1		CHEMBL3687172	=	IC50	nM	45.0	CHEMBL3529	Homo sapiens	IC50	nM	45.0
280467	16285590	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(C4CCNCC4)c3)n2)ccc1OC1CCOCC1		CHEMBL3682420	=	IC50	nM	6.0	CHEMBL3529	Homo sapiens	IC50	nM	6.0
280519	16287165	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	[C-]#[N+]c1cc(-c2ccnc(Nc3cnn(C4CCNCC4)c3)c2)ccc1OCC1CCN(C(C)=O)CC1		CHEMBL3687146	=	IC50	nM	190.0	CHEMBL3529	Homo sapiens	IC50	nM	190.0
280517	16287196	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	[C-]#[N+]c1cc(-c2ccnc(Nc3cnn(CCOC)c3)c2)ccc1OCC1CCN(C(C)=O)CC1		CHEMBL3687144	=	IC50	nM	650.0	CHEMBL3529	Homo sapiens	IC50	nM	650.0
280445	16287233	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	COCCCn1cc(Nc2cc(-c3ccc(OC4CCOCC4)c(C#N)c3)ccn2)cn1		CHEMBL3687165	=	IC50	nM	160.0	CHEMBL3529	Homo sapiens	IC50	nM	160.0
280482	16287624	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCO)c3)c2)ccc1OC1CCOCC1		CHEMBL3682435	=	IC50	nM	91.0	CHEMBL3529	Homo sapiens	IC50	nM	91.0
286021	16287947	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cc1cnc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)s1		CHEMBL3650713	<	IC50	nM	9000.0	CHEMBL3529	Homo sapiens	IC50	nM	9000.0
280458	16287958	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(C(N)=O)cn3)c2)ccc1OC1CCOCC1		CHEMBL3687178	=	IC50	nM	21.0	CHEMBL3529	Homo sapiens	IC50	nM	21.0
286056	16288185	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CC(=O)Nc1ccc(Nc2nccc(-c3ccc(N4CC[C@@H](O)C4)c(C#N)c3)n2)cn1		CHEMBL3650748	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280507	16288339	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cn[nH]c3)c2)ccc1OCC1CC1		CHEMBL3687134	=	IC50	nM	96.0	CHEMBL3529	Homo sapiens	IC50	nM	96.0
280463	16288501	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc4oc(C(N)=O)cc4c3)n2)ccc1OC1CCOCC1		CHEMBL3687183	=	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
280499	16289122	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cncc(C4CCNCC4)n3)c2)ccc1OC1CCOCC1		CHEMBL3687126	=	IC50	nM	40.0	CHEMBL3529	Homo sapiens	IC50	nM	40.0
280451	16290184	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCC4CCN(C(=O)CO)CC4)c3)c2)ccc1OC1CCOCC1		CHEMBL3687171	=	IC50	nM	88.0	CHEMBL3529	Homo sapiens	IC50	nM	88.0
286025	16290983	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN(C)CCN(C)c1ccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)cn1		CHEMBL3650717	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
286036	16291512	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CC(=O)Nc1ccc(Nc2nccc(-c3ccc(N4CCOCC4)c(C#N)c3)n2)cn1		CHEMBL3650728	<	IC50	nM	300.0	CHEMBL3529	Homo sapiens	IC50	nM	300.0
280442	16292256	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CC(F)F)c3)c2)ccc1OC1CCOCC1		CHEMBL3687162	=	IC50	nM	51.0	CHEMBL3529	Homo sapiens	IC50	nM	51.0
286051	16292992	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CNC(=O)C1CCN(c2ccc(-c3ccnc(Nc4ccc(NC(C)=O)nc4)n3)cc2C#N)CC1		CHEMBL3650743	<	IC50	nM	300.0	CHEMBL3529	Homo sapiens	IC50	nM	300.0
280511	16293267	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(N4CCOCC4)cn3)c2)ccc1OCC1CC1		CHEMBL3687138	=	IC50	nM	45.0	CHEMBL3529	Homo sapiens	IC50	nM	45.0
286063	16293991	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN1CCC(Nc2ccc(Nc3nccc(-c4ccc(N5CCC(F)(F)C5)c(C#N)c4)n3)cn2)CC1		CHEMBL3650755	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280477	16296117	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cc(C4CCNCC4)ccn3)c2)ccc1OC1CCOCC1		CHEMBL3682430	=	IC50	nM	1.0	CHEMBL3529	Homo sapiens	IC50	nM	1.0
280484	16296441	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	CN(C)Cc1ccnc(Nc2cc(-c3ccc(OC4CCOCC4)c(C#N)c3)ccn2)c1		CHEMBL3687111	=	IC50	nM	10.0	CHEMBL3529	Homo sapiens	IC50	nM	10.0
286016	16297076	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cn1cncc1Nc1nccc(-c2ccc(N3CCCC3)c(C#N)c2)n1		CHEMBL3650708	<	IC50	nM	300.0	CHEMBL3529	Homo sapiens	IC50	nM	300.0
286044	16298071	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN1CCN(c2ccc(Nc3nccc(-c4ccc(N5CCC[C@@H]5C(N)=O)c(C#N)c4)n3)cn2)CC1		CHEMBL3650736	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280455	16298367	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cn[nH]c3)n2)ccc1OC1CCOCC1		CHEMBL3687175	=	IC50	nM	6.0	CHEMBL3529	Homo sapiens	IC50	nM	6.0
286058	16298377	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cn1cc(Nc2nccc(-c3ccc(N4CCC(C(N)=O)CC4)c(C#N)c3)n2)cn1		CHEMBL3650750	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
286001	16299119	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	N#Cc1cc(-c2ccnc(Nc3ccccc3)n2)ccc1N1CCCC1		CHEMBL3650694	<	IC50	nM	9000.0	CHEMBL3529	Homo sapiens	IC50	nM	9000.0
286034	16299803	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN1CCC(NC(=O)c2cccc(Nc3nccc(-c4ccc(N5CCCC5)c(C#N)c4)n3)c2)CC1		CHEMBL3650726	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280435	16300884	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cc(C4CC4)n[nH]3)c2)ccc1OC1CCOCC1		CHEMBL3687155	=	IC50	nM	25.0	CHEMBL3529	Homo sapiens	IC50	nM	25.0
286028	16301456	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	N#Cc1cc(-c2ccnc(Nc3ncc(C(N)=O)o3)n2)ccc1N1CCCC1		CHEMBL3650720	<	IC50	nM	9000.0	CHEMBL3529	Homo sapiens	IC50	nM	9000.0
198639	16301498	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cncc(-c4cccnc4)c3)c2)ccc1OC1CCOCC1		CHEMBL3687187	=	IC50	nM	370.0	CHEMBL3529	Homo sapiens	IC50	nM	370.0
286022	16302306	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	N#Cc1cc(-c2ccnc(Nc3ncco3)n2)ccc1N1CCCC1		CHEMBL3650714	<	IC50	nM	9000.0	CHEMBL3529	Homo sapiens	IC50	nM	9000.0
286024	16302494	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN(C)CCNc1ccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)cn1		CHEMBL3650716	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280470	16302514	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(C[C@H]4C[C@@H]4CO)c3)n2)ccc1OC1CCOCC1		CHEMBL3682423	=	IC50	nM	4.0	CHEMBL3529	Homo sapiens	IC50	nM	4.0
280513	16303333	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	COCCn1cc(Nc2cc(-c3ccc(OCC4CCC4)c(C#N)c3)ccn2)cn1		CHEMBL3687140	=	IC50	nM	82.0	CHEMBL3529	Homo sapiens	IC50	nM	82.0
280515	16304625	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	[C-]#[N+]c1cc(-c2ccnc(Nc3ccn(C4CCNCC4)n3)c2)ccc1OCC1CCC1		CHEMBL3687142	=	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280492	16305129	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3nccc(C4CCNCC4)n3)c2)ccc1OC1CCOCC1		CHEMBL3687119	=	IC50	nM	120.0	CHEMBL3529	Homo sapiens	IC50	nM	120.0
280447	16305932	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(C4CNC4)c3)c2)ccc1OC1CCOCC1		CHEMBL3687167	=	IC50	nM	67.0	CHEMBL3529	Homo sapiens	IC50	nM	67.0
280431	16306044	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(N4CCOCC4)cn3)c2)ccc1OC1CCOCC1		CHEMBL3687151	=	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
286054	16306064	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	COC[C@H]1CCCN1c1ccc(-c2ccnc(Nc3ccc(NC(C)=O)nc3)n2)cc1C#N		CHEMBL3650746	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
286027	16306515	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN(C)CCOc1ccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)cn1		CHEMBL3650719	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280498	16307039	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(C[C@H]4C[C@@H]4CO)c3)n2)ccc1OCC1CCC1		CHEMBL3687125	=	IC50	nM	8.0	CHEMBL3529	Homo sapiens	IC50	nM	8.0
280465	16307318	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CC(F)F)c3)n2)ccc1OC1CCOCC1		CHEMBL3687185	=	IC50	nM	10.0	CHEMBL3529	Homo sapiens	IC50	nM	10.0
280516	16307339	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(N4CCOCC4)cn3)c2)ccc1CCC1CCC1		CHEMBL3687143	=	IC50	nM	120.0	CHEMBL3529	Homo sapiens	IC50	nM	120.0
280439	16307621	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(C4CCNCC4)c3)c2)ccc1OC1CCOCC1		CHEMBL3687159	=	IC50	nM	7.0	CHEMBL3529	Homo sapiens	IC50	nM	7.0
280446	16308167	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CC4CC4C#N)c3)c2)ccc1OC1CCOCC1		CHEMBL3687166	=	IC50	nM	89.0	CHEMBL3529	Homo sapiens	IC50	nM	89.0
286009	16308676	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN1CCN(c2ccc(Nc3nccc(-c4ccc(N5CCCC5)c(C#N)c4)n3)cn2)CC1		CHEMBL3650701	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280518	16309181	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	[C-]#[N+]c1cc(-c2ccnc(Nc3ccc(CO)cn3)c2)ccc1OCC1CCN(C(C)=O)CC1		CHEMBL3687145	=	IC50	nM	1100.0	CHEMBL3529	Homo sapiens	IC50	nM	1100.0
280496	16310071	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	Cc1coc(Nc2nccc(-c3ccc(OC4CCOCC4)c(C#N)c3)n2)n1		CHEMBL3687123	=	IC50	nM	310.0	CHEMBL3529	Homo sapiens	IC50	nM	310.0
280502	16311022	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnc(CO)cn3)c2)ccc1OC1CCOCC1		CHEMBL3687129	=	IC50	nM	8.0	CHEMBL3529	Homo sapiens	IC50	nM	8.0
280512	16312222	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cn[nH]c3)c2)ccc1OCC1CCC1		CHEMBL3687139	=	IC50	nM	140.0	CHEMBL3529	Homo sapiens	IC50	nM	140.0
280503	16312303	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(C4CCOCC4)nn3)c2)ccc1OC1CCOCC1		CHEMBL3687130	=	IC50	nM	39.0	CHEMBL3529	Homo sapiens	IC50	nM	39.0
280509	16312661	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(CO)cn3)c2)ccc1OCC1CC1		CHEMBL3687136	=	IC50	nM	46.0	CHEMBL3529	Homo sapiens	IC50	nM	46.0
286050	16312924	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CNC(=O)[C@H]1CCCN1c1ccc(-c2ccnc(Nc3ccc(NC(C)=O)nc3)n2)cc1C#N		CHEMBL3650742	<	IC50	nM	9000.0	CHEMBL3529	Homo sapiens	IC50	nM	9000.0
286013	16314520	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cn1cnc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)c1		CHEMBL3650705	<	IC50	nM	300.0	CHEMBL3529	Homo sapiens	IC50	nM	300.0
280473	16315519	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cc(CO)ccn3)n2)ccc1OC1CCOCC1		CHEMBL3682426	=	IC50	nM	140.0	CHEMBL3529	Homo sapiens	IC50	nM	140.0
280483	16316835	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	Cc1cc(Nc2nccc(-c3ccc(OC4CCOCC4)c(C#N)c3)n2)no1		CHEMBL3687110	=	IC50	nM	210.0	CHEMBL3529	Homo sapiens	IC50	nM	210.0
286011	16318484	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cc1cc(C(N)=O)ccc1Nc1nccc(-c2ccc(N3CCCC3)c(C#N)c2)n1		CHEMBL3650703	<	IC50	nM	300.0	CHEMBL3529	Homo sapiens	IC50	nM	300.0
280469	16320104	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ncc(C4CCNCC4)cn3)c2)ccc1OC1CCOCC1		CHEMBL3682422	=	IC50	nM	82.0	CHEMBL3529	Homo sapiens	IC50	nM	82.0
286049	16320258	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CC(=O)Nc1ccc(Nc2nccc(-c3ccc(N4CC(O)C4)c(C#N)c3)n2)cn1		CHEMBL3650741	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
286045	16320421	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN(C)CCNc1ccc(Nc2nccc(-c3ccc(N4CC[C@H](O)C4)c(C#N)c3)n2)cn1		CHEMBL3650737	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280460	16320894	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCN4CCOCC4)c3)n2)ccc1OC1CCOCC1		CHEMBL3687180	=	IC50	nM	25.0	CHEMBL3529	Homo sapiens	IC50	nM	25.0
286048	16321752	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN(C)CCNc1ccc(Nc2nccc(-c3ccc(N4CCC(O)CC4)c(C#N)c3)n2)cn1		CHEMBL3650740	<	IC50	nM	300.0	CHEMBL3529	Homo sapiens	IC50	nM	300.0
286055	16322205	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN(C)CCNc1ccc(Nc2nccc(-c3ccc(N4CCC[C@@H]4C(N)=O)c(C#N)c3)n2)cn1		CHEMBL3650747	<	IC50	nM	300.0	CHEMBL3529	Homo sapiens	IC50	nM	300.0
280459	16322503	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCn4cccn4)c3)c2)ccc1OC1CCOCC1		CHEMBL3687179	=	IC50	nM	320.0	CHEMBL3529	Homo sapiens	IC50	nM	320.0
286031	16322658	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cn1nc(C(N)=O)cc1Nc1nccc(-c2ccc(N3CCCC3)c(C#N)c2)n1		CHEMBL3650723	<	IC50	nM	300.0	CHEMBL3529	Homo sapiens	IC50	nM	300.0
280438	16322985	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(CO)cn3)c2)ccc1OC1CCOCC1		CHEMBL3687158	=	IC50	nM	21.0	CHEMBL3529	Homo sapiens	IC50	nM	21.0
280479	16323203	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	COc1nc(Nc2nccc(-c3ccc(OC4CCOCC4)c(C#N)c3)n2)ccc1C1=CCNCC1		CHEMBL3682432	=	IC50	nM	21.0	CHEMBL3529	Homo sapiens	IC50	nM	21.0
286042	16324074	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cn1nccc1Nc1nccc(-c2ccc(N3CCC[C@@H]3C(N)=O)c(C#N)c2)n1		CHEMBL3650734	<	IC50	nM	300.0	CHEMBL3529	Homo sapiens	IC50	nM	300.0
286053	16324852	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CC(=O)Nc1ccc(Nc2nccc(-c3ccc(N4CCC[C@H]4C(N)=O)c(C#N)c3)n2)cn1		CHEMBL3650745	<	IC50	nM	300.0	CHEMBL3529	Homo sapiens	IC50	nM	300.0
280487	16327201	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	CN1CCN(c2ccnc(Nc3cc(-c4ccc(OC5CCOCC5)c(C#N)c4)ccn3)c2)CC1		CHEMBL3687114	=	IC50	nM	210.0	CHEMBL3529	Homo sapiens	IC50	nM	210.0
280466	16327730	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCC4CCNCC4)c3)n2)ccc1OC1CCOCC1		CHEMBL3687186	=	IC50	nM	2.0	CHEMBL3529	Homo sapiens	IC50	nM	2.0
286006	16327878	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	N#Cc1cc(-c2ccnc(Nc3ccc(N4CCOCC4)nc3)n2)ccc1N1CCCC1		CHEMBL3639495	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280456	16328271	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	COCCn1cc(Nc2nccc(-c3ccc(OC4CCOCC4)c(C#N)c3)n2)cn1		CHEMBL3687176	=	IC50	nM	18.0	CHEMBL3529	Homo sapiens	IC50	nM	18.0
286035	16330328	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN(C)CCNC(=O)c1cccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)c1		CHEMBL3650727	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280430	16330689	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	Cn1ccc(Nc2cc(-c3ccc(OC4CCOCC4)c(C#N)c3)ccn2)n1		CHEMBL3687150	=	IC50	nM	110.0	CHEMBL3529	Homo sapiens	IC50	nM	110.0
286017	16330715	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cc1cc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)no1		CHEMBL3650709	<	IC50	nM	9000.0	CHEMBL3529	Homo sapiens	IC50	nM	9000.0
280429	16334403	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	Cc1cc(Nc2cc(-c3ccc(OC4CCOCC4)c(C#N)c3)ccn2)no1		CHEMBL3687149	=	IC50	nM	38.0	CHEMBL3529	Homo sapiens	IC50	nM	38.0
286030	16335255	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cn1nc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)cc1C(N)=O		CHEMBL3650722	<	IC50	nM	300.0	CHEMBL3529	Homo sapiens	IC50	nM	300.0
286023	16335633	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cc1csc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)n1		CHEMBL3650715	<	IC50	nM	9000.0	CHEMBL3529	Homo sapiens	IC50	nM	9000.0
286008	16335977	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	N#Cc1cc(-c2ccnc(Nc3cccnc3)n2)ccc1N1CCCC1		CHEMBL3650700	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
286012	16336665	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cn1cc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)cn1		CHEMBL3650704	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280508	16336744	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	COCCn1cc(Nc2cc(-c3ccc(OCC4CC4)c(C#N)c3)ccn2)cn1		CHEMBL3687135	=	IC50	nM	65.0	CHEMBL3529	Homo sapiens	IC50	nM	65.0
286061	16338717	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN1CCC(Nc2ccc(Nc3nccc(-c4ccc(N5CC[C@H](F)C5)c(C#N)c4)n3)cn2)CC1		CHEMBL3650753	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280433	16338753	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	CC(C)(C)c1cc(Nc2cc(-c3ccc(OC4CCOCC4)c(C#N)c3)ccn2)n[nH]1		CHEMBL3687153	=	IC50	nM	43.0	CHEMBL3529	Homo sapiens	IC50	nM	43.0
280441	16338771	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc4oc(C(N)=O)cc4c3)c2)ccc1OC1CCOCC1		CHEMBL3687161	=	IC50	nM	390.0	CHEMBL3529	Homo sapiens	IC50	nM	390.0
285994	16339767	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	N#Cc1cc(-c2ccnc(Nc3ccc(F)cc3)n2)ccc1N1CCCC1		CHEMBL3650687	<	IC50	nM	300.0	CHEMBL3529	Homo sapiens	IC50	nM	300.0
285995	16339844	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	COc1cccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)c1		CHEMBL3650688	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
286033	16340139	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN1CCN(C(=O)c2cccc(Nc3nccc(-c4ccc(N5CCCC5)c(C#N)c4)n3)c2)CC1		CHEMBL3650725	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280443	16340403	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCC4CCNCC4)c3)c2)ccc1OC1CCOCC1		CHEMBL3687163	=	IC50	nM	37.0	CHEMBL3529	Homo sapiens	IC50	nM	37.0
280497	16340480	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCO)c3)n2)ccc1OCC1CCC1		CHEMBL3687124	=	IC50	nM	18.0	CHEMBL3529	Homo sapiens	IC50	nM	18.0
286018	16341284	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cc1cc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)on1		CHEMBL3650710	<	IC50	nM	300.0	CHEMBL3529	Homo sapiens	IC50	nM	300.0
280489	16342039	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cc(C4=CCCCO4)ccn3)c2)ccc1OC1CCOCC1		CHEMBL3687116	=	IC50	nM	300.0	CHEMBL3529	Homo sapiens	IC50	nM	300.0
286052	16342363	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN(C)CCNc1ccc(Nc2nccc(-c3ccc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3650744	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
286029	16342428	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	N#Cc1cc(-c2ccnc(Nc3nc(C(N)=O)co3)n2)ccc1N1CCCC1		CHEMBL3650721	<	IC50	nM	9000.0	CHEMBL3529	Homo sapiens	IC50	nM	9000.0
285998	16342503	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	N#Cc1cc(-c2ccnc(Nc3ccc(C(N)=O)cc3)n2)ccc1N1CCCC1		CHEMBL3650691	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
286020	16342647	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cn1ccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)n1		CHEMBL3650712	<	IC50	nM	300.0	CHEMBL3529	Homo sapiens	IC50	nM	300.0
286014	16343308	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	COc1ccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)cn1		CHEMBL3650706	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280481	16343749	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	CN1CCC(c2ccnc(Nc3cc(-c4ccc(OC5CCOCC5)c(C#N)c4)ccn3)c2)CC1		CHEMBL3682434	=	IC50	nM	6.0	CHEMBL3529	Homo sapiens	IC50	nM	6.0
280474	16344047	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(C4CCNCC4)nn3)c2)ccc1OC1CCOCC1		CHEMBL3682427	=	IC50	nM	6.0	CHEMBL3529	Homo sapiens	IC50	nM	6.0
285993	16344265	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	N#Cc1cc(-c2ccnc(Nc3cccc(F)c3)n2)ccc1N1CCCC1		CHEMBL3650686	<	IC50	nM	300.0	CHEMBL3529	Homo sapiens	IC50	nM	300.0
285997	16345554	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CC(=O)Nc1cccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)c1		CHEMBL3650690	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
285996	16346761	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	COc1ccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)cc1		CHEMBL3650689	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280501	16346897	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnc(C4CCOCC4)cn3)c2)ccc1OC1CCOCC1		CHEMBL3687128	=	IC50	nM	8.0	CHEMBL3529	Homo sapiens	IC50	nM	8.0
280448	16348472	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(C[C@H]4C[C@@H]4CO)c3)c2)ccc1OC1CCOCC1		CHEMBL3687168	=	IC50	nM	27.0	CHEMBL3529	Homo sapiens	IC50	nM	27.0
280437	16349263	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ncccn3)c2)ccc1OC1CCOCC1		CHEMBL3687157	=	IC50	nM	1200.0	CHEMBL3529	Homo sapiens	IC50	nM	1200.0
280478	16349392	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCO)c3)n2)ccc1OC1CCOCC1		CHEMBL3682431	=	IC50	nM	4.0	CHEMBL3529	Homo sapiens	IC50	nM	4.0
280493	16349418	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(N4CCOCC4)nn3)c2)ccc1OC1CCOCC1		CHEMBL3687120	=	IC50	nM	98.0	CHEMBL3529	Homo sapiens	IC50	nM	98.0
286000	16349566	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CS(=O)(=O)c1cccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)c1		CHEMBL3650693	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280428	16350043	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	CN1CCC(n2cc(Nc3cc(-c4ccc(OC5CCOCC5)c(C#N)c4)ccn3)cn2)CC1		CHEMBL3687148	=	IC50	nM	20.0	CHEMBL3529	Homo sapiens	IC50	nM	20.0
280462	16350279	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CC4CCOC4)c3)n2)ccc1OC1CCOCC1		CHEMBL3687182	=	IC50	nM	25.0	CHEMBL3529	Homo sapiens	IC50	nM	25.0
286032	16350656	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	N#Cc1cc(-c2ccnc(Nc3cccc(C(=O)O)c3)n2)ccc1N1CCCC1		CHEMBL3650724	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280436	16351290	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(C(F)(F)F)cn3)c2)ccc1OC1CCOCC1		CHEMBL3687156	=	IC50	nM	530.0	CHEMBL3529	Homo sapiens	IC50	nM	530.0
280514	16351647	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(CO)cn3)c2)ccc1OCC1CCC1		CHEMBL3687141	=	IC50	nM	200.0	CHEMBL3529	Homo sapiens	IC50	nM	200.0
286047	16352001	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN(C)CCNc1ccc(Nc2nccc(-c3ccc(N4CCC(C(N)=O)CC4)c(C#N)c3)n2)cn1		CHEMBL3650739	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
286046	16352763	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	C[C@H]1CCCN1c1ccc(-c2ccnc(Nc3ccc(NCCN(C)C)nc3)n2)cc1C#N		CHEMBL3650738	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
286059	16353050	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CO[C@H]1CCN(c2ccc(-c3ccnc(Nc4ccc(NC(C)=O)nc4)n3)cc2C#N)C1		CHEMBL3650751	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280461	16353566	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(C4CCNC4)c3)n2)ccc1OC1CCOCC1		CHEMBL3687181	=	IC50	nM	5.0	CHEMBL3529	Homo sapiens	IC50	nM	5.0
280495	16353589	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cncc(C4=CCCCO4)n3)c2)ccc1OC1CCOCC1		CHEMBL3687122	=	IC50	nM	930.0	CHEMBL3529	Homo sapiens	IC50	nM	930.0
285992	16353914	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	N#Cc1cc(-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)ccc1N1CCCC1		CHEMBL3650685	<	IC50	nM	9000.0	CHEMBL3529	Homo sapiens	IC50	nM	9000.0
280480	16354209	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cc(CN)ccn3)c2)ccc1OC1CCOCC1		CHEMBL3682433	=	IC50	nM	12.0	CHEMBL3529	Homo sapiens	IC50	nM	12.0
286010	16354226	CHEMBL3706330	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN(C)c1ccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)cn1		CHEMBL3650702	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
280506	16354699	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	COCCn1cc(Nc2nccc(-c3ccc(OCC4CCC4)c(C#N)c3)n2)cn1		CHEMBL3687132	=	IC50	nM	8.0	CHEMBL3529	Homo sapiens	IC50	nM	8.0
280434	16355074	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1ccc(Nc2cc(-c3ccc(OC4CCOCC4)c(C#N)c3)ccn2)nc1		CHEMBL3687154	=	IC50	nM	240.0	CHEMBL3529	Homo sapiens	IC50	nM	240.0
280453	16356396	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	CC(C)(C)c1cc(Nc2cc(-c3ccc(OC4CCOCC4)c(C#N)c3)ccn2)on1		CHEMBL3687173	=	IC50	nM	850.0	CHEMBL3529	Homo sapiens	IC50	nM	850.0
280494	16356441	CHEMBL3707546	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cccc(C4CCNCC4)n3)c2)ccc1OC1CCOCC1		CHEMBL3687121	=	IC50	nM	8.0	CHEMBL3529	Homo sapiens	IC50	nM	8.0
	16426115	CHEMBL3751286	Inhibition of IKKepsilon (unknown origin) at 1 uM	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)ccc(F)c1NC(=O)c1cc2ccccc2s1		CHEMBL3746293	=	Inhibition	%	-5.8	CHEMBL3529	Homo sapiens	INH	%	-5.8
	16431864	CHEMBL3748218	Inhibition of human IKKepsilon using casein as substrate	B	Cn1c(=O)c(S(=O)(=O)c2ccc(F)cc2F)cc2cnc(Nc3ccc4[nH]ccc4c3)nc21		CHEMBL3745885	>	IC50	nM	10000.0	CHEMBL3529	Homo sapiens	IC50	uM	10.0
	16450873	CHEMBL3762889	Inhibition of IKKepsilon (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4ccccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758502	=	Inhibition	%	-8.7	CHEMBL3529	Homo sapiens	INH	%	-8.7
	16451725	CHEMBL3762889	Inhibition of IKKepsilon (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4c(Cl)cccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758602	=	Inhibition	%	3.2	CHEMBL3529	Homo sapiens	INH	%	3.2
	16451814	CHEMBL3761301	Inhibition of IKKepsilon (unknown origin) at 1000 nM	B	CC1(C)OCc2c(Nc3n[nH]c4c(Cl)cccc34)nc(-c3cn[nH]c3C(F)F)nc21		CHEMBL3758739	=	Inhibition	%	1.9	CHEMBL3529	Homo sapiens	INH	%	1.9
	16474691	CHEMBL3767311	Inhibition of IKKepsilon (unknown origin) at 10 uM	B	CN1CCN(CCCOc2ccc(N3C(=O)/C(=C/c4ccc(Oc5ccc(F)cc5)cc4)SC3=S)cc2)CC1		CHEMBL3765499	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	INH	%	0.0
	16611919	CHEMBL3815420	Inhibition of human IKBKE (1 to 716 residues) assessed as enzyme activity at 1 uM using 33P ATP by radioactive filter binding assay	B	Nc1nccc(-c2c[nH]c3ncccc23)n1		CHEMBL405665	=	Activity	%	-22.0	CHEMBL3529	Homo sapiens	Activity	%	-22.0
	16611920	CHEMBL3815420	Inhibition of human IKBKE (1 to 716 residues) assessed as enzyme activity at 1 uM using 33P ATP by radioactive filter binding assay	B	CCCCc1cc(-c2c[nH]c3ncccc23)nc(N)n1		CHEMBL3814340	=	Activity	%	-48.0	CHEMBL3529	Homo sapiens	Activity	%	-48.0
	16611921	CHEMBL3815420	Inhibition of human IKBKE (1 to 716 residues) assessed as enzyme activity at 1 uM using 33P ATP by radioactive filter binding assay	B	CCc1cc(-c2c[nH]c3ncc(-c4cnn(C5CCNCC5)c4)cc23)nc(N)n1		CHEMBL3814140	=	Activity	%	-78.0	CHEMBL3529	Homo sapiens	Activity	%	-78.0
	16611922	CHEMBL3815420	Inhibition of human IKBKE (1 to 716 residues) assessed as enzyme activity at 1 uM using 33P ATP by radioactive filter binding assay	B	CCCCc1cc(-c2c[nH]c3ncc(-c4cnn(C5CCNCC5)c4)cc23)nc(N)n1		CHEMBL3815046	=	Activity	%	-91.0	CHEMBL3529	Homo sapiens	Activity	%	-91.0
	16614505	CHEMBL3816703	Inhibition of human IKKepsilon at 1 uM using casein as substrate	B	CNS(=O)(=O)c1ccc(N(C)C)c(Nc2ncnc3cc(OC)c(OC)cc23)c1		CHEMBL3815093	=	Inhibition	%	4.0	CHEMBL3529	Homo sapiens	INH	%	4.0
	16618190	CHEMBL3817243	Inhibition of full length recombinant human GST-tagged IKK-epsilon expressed in baculovirus expression system at 1 uM relative to control	B	CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL3813842	<	Inhibition	%	50.0	CHEMBL3529	Homo sapiens	INH	%	50.0
	16628491	CHEMBL3820303	Inhibition of human recombinant full-length IKKepsilon expressed in insect Sf21 cells at 1 uM using MBP as substrate after 30 mins	B	O=C(Nc1cc(Nc2c(Cl)cnc3c2OCO3)ccn1)C1CC1		CHEMBL3818173	<	Inhibition	%	80.0	CHEMBL3529	Homo sapiens	INH	%	80.0
	16654118	CHEMBL3829296	Inhibition of human IKKe (1 to 716 residues) assessed as remaining enzyme activity at 50 uM after 30 mins by 33P-ATP filter-binding assay	B	Cc1cc(=O)c2c(O)cc(O)c([C@H]3CCN(C)C[C@H]3O)c2o1		CHEMBL1077604	=	Activity	%	69.0	CHEMBL3529	Homo sapiens	Activity	%	69.0
	16837439	CHEMBL3876071	Inhibition of human recombinant full length GST-tagged IKKepsilon expressed in baculovirus expression system	B	CC1(C)C(=O)N([C@H]2CCc3c(O)cccc32)c2nc(Nc3ccccc3)ncc21		CHEMBL3884319	=	IC50	nM	10000.0	CHEMBL3529	Homo sapiens	IC50	nM	10000.0
363298	17738673	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	CN1CCN(Cc2ccc(C(=O)Nc3sc(-c4ccnc(F)c4)nc3C(N)=O)cc2)CC1		CHEMBL3926136	=	IC50	nM	540.0	CHEMBL3529	Homo sapiens	IC50	nM	540.0
363299	17738674	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Cc1cc(-c2nc(C(N)=O)c(NC(=O)c3ccc(CN4CCN(C)CC4)cc3)s2)ccn1		CHEMBL3896866	=	IC50	nM	390.0	CHEMBL3529	Homo sapiens	IC50	nM	390.0
363300	17738675	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	CN1CCN(Cc2ccc(C(=O)Nc3sc(-c4ccnc(C(F)(F)F)c4)nc3C(N)=O)cc2)CC1		CHEMBL3921400	=	IC50	nM	2100.0	CHEMBL3529	Homo sapiens	IC50	nM	2100.0
363301	17738676	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	CN1CCN(Cc2ccc(C(=O)Nc3sc(-c4ccnc(C#N)c4)nc3C(N)=O)cc2)CC1		CHEMBL3956191	=	IC50	nM	740.0	CHEMBL3529	Homo sapiens	IC50	nM	740.0
363302	17738677	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	CN1CCN(Cc2ccc(Nc3sc(-c4ccncc4)nc3C(N)=O)cc2)CC1		CHEMBL3968131	=	IC50	nM	420.0	CHEMBL3529	Homo sapiens	IC50	nM	420.0
363303	17738678	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Cc1cc(-c2nc(C(N)=O)c(NC(=O)c3ccc(CN4CCN(C)CC4)cc3)s2)cc(C)n1		CHEMBL3953752	=	IC50	nM	3800.0	CHEMBL3529	Homo sapiens	IC50	nM	3800.0
363304	17738679	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	CN1CCN(Cc2ccc(C(=O)Nc3sc(-c4ccncc4C(F)(F)F)nc3C(N)=O)cc2)CC1		CHEMBL3901254	=	IC50	nM	140.0	CHEMBL3529	Homo sapiens	IC50	nM	140.0
363305	17738680	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	CN1CCN(Cc2ccc(C(=O)Nc3sc(-c4ccncc4Br)nc3C(N)=O)cc2)CC1		CHEMBL3913460	=	IC50	nM	190.0	CHEMBL3529	Homo sapiens	IC50	nM	190.0
363306	17738681	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	CN1CCN(Cc2ccc(C(=O)Nc3sc(-c4ccncc4F)nc3C(N)=O)cc2)CC1		CHEMBL3944901	=	IC50	nM	280.0	CHEMBL3529	Homo sapiens	IC50	nM	280.0
363307	17738682	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	CN1CCN(Cc2ccc(C(=O)Nc3sc(-c4ccncc4Cl)nc3C(N)=O)cc2)CC1		CHEMBL3922448	=	IC50	nM	630.0	CHEMBL3529	Homo sapiens	IC50	nM	630.0
363308	17738683	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	COc1cnccc1-c1nc(C(N)=O)c(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)s1		CHEMBL3950168	=	IC50	nM	14.0	CHEMBL3529	Homo sapiens	IC50	nM	14.0
363309	17738684	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Cc1cnccc1-c1nc(C(N)=O)c(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)s1		CHEMBL3934866	=	IC50	nM	300.0	CHEMBL3529	Homo sapiens	IC50	nM	300.0
363310	17738685	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	NC(=O)c1nc(-c2ccncc2)sc1NC(=O)c1ccc(CN2CCNCC2)cc1		CHEMBL3923270	=	IC50	nM	260.0	CHEMBL3529	Homo sapiens	IC50	nM	260.0
363311	17738686	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	CN1CCC(Cc2ccc(C(=O)Nc3sc(-c4ccncc4)nc3C(N)=O)cc2)CC1		CHEMBL3943590	=	IC50	nM	31.0	CHEMBL3529	Homo sapiens	IC50	nM	31.0
363312	17738687	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	CC(=O)N1CCN(Cc2ccc(C(=O)Nc3sc(-c4ccncc4)nc3C(N)=O)cc2)CC1		CHEMBL3973084	=	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
363313	17738688	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	CN1CCN(Cc2ccc(C(=O)Nc3sc(-c4ccncc4)nc3C(N)=O)cc2)CC1		CHEMBL3906947	=	IC50	nM	200.0	CHEMBL3529	Homo sapiens	IC50	nM	200.0
363314	17738689	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	CN(C)Cc1ccc(C(=O)Nc2sc(-c3ccncc3)nc2C(N)=O)cc1		CHEMBL3960048	=	IC50	nM	280.0	CHEMBL3529	Homo sapiens	IC50	nM	280.0
363315	17738690	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	NC(=O)c1nc(-c2ccncc2)sc1NC(=O)c1cn[nH]c1		CHEMBL3964075	=	IC50	nM	730.0	CHEMBL3529	Homo sapiens	IC50	nM	730.0
363316	17738691	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	NC(=O)c1nc(-c2ccncc2)sc1NC(=O)c1ccc(N2CCOCC2)nc1		CHEMBL3923590	=	IC50	nM	2000.0	CHEMBL3529	Homo sapiens	IC50	nM	2000.0
363317	17738692	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Cc1ccc(C(=O)Nc2sc(-c3ccncc3)nc2C(N)=O)cc1		CHEMBL3956718	=	IC50	nM	5300.0	CHEMBL3529	Homo sapiens	IC50	nM	5300.0
363318	17738693	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	CN(C)c1ccc(C(=O)Nc2sc(-c3ccncc3)nc2C(N)=O)cc1		CHEMBL3919767	=	IC50	nM	1600.0	CHEMBL3529	Homo sapiens	IC50	nM	1600.0
363319	17738694	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	NC(=O)c1nc(-c2ccncc2)sc1NC(=O)c1ccc(N)cc1		CHEMBL3956252	=	IC50	nM	180.0	CHEMBL3529	Homo sapiens	IC50	nM	180.0
363320	17738695	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Cn1cccc1C(=O)Nc1sc(-c2ccncc2)nc1C(N)=O		CHEMBL3925224	=	IC50	nM	1200.0	CHEMBL3529	Homo sapiens	IC50	nM	1200.0
363321	17738696	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	NC(=O)c1nc(-c2ccncc2)sc1NC(=O)c1ccco1		CHEMBL3935343	=	IC50	nM	6300.0	CHEMBL3529	Homo sapiens	IC50	nM	6300.0
363322	17738697	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	NC(=O)c1nc(-c2ccncc2)sc1NC(=O)c1ccc[nH]1		CHEMBL3934112	=	IC50	nM	140.0	CHEMBL3529	Homo sapiens	IC50	nM	140.0
363323	17738698	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	NC(=O)c1nc(-c2ccncc2)sc1NC(=O)c1cc[nH]n1		CHEMBL3946536	=	IC50	nM	7300.0	CHEMBL3529	Homo sapiens	IC50	nM	7300.0
363324	17738699	CHEMBL3887916	IKKε Kinase Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKε, 800 nM biotinylated IκBα(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol, 0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	NC(=O)c1nc(-c2ccncc2)sc1NC(=O)c1ccsc1		CHEMBL3955236	=	IC50	nM	480.0	CHEMBL3529	Homo sapiens	IC50	nM	480.0
370589	17745373	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2ccc(CN3CCCCC3)s2)cc1C(=O)Nc1ccncc1		CHEMBL3961973	=	IC50	nM	120.0	CHEMBL3529	Homo sapiens	IC50	nM	120.0
370590	17745374	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2ccc(CN3CCCC3)s2)cc1C(=O)Nc1ccncc1		CHEMBL3924260	=	IC50	nM	110.0	CHEMBL3529	Homo sapiens	IC50	nM	110.0
370591	17745375	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Cc1ccc(-c2cnc(N)c(C(=O)Nc3ccncc3)c2)s1		CHEMBL3900950	=	IC50	nM	150.0	CHEMBL3529	Homo sapiens	IC50	nM	150.0
370592	17745376	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	COCCn1cc(-c2cnc(N)c(C(=O)Nc3ccncc3)c2)cn1		CHEMBL3937942	=	IC50	nM	1900.0	CHEMBL3529	Homo sapiens	IC50	nM	1900.0
370593	17745377	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2ccc(S(N)(=O)=O)cc2)cc1C(=O)Nc1ccncc1		CHEMBL3915353	=	IC50	nM	1800.0	CHEMBL3529	Homo sapiens	IC50	nM	1800.0
370594	17745378	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Cc1cc(NC(=O)c2cc(-c3ccc(CN4CCOCC4)s3)cnc2N)ccn1		CHEMBL3943325	=	IC50	nM	830.0	CHEMBL3529	Homo sapiens	IC50	nM	830.0
370595	17745379	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	CCOc1cc(NC(=O)c2cc(-c3ccc(CN4CCOCC4)s3)cnc2N)ccn1		CHEMBL3899705	=	IC50	nM	660.0	CHEMBL3529	Homo sapiens	IC50	nM	660.0
370596	17745380	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2ccc(N3CCNCC3)nc2)cc1C(=O)Nc1ccncc1		CHEMBL3936692	=	IC50	nM	540.0	CHEMBL3529	Homo sapiens	IC50	nM	540.0
370597	17745381	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2cnn(CC3OCCO3)c2)nc1C(=O)Nc1ccncc1		CHEMBL3974895	=	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
370598	17745382	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2ccc(CN3CCCCC3)s2)nc1C(=O)Nc1ccncc1		CHEMBL3919706	=	IC50	nM	1900.0	CHEMBL3529	Homo sapiens	IC50	nM	1900.0
370599	17745383	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2ccc(CN3CCCC3)s2)nc1C(=O)Nc1ccncc1		CHEMBL3891661	=	IC50	nM	1900.0	CHEMBL3529	Homo sapiens	IC50	nM	1900.0
370600	17745384	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Cc1cc(NC(=O)c2cc(-c3csc(CN4CCOCC4)c3)cnc2N)ccn1		CHEMBL3914197	=	IC50	nM	2000.0	CHEMBL3529	Homo sapiens	IC50	nM	2000.0
370601	17745385	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2ccc(CN3CCOCC3)s2)cc1C(=O)Nc1ccnnc1		CHEMBL3980829	=	IC50	nM	110.0	CHEMBL3529	Homo sapiens	IC50	nM	110.0
370602	17745386	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Cc1cc(NC(=O)c2cc(-c3cnn(Cc4ccccc4)c3)cnc2N)ccn1		CHEMBL3975991	=	IC50	nM	340.0	CHEMBL3529	Homo sapiens	IC50	nM	340.0
370603	17745387	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2cccc(-n3cccn3)c2)cc1C(=O)Nc1ccnnc1		CHEMBL3936393	=	IC50	nM	640.0	CHEMBL3529	Homo sapiens	IC50	nM	640.0
370604	17745388	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Cc1cnccc1NC(=O)c1cc(-c2ccc(-n3cccn3)cc2)cnc1N		CHEMBL3911981	=	IC50	nM	2800.0	CHEMBL3529	Homo sapiens	IC50	nM	2800.0
370605	17745389	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	COCCn1cc(-c2cnc(N)c(C(=O)Nc3ccnc(C)c3)c2)cn1		CHEMBL3953248	=	IC50	nM	610.0	CHEMBL3529	Homo sapiens	IC50	nM	610.0
370606	17745390	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Cc1cnccc1NC(=O)c1cc(-c2ccc(CN3CCOCC3)s2)cnc1N		CHEMBL3892127	=	IC50	nM	910.0	CHEMBL3529	Homo sapiens	IC50	nM	910.0
370607	17745391	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	COCCn1cc(-c2cnc(N)c(C(=O)Nc3ccncc3C)c2)cn1		CHEMBL3952415	=	IC50	nM	2400.0	CHEMBL3529	Homo sapiens	IC50	nM	2400.0
370608	17745392	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Cc1ccc(-c2cccc(-c3cnc(N)c(C(=O)Nc4ccncc4)c3)c2)cc1		CHEMBL3981212	=	IC50	nM	2200.0	CHEMBL3529	Homo sapiens	IC50	nM	2200.0
370609	17745393	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	COCCn1cc(-c2cnc(N)c(C(=O)Nc3ccnnc3)c2)cn1		CHEMBL3915602	=	IC50	nM	890.0	CHEMBL3529	Homo sapiens	IC50	nM	890.0
370610	17745394	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	NC(=O)Cn1cc(-c2cnc(N)c(C(=O)Nc3ccncc3)c2)cn1		CHEMBL3976366	=	IC50	nM	530.0	CHEMBL3529	Homo sapiens	IC50	nM	530.0
370611	17745395	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Cc1cc(NC(=O)c2cc(-c3ccc(CN4CCOCC4)s3)cnc2N)cc(C)n1		CHEMBL3910247	=	IC50	nM	5200.0	CHEMBL3529	Homo sapiens	IC50	nM	5200.0
370612	17745396	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2ccc(CN3CCOCC3)s2)cc1C(=O)Nc1ccncn1		CHEMBL3938167	=	IC50	nM	2600.0	CHEMBL3529	Homo sapiens	IC50	nM	2600.0
370613	17745397	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	COCCn1cc(-c2cnc(N)c(C(=O)Nc3ccnc4ccoc34)c2)cn1		CHEMBL3901173	=	IC50	nM	2900.0	CHEMBL3529	Homo sapiens	IC50	nM	2900.0
370614	17745398	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2ccc(CN3CCOCC3)s2)cc1C(=O)Nc1ccnc2ccoc12		CHEMBL3925708	=	IC50	nM	2400.0	CHEMBL3529	Homo sapiens	IC50	nM	2400.0
370615	17745399	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	COC(=O)c1ccc(-c2cnc(N)c(C(=O)Nc3ccncc3)c2)cc1		CHEMBL3967420	=	IC50	nM	1900.0	CHEMBL3529	Homo sapiens	IC50	nM	1900.0
370616	17745400	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2ccc(C(=O)O)cc2)cc1C(=O)Nc1ccncc1		CHEMBL3937785	=	IC50	nM	990.0	CHEMBL3529	Homo sapiens	IC50	nM	990.0
370617	17745401	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2ccc(CCC(=O)O)cc2)cc1C(=O)Nc1ccncc1		CHEMBL3975928	=	IC50	nM	600.0	CHEMBL3529	Homo sapiens	IC50	nM	600.0
370618	17745402	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2ccc(CN3CCOCC3)s2)cc1C(=O)Nc1ccncc1Cl		CHEMBL3950028	=	IC50	nM	600.0	CHEMBL3529	Homo sapiens	IC50	nM	600.0
370619	17745403	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2cn[nH]c2)cc1C(=O)Nc1ccncc1		CHEMBL3923200	=	IC50	nM	740.0	CHEMBL3529	Homo sapiens	IC50	nM	740.0
370620	17745404	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	CC(=O)Nc1cc(NC(=O)c2cc(-c3ccc(CN4CCOCC4)s3)cnc2N)ccn1		CHEMBL3959788	=	IC50	nM	540.0	CHEMBL3529	Homo sapiens	IC50	nM	540.0
370621	17745405	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2cccc(C(=O)O)c2)cc1C(=O)Nc1ccncc1		CHEMBL3900659	=	IC50	nM	3200.0	CHEMBL3529	Homo sapiens	IC50	nM	3200.0
370622	17745406	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	COCCn1cc(-c2cnc(N)c(C(=O)Nc3ccncc3Cl)c2)cn1		CHEMBL3901749	=	IC50	nM	1500.0	CHEMBL3529	Homo sapiens	IC50	nM	1500.0
370623	17745407	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	COc1ccc(NC(=O)c2cc(-c3ccc(CN4CCOCC4)s3)cnc2N)cc1		CHEMBL3972829	=	IC50	nM	390.0	CHEMBL3529	Homo sapiens	IC50	nM	390.0
370624	17745408	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2cnn(CCO)c2)cc1C(=O)Nc1ccncc1		CHEMBL3897770	=	IC50	nM	1700.0	CHEMBL3529	Homo sapiens	IC50	nM	1700.0
370625	17745409	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2csc(CN3CCOCC3)c2)cc1C(=O)Nc1ccncc1		CHEMBL3922312	=	IC50	nM	330.0	CHEMBL3529	Homo sapiens	IC50	nM	330.0
370626	17745410	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	CC(=O)c1c[nH]c(-c2cnc(N)c(C(=O)Nc3ccncc3)c2)c1		CHEMBL3970040	=	IC50	nM	420.0	CHEMBL3529	Homo sapiens	IC50	nM	420.0
370627	17745411	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2ccoc2)cc1C(=O)Nc1ccncc1		CHEMBL3898836	=	IC50	nM	140.0	CHEMBL3529	Homo sapiens	IC50	nM	140.0
370628	17745412	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2cnn(Cc3ccccc3)c2)cc1C(=O)Nc1ccncc1		CHEMBL3975183	=	IC50	nM	240.0	CHEMBL3529	Homo sapiens	IC50	nM	240.0
370629	17745413	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Cn1ccc(-c2cnc(N)c(C(=O)Nc3ccncc3)c2)n1		CHEMBL3902251	=	IC50	nM	380.0	CHEMBL3529	Homo sapiens	IC50	nM	380.0
370630	17745414	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2ccsc2)cc1C(=O)Nc1ccncc1		CHEMBL3964958	=	IC50	nM	930.0	CHEMBL3529	Homo sapiens	IC50	nM	930.0
370631	17745415	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2cnn(CCN3CCOCC3)c2)cc1C(=O)Nc1ccncc1		CHEMBL3939553	=	IC50	nM	270.0	CHEMBL3529	Homo sapiens	IC50	nM	270.0
370632	17745416	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	CC(=O)c1ccc(-c2cnc(N)c(C(=O)Nc3ccncc3)c2)s1		CHEMBL3943921	=	IC50	nM	510.0	CHEMBL3529	Homo sapiens	IC50	nM	510.0
370633	17745417	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2ccc(CN3CCOCC3)s2)cc1C(=O)Nc1ccncc1		CHEMBL3982817	=	IC50	nM	450.0	CHEMBL3529	Homo sapiens	IC50	nM	450.0
370634	17745418	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2c[nH]c3ccccc23)cc1C(=O)Nc1ccncc1		CHEMBL3931286	=	IC50	nM	340.0	CHEMBL3529	Homo sapiens	IC50	nM	340.0
370635	17745419	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2ccc[nH]2)cc1C(=O)Nc1ccncc1		CHEMBL3945410	=	IC50	nM	3300.0	CHEMBL3529	Homo sapiens	IC50	nM	3300.0
370636	17745420	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2cnc3ccccn23)cc1C(=O)Nc1ccncc1		CHEMBL3976903	=	IC50	nM	1800.0	CHEMBL3529	Homo sapiens	IC50	nM	1800.0
370637	17745421	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2cc[nH]c2)cc1C(=O)Nc1ccncc1		CHEMBL3899325	=	IC50	nM	830.0	CHEMBL3529	Homo sapiens	IC50	nM	830.0
370638	17745422	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Nc1ncc(-c2coc3ccccc23)cc1C(=O)Nc1ccncc1		CHEMBL3953224	=	IC50	nM	300.0	CHEMBL3529	Homo sapiens	IC50	nM	300.0
370639	17745423	CHEMBL3888071	IKKepsilon Flashplate Assay: The kinase assay is performed either as 384-well Flashplate assay (for e.g. Topcount measurement). 1 nM IKKepsilon, 800 nM biotinylated IkappaBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) SEQ ID NO: 1 and 10 uM ATP (spiked with 0.3 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM Dithiothreitol,0.02% Brij35, 0.1% BSA, 0.1% BioStab, pH 7.5) with or without test compound for 2 hours at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution. Non-specific reaction is determined in presence of 3 uM MSC2119074 (BX-795). Radioactivity is measured with Topcount (PerkinElmer).	B	Cn1cc(-c2cnc(N)c(C(=O)Nc3ccncc3)c2)cn1		CHEMBL3925601	=	IC50	nM	480.0	CHEMBL3529	Homo sapiens	IC50	nM	480.0
428845	17790515	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1CCC(NC(=O)c2cccc(Nc3nccc(-c4cnc(N5CC[C@H](F)C5)c(C#N)c4)n3)c2)CC1		CHEMBL3931115	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428846	17790516	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cccc(C(N)=O)c3)n2)cnc1N1CCCC1		CHEMBL3927043	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428847	17790517	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1CCN(c2ccc(Nc3nccc(-c4cnc(N5CCCC5)c(C#N)c4)n3)cn2)CC1		CHEMBL3930440	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
428848	17790518	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cccc(C(=O)N4CCNCC4)c3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3921622	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428849	17790519	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cnc1N1CCCC1		CHEMBL3963738	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428850	17790520	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1CCN(C(=O)c2cccc(Nc3nccc(-c4cnc(N5CC[C@H](F)C5)c(C#N)c4)n3)c2)CC1		CHEMBL3920382	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428851	17790521	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cn1cc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3944797	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428852	17790522	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(=O)Nc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3907890	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428853	17790523	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1CCC(Nc2ccc(Nc3nccc(-c4cnc(N5CC[C@H](F)C5)c(C#N)c4)n3)cn2)CC1		CHEMBL3935860	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
428854	17790524	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(NC4CCNCC4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3891126	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428855	17790525	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cccc(C(=O)NC4CCNCC4)c3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3922677	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428856	17790526	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1CCC(NC(=O)c2cccc(Nc3nccc(-c4cnc(N5CC[C@H](O)C5)c(C#N)c4)n3)c2)CC1		CHEMBL3967101	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428857	17790527	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1CCC(Nc2ccc(Nc3nccc(-c4cnc(N5CC[C@H](O)C5)c(C#N)c4)n3)cn2)CC1		CHEMBL3940936	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428858	17790528	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1CCC(NC(=O)c2cccc(Nc3nccc(-c4cnc(N5CCC(F)(F)C5)c(C#N)c4)n3)c2)CC1		CHEMBL3955989	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428859	17790529	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1CCC(Nc2ccc(Nc3nccc(-c4cnc(N5CCC(F)(F)C5)c(C#N)c4)n3)cn2)CC1		CHEMBL3928378	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428860	17790530	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cn1cc(Nc2nccc(-c3cnc(N4CC[C@H](O)C4)c(C#N)c3)n2)cn1		CHEMBL3950694	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428861	17790531	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(NC(=O)CN4CCOCC4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3919474	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428862	17790532	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(C(=O)Nc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1)N(C)C		CHEMBL3941967	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428863	17790533	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(NC(=O)C4CC4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3913990	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428864	17790534	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cnc(N4CCOCC4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3929435	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428865	17790535	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCN(C)CC(=O)Nc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3904988	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428866	17790536	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(C)(O)CNc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3980518	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
428867	17790537	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(C)N1CCN(CC(=O)Nc2ccc(Nc3nccc(-c4cnc(N5CC[C@H](F)C5)c(C#N)c4)n3)cn2)CC1		CHEMBL3910408	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428868	17790538	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1CCN(c2ccc(Nc3nccc(-c4cnc(N5CC[C@H](F)C5)c(C#N)c4)n3)cn2)CC1		CHEMBL3985538	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
428869	17790539	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(N4CCNCC4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3919338	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
428870	17790540	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	C[C@@H]1CN(c2ccc(Nc3nccc(-c4cnc(N5CC[C@H](O)C5)c(C#N)c4)n3)cn2)CCN1		CHEMBL4110039	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428871	17790541	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(NC(=O)CO)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3924783	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428872	17790542	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1CCC(NC(=O)c2ccc(Nc3ncc(F)c(-c4cnc(N5CC[C@H](F)C5)c(C#N)c4)n3)cc2)CC1		CHEMBL3909307	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
428873	17790543	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(NC(=O)CN4CCC(O)CC4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3959400	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428874	17790544	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)cc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3915872	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
428875	17790545	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(NC(=O)CN4CCNCC4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3943824	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428876	17790546	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(C(=O)Nc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1)N1CCOCC1		CHEMBL3938197	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428877	17790547	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cnn(C4CCOCC4)c3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3910276	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
428878	17790548	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccnc(NC(=O)CN4CCOCC4)c3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3957230	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428879	17790549	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(NC(=O)CC4CC[C@H](O)C4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3950524	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428880	17790550	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccnc(N4CCOCC4)c3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3923747	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
428881	17790551	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(C)(N)C(=O)Nc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3895745	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428882	17790552	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cn[nH]c3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3932700	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
428883	17790553	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccn[nH]3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3901208	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428884	17790554	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(NC(=O)C4CCCN4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3904619	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428885	17790555	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(NC(=O)CN4CCCC4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3975437	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428886	17790556	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(NCCN4CCOCC4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3919184	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
428887	17790557	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3943587	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
428888	17790558	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(NC(=O)CN4CC[C@H](F)C4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3977169	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428889	17790559	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(OCCN4CC[C@H](F)C4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3906502	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428890	17790560	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccnc(N4CCOCC4)c3)n2)cnc1N1CC[C@H](O)C1		CHEMBL3968667	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428891	17790561	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCNc1cc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)ccn1		CHEMBL3901065	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428892	17790562	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cccc(=O)[nH]3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3961080	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428893	17790563	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN(C(=O)CN1CCOCC1)c1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3892095	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428894	17790564	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN(C(=O)CN1CCOCC1)c1ccc(Nc2nccc(-c3cnc(N4CC[C@H](O)C4)c(C#N)c3)n2)cn1		CHEMBL3954664	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428895	17790565	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1Cc2ccc(Nc3nccc(-c4cnc(N5CC[C@H](F)C5)c(C#N)c4)n3)cc2C1		CHEMBL3980158	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
428896	17790566	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCNCc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3935316	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428897	17790567	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	C[C@H]1COCCN1Cc1cc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)ccn1		CHEMBL3934205	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428898	17790568	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	C[C@H]1COCCN1Cc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3915896	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428899	17790569	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CC[C@H](F)C4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3898354	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
428900	17790570	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cc1nccn1Cc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3949617	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428901	17790571	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCN(C)Cc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3925343	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428902	17790572	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COC1CN(Cc2ccc(Nc3nccc(-c4cnc(N5CC[C@H](F)C5)c(C#N)c4)n3)cn2)C1		CHEMBL3940846	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428903	17790573	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cnc1N1CCCOCC1		CHEMBL3912853	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428904	17790574	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(NC(=O)CN4CCOCC4)nc3)n2)cnc1N1CCCOCC1		CHEMBL3927596	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428905	17790575	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2nc(Nc3ccc(NC(=O)CN4CCOCC4)nc3)ncc2F)cnc1N1CCCOCC1		CHEMBL3896079	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428906	17790576	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2nc(Nc3ccc(CN4CCOCC4)nc3)ncc2F)cnc1N1CCCOCC1		CHEMBL3895616	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428907	17790577	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2nc(Nc3ccc(NC(=O)CN4CCOCC4)nc3)ncc2F)cnc1N1CC[C@H](F)C1		CHEMBL3923611	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428908	17790578	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2nc(Nc3ccc(CN4CCOCC4)nc3)ncc2F)cnc1N1CC[C@H](F)C1		CHEMBL3978449	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428910	17790579	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2nc(Nc3ccnc(NC(=O)CN4CCOCC4)c3)ncc2F)cnc1N1CC[C@H](F)C1		CHEMBL3979474	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428911	17790580	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cnc1N1CCC2(COC2)C1		CHEMBL3909236	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428912	17790581	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccnc(NC(=O)CN4CCOCC4)c3)n2)cnc1N1CCC2(COC2)C1		CHEMBL3984412	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428913	17790582	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2nc(Nc3ccnc(NC(=O)CN4CCOCC4)c3)ncc2F)cnc1N1CCCOCC1		CHEMBL3968490	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428914	17790583	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCNc1cc(Nc2ncc(F)c(-c3cnc(N4CCCOCC4)c(C#N)c3)n2)ccn1		CHEMBL3903354	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428915	17790584	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(c1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1)N1CCOCC1		CHEMBL3931338	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428916	17790585	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CO[C@H]1CCN(Cc2ccc(Nc3nccc(-c4cnc(N5CC[C@H](F)C5)c(C#N)c4)n3)cn2)C1		CHEMBL3984119	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428917	17790586	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CS(=O)(=O)CCNCc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3952082	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428918	17790587	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccnc(CN4CCOCC4)c3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3976096	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428919	17790588	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cncc(CN4CCOCC4)c3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3946780	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428920	17790589	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN(CCO)c1cc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)ccn1		CHEMBL3928858	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428921	17790590	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCNC(=O)C4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3904385	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
428922	17790591	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCCOCC4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3891771	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428923	17790592	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN(CCO)Cc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3960782	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428925	17790593	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4C(=O)OCC4CO)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3918874	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428926	17790594	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCNCc1cncc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)c1		CHEMBL3915999	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428927	17790595	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(C)(N)c1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3943961	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428928	17790596	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cncc(NC(=O)CN4CCOCC4)c3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3928470	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428929	17790597	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cnc4c(c3)CNC4)n2)cnc1N1CC[C@H](F)C1		CHEMBL3952708	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428930	17790598	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC1(O)CN(Cc2ccc(Nc3nccc(-c4cnc(N5CC[C@H](F)C5)c(C#N)c4)n3)cn2)C1		CHEMBL3929670	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428931	17790599	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccnc(NC(=O)CN4CCOCC4)c3)n2)cnc1N1CC[C@@H](F)C1		CHEMBL4114133	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428932	17790600	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(NC(=O)CN4CCOCC4)nc3)n2)cnc1N1CC[C@@H](F)C1		CHEMBL4109686	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
428933	17790601	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(=O)Nc1ccc(Nc2nccc(-c3cnc(NC4CCOC4)c(C#N)c3)n2)cn1		CHEMBL3938562	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428934	17790602	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1CCC(Nc2ccc(Nc3nccc(-c4cnc(NC5CCOC5)c(C#N)c4)n3)cn2)CC1		CHEMBL3904581	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428935	17790603	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1CCC(NC(=O)c2cccc(Nc3nccc(-c4cnc(NC5CCOC5)c(C#N)c4)n3)c2)CC1		CHEMBL3936211	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428936	17790604	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cn1cc(Nc2nccc(-c3cnc(NC4CCOC4)c(C#N)c3)n2)cn1		CHEMBL3950198	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428937	17790605	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cccc(C(=O)NC4CCNCC4)c3)n2)cnc1NC1CCOC1		CHEMBL3922477	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428938	17790606	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCNc1ncc(-c2ccnc(Nc3ccc(NC4CCN(C)CC4)nc3)n2)cc1C#N		CHEMBL3931256	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428939	17790607	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CNc1ncc(-c2ccnc(Nc3ccc(NC4CCN(C)CC4)nc3)n2)cc1C#N		CHEMBL3927876	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428940	17790608	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1CCC(Nc2ccc(Nc3nccc(-c4cnc(NCCO)c(C#N)c4)n3)cn2)CC1		CHEMBL3985702	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428941	17790609	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cnc1NC1CC1		CHEMBL3908778	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428942	17790610	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2nc(Nc3ccc(CN4CCOCC4)nc3)ncc2F)cnc1NC1CC1		CHEMBL3945627	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428943	17790611	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2nc(Nc3ccnc(NC(=O)CN4CCOCC4)c3)ncc2F)cnc1NC1CC1		CHEMBL3921247	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428944	17790612	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCNc1cc(Nc2ncc(F)c(-c3cnc(NC4CC4)c(C#N)c3)n2)ccn1		CHEMBL3914507	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428945	17790613	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc4c(c3)CNC4)n2)cnc1N1CC[C@H](F)C1		CHEMBL3984327	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
428946	17790614	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCN1Cc2ccc(Nc3nccc(-c4cnc(N5CC[C@H](F)C5)c(C#N)c4)n3)cc2C1		CHEMBL3892171	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
428947	17790615	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCO)c3)n2)cnc1N1CCCC1		CHEMBL3934438	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428948	17790616	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(C(N)=O)cc3)n2)cnc1N1CCCC1		CHEMBL3971959	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
428949	17790617	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cnn(C[C@H](O)CO)c3)n2)cnc1N1CCCC1		CHEMBL3943196	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428950	17790618	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cnn(C[C@@H](O)CO)c3)n2)cnc1N1CCCC1		CHEMBL4106630	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428951	17790619	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cn1cc(Nc2nccc(-c3cnc(N4CCC[C@@H]4C(=O)O)c(C#N)c3)n2)cn1		CHEMBL4109238	<	IC50	nM	9000.0	CHEMBL3529	Homo sapiens	IC50	nM	9000.0
428952	17790620	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cn1cc(NC(=O)[C@H]2CCCN2c2ncc(-c3ccnc(Nc4cnn(C)c4)n3)cc2C#N)cn1		CHEMBL4112421	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428953	17790621	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cn1cc(Nc2nccc(-c3cnc(N4CCC[C@H]4C#N)c(C#N)c3)n2)cn1		CHEMBL3900993	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428954	17790622	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cn1cc(Nc2nccc(-c3cnc(N4CCC[C@@H]4C(N)=O)c(C#N)c3)n2)cn1		CHEMBL4115221	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428955	17790623	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cn1cc(Nc2nccc(-c3cnc(N4C5CCC4CC(O)C5)c(C#N)c3)n2)cn1		CHEMBL3985522	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428956	17790624	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cn1cc(Nc2nccc(-c3cnc(N4C5CCC4COC5)c(C#N)c3)n2)cn1		CHEMBL3896086	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428957	17790625	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCO)c3)n2)cnc1N1C2CCC1COC2		CHEMBL3970737	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428958	17790626	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(C(N)=O)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3984886	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428959	17790627	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(C(=O)NCCO)cc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3956235	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
428960	17790628	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cnc1N1CC[C@H](O)C1		CHEMBL3979910	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
428961	17790629	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(N4CCOCC4)nc3)n2)cnc1N1CC[C@H](O)C1		CHEMBL3947539	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428962	17790630	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCO)c3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3971833	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428963	17790631	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCCO)c3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3942227	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428964	17790632	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCN4CCOCC4)c3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3957288	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428965	17790633	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCNCC(=O)Nc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3933243	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428966	17790634	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(NCc1ccccc1)C(=O)Nc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3956706	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428967	17790635	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(N)C(=O)Nc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3985372	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428968	17790636	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cc1nccn1CC(=O)Nc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3962112	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428969	17790637	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(N)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3982149	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428970	17790638	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(=O)NCC1CCCN1c1ncc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cc1C#N		CHEMBL3973089	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428971	17790639	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cnc1N1CCCC1CC(N)=O		CHEMBL3902062	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428972	17790640	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cnc1N1CCC(CC(N)=O)C1		CHEMBL3984323	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428973	17790641	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC1CN(c2ncc(-c3ccnc(Nc4ccc(CN5CCOCC5)nc4)n3)cc2C#N)CCO1		CHEMBL3921294	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428974	17790642	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(=O)NC1CCN(c2ncc(-c3ccnc(Nc4ccc(CN5CCOCC5)nc4)n3)cc2C#N)C1		CHEMBL3911737	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428975	17790643	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCC1CCN(c2ncc(-c3ccnc(Nc4ccc(CN5CCOCC5)nc4)n3)cc2C#N)C1		CHEMBL3971527	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428976	17790644	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cnc1N1CCC(OC(F)F)C1		CHEMBL3903934	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428977	17790645	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cnc1N1CCC(CCC(N)=O)C1		CHEMBL3974819	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428978	17790646	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cnc1N1CCNC(=O)CC1		CHEMBL3941055	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428979	17790647	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(Nc1ncc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cc1C#N)C(N)=O		CHEMBL3916574	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428980	17790648	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(C(N)=O)N(C)c1ncc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cc1C#N		CHEMBL3889505	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428981	17790649	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(C)C(Nc1ncc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cc1C#N)C(N)=O		CHEMBL3916897	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
428982	17790650	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN(CC1CCOC1)c1ncc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cc1C#N		CHEMBL3943539	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428983	17790651	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cnc1NCC1CCOC1		CHEMBL3966321	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428984	17790652	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cnc1NC1CCCC1		CHEMBL3969564	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428985	17790653	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCN(C)c1ncc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cc1C#N		CHEMBL3939994	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
428986	17790654	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN(c1ncc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cc1C#N)C1CCOC1		CHEMBL3931468	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428987	17790655	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)ccc1N1CC[C@H](O)C1		CHEMBL3955566	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428988	17790656	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)ccc1N1CCCC1		CHEMBL3890843	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
428989	17790657	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cn1cc(Nc2nccc(-c3ccc(N4CC[C@H](O)C4)c(C#N)n3)n2)cn1		CHEMBL3918912	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428990	17790658	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cn1cc(Nc2nccc(-c3ccc(N4CCC(C(N)=O)CC4)c(C#N)n3)n2)cn1		CHEMBL3980121	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428991	17790659	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(NC(=O)CN4CCOCC4)nc3)n2)ccc1N1CC[C@H](O)C1		CHEMBL3954923	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428992	17790660	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(NC(=O)CN4CCOCC4)nc3)n2)ccc1N1CC[C@H](F)C1		CHEMBL3975272	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
428993	17790661	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)ccc1N1CC[C@H](F)C1		CHEMBL3904420	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
428994	17790662	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)ccc1N1CC[C@H](O)C1		CHEMBL3968958	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428995	17790663	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(NC(=O)CN4CC[C@H](F)C4)nc3)n2)ccc1N1CC[C@H](F)C1		CHEMBL3894306	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
428996	17790664	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(NC(=O)CN4CC[C@H](F)C4)nc3)n2)ccc1N1CC[C@H](O)C1		CHEMBL3926764	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428997	17790665	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(OCCN4CC[C@H](F)C4)nc3)n2)ccc1N1CC[C@H](F)C1		CHEMBL3895278	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428998	17790666	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(OCCN4CC[C@H](F)C4)nc3)n2)ccc1N1CC[C@H](O)C1		CHEMBL3917806	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
428999	17790667	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	C[C@H]1COCCN1Cc1ccc(Nc2nccc(-c3cc(C#N)c(N4CC[C@H](F)C4)c(C#N)n3)n2)cn1		CHEMBL3889803	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
429000	17790668	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(CN4CC[C@H](F)C4)nc3)n2)ccc1N1CC[C@H](F)C1		CHEMBL3941194	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
429001	17790669	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cc1nccn1Cc1ccc(Nc2nccc(-c3ccc(N4CC[C@H](F)C4)c(C#N)n3)n2)cn1		CHEMBL3916744	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
429002	17790670	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCN(C)Cc1ccc(Nc2nccc(-c3ccc(N4CC[C@H](F)C4)c(C#N)n3)n2)cn1		CHEMBL3932195	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
429003	17790671	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2nc(Nc3ccc(N4CCOCC4)cc3)ncc2F)ccc1N1CC[C@H](F)C1		CHEMBL3904190	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
429004	17790672	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)ccc1N1CCCOCC1		CHEMBL3919044	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
429005	17790673	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)ccc1N1CCC2(COC2)C1		CHEMBL3985241	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
429006	17790674	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(NC(=O)CN4CCOCC4)nc3)n2)ccc1N1CCCOCC1		CHEMBL3961831	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
429007	17790675	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(NC(=O)CN4CCOCC4)nc3)n2)ccc1N1CCC2(COC2)C1		CHEMBL3892819	<	IC50	nM	30.0	CHEMBL3529	Homo sapiens	IC50	nM	30.0
429008	17790676	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN(C)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)nc1C#N		CHEMBL3946601	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
429009	17790677	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCN(C)c1ccc(-c2ccnc(Nc3cnn(C)c3)n2)nc1C#N		CHEMBL3972720	<	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	nM	1000.0
429010	17790678	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(CN4CCNC(=O)C4)nc3)n2)ccc1N1CC[C@H](F)C1		CHEMBL3947772	<	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
429011	17790679	CHEMBL3889016	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCNCc1ccc(Nc2nccc(-c3ccc(N4CC[C@H](F)C4)c(C#N)n3)n2)cn1		CHEMBL3977034	<	IC50	nM	100.0	CHEMBL3529	Homo sapiens	IC50	nM	100.0
Inactive	17907090	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907091	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F		CHEMBL3039513	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907092	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1		CHEMBL2041933	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907093	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(C(=O)Nc2ccc(C(=O)N3CCN(C)CC3)cc2)nnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL2376648	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907094	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1		CHEMBL3039517	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907095	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F		CHEMBL1090090	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907096	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907097	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(/C=C/c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1		CHEMBL1614707	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907098	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1C#CC(C)(C)N1CCN(C)CC1		CHEMBL2138625	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907099	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12		CHEMBL3544944	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907100	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc3[nH]ncc23)CC1		CHEMBL3545076	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907101	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL3353410	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907102	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12		CHEMBL1614710	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907103	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1		CHEMBL3545308	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907104	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1		CHEMBL571546	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907105	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1		CHEMBL598797	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907106	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1		CHEMBL3039525	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907107	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL3545154	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907108	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1		CHEMBL3301612	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907109	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907110	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@H](N2CCC2)C1		CHEMBL551064	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907111	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1N=C(N)c2cn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL462018	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907112	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1		CHEMBL2035187	=	Kd	nM	715.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	715.0
Inactive	17907113	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1		CHEMBL2110732	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907114	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL507361	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907115	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12		CHEMBL3408248	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907116	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1		CHEMBL3590106	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907117	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)C1(Cc2cccc(Nc3nccs3)n2)CCC(Oc2cccc(Cl)c2F)CC1		CHEMBL3182444	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907118	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907119	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1		CHEMBL1236682	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907120	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	443.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	443.0
Inactive	17907121	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc2cc(-c3nc([C@H]4CC[C@H](C(=O)O)CC4)n4ncnc(N)c34)[nH]c12		CHEMBL3120215	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907122	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907123	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL3545360	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907124	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907125	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	642.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	642.0
Inactive	17907126	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)c1cccc(-c2cc(C(=O)NC3CCN(C)CC3)c(C)c3[nH]c4ncc(C)cc4c23)c1		CHEMBL3544932	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907127	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O		CHEMBL536151	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907128	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907129	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1		CHEMBL1946170	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907130	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1		CHEMBL587723	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907131	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907132	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1		CHEMBL2103875	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907133	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907134	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2[nH]nc3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1		CHEMBL3128043	=	Kd	nM	658.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	658.0
Inactive	17907135	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1csc(-c2nnc(Nc3ccc(Oc4ncccc4-c4ccnc(N)n4)cc3)c3ccccc23)c1		CHEMBL2140408	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907136	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	2034.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	2034.0
Active	17907137	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Kd	nM	1510.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	1510.0
Inactive	17907138	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC[C@H](O)CO)c1ccncc1Nc1ccc(I)cc1F		CHEMBL2107832	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907139	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C		CHEMBL1233528	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907140	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	=	Kd	nM	2620.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	2620.0
Inactive	17907141	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907142	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1		CHEMBL2323775	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907143	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907144	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC		CHEMBL2029988	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907145	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1		CHEMBL3402762	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907146	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@@H]23)OCO4)cc(OC)c1OC		CHEMBL283120	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907147	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O		CHEMBL1289601	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907148	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907149	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12		CHEMBL3426621	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907150	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1		CHEMBL2396661	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907151	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F		CHEMBL3188267	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907152	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	1731.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	1731.0
Inactive	17907153	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12		CHEMBL2220486	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907154	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907155	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907156	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907157	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL2408045	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907158	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1		CHEMBL2364611	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907159	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1.Cl		CHEMBL3991929	=	Kd	nM	1291.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	1291.0
Inactive	17907160	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1		CHEMBL3218578	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907161	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)C(=O)CC[C@@H]12)CC=C		CHEMBL411907	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907162	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1		CHEMBL1241855	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907163	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1		CHEMBL1088752	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907164	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2o1		CHEMBL3991933	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907165	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21		CHEMBL3334567	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907166	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907167	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1		CHEMBL3544983	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907168	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907169	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	=	Kd	nM	2728.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	2728.0
Inactive	17907170	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907171	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907172	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O		CHEMBL3182621	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907173	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL2103839	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907174	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907175	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907176	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907177	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1		CHEMBL3991932	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907178	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCNC(=O)C#Cc1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN(C)C)cc1)c1ccccc1		CHEMBL3699142	=	Kd	nM	408.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	408.0
Inactive	17907179	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3991931	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907180	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	=	Kd	nM	689.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	689.0
Inactive	17907181	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907182	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4nnc[nH]4)cc23)c1		CHEMBL1614713	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907183	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N[C@@H]1CCCN(c2c(/C=C3\SC(=O)NC3=O)cccc2-c2ccccc2)C1		CHEMBL2048872	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907184	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907185	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F		CHEMBL3264002	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907186	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907187	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccccc5)cc4F)c3s2)c1		CHEMBL254760	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907188	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907189	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1		CHEMBL592445	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907190	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1		CHEMBL3545085	=	Kd	nM	1387.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	1387.0
Inactive	17907191	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1		CHEMBL2165191	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907192	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1		CHEMBL206834	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907193	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C		CHEMBL1230607	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907194	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907195	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907196	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1		CHEMBL2103842	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907197	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	=	Kd	nM	838.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	838.0
Inactive	17907198	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B			CHEMBL4084193	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907199	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907200	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O		CHEMBL1738797	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907201	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1		CHEMBL1738757	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907202	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907203	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC		CHEMBL2105717	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907204	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907205	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907206	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12		CHEMBL1171837	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907207	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H]1CO.Cl		CHEMBL3991935	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907208	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1		CHEMBL3545157	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907209	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907210	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907211	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12		CHEMBL2103882	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907212	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907213	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1		CHEMBL3301622	=	Kd	nM	1468.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	1468.0
Inactive	17907214	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907215	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907216	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1		CHEMBL2386889	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907217	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)/C(=C/c2ccc3nccc(-c4ccncc4)c3c2)S1		CHEMBL3544966	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907218	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1201182	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907219	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1		CHEMBL2087361	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907220	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(CCc2cc(NC(=O)c3ccc(N4CC(C)NC(C)C4)cc3)n[nH]2)cc(OC)c1		CHEMBL3184679	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907221	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1		CHEMBL3989868	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907222	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO		CHEMBL1801204	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907223	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F		CHEMBL1236962	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907224	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1		CHEMBL1088751	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907225	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1		CHEMBL3545328	=	Kd	nM	342.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	342.0
Inactive	17907226	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1		CHEMBL571948	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907227	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCc1c(-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)c(F)c2)c2c(N)ncnn2c1CN1CCOCC1		CHEMBL3991934	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907228	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1		CHEMBL3186534	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907229	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1		CHEMBL1091644	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907230	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907231	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21		CHEMBL3187723	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907232	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1		CHEMBL496102	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907233	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1		CHEMBL1231124	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907234	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1		CHEMBL1976040	=	Kd	nM	2057.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	2057.0
Inactive	17907235	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3137336	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907236	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1		CHEMBL460702	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907237	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21		CHEMBL3218576	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907238	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL574737	=	Kd	nM	528.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	528.0
Active	17907239	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1		CHEMBL1090479	=	Kd	nM	992.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	992.0
Inactive	17907240	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1		CHEMBL482968	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907241	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1		CHEMBL2017974	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907242	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1		CHEMBL2146883	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907243	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL1614766	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907244	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907245	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907246	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]ccc2cc(OC3CCNCC3)ccc12		CHEMBL1667969	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907247	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907248	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907249	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL403989	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907250	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1		CHEMBL2105759	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907251	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1		CHEMBL1078178	=	Kd	nM	200.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	200.0
Active	17907252	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Kd	nM	494.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	494.0
Inactive	17907253	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12		CHEMBL1645462	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907254	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907255	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL1922094	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907256	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907257	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907258	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1		CHEMBL3545396	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907259	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1		CHEMBL2103851	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907260	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	=	Kd	nM	176.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	176.0
Inactive	17907261	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1		CHEMBL270995	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907262	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1		CHEMBL1952329	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907263	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	=	Kd	nM	796.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	796.0
Inactive	17907264	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL2219422	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907265	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1		CHEMBL2105728	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907266	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907267	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2		CHEMBL564829	=	Kd	nM	2966.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	2966.0
Inactive	17907268	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21		CHEMBL1614725	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907269	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1		CHEMBL372764	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907270	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907271	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=Nc3cc(NC(=O)C(N)C4CCCCC4)cc4c3C2=CNNC4=O)cn1		CHEMBL3545137	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907272	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1		CHEMBL2079588	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907273	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907274	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907275	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688339	=	Kd	nM	182.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	182.0
Inactive	17907276	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1		CHEMBL217092	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907277	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F		CHEMBL1229517	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907278	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(O)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL400402	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907279	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21		CHEMBL3545215	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907280	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2ccc3nsnc3c2)cc1		CHEMBL3218575	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907281	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907282	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907283	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1		CHEMBL1822792	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907284	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21		CHEMBL1615025	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907285	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2c(O)nccc12)N1CCCNCC1		CHEMBL1233300	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907286	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	=	Kd	nM	2264.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	2264.0
Inactive	17907287	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1		CHEMBL2001019	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907288	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1		CHEMBL3545307	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907289	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(S(=O)(=O)N(C(C)=O)c2ccccc2/C=C/c2cc[n+]([O-])cc2)cc1		CHEMBL3991927	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907290	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21		CHEMBL1879463	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907291	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907292	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1		CHEMBL1950289	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907293	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1		CHEMBL575448	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907294	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1		CHEMBL3348923	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907295	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907296	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907297	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3544960	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907298	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2ccc(-n3ncc(C(=O)c4cc5ccccc5[nH]4)c3N)cc2[nH]1		CHEMBL3907479	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907299	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1		CHEMBL2028663	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907300	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL2103830	=	Kd	nM	1320.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	1320.0
Inactive	17907301	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1		CHEMBL2180604	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907302	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907303	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907304	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907305	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1		CHEMBL495727	=	Kd	nM	215.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	215.0
Inactive	17907306	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc32)cccc1C(F)(F)F		CHEMBL3188551	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907307	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907308	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907309	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907310	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL402548	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907311	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1		CHEMBL2216870	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907312	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C		CHEMBL488436	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907313	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	=	Kd	nM	173.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	173.0
Inactive	17907314	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1nccc1Nc1nccc(-c2ccn([C@H](CO)c3ccc(Cl)c(F)c3)c(=O)c2)n1		CHEMBL3544964	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907315	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907316	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907317	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1908360	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907318	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(C(F)(F)c4ccc5ncccc5c4)n3n2)cn1		CHEMBL2133806	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907319	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907320	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(N2CCN(C)CC2)cc1Nc1ncc2c(n1)-c1c(c(C(N)=O)nn1C)CC2		CHEMBL1094408	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907321	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1		CHEMBL3301607	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907322	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1		CHEMBL1234354	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907323	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC		CHEMBL405130	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907324	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3		CHEMBL3109738	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907325	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1		CHEMBL2336325	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907326	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1		CHEMBL1079175	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907327	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCCN1CCN(Cc2ccc(-c3n[nH]c4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1		CHEMBL3545083	=	Kd	nM	1902.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	1902.0
Inactive	17907328	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3545110	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17907329	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1		CHEMBL1944698	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
Active	17907330	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL274654	=	Kd	nM	1430.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	1430.0
Inactive	17907331	CHEMBL3991736	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CN(C(=O)c2cc3c(C(=O)C(=O)N(C)C)cn(C)c3cc2Cl)[C@H](C)CN1Cc1ccc(F)cc1		CHEMBL514201	>	Kd	nM	30000.0	CHEMBL3529	Homo sapiens	Kd apparent	nM	30000.0
	18031728	CHEMBL4007713	Inhibition of IKKE (unknown origin) after 60 mins by TR-FRET assay	B	CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3cc[nH]c3n2)cc1		CHEMBL2006765	=	IC50	nM	1700.0	CHEMBL3529	Homo sapiens	IC50	uM	1.7
	18031729	CHEMBL4007713	Inhibition of IKKE (unknown origin) after 60 mins by TR-FRET assay	B	FC(F)(F)CNc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2ccoc12		CHEMBL4078893	>	IC50	nM	10000.0	CHEMBL3529	Homo sapiens	IC50	uM	10.0
	18031730	CHEMBL4007713	Inhibition of IKKE (unknown origin) after 60 mins by TR-FRET assay	B	FC(F)(F)CNc1nc(Nc2ccc3cn[nH]c3c2)nc2ccoc12		CHEMBL4066664	>	IC50	nM	10000.0	CHEMBL3529	Homo sapiens	IC50	uM	10.0
	18031731	CHEMBL4007713	Inhibition of IKKE (unknown origin) after 60 mins by TR-FRET assay	B	CC1(C)OCC(=O)Nc2cc(Nc3nc(NCC(F)(F)F)c4occc4n3)ccc21		CHEMBL4069365	=	IC50	nM	3430.0	CHEMBL3529	Homo sapiens	IC50	uM	3.43
	18031732	CHEMBL4007713	Inhibition of IKKE (unknown origin) after 60 mins by TR-FRET assay	B	Cc1n[nH]c2cc(Nc3nc(NC4CC4)c4occc4n3)ccc12		CHEMBL4062803	>	IC50	nM	10000.0	CHEMBL3529	Homo sapiens	IC50	uM	10.0
Not Active	18092342	CHEMBL4020198	Inhibition of IKKepsilon (unknown origin)	B	Fc1cccc(Cl)c1CNc1nc(-c2ccco2)n[nH]1		CHEMBL1354522		Inhibition	%		CHEMBL3529	Homo sapiens	INH		
	18114313	CHEMBL4025181	Inhibition of wild-type human full length IKK-epsilon (M1 to V716 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	Activity	%	100.0	CHEMBL3529	Homo sapiens	Activity	%	100.0
	18153309	CHEMBL4034339	Inhibition of IKKe Lysine 2 labelling site (unknown origin) at 10 uM	B	c1cc(-c2c[nH]c3cnccc23)ccn1		CHEMBL4084955	=	Inhibition	%	-0.7	CHEMBL3529	Homo sapiens	INH	%	-0.7
	18203705	CHEMBL4043992	Inhibition of wild-type human full length IKK-epsilon (M1 to V716 residues) expressed in HEK293 cells assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control	B	COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4ccc(F)cc4)nc3N(C3CCN(C(=O)/C=C/CN(C)C)CC3)C2=O)c1Cl		CHEMBL4092508	=	Activity	%	100.0	CHEMBL3529	Homo sapiens	Activity	%	100.0
	18211625	CHEMBL4045696	Inhibition of IKKe conserved Lys2 (DIKPGNIMR) in human PBMC at 1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	11.0	CHEMBL3529	Homo sapiens	INH	%	11.0
	18211636	CHEMBL4045695	Inhibition of IKKe conserved Lys1 (SGELVAVKVFNTTSYLRPR) in human PBMC at 1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	5.5	CHEMBL3529	Homo sapiens	INH	%	5.5
	18211840	CHEMBL4045936	Inhibition of IKKe conserved Lys1 (SGELVAVKVFNTTSYLRPR) in human PBMC at 0.1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	6.2	CHEMBL3529	Homo sapiens	INH	%	6.2
	18211841	CHEMBL4045937	Inhibition of IKKe conserved Lys2 (DIKPGNIMR) in human PBMC at 0.1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	21.7	CHEMBL3529	Homo sapiens	INH	%	21.7
	18232211	CHEMBL4050295	Inhibition of human IKKe assessed as residual activity at 1 uM in presence of 33P-ATP by filter-binding assay relative to control	B	NCCCC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCCOc1nc2cc(C(=O)O)ccc2c2cnccc12)C(=O)O		CHEMBL4077554	=	Activity	%	13.0	CHEMBL3529	Homo sapiens	Activity	%	13.0
	18253837	CHEMBL4055203	Inhibition of wild-type human full length IKK-epsilon (M1 to V716 residues) expressed in mammalian expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N		CHEMBL4096145	=	Activity	%	100.0	CHEMBL3529	Homo sapiens	Activity	%	100.0
	18253838	CHEMBL4055203	Inhibition of wild-type human full length IKK-epsilon (M1 to V716 residues) expressed in mammalian expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1		CHEMBL4080797	=	Activity	%	91.0	CHEMBL3529	Homo sapiens	Activity	%	91.0
	18265807	CHEMBL4057257	Inhibition of IKBKE (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1		CHEMBL4095072	=	Inhibition	%	6.3	CHEMBL3529	Homo sapiens	INH	%	6.3
	18266005	CHEMBL4057455	Inhibition of IKBKE (unknown origin) at 0.49 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(NC(=O)C3CC3)noc2c1		CHEMBL4088455	=	Inhibition	%	1.7	CHEMBL3529	Homo sapiens	INH	%	1.7
	18274947	CHEMBL4118361	Inhibition of IKKe in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled DIKPGNIMR probe by mass-spectrometric analysis relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1Cl		CHEMBL3883384	=	Inhibition	%	59.3	CHEMBL3529	Homo sapiens	INH	%	59.3
	18274948	CHEMBL4118361	Inhibition of IKKe in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled DIKPGNIMR probe by mass-spectrometric analysis relative to control	B	C=CC(=O)Nc1ccccc1Oc1nc(Nc2cnn(CCOC)c2)ncc1Cl	Outside typical range	CHEMBL3884839	=	Inhibition	%	-47.6	CHEMBL3529	Homo sapiens	INH	%	-47.6
	18274949	CHEMBL4118361	Inhibition of IKKe in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled DIKPGNIMR probe by mass-spectrometric analysis relative to control	B	COc1cc(O)c2c(c1)/C=C/C[C@H](O)[C@H](O)C(=O)/C=C\C[C@H](C)OC2=O	Outside typical range	CHEMBL1077979	=	Inhibition	%	-28.7	CHEMBL3529	Homo sapiens	INH	%	-28.7
	18282076	CHEMBL4120031	Inhibition of recombinant full length GST-tagged human IKKepsilon expressed in baculovirus expression system at 1 uM by FRET relative to control	B	CC(C)n1nc(-c2cnc(N)c(OC(F)(F)F)c2)cc1[C@@H]1[C@H]2CN(C3COC3)C[C@H]21		CHEMBL3719135	=	Inhibition	%	5.1	CHEMBL3529	Homo sapiens	INH	%	5.1
	18282395	CHEMBL4120031	Inhibition of recombinant full length GST-tagged human IKKepsilon expressed in baculovirus expression system at 1 uM by FRET relative to control	B	Nc1ncc(-c2cc([C@@H]3[C@H]4CN(C5COC5)C[C@H]43)n(CC3CC3)n2)cc1C(F)(F)F		CHEMBL3715238	=	Inhibition	%	1.9	CHEMBL3529	Homo sapiens	INH	%	1.9
	18282794	CHEMBL4120379	Inhibition of IKBKE (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1		CHEMBL4095072	=	Inhibition	%	6.3	CHEMBL3529	Homo sapiens	INH	%	6.3
	18283021	CHEMBL4120606	Inhibition of IKBKE (unknown origin) at 0.19 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(-c3ccc(N4CCN(C)CC4)nc3)n[nH]c2c1		CHEMBL4125807	=	Inhibition	%	1.0	CHEMBL3529	Homo sapiens	INH	%	1.0
	18283245	CHEMBL4120830	Inhibition of IKBKE (unknown origin) at 0.164 uM relative to control	B	COC(=O)Nc1cc(-c2c(C3CC3)n[nH]c2C)cc2[nH]ncc12		CHEMBL4129737	=	Inhibition	%	0.3	CHEMBL3529	Homo sapiens	INH	%	0.3
	18416469	CHEMBL4153202	Inhibition of human recombinant IKKepsilon using Ulight-FLGFTYVAP as substrate after 90 mins relative to control	B	Cc1cc(/N=N/c2ccc(S(=O)(=O)NC3CCCC3)cc2)c(N)cc1O		CHEMBL4159382	=	Activity	%	-26.2	CHEMBL3529	Homo sapiens	Activity	%	-26.2
	18434117	CHEMBL4156100	Inhibition of recombinant full-length human GST-tagged IKKepsilon expressed in baculovirus expression system at 500 nM by Z-LYTE assay relative to control	B	OC[C@@H](Nc1ncnc2sc(-c3ccc(O)cc3)cc12)c1ccccc1		CHEMBL4177361	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	INH	%	-1.0
	18434227	CHEMBL4156100	Inhibition of recombinant full-length human GST-tagged IKKepsilon expressed in baculovirus expression system at 500 nM by Z-LYTE assay relative to control	B	CCC(=O)Nc1ccc(-c2c[nH]c3ncnc(N[C@H](C)c4ccccc4)c23)cc1		CHEMBL4167749	=	Inhibition	%	-2.0	CHEMBL3529	Homo sapiens	INH	%	-2.0
	18434287	CHEMBL4156100	Inhibition of recombinant full-length human GST-tagged IKKepsilon expressed in baculovirus expression system at 500 nM by Z-LYTE assay relative to control	B	CN(C)CCn1cc(-c2cccc(O)c2)c2c(N)ncnc21		CHEMBL4159505	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	INH	%	3.0
	18434359	CHEMBL4156100	Inhibition of recombinant full-length human GST-tagged IKKepsilon expressed in baculovirus expression system at 500 nM by Z-LYTE assay relative to control	B	OCc1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)cc1		CHEMBL4175024	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	INH	%	3.0
	18440247	CHEMBL4157071	Binding affinity to wild-type human full length IKK-epsilon (M1 to V716 residues) expressed in mammalian expression system assessed as residual binding at 1 uM by Kinomescan method relative to control	B	Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1		CHEMBL4174988	=	Activity	%	64.0	CHEMBL3529	Homo sapiens	Activity	%	64.0
	18449888	CHEMBL4178122	Inhibition of human IKKepsilon (1 to 716 residues) assessed as residual activity at 500 nM in presence of 33P-ATP by filter binding assay relative to control	B	Cc1cccc(-c2nc(N)sc2-c2ccc3ncccc3n2)c1		CHEMBL4209540	=	Activity	%	101.0	CHEMBL3529	Homo sapiens	Activity	%	101.0
	18484203	CHEMBL4185850	Binding affinity to wild-type human full length IKK-epsilon (M1 to V716 residues) expressed in HEK293 cells at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL3969370	=	Activity	%	88.0	CHEMBL3529	Homo sapiens	Activity	%	88.0
	18484687	CHEMBL4185850	Binding affinity to wild-type human full length IKK-epsilon (M1 to V716 residues) expressed in HEK293 cells at 1 uM by Kinomescan method relative to control	B	CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL4206831	=	Activity	%	68.0	CHEMBL3529	Homo sapiens	Activity	%	68.0
	18507754	CHEMBL4191008	Inhibition of recombinant full-length human IKKepsilon at 1 uM using casein as substrate after 40 mins in presence of [gamma-33P]ATP by scintillation counting method	B	CS(=O)(=O)c1ccc(-n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc1		CHEMBL4207014	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	INH	%	3.0
	18566306	CHEMBL4219641	Inhibition of IKKepsilon (unknown origin)	B	Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)COCCCOCCCCOCCCOc2ccc(Nc3ncc(Br)c(NCCCN(C)C(=O)C4CCC4)n3)cc2)C(C)(C)C)cc1		CHEMBL4227907	=	IC50	nM	8.7	CHEMBL3529	Homo sapiens	IC50	nM	8.7
	18566307	CHEMBL4219642	Binding affinity to human full length wild-type IKKepsilon expressed in mammalian expression system	B	Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)COCCCOCCCCOCCCOc2ccc(Nc3ncc(Br)c(NCCCN(C)C(=O)C4CCC4)n3)cc2)C(C)(C)C)cc1		CHEMBL4227907	=	Kd	nM	70.0	CHEMBL3529	Homo sapiens	Kd	nM	70.0
	18653591	CHEMBL4230108	Inhibition of IKK-epsilon (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc(NC(=O)c3cccc(C(F)(F)F)c3)c2)c2c(N)ncnc21		CHEMBL3736320	=	Inhibition	%	17.0	CHEMBL3529	Homo sapiens	INH	%	17.0
	18653592	CHEMBL4230108	Inhibition of IKK-epsilon (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc3cc(-c4cccc(C(F)(F)F)c4)ncc23)c2c(N)ncnc21		CHEMBL4247506	=	Inhibition	%	8.0	CHEMBL3529	Homo sapiens	INH	%	8.0
	18655485	CHEMBL4230750	Binding affinity to wild-type human full length IKK-epsilon (M1 to V716 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	Cc1ccc(NC(=O)c2ccc(CN(CCN(C)C)C(=O)c3cccnc3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL4247298	=	Activity	%	100.0	CHEMBL3529	Homo sapiens	Activity	%	100.0
	18665410	CHEMBL4233337	Inhibition of IKKi (unknown origin)	B	O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4245507	>	IC50	nM	5000.0	CHEMBL3529	Homo sapiens	IC50	nM	5000.0
	18665482	CHEMBL4233337	Inhibition of IKKi (unknown origin)	B	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4251324	>	IC50	nM	5000.0	CHEMBL3529	Homo sapiens	IC50	nM	5000.0
Not Active	18723850	CHEMBL4258700	Inhibition of human activated IKKepsilon using casein as substrate at 100 uM after 40 mins in presence of [gamma-33P-ATP] by scintillation counting analysis	B	CCOc1c(S(=O)(=O)NC2CC(C)(C)NC(C)(C)C2)ccc(Cl)c1Cl		CHEMBL1502722		Inhibition	%		CHEMBL3529	Homo sapiens	INH		
	18725168	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	O=C(Nc1cc(Cl)c2c(c1)[nH]c1cnccc12)c1cccnc1		CHEMBL4287264	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725169	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	COCCOc1cnc(N)nc1-c1c[nH]c2ccc(C#CC(C)(C)O)cc12		CHEMBL2334589	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725170	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1[nH]nc(N)c1-c1ccc(Cl)c(Cl)c1		CHEMBL4283909	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725171	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1n[nH]c(N)c1-c1ccccc1		CHEMBL1609052	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725172	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1ccc(-c2c(N)n[nH]c2C)cc1C		CHEMBL4280454	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725173	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1[nH]nc(N)c1-c1ccc2ccccc2c1		CHEMBL4288356	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725174	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1[nH]nc(N)c1-c1ccc2c(c1)OCO2		CHEMBL4289568	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725175	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1cccc(-c2c(N)n[nH]c2C)c1		CHEMBL4281692	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725176	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1[nH]nc(N)c1-c1cccc(Cl)c1		CHEMBL4292952	=	IC50	nM	93400.0	CHEMBL3529	Homo sapiens	IC50	uM	93.4
	18725177	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1[nH]nc(N)c1-c1cccc(Br)c1		CHEMBL4285123	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725178	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1[nH]nc(N)c1-c1cccc(OC(F)(F)F)c1		CHEMBL4282760	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725179	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1[nH]nc(N)c1-c1cccc(C(F)(F)F)c1		CHEMBL4293369	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725180	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1ccc(-c2c(N)n[nH]c2C)cc1		CHEMBL4286140	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725181	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1n[nH]c(N)c1-c1ccc(Cl)cc1		CHEMBL1885200	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725182	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1[nH]nc(N)c1-c1ccc(Br)cc1		CHEMBL4294454	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725183	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1[nH]nc(N)c1-c1ccc(OCc2ccccc2)cc1		CHEMBL4286561	=	IC50	nM	15400.0	CHEMBL3529	Homo sapiens	IC50	uM	15.4
	18725184	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1[nH]nc(N)c1-c1cc(C(F)(F)F)cc(C(F)(F)F)c1		CHEMBL4292088	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725185	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1c(N)n[nH]c1-c1ccc(Cl)c(Cl)c1		CHEMBL4281464	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725186	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	CC(=O)n1nc(C)c(-c2ccc(Cl)c(Cl)c2)c1N		CHEMBL4276946	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725187	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	CCC(=O)n1nc(C)c(-c2ccc(Cl)c(Cl)c2)c1N		CHEMBL4284888	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725188	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	CCCC(=O)n1nc(C)c(-c2ccc(Cl)c(Cl)c2)c1N		CHEMBL4280373	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725189	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1nn(C(=O)C2CC2)c(N)c1-c1ccc(Cl)c(Cl)c1		CHEMBL4288275	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725201	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1nn(C(=O)C2CCC2)c(N)c1-c1ccc(Cl)c(Cl)c1		CHEMBL4283832	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725202	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1nn(C(=O)C2CCCC2)c(N)c1-c1ccc(Cl)c(Cl)c1		CHEMBL4291690	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725203	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1nn(C(=O)C2CCCCC2)c(N)c1-c1ccc(Cl)c(Cl)c1		CHEMBL4287399	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725204	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1nn(C(=O)c2ccccc2)c(N)c1-c1ccc(Cl)c(Cl)c1		CHEMBL4286341	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725205	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1nn(C(=O)c2cccnc2)c(N)c1-c1ccc(Cl)c(Cl)c1		CHEMBL4290916	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725206	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1nn(C(=O)c2ccncc2)c(N)c1-c1ccc(Cl)c(Cl)c1		CHEMBL4283047	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725207	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	CC(=O)n1nc(C)c(-c2ccc(Cl)cc2)c1N		CHEMBL4287493	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725208	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1nn(C(=O)C2CC2)c(N)c1-c1ccc(Cl)cc1		CHEMBL4279585	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725209	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	CC(=O)n1nc(C)c(-c2cccc(Cl)c2)c1N		CHEMBL4284120	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725210	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	CC(=O)n1nc(C)c(-c2cccc(C(F)(F)F)c2)c1N		CHEMBL4294725	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725211	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	CC(=O)n1nc(C)c(-c2ccc(C)c(C)c2)c1N		CHEMBL4280665	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725212	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	CCc1nn(C(C)=O)c(N)c1-c1ccc(Cl)c(Cl)c1		CHEMBL4291313	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725213	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1nn(C(=O)OC(C)(C)C)c(N)c1-c1ccc(Cl)c(Cl)c1		CHEMBL4286012	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725214	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	CCNC(=O)n1nc(C)c(-c2ccc(Cl)c(Cl)c2)c1N		CHEMBL4278086	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725215	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	CC(=O)n1nc(C)c(Br)c1N		CHEMBL4288230	=	IC50	nM	22900.0	CHEMBL3529	Homo sapiens	IC50	uM	22.9
	18725216	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	CC(=O)n1nc(N)c(-c2ccc(Cl)c(Cl)c2)c1C		CHEMBL4277586	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725217	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1c(-c2ccc(Cl)c(Cl)c2)c(N)nn1C(=O)C1CCC1		CHEMBL4284828	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725218	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1c(-c2ccc(Cl)c(Cl)c2)c(N)nn1C(=O)c1cccnc1		CHEMBL4292701	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725219	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	CC(=O)n1nc(N)c(Br)c1C		CHEMBL4295066	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725220	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1c(-c2ccc(Cl)c(Cl)c2)c(N)nn1C		CHEMBL4284415	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725221	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1nn(C)c(N)c1-c1ccc(Cl)c(Cl)c1		CHEMBL4291646	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725222	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1[nH]nc(NC(=O)c2ccccn2)c1-c1ccc(Cl)c(Cl)c1		CHEMBL4281003	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18725223	CHEMBL4259040	Inhibition of recombinant human full-length N-terminal GST-fused/His6-tagged IKKepsilon (M1 to V716 residues) expressed in Sf9 insect cells using ERLLDDRHDSGLDSMKDEE peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	Cc1[nH]nc(NC(=O)C(F)(F)F)c1-c1ccc(Cl)c(Cl)c1		CHEMBL4283382	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18746438	CHEMBL4263047	Inhibition of human IKKepsilon using ERLLDDRHDSGLDSMKDEE as substrate after 60 mins in presence of ATP by ADP-Glo kinase assay	B	O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O		CHEMBL536151	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18746439	CHEMBL4263047	Inhibition of human IKKepsilon using ERLLDDRHDSGLDSMKDEE as substrate after 60 mins in presence of ATP by ADP-Glo kinase assay	B	O=C(Nc1cc(Cl)cc2c1[nH]c1cnccc12)c1cccnc1		CHEMBL79004	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18746440	CHEMBL4263047	Inhibition of human IKKepsilon using ERLLDDRHDSGLDSMKDEE as substrate after 60 mins in presence of ATP by ADP-Glo kinase assay	B	O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1nonc1O		CHEMBL4287256	=	IC50	nM	58500.0	CHEMBL3529	Homo sapiens	IC50	uM	58.5
	18746441	CHEMBL4263047	Inhibition of human IKKepsilon using ERLLDDRHDSGLDSMKDEE as substrate after 60 mins in presence of ATP by ADP-Glo kinase assay	B	O=C(Nc1cccc(C(F)(F)F)c1)c1nonc1O		CHEMBL4177097	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18746442	CHEMBL4263047	Inhibition of human IKKepsilon using ERLLDDRHDSGLDSMKDEE as substrate after 60 mins in presence of ATP by ADP-Glo kinase assay	B	Nc1nonc1C(=O)Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1		CHEMBL4279494	=	IC50	nM	44800.0	CHEMBL3529	Homo sapiens	IC50	uM	44.8
	18746443	CHEMBL4263047	Inhibition of human IKKepsilon using ERLLDDRHDSGLDSMKDEE as substrate after 60 mins in presence of ATP by ADP-Glo kinase assay	B	O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1nsnc1O		CHEMBL4284710	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18746444	CHEMBL4263047	Inhibition of human IKKepsilon using ERLLDDRHDSGLDSMKDEE as substrate after 60 mins in presence of ATP by ADP-Glo kinase assay	B	O=C(Nc1cccc(C(F)(F)F)c1)c1nsnc1O		CHEMBL4166474	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18746445	CHEMBL4263047	Inhibition of human IKKepsilon using ERLLDDRHDSGLDSMKDEE as substrate after 60 mins in presence of ATP by ADP-Glo kinase assay	B	COc1nsnc1C(=O)Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1		CHEMBL4294749	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18746446	CHEMBL4263047	Inhibition of human IKKepsilon using ERLLDDRHDSGLDSMKDEE as substrate after 60 mins in presence of ATP by ADP-Glo kinase assay	B	Cn1nc(O)c(C(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1		CHEMBL4283501	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18746447	CHEMBL4263047	Inhibition of human IKKepsilon using ERLLDDRHDSGLDSMKDEE as substrate after 60 mins in presence of ATP by ADP-Glo kinase assay	B	Cn1nnc(O)c1C(=O)Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1		CHEMBL4280067	=	IC50	nM	58500.0	CHEMBL3529	Homo sapiens	IC50	uM	58.5
	18746448	CHEMBL4263047	Inhibition of human IKKepsilon using ERLLDDRHDSGLDSMKDEE as substrate after 60 mins in presence of ATP by ADP-Glo kinase assay	B	O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1n[nH]nc1O		CHEMBL4293673	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18746449	CHEMBL4263047	Inhibition of human IKKepsilon using ERLLDDRHDSGLDSMKDEE as substrate after 60 mins in presence of ATP by ADP-Glo kinase assay	B	Cn1cc(C(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c(O)n1		CHEMBL4283080	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18746450	CHEMBL4263047	Inhibition of human IKKepsilon using ERLLDDRHDSGLDSMKDEE as substrate after 60 mins in presence of ATP by ADP-Glo kinase assay	B	Cc1c(C(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c(O)nn1C		CHEMBL4290266	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18746451	CHEMBL4263048	Inhibition of human IKKepsilon at 100 uM using ERLLDDRHDSGLDSMKDEE as substrate after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O		CHEMBL536151	=	Inhibition	%	30.5	CHEMBL3529	Homo sapiens	INH	%	30.5
	18746452	CHEMBL4263048	Inhibition of human IKKepsilon at 100 uM using ERLLDDRHDSGLDSMKDEE as substrate after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	O=C(Nc1cccc(C(F)(F)F)c1)c1nonc1O		CHEMBL4177097	=	Inhibition	%	32.1	CHEMBL3529	Homo sapiens	INH	%	32.1
	18746453	CHEMBL4263048	Inhibition of human IKKepsilon at 100 uM using ERLLDDRHDSGLDSMKDEE as substrate after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1nsnc1O		CHEMBL4284710	=	Inhibition	%	30.2	CHEMBL3529	Homo sapiens	INH	%	30.2
	18746454	CHEMBL4263048	Inhibition of human IKKepsilon at 100 uM using ERLLDDRHDSGLDSMKDEE as substrate after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	O=C(Nc1cccc(C(F)(F)F)c1)c1nsnc1O		CHEMBL4166474	=	Inhibition	%	25.8	CHEMBL3529	Homo sapiens	INH	%	25.8
	18746455	CHEMBL4263048	Inhibition of human IKKepsilon at 100 uM using ERLLDDRHDSGLDSMKDEE as substrate after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	COc1nsnc1C(=O)Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1		CHEMBL4294749	=	Inhibition	%	21.9	CHEMBL3529	Homo sapiens	INH	%	21.9
	18746456	CHEMBL4263048	Inhibition of human IKKepsilon at 100 uM using ERLLDDRHDSGLDSMKDEE as substrate after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	Cn1nc(O)c(C(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1		CHEMBL4283501	=	Inhibition	%	6.92	CHEMBL3529	Homo sapiens	INH	%	6.92
	18746457	CHEMBL4263048	Inhibition of human IKKepsilon at 100 uM using ERLLDDRHDSGLDSMKDEE as substrate after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1n[nH]nc1O		CHEMBL4293673	=	Inhibition	%	15.3	CHEMBL3529	Homo sapiens	INH	%	15.3
	18746458	CHEMBL4263048	Inhibition of human IKKepsilon at 100 uM using ERLLDDRHDSGLDSMKDEE as substrate after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	Cn1cc(C(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c(O)n1		CHEMBL4283080	=	Inhibition	%	17.2	CHEMBL3529	Homo sapiens	INH	%	17.2
	18746459	CHEMBL4263048	Inhibition of human IKKepsilon at 100 uM using ERLLDDRHDSGLDSMKDEE as substrate after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	Cc1c(C(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c(O)nn1C		CHEMBL4290266	=	Inhibition	%	14.2	CHEMBL3529	Homo sapiens	INH	%	14.2
	18751088	CHEMBL4263826	Inhibition of IKK-EPSILON (unknown origin) at 1 uM relative to control	B	NC1(c2ccc(-c3cnc4c(-c5ccc(S(N)(=O)=O)c6ccccc56)cnn4c3)cc2)CCC1		CHEMBL4278763	=	Inhibition	%	5.0	CHEMBL3529	Homo sapiens	INH	%	5.0
	18751564	CHEMBL4264339	Binding affinity to wild-type human full length IKK-epsilon (M1 to V716 residues) expressed in mammalian expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048	=	Activity	%	99.0	CHEMBL3529	Homo sapiens	Activity	%	99.0
	18764623	CHEMBL4267110	Inhibition of human IKKepsilon at 100 nM	B	CN1CCC(c2nc(-c3ccc(F)cc3)c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)s2)CC1		CHEMBL4288103	<	Inhibition	%	70.0	CHEMBL3529	Homo sapiens	INH	%	70.0
	18764624	CHEMBL4267110	Inhibition of human IKKepsilon at 100 nM	B	CN1CCC(c2nc(-c3cccc(S(C)(=O)=O)c3)c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)s2)CC1		CHEMBL4286880	<	Inhibition	%	70.0	CHEMBL3529	Homo sapiens	INH	%	70.0
	18764625	CHEMBL4267110	Inhibition of human IKKepsilon at 100 nM	B	CN1CCC(c2nc(-c3ccc(F)c(NS(C)(=O)=O)c3)c(-c3ccnc(NCC4CC4)n3)s2)CC1		CHEMBL4286841	<	Inhibition	%	70.0	CHEMBL3529	Homo sapiens	INH	%	70.0
	18781590	CHEMBL4270224	Inhibition of IKK-epsilon (unknown origin) using fluorescein-labelled DRHDSGLDSMKDE as substrate after 1 hr by TR-FRET assay	B	N#Cc1cc(-c2ccnc(Nc3ccc(NC(=O)CN4CCOCC4)nc3)n2)cnc1N1CC[C@H](F)C1	Non standard unit for type	CHEMBL3919474	<	INH	nM	30.0	CHEMBL3529	Homo sapiens	INH	nM	30.0
	18781591	CHEMBL4270224	Inhibition of IKK-epsilon (unknown origin) using fluorescein-labelled DRHDSGLDSMKDE as substrate after 1 hr by TR-FRET assay	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCNC(=O)C4)nc3)n2)cnc1N1CC[C@H](F)C1	Non standard unit for type	CHEMBL3904385	<	INH	nM	15.0	CHEMBL3529	Homo sapiens	INH	nM	15.0
	18781592	CHEMBL4270224	Inhibition of IKK-epsilon (unknown origin) using fluorescein-labelled DRHDSGLDSMKDE as substrate after 1 hr by TR-FRET assay	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cnc1N1CC[C@H](F)C1	Non standard unit for type	CHEMBL3943587	<	INH	nM	15.0	CHEMBL3529	Homo sapiens	INH	nM	15.0
	18781593	CHEMBL4270224	Inhibition of IKK-epsilon (unknown origin) using fluorescein-labelled DRHDSGLDSMKDE as substrate after 1 hr by TR-FRET assay	B	CN1CCN(Cc2ccc(Nc3nccc(-c4cnc(N5CC[C@H](F)C5)c(C#N)c4)n3)cn2)CC1	Non standard unit for type	CHEMBL4280039	=	INH	nM	24.0	CHEMBL3529	Homo sapiens	INH	nM	24.0
	18781594	CHEMBL4270224	Inhibition of IKK-epsilon (unknown origin) using fluorescein-labelled DRHDSGLDSMKDE as substrate after 1 hr by TR-FRET assay	B	CCN1CCN(Cc2ccc(Nc3nccc(-c4cnc(N5CC[C@@H](F)C5)c(C#N)c4)n3)cn2)CC1	Non standard unit for type	CHEMBL4287265	=	INH	nM	21.0	CHEMBL3529	Homo sapiens	INH	nM	21.0
	18781595	CHEMBL4270224	Inhibition of IKK-epsilon (unknown origin) using fluorescein-labelled DRHDSGLDSMKDE as substrate after 1 hr by TR-FRET assay	B	CCN1CCN(Cc2ccc(Nc3nccc(-c4cnc(N5CC[C@H](F)C5)c(C#N)c4)n3)cn2)CC1	Non standard unit for type	CHEMBL4295211	=	INH	nM	16.0	CHEMBL3529	Homo sapiens	INH	nM	16.0
	18811399	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL1096	=	Inhibition	%	29.0	CHEMBL3529	Homo sapiens	INH	%	29.0
	18811400	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CN(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4279379	=	Inhibition	%	35.0	CHEMBL3529	Homo sapiens	INH	%	35.0
	18811401	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CN(C)CCCc1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4287613	=	Inhibition	%	21.0	CHEMBL3529	Homo sapiens	INH	%	21.0
	18811402	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CN(C)CC#Cc1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4279893	=	Inhibition	%	17.0	CHEMBL3529	Homo sapiens	INH	%	17.0
	18811403	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)CCc1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cc1F		CHEMBL4291630	=	Inhibition	%	-5.7	CHEMBL3529	Homo sapiens	INH	%	-5.7
	18811404	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)(C)CCc1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cc1F		CHEMBL4281895	=	Inhibition	%	0.6	CHEMBL3529	Homo sapiens	INH	%	0.6
	18811405	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)(C)/C=C/c1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cc1F		CHEMBL4288219	=	Inhibition	%	-3.1	CHEMBL3529	Homo sapiens	INH	%	-3.1
	18811406	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4290720	=	Inhibition	%	25.0	CHEMBL3529	Homo sapiens	INH	%	25.0
	18811407	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4280074	=	Inhibition	%	9.2	CHEMBL3529	Homo sapiens	INH	%	9.2
	18811408	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4287304	=	Inhibition	%	9.0	CHEMBL3529	Homo sapiens	INH	%	9.0
	18811409	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4276661	=	Inhibition	%	41.0	CHEMBL3529	Homo sapiens	INH	%	41.0
	18811410	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCCCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4278971	=	Inhibition	%	9.2	CHEMBL3529	Homo sapiens	INH	%	9.2
	18811411	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3cc(C4CCCCC4)ccc3c(=O)c2cc1C(=O)O		CHEMBL4286893	=	Inhibition	%	8.2	CHEMBL3529	Homo sapiens	INH	%	8.2
	18811412	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3cc(C4=CCCCC4)ccc3c(=O)c2cc1C(=O)O		CHEMBL4294121	=	Inhibition	%	15.0	CHEMBL3529	Homo sapiens	INH	%	15.0
	18811413	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(-c4ccccc4)cc3c(=O)c2cc1C(=O)O		CHEMBL4283536	=	Inhibition	%	33.0	CHEMBL3529	Homo sapiens	INH	%	33.0
	18811414	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCC(F)(F)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4277066	=	Inhibition	%	11.0	CHEMBL3529	Homo sapiens	INH	%	11.0
	18811415	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCC(F)(F)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4285013	=	Inhibition	%	19.0	CHEMBL3529	Homo sapiens	INH	%	19.0
	18811416	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC1CCC(c2ccc3oc4nc(N)c(C(=O)O)cc4c(=O)c3c2)CC1		CHEMBL4293209	=	Inhibition	%	3.2	CHEMBL3529	Homo sapiens	INH	%	3.2
	18811417	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCC(C(F)(F)F)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4290078	=	Inhibition	%	11.0	CHEMBL3529	Homo sapiens	INH	%	11.0
	18811418	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCC(C(F)(F)F)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4282863	=	Inhibition	%	0.4	CHEMBL3529	Homo sapiens	INH	%	0.4
	18811419	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC1(C)CCC(c2ccc3oc4nc(N)c(C(=O)O)cc4c(=O)c3c2)CC1		CHEMBL4293465	=	Inhibition	%	-0.7	CHEMBL3529	Homo sapiens	INH	%	-0.7
	18811420	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC1(C)CC=C(c2ccc3oc4nc(N)c(C(=O)O)cc4c(=O)c3c2)CC1		CHEMBL4286247	=	Inhibition	%	22.0	CHEMBL3529	Homo sapiens	INH	%	22.0
	18811421	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCC(O)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4278331	=	Inhibition	%	12.0	CHEMBL3529	Homo sapiens	INH	%	12.0
	18811422	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCC(O)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4289666	=	Inhibition	%	26.0	CHEMBL3529	Homo sapiens	INH	%	26.0
	18811423	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCC(=O)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4281788	=	Inhibition	%	27.0	CHEMBL3529	Homo sapiens	INH	%	27.0
	18811424	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCC5(CC4)OCCO5)cc3c(=O)c2cc1C(=O)O		CHEMBL4285588	=	Inhibition	%	30.0	CHEMBL3529	Homo sapiens	INH	%	30.0
	18811425	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCC5(CC4)OCCO5)cc3c(=O)c2cc1C(=O)O		CHEMBL4278727	=	Inhibition	%	63.0	CHEMBL3529	Homo sapiens	INH	%	63.0
	18811426	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Cl.Nc1nc2oc3ccc(C4CCNCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4278266	=	Inhibition	%	7.9	CHEMBL3529	Homo sapiens	INH	%	7.9
	18811427	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCNCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4286183	=	Inhibition	%	23.0	CHEMBL3529	Homo sapiens	INH	%	23.0
	18811428	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCN(C=O)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4281733	=	Inhibition	%	34.0	CHEMBL3529	Homo sapiens	INH	%	34.0
	18811429	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(=O)N1CCC(c2ccc3oc4nc(N)c(C(=O)O)cc4c(=O)c3c2)CC1		CHEMBL4289613	=	Inhibition	%	26.0	CHEMBL3529	Homo sapiens	INH	%	26.0
	18811430	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCOCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4290024	=	Inhibition	%	32.0	CHEMBL3529	Homo sapiens	INH	%	32.0
	18811431	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCOCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4279336	=	Inhibition	%	50.0	CHEMBL3529	Homo sapiens	INH	%	50.0
	18811432	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCSCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4293403	=	Inhibition	%	18.0	CHEMBL3529	Homo sapiens	INH	%	18.0
	18811433	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCS(=O)(=O)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4282790	=	Inhibition	%	23.0	CHEMBL3529	Homo sapiens	INH	%	23.0
	18811434	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(N4CCOCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4291939	=	Inhibition	%	3.5	CHEMBL3529	Homo sapiens	INH	%	3.5
	18811435	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3cc(F)c(C4CCCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4281322	=	Inhibition	%	8.2	CHEMBL3529	Homo sapiens	INH	%	8.2
	18811436	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3cc(F)c(C4=CCCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4285590	=	Inhibition	%	-0.5	CHEMBL3529	Homo sapiens	INH	%	-0.5
	18811437	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3cnc(C4CCCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4277647	=	Inhibition	%	7.0	CHEMBL3529	Homo sapiens	INH	%	7.0
	18811438	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3cnc(C4=CCCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4282158	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	INH	%	3.0
	18811439	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(CCC4CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4292770	=	Inhibition	%	7.7	CHEMBL3529	Homo sapiens	INH	%	7.7
	18811440	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(/C=C/C4CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4292376	=	Inhibition	%	10.0	CHEMBL3529	Homo sapiens	INH	%	10.0
	18811441	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C#CC4CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4284481	=	Inhibition	%	-6.0	CHEMBL3529	Homo sapiens	INH	%	-6.0
	18811442	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(CCC4CCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4288976	=	Inhibition	%	8.7	CHEMBL3529	Homo sapiens	INH	%	8.7
	18811443	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(CCC4CCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4281068	=	Inhibition	%	4.8	CHEMBL3529	Homo sapiens	INH	%	4.8
	18811444	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(/C=C/C4CCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4282053	=	Inhibition	%	13.0	CHEMBL3529	Homo sapiens	INH	%	13.0
	18811445	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3cc(CCC4CCCC4)ccc3c(=O)c2cc1C(=O)O		CHEMBL4290240	=	Inhibition	%	5.2	CHEMBL3529	Homo sapiens	INH	%	5.2
	18811446	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3cc(/C=C/C4CCCC4)ccc3c(=O)c2cc1C(=O)O		CHEMBL4283708	=	Inhibition	%	6.5	CHEMBL3529	Homo sapiens	INH	%	6.5
	18811447	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3cc(F)c(CCC4CCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4291565	=	Inhibition	%	-7.1	CHEMBL3529	Homo sapiens	INH	%	-7.1
	18811448	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3cc(F)c(/C=C/C4CCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4280251	=	Inhibition	%	-0.2	CHEMBL3529	Homo sapiens	INH	%	-0.2
	18811449	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(CCC4CCCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4288153	=	Inhibition	%	-4.1	CHEMBL3529	Homo sapiens	INH	%	-4.1
	18811450	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(/C=C/C4CCCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4276820	=	Inhibition	%	4.3	CHEMBL3529	Homo sapiens	INH	%	4.3
	18811451	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCCCC4)cc3c(=O)c2cc1-c1nn[nH]n1		CHEMBL4284757	=	Inhibition	%	30.0	CHEMBL3529	Homo sapiens	INH	%	30.0
	18811452	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCCCC4)cc3c(=O)c2cc1-c1nn[nH]n1		CHEMBL4291966	=	Inhibition	%	79.0	CHEMBL3529	Homo sapiens	INH	%	79.0
	18811453	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CN(C)c1ccc2oc3nc(N)c(-c4nn[nH]n4)cc3c(=O)c2c1		CHEMBL4281345	=	Inhibition	%	65.0	CHEMBL3529	Homo sapiens	INH	%	65.0
	18811454	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(N4CCOCC4)cc3c(=O)c2cc1-c1nn[nH]n1		CHEMBL4288542	=	Inhibition	%	70.0	CHEMBL3529	Homo sapiens	INH	%	70.0
	18811455	CHEMBL4276008	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells at 5 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(N4CCOCC4)cc3c(=O)c2cc1C(=O)Nc1nn[nH]n1		CHEMBL4277887	=	Inhibition	%	57.0	CHEMBL3529	Homo sapiens	INH	%	57.0
	18811456	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL1096	=	IC50	nM	5100.0	CHEMBL3529	Homo sapiens	IC50	uM	5.1
	18811457	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	C=C(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4277614	=	IC50	nM	1300.0	CHEMBL3529	Homo sapiens	IC50	uM	1.3
	18811458	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)c1ccc2c(=O)c3cc(C(=O)O)c(N)nc3oc2c1		CHEMBL4285560	=	IC50	nM	4700.0	CHEMBL3529	Homo sapiens	IC50	uM	4.7
	18811459	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	C=C(C)c1ccc2c(=O)c3cc(C(=O)O)c(N)nc3oc2c1		CHEMBL4281039	=	IC50	nM	7200.0	CHEMBL3529	Homo sapiens	IC50	uM	7.2
	18811460	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)c1cccc2oc3nc(N)c(C(=O)O)cc3c(=O)c12		CHEMBL4288939	=	IC50	nM	6000.0	CHEMBL3529	Homo sapiens	IC50	uM	6.0
	18811461	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)c1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cc1F		CHEMBL4284443	=	IC50	nM	5400.0	CHEMBL3529	Homo sapiens	IC50	uM	5.4
	18811462	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	C=C(C)c1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cc1F		CHEMBL4292344	=	IC50	nM	1700.0	CHEMBL3529	Homo sapiens	IC50	uM	1.7
	18811463	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)c1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cn1		CHEMBL4287847	=	IC50	nM	3100.0	CHEMBL3529	Homo sapiens	IC50	uM	3.1
	18811464	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	C=C(C)c1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cn1		CHEMBL4277195	=	IC50	nM	5300.0	CHEMBL3529	Homo sapiens	IC50	uM	5.3
	18811465	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CN(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4279379	=	IC50	nM	1600.0	CHEMBL3529	Homo sapiens	IC50	uM	1.6
	18811466	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)Cc1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4290544	=	IC50	nM	4900.0	CHEMBL3529	Homo sapiens	IC50	uM	4.9
	18811467	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)CCc1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4295050	=	IC50	nM	3400.0	CHEMBL3529	Homo sapiens	IC50	uM	3.4
	18811468	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)C#Cc1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4287123	=	IC50	nM	20000.0	CHEMBL3529	Homo sapiens	IC50	uM	20.0
	18811469	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4278101	=	IC50	nM	10600.0	CHEMBL3529	Homo sapiens	IC50	uM	10.6
	18811470	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4290720	=	IC50	nM	3100.0	CHEMBL3529	Homo sapiens	IC50	uM	3.1
	18811471	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4280074	=	IC50	nM	6300.0	CHEMBL3529	Homo sapiens	IC50	uM	6.3
	18811472	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4287304	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	18811473	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4276661	=	IC50	nM	5400.0	CHEMBL3529	Homo sapiens	IC50	uM	5.4
	18811474	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCC(=O)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4281788	=	IC50	nM	1500.0	CHEMBL3529	Homo sapiens	IC50	uM	1.5
	18811475	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCC5(CC4)OCCO5)cc3c(=O)c2cc1C(=O)O		CHEMBL4285588	=	IC50	nM	3200.0	CHEMBL3529	Homo sapiens	IC50	uM	3.2
	18811476	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCC5(CC4)OCCO5)cc3c(=O)c2cc1C(=O)O		CHEMBL4278727	=	IC50	nM	2100.0	CHEMBL3529	Homo sapiens	IC50	uM	2.1
	18811477	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCN(C=O)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4281733	=	IC50	nM	5200.0	CHEMBL3529	Homo sapiens	IC50	uM	5.2
	18811478	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(=O)N1CCC(c2ccc3oc4nc(N)c(C(=O)O)cc4c(=O)c3c2)CC1		CHEMBL4289613	=	IC50	nM	1900.0	CHEMBL3529	Homo sapiens	IC50	uM	1.9
	18811479	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCOCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4290024	=	IC50	nM	11000.0	CHEMBL3529	Homo sapiens	IC50	uM	11.0
	18811480	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCOCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4279336	=	IC50	nM	2000.0	CHEMBL3529	Homo sapiens	IC50	uM	2.0
	18811481	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCSCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4293403	=	IC50	nM	1200.0	CHEMBL3529	Homo sapiens	IC50	uM	1.2
	18811482	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCS(=O)(=O)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4282790	=	IC50	nM	11000.0	CHEMBL3529	Homo sapiens	IC50	uM	11.0
	18811483	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCCCC4)cc3c(=O)c2cc1-c1nn[nH]n1		CHEMBL4284757	=	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	IC50	uM	1.0
	18811484	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCCCC4)cc3c(=O)c2cc1-c1nn[nH]n1		CHEMBL4291966	=	IC50	nM	210.0	CHEMBL3529	Homo sapiens	IC50	uM	0.21
	18811485	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CN(C)c1ccc2oc3nc(N)c(-c4nn[nH]n4)cc3c(=O)c2c1		CHEMBL4281345	=	IC50	nM	580.0	CHEMBL3529	Homo sapiens	IC50	uM	0.58
	18811486	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(N4CCOCC4)cc3c(=O)c2cc1-c1nn[nH]n1		CHEMBL4288542	=	IC50	nM	310.0	CHEMBL3529	Homo sapiens	IC50	uM	0.31
	18811487	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(N4CCOCC4)cc3c(=O)c2cc1C(=O)Nc1nn[nH]n1		CHEMBL4277887	=	IC50	nM	1200.0	CHEMBL3529	Homo sapiens	IC50	uM	1.2
	18811488	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL1096	=	IC50	nM	5128.61	CHEMBL3529	Homo sapiens	pIC50		5.29
	18811489	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	C=C(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4277614	=	IC50	nM	1288.25	CHEMBL3529	Homo sapiens	pIC50		5.89
	18811490	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)c1ccc2c(=O)c3cc(C(=O)O)c(N)nc3oc2c1		CHEMBL4285560	=	IC50	nM	4677.35	CHEMBL3529	Homo sapiens	pIC50		5.33
	18811491	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	C=C(C)c1ccc2c(=O)c3cc(C(=O)O)c(N)nc3oc2c1		CHEMBL4281039	=	IC50	nM	7244.36	CHEMBL3529	Homo sapiens	pIC50		5.14
	18811492	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)c1cccc2oc3nc(N)c(C(=O)O)cc3c(=O)c12		CHEMBL4288939	=	IC50	nM	6025.6	CHEMBL3529	Homo sapiens	pIC50		5.22
	18811493	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)c1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cc1F		CHEMBL4284443	=	IC50	nM	5370.32	CHEMBL3529	Homo sapiens	pIC50		5.27
	18811494	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	C=C(C)c1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cc1F		CHEMBL4292344	=	IC50	nM	1698.24	CHEMBL3529	Homo sapiens	pIC50		5.77
	18811495	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)c1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cn1		CHEMBL4287847	=	IC50	nM	3090.3	CHEMBL3529	Homo sapiens	pIC50		5.51
	18811496	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	C=C(C)c1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cn1		CHEMBL4277195	=	IC50	nM	5248.07	CHEMBL3529	Homo sapiens	pIC50		5.28
	18811497	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CN(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4279379	=	IC50	nM	1584.89	CHEMBL3529	Homo sapiens	pIC50		5.8
	18811498	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)Cc1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4290544	=	IC50	nM	4897.79	CHEMBL3529	Homo sapiens	pIC50		5.31
	18811499	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)CCc1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4295050	=	IC50	nM	3388.44	CHEMBL3529	Homo sapiens	pIC50		5.47
	18811500	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)C#Cc1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4287123	=	IC50	nM	19952.62	CHEMBL3529	Homo sapiens	pIC50		4.7
	18811501	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4287304	<	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	pIC50		4.0
	18811502	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCC(=O)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4281788	=	IC50	nM	1513.56	CHEMBL3529	Homo sapiens	pIC50		5.82
	18811503	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(=O)N1CCC(c2ccc3oc4nc(N)c(C(=O)O)cc4c(=O)c3c2)CC1		CHEMBL4289613	=	IC50	nM	1905.46	CHEMBL3529	Homo sapiens	pIC50		5.72
	18811504	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCOCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4279336	=	IC50	nM	1995.26	CHEMBL3529	Homo sapiens	pIC50		5.7
	18811505	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCSCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4293403	=	IC50	nM	1202.26	CHEMBL3529	Homo sapiens	pIC50		5.92
	18811506	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCCCC4)cc3c(=O)c2cc1-c1nn[nH]n1		CHEMBL4284757	=	IC50	nM	1000.0	CHEMBL3529	Homo sapiens	pIC50		6.0
	18811507	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCCCC4)cc3c(=O)c2cc1-c1nn[nH]n1		CHEMBL4291966	=	IC50	nM	208.93	CHEMBL3529	Homo sapiens	pIC50		6.68
	18811508	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CN(C)c1ccc2oc3nc(N)c(-c4nn[nH]n4)cc3c(=O)c2c1		CHEMBL4281345	=	IC50	nM	575.44	CHEMBL3529	Homo sapiens	pIC50		6.24
	18811509	CHEMBL4276012	Inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(N4CCOCC4)cc3c(=O)c2cc1-c1nn[nH]n1		CHEMBL4288542	=	IC50	nM	309.03	CHEMBL3529	Homo sapiens	pIC50		6.51
	18811510	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	C=C(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4277614	=	Ratio IC50		3.9	CHEMBL3529	Homo sapiens	Ratio IC50		3.9
	18811511	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	CC(C)c1ccc2c(=O)c3cc(C(=O)O)c(N)nc3oc2c1		CHEMBL4285560	=	Ratio IC50		1.1	CHEMBL3529	Homo sapiens	Ratio IC50		1.1
	18811512	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	C=C(C)c1ccc2c(=O)c3cc(C(=O)O)c(N)nc3oc2c1		CHEMBL4281039	=	Ratio IC50		0.7	CHEMBL3529	Homo sapiens	Ratio IC50		0.7
	18811513	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	CC(C)c1cccc2oc3nc(N)c(C(=O)O)cc3c(=O)c12		CHEMBL4288939	=	Ratio IC50		0.9	CHEMBL3529	Homo sapiens	Ratio IC50		0.9
	18811514	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	CC(C)c1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cc1F		CHEMBL4284443	=	Ratio IC50		0.9	CHEMBL3529	Homo sapiens	Ratio IC50		0.9
	18811515	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	C=C(C)c1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cc1F		CHEMBL4292344	=	Ratio IC50		3.0	CHEMBL3529	Homo sapiens	Ratio IC50		3.0
	18811516	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	CC(C)c1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cn1		CHEMBL4287847	=	Ratio IC50		1.6	CHEMBL3529	Homo sapiens	Ratio IC50		1.6
	18811517	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	C=C(C)c1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cn1		CHEMBL4277195	=	Ratio IC50		1.0	CHEMBL3529	Homo sapiens	Ratio IC50		1.0
	18811518	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	CN(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4279379	=	Ratio IC50		3.2	CHEMBL3529	Homo sapiens	Ratio IC50		3.2
	18811519	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	CC(C)Cc1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4290544	=	Ratio IC50		1.0	CHEMBL3529	Homo sapiens	Ratio IC50		1.0
	18811520	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	CC(C)CCc1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4295050	=	Ratio IC50		1.5	CHEMBL3529	Homo sapiens	Ratio IC50		1.5
	18811521	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	CC(C)C#Cc1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4287123	=	Ratio IC50		0.3	CHEMBL3529	Homo sapiens	Ratio IC50		0.3
	18811522	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	Nc1nc2oc3ccc(C4CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4278101	=	Ratio IC50		0.5	CHEMBL3529	Homo sapiens	Ratio IC50		0.5
	18811523	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	Nc1nc2oc3ccc(C4CCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4290720	=	Ratio IC50		1.6	CHEMBL3529	Homo sapiens	Ratio IC50		1.6
	18811524	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	Nc1nc2oc3ccc(C4CCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4280074	=	Ratio IC50		0.8	CHEMBL3529	Homo sapiens	Ratio IC50		0.8
	18811525	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	Nc1nc2oc3ccc(C4=CCCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4276661	=	Ratio IC50		0.9	CHEMBL3529	Homo sapiens	Ratio IC50		0.9
	18811526	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	Nc1nc2oc3ccc(C4CCC(=O)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4281788	=	Ratio IC50		3.4	CHEMBL3529	Homo sapiens	Ratio IC50		3.4
	18811527	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	Nc1nc2oc3ccc(C4CCC5(CC4)OCCO5)cc3c(=O)c2cc1C(=O)O		CHEMBL4285588	=	Ratio IC50		1.6	CHEMBL3529	Homo sapiens	Ratio IC50		1.6
	18811528	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	Nc1nc2oc3ccc(C4=CCC5(CC4)OCCO5)cc3c(=O)c2cc1C(=O)O		CHEMBL4278727	=	Ratio IC50		2.4	CHEMBL3529	Homo sapiens	Ratio IC50		2.4
	18811529	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	Nc1nc2oc3ccc(C4CCN(C=O)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4281733	=	Ratio IC50		1.0	CHEMBL3529	Homo sapiens	Ratio IC50		1.0
	18811530	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	CC(=O)N1CCC(c2ccc3oc4nc(N)c(C(=O)O)cc4c(=O)c3c2)CC1		CHEMBL4289613	=	Ratio IC50		2.7	CHEMBL3529	Homo sapiens	Ratio IC50		2.7
	18811531	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	Nc1nc2oc3ccc(C4CCOCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4290024	=	Ratio IC50		0.5	CHEMBL3529	Homo sapiens	Ratio IC50		0.5
	18811532	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	Nc1nc2oc3ccc(C4=CCOCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4279336	=	Ratio IC50		2.6	CHEMBL3529	Homo sapiens	Ratio IC50		2.6
	18811533	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	Nc1nc2oc3ccc(C4CCSCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4293403	=	Ratio IC50		4.3	CHEMBL3529	Homo sapiens	Ratio IC50		4.3
	18811534	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	Nc1nc2oc3ccc(C4CCS(=O)(=O)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4282790	=	Ratio IC50		0.5	CHEMBL3529	Homo sapiens	Ratio IC50		0.5
	18811535	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	Nc1nc2oc3ccc(C4CCCCC4)cc3c(=O)c2cc1-c1nn[nH]n1		CHEMBL4284757	=	Ratio IC50		5.1	CHEMBL3529	Homo sapiens	Ratio IC50		5.1
	18811536	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	Nc1nc2oc3ccc(C4=CCCCC4)cc3c(=O)c2cc1-c1nn[nH]n1		CHEMBL4291966	=	Ratio IC50		24.0	CHEMBL3529	Homo sapiens	Ratio IC50		24.0
	18811537	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	CN(C)c1ccc2oc3nc(N)c(-c4nn[nH]n4)cc3c(=O)c2c1		CHEMBL4281345	=	Ratio IC50		8.8	CHEMBL3529	Homo sapiens	Ratio IC50		8.8
	18811538	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	Nc1nc2oc3ccc(N4CCOCC4)cc3c(=O)c2cc1-c1nn[nH]n1		CHEMBL4288542	=	Ratio IC50		16.0	CHEMBL3529	Homo sapiens	Ratio IC50		16.0
	18811539	CHEMBL4276013	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human IKKepsilon (1 to 655 residues) expressed in Baculovirus infected SF9 insect cell	B	Nc1nc2oc3ccc(N4CCOCC4)cc3c(=O)c2cc1C(=O)Nc1nn[nH]n1		CHEMBL4277887	=	Ratio IC50		4.3	CHEMBL3529	Homo sapiens	Ratio IC50		4.3
	18858003	CHEMBL4307849	Binding affinity to wild-type human full length IKK-epsilon (M1 to V716 residues) expressed in mammalian expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	CC(C)N1C(=O)C(NCCCN(C)C)=C(c2cn(C)c3ccccc23)C1=O.Cl		CHEMBL4533018	=	Activity	%	77.0	CHEMBL3529	Homo sapiens	Activity	%	77.0
	18892633	CHEMBL4314668	Inhibition of recombinant full-length human IKKepsilon assessed as residual activity at 10 uM using casein as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	Cc1cc(C)c(CNc2nc(Cl)nc3c2ncn3C2CCCC2)c(=O)[nH]1		CHEMBL4557538	=	Activity	%	98.5	CHEMBL3529	Homo sapiens	Activity	%	98.5
	18919518	CHEMBL4322874	Binding affinity to recombinant full-length N-terminal His-FLAG-GST-tagged IKBKE (unknown origin) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](NCCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4465866	=	Kd	nM	58.0	CHEMBL3529	Homo sapiens	Kd	nM	58.0
	18919706	CHEMBL4322874	Binding affinity to recombinant full-length N-terminal His-FLAG-GST-tagged IKBKE (unknown origin) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](N(C)CCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4576489	=	Kd	nM	44.0	CHEMBL3529	Homo sapiens	Kd	nM	44.0
	18937995	CHEMBL4327724	Inhibition of human IKKepsilon assessed as residual activity at 1 uM using casein as substrate by [gamma-33P]-ATP assay relative to control	B	ClC/C=C/C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4438024	=	Activity	%	110.53	CHEMBL3529	Homo sapiens	Activity	%	110.53
	18937996	CHEMBL4327724	Inhibition of human IKKepsilon assessed as residual activity at 1 uM using casein as substrate by [gamma-33P]-ATP assay relative to control	B	C(=C/c1ccccc1)\C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4446405	=	Activity	%	107.18	CHEMBL3529	Homo sapiens	Activity	%	107.18
	18938569	CHEMBL4328088	Inhibition of human IKKepsilon assessed as residual activity at 100 uM using casein as substrate by [gamma-33P]-ATP assay relative to control	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	<	Activity	%	65.0	CHEMBL3529	Homo sapiens	Activity	%	65.0
	18938948	CHEMBL4328452	Inhibition of human IKKepsilon using casein as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	0.439	CHEMBL3529	Homo sapiens	IC50	10'-10M	4.39
	18958915	CHEMBL4333437	Binding affinity to wild-type human full length IKK-epsilon (M1 to V716 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N		CHEMBL4563315	=	Activity	%	100.0	CHEMBL3529	Homo sapiens	Activity	%	100.0
	18964365	CHEMBL4335120	Inhibition of full length human IKKepsilon assessed as residual activity at 1 uM using casein as substrate after 40 mins by [gamma-33ATP] radiometric assay relative to control	B	N=C1NC(=O)/C(=C\c2ccc(-c3cccc([N+](=O)[O-])c3)o2)S1		CHEMBL4455512	=	Activity	%	100.0	CHEMBL3529	Homo sapiens	Activity	%	100.0
	18964366	CHEMBL4335120	Inhibition of full length human IKKepsilon assessed as residual activity at 1 uM using casein as substrate after 40 mins by [gamma-33ATP] radiometric assay relative to control	B	C=CCOC(=O)c1cc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)ccc1Cl		CHEMBL4568120	=	Activity	%	98.0	CHEMBL3529	Homo sapiens	Activity	%	98.0
	18971937	CHEMBL4336947	Inhibition of full length human IKKepsilon assessed as residual activity at 10 uM using peptide as substrate after 40 mins by [gamma-33ATP] radiometric assay relative to control	B	C[C@@H](c1ccccc1)n1nnc2cnc3ccc(-c4cnc5[nH]ccc5c4)cc3c21		CHEMBL4472294	=	Activity	%	94.0	CHEMBL3529	Homo sapiens	Activity	%	94.0
Not Active	19039744	CHEMBL4351898	Inhibition of recombinant full-length human IKKepsilon at 10 uM using casein as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	CN1C[C@H](Nc2nc3cc[nH]c3c(=O)n2C)C[C@H](c2ccc3c(c2)OCCO3)C1		CHEMBL4574669		Inhibition	%		CHEMBL3529	Homo sapiens	INH		
Active	19041143	CHEMBL4352404	Inhibition of human IKKepsilon at 10 uM using casein as substrate in presence of [gamma-33P]-ATP	B	CC(C)(C)C(=O)N1N=CC[C@H]1c1ccccc1		CHEMBL4521353		Inhibition	%		CHEMBL3529	Homo sapiens	INH		
	19059627	CHEMBL4357928	Binding affinity to wild-type human full length IKK-epsilon (M1 to V716 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1C(=O)Nc1c(C)cccc1Cl		CHEMBL4515441	=	Activity	%	100.0	CHEMBL3529	Homo sapiens	Activity	%	100.0
Not Active	19084228	CHEMBL4364413	Binding affinity to phosphorylated IKKepsilon in calyculin A stimulated human Ramos cell lysate incubated for 45 mins by kinobeads based assay	B	Cc1nn(CC(F)(F)F)cc1Nc1ncc(Br)c(NCc2ccc(S(N)(=O)=O)cc2)n1		CHEMBL4446892		Activity			CHEMBL3529	Homo sapiens	Activity		
	19084238	CHEMBL4364420	Binding affinity to IKKepsilon in human HEK293/K562/placenta/HepG2 cell lysate mixture incubated for 45 mins by kinobeads based assay	B	Cc1nn(CC(F)(F)F)cc1Nc1ncc(Br)c(NCc2ccc(S(N)(=O)=O)cc2)n1		CHEMBL4446892	=	Kd	nM	1000.0	CHEMBL3529	Homo sapiens	pKd		6.0
Not Active	19084245	CHEMBL4364423	Binding affinity to IKKepsilon in human Ramos cell lysate incubated for 45 mins by kinobeads based assay	B	Cc1nn(CC(F)(F)F)cc1Nc1ncc(Br)c(NCc2ccc(S(N)(=O)=O)cc2)n1		CHEMBL4446892		Activity			CHEMBL3529	Homo sapiens	Activity		
	19090192	CHEMBL4365766	Inhibition of wild-type human full length IKK-epsilon (M1 to V716 residues) expressed in mammalian expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1		CHEMBL4436895	=	Activity	%	100.0	CHEMBL3529	Homo sapiens	Activity	%	100.0
	19091961	CHEMBL4366435	Inhibition of human IKKepsilon at 100 nM using casein as substrate by [gamma-33P]-ATP assay	B	COc1ccc(N2C(=O)COc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5)c4)cc32)cc1	Outside typical range	CHEMBL4528675	=	Inhibition	%	-13.12	CHEMBL3529	Homo sapiens	INH	%	-13.12
	19114500	CHEMBL4371420	Binding affinity to IKKE in SILAC-labeled human MDA-MB-231 cells lysate by mass spectrometry based kinAffinity assay	B	COc1cc2c(Oc3ccc(NS(=O)(=O)c4cc(F)ccc4F)cc3F)ccnc2cc1OCCCN1CCN(C)CC1		CHEMBL4443828	=	Kd	nM	282.0	CHEMBL3529	Homo sapiens	Kd(free)	uM	0.282
	19114692	CHEMBL4371420	Binding affinity to IKKE in SILAC-labeled human MDA-MB-231 cells lysate by mass spectrometry based kinAffinity assay	B	COc1cc2c(Oc3ccc(NS(=O)(=O)c4c(F)cccc4F)cc3F)ccnc2cc1OCCCN1CCN(C)CC1		CHEMBL4462318	=	Kd	nM	122.0	CHEMBL3529	Homo sapiens	Kd(free)	uM	0.122
	19144878	CHEMBL4377894	Inhibition of recombinant full-length human IKKepsilon at 1 uM using casein as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580	=	Inhibition	%	-4.0	CHEMBL3529	Homo sapiens	INH	%	-4.0
	19146955	CHEMBL4378837	Inhibition of full length recombinant human IKKepsilon at 10 uM using casein as substrate after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	C=CS(=O)(=O)Nc1ccc(Cc2ccc3ccccc3c2)cc1		CHEMBL4459587	=	Inhibition	%	5.0	CHEMBL3529	Homo sapiens	INH	%	5.0
	19147888	CHEMBL4379362	Inhibition of recombinant full length human IKKepsilon using casein as substrate after 40 mins by [gamma-33ATP] by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4438748	>	IC50	nM	10000.0	CHEMBL3529	Homo sapiens	IC50	uM	10.0
	19152957	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	IC50	nM	18.0	CHEMBL3529	Homo sapiens	IC50	nM	18.0
	19152958	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	N#Cc1ccc2nc(Nc3cc(CN4CCN(C(=O)CC(F)(F)F)CC4)ccn3)[nH]c2c1		CHEMBL4459120	=	IC50	nM	17.0	CHEMBL3529	Homo sapiens	IC50	nM	17.0
	19152959	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	O=C(NCC1CC1)c1ccc2nc(Nc3cc(CN4CCN(C(=O)CC(F)(F)F)CC4)ccn3)[nH]c2c1		CHEMBL4456062	=	IC50	nM	80.0	CHEMBL3529	Homo sapiens	IC50	nM	80.0
	19152960	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4549459	=	IC50	nM	168.0	CHEMBL3529	Homo sapiens	IC50	nM	168.0
	19152961	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)OC(C)(C)C)CC5)ccn4)[nH]c3c2)n1		CHEMBL4545291	=	IC50	nM	914.0	CHEMBL3529	Homo sapiens	IC50	nM	914.0
	19152962	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCNCC5)ccn4)[nH]c3c2)n1		CHEMBL4575832	=	IC50	nM	940.0	CHEMBL3529	Homo sapiens	IC50	nM	940.0
Not Determined	19152963	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	CCCN1CCN(Cc2ccnc(Nc3nc4ccc(-c5nc(C)no5)cc4[nH]3)c2)CC1		CHEMBL4461416		IC50			CHEMBL3529	Homo sapiens	IC50		
Not Determined	19152964	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(CCO)CC5)ccn4)[nH]c3c2)n1		CHEMBL4521346		IC50			CHEMBL3529	Homo sapiens	IC50		
	19152965	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(CCC(F)(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4566710	=	IC50	nM	1170.0	CHEMBL3529	Homo sapiens	IC50	nM	1170.0
	19152966	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(CC(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4587843	=	IC50	nM	730.0	CHEMBL3529	Homo sapiens	IC50	nM	730.0
Not Determined	19152967	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(CC(F)(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4438389		IC50			CHEMBL3529	Homo sapiens	IC50		
	19152968	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)C6CC6)CC5)ccn4)[nH]c3c2)n1		CHEMBL4450510	=	IC50	nM	154.0	CHEMBL3529	Homo sapiens	IC50	nM	154.0
	19152969	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC6CC6)CC5)ccn4)[nH]c3c2)n1		CHEMBL4483062	=	IC50	nM	226.0	CHEMBL3529	Homo sapiens	IC50	nM	226.0
	19152970	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)C6CCC6)CC5)ccn4)[nH]c3c2)n1		CHEMBL4573638	=	IC50	nM	433.0	CHEMBL3529	Homo sapiens	IC50	nM	433.0
Not Determined	19152971	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)c6ccco6)CC5)ccn4)[nH]c3c2)n1		CHEMBL4462056		IC50			CHEMBL3529	Homo sapiens	IC50		
	19152972	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(C(C)N5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4455930	=	IC50	nM	593.0	CHEMBL3529	Homo sapiens	IC50	nM	593.0
	19152973	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc([C@H](C)N5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4577511	=	IC50	nM	200.0	CHEMBL3529	Homo sapiens	IC50	nM	200.0
	19152974	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc([C@@H](C)N5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4553949	=	IC50	nM	37.0	CHEMBL3529	Homo sapiens	IC50	nM	37.0
	19152975	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(C(=O)N5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4524534	=	IC50	nM	3880.0	CHEMBL3529	Homo sapiens	IC50	nM	3880.0
	19152976	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	O=C(CC(F)(F)F)N1CCN(Cc2ccnc(Nc3nc4ccc(-c5nc(C6CC6)no5)cc4[nH]3)c2)CC1		CHEMBL4466150	=	IC50	nM	41.0	CHEMBL3529	Homo sapiens	IC50	nM	41.0
	19152977	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	CC(C)Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4547610	=	IC50	nM	89.0	CHEMBL3529	Homo sapiens	IC50	nM	89.0
	19152978	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cn1cc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)cn1		CHEMBL4436416	=	IC50	nM	197.0	CHEMBL3529	Homo sapiens	IC50	nM	197.0
	19152979	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	CCn1cc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)cn1		CHEMBL4453481	=	IC50	nM	98.0	CHEMBL3529	Homo sapiens	IC50	nM	98.0
	19152980	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	O=C(CC(F)(F)F)N1CCN(Cc2ccnc(Nc3nc4ccc(-c5cnn(CC6CC6)c5)cc4[nH]3)c2)CC1		CHEMBL4468020	=	IC50	nM	7.0	CHEMBL3529	Homo sapiens	IC50	nM	7.0
	19152981	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cnn(CC5CC5)c4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4435393	=	IC50	nM	6.0	CHEMBL3529	Homo sapiens	IC50	nM	6.0
	19152982	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cnn(CC5CCC5)c4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4436188	=	IC50	nM	4.0	CHEMBL3529	Homo sapiens	IC50	nM	4.0
	19152983	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1cc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)ccn1		CHEMBL4515413	=	IC50	nM	15.0	CHEMBL3529	Homo sapiens	IC50	nM	15.0
	19152984	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	CN(C)c1cc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)ccn1		CHEMBL4451595	=	IC50	nM	35.0	CHEMBL3529	Homo sapiens	IC50	nM	35.0
	19152985	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1cc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)ncn1		CHEMBL4552254	=	IC50	nM	16.0	CHEMBL3529	Homo sapiens	IC50	nM	16.0
	19152986	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1cc(-c2ccc3nc(Nc4cc([C@@H](C)N5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)ncn1		CHEMBL4538751	=	IC50	nM	4.0	CHEMBL3529	Homo sapiens	IC50	nM	4.0
	19152987	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	COCc1cc(-c2ccc3nc(Nc4cc([C@@H](C)N5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)ncn1		CHEMBL4566796	=	IC50	nM	2.0	CHEMBL3529	Homo sapiens	IC50	nM	2.0
	19152988	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(OCC5CC5)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4454902	=	IC50	nM	4.0	CHEMBL3529	Homo sapiens	IC50	nM	4.0
	19152989	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	CNc1cc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)ncn1		CHEMBL4594167	=	IC50	nM	10.0	CHEMBL3529	Homo sapiens	IC50	nM	10.0
	19152990	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	CN(C)c1cc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)ncn1		CHEMBL4453292	=	IC50	nM	10.0	CHEMBL3529	Homo sapiens	IC50	nM	10.0
	19152991	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673	=	IC50	nM	2.0	CHEMBL3529	Homo sapiens	IC50	nM	2.0
Not Determined	19152992	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	CC(C)Oc1cncnc1-c1ccc2nc(Nc3cc([C@@H](C)N4CCN(C(=O)CC(F)(F)F)CC4)ccn3)[nH]c2c1		CHEMBL4543618		IC50			CHEMBL3529	Homo sapiens	IC50		
	19152993	CHEMBL4380519	Inhibition of recombinant full length human C-terminal GST-tagged IKKepsilon expressed in baculovirus expression system using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	CN(C)c1ncnc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)c1Cl		CHEMBL4538591	=	IC50	nM	1280.0	CHEMBL3529	Homo sapiens	IC50	nM	1280.0
	19159455	CHEMBL4382559	Binding affinity to wild-type human full length IKK-epsilon (M1 to V716 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4473365	=	Activity	%	21.0	CHEMBL3529	Homo sapiens	Activity	%	21.0
	19181052	CHEMBL4387263	Inhibition of recombinant full length human GST-tagged IKKepsilon expressed in baculovirus expression system at 0.1 uM using serine/threonine-11 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	=	Inhibition	%	8.0	CHEMBL3529	Homo sapiens	INH	%	8.0
	19181278	CHEMBL4387263	Inhibition of recombinant full length human GST-tagged IKKepsilon expressed in baculovirus expression system at 0.1 uM using serine/threonine-11 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CC2(C1)CN(c1ccc(Nc3ncc(F)c(-c4cnn5c4[C@H](C)CCCC5)n3)nc1)C2		CHEMBL4545456	=	Inhibition	%	3.5	CHEMBL3529	Homo sapiens	INH	%	3.5
	19191552	CHEMBL4389278	Inhibition of wild-type human full length IKK-epsilon (M1 to V716 residues) expressed in mammalian expression system at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1		CHEMBL4555459	=	Inhibition	%	67.0	CHEMBL3529	Homo sapiens	INH	%	67.0
	19191941	CHEMBL4389755	Inhibition of wild-type human full length IKK-epsilon (M1 to V716 residues) expressed in mammalian expression system at 1 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1		CHEMBL4564973	=	Inhibition	%	96.0	CHEMBL3529	Homo sapiens	INH	%	96.0
	19200197	CHEMBL4391381	Binding affinity to wild-type human full length IKK-epsilon (M1 to V716 residues) expressed in mammalian expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cc(-c2cn(CCNc3c4c(nc5ccccc35)CCCC4)nn2)ccn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL4559936	=	Activity	%	52.0	CHEMBL3529	Homo sapiens	Activity	%	52.0
	19266457	CHEMBL4405407	Inhibition of wild-type human full length IKK-epsilon (M1 to V716 residues) expressed in mammalian expression system at 1 uM by Kinomescan method relative to control	B	CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1		CHEMBL4455923	<	Inhibition	%	50.0	CHEMBL3529	Homo sapiens	INH	%	50.0
	19274937	CHEMBL4407594	Inhibition of recombinant human full-length GST-tagged IKBKE expressed in baculovirus expression system at 25 uM using FRET-labeled Ser/Thr 11 peptide as substrate measured after 1 hr by Z'-lyte assay relative to control	A	Nc1ncc2cc(-c3c(Br)cccc3Br)c(N)nc2n1		CHEMBL57531	=	Inhibition	%	-7.0	CHEMBL3529	Homo sapiens	INH	%	-7.0
	19274938	CHEMBL4407594	Inhibition of recombinant human full-length GST-tagged IKBKE expressed in baculovirus expression system at 25 uM using FRET-labeled Ser/Thr 11 peptide as substrate measured after 1 hr by Z'-lyte assay relative to control	A	Nc1ncc2cc(-c3c(Cl)cccc3-c3cccnc3)c(N3C[C@H]4[C@H](N)[C@H]4C3)nc2n1		CHEMBL4453148	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	INH	%	3.0
	19274939	CHEMBL4407594	Inhibition of recombinant human full-length GST-tagged IKBKE expressed in baculovirus expression system at 25 uM using FRET-labeled Ser/Thr 11 peptide as substrate measured after 1 hr by Z'-lyte assay relative to control	A	CC(C)COc1cccc(Cl)c1-c1cc2cnc(N)nc2nc1N1C[C@H]2[C@H](N)[C@H]2C1		CHEMBL4546703	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	INH	%	0.0
	19276016	CHEMBL4408019	Inhibition of recombinant human full length IKKepsilon at 1 uM using casein as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method relative to control	B	Cc1ccc(NC(=O)C2(C(=O)Nc3ccc(Nc4ncc(F)c(-c5cc(F)c6nc(C)n(C(C)C)c6c5)n4)cc3)CC2)cc1		CHEMBL4445335	=	Inhibition	%	47.0	CHEMBL3529	Homo sapiens	INH	%	47.0
	19476581	CHEMBL4479729	Inhibition of full-length recombinant human GST-tagged IKK-epsilon expressed in baculovirus expression system by Z'-LYTE assay	B	O=C(NCC(F)(F)F)c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)cs1		CHEMBL4569508	<	IC50	nM	10.0	CHEMBL3529	Homo sapiens	IC50	nM	10.0
	19476681	CHEMBL4479729	Inhibition of full-length recombinant human GST-tagged IKK-epsilon expressed in baculovirus expression system by Z'-LYTE assay	B	Cn1cc(-c2cnc3c(-c4csc(C(=O)NCC(F)(F)F)c4)cnn3c2)cn1		CHEMBL4550702	<	IC50	nM	10.0	CHEMBL3529	Homo sapiens	IC50	nM	10.0
	19476781	CHEMBL4479729	Inhibition of full-length recombinant human GST-tagged IKK-epsilon expressed in baculovirus expression system by Z'-LYTE assay	B	Cn1cc(-c2cnc3c(-c4csc(C(=O)N[C@@H]5CCCC[C@@H]5N)c4)cnn3c2)cn1		CHEMBL4568087	=	IC50	nM	7.1	CHEMBL3529	Homo sapiens	IC50	nM	7.1
	19476881	CHEMBL4479729	Inhibition of full-length recombinant human GST-tagged IKK-epsilon expressed in baculovirus expression system by Z'-LYTE assay	B	Cc1sc(C(=O)N[C@@H]2[C@H](N)CCCC2(F)F)cc1-c1cnn2cc(Cl)cnc12		CHEMBL4552628	=	IC50	nM	48.0	CHEMBL3529	Homo sapiens	IC50	nM	48.0
	20600551	CHEMBL4603503	Inhibition of recombinant human full-length GST-tagged IKBKE expressed in baculovirus expression system using Ser/Thr 11 peptide as substrate measured after 1 hr in presence of ATP by Z'-lyte assay	B	C[C@@H]1C[C@H]1C(=O)N1CCN(c2cnc(C#N)c(-c3cnn(C)c3)n2)C[C@H]1C		CHEMBL4634634	>	IC50	nM	100000.0	CHEMBL3529	Homo sapiens	IC50	uM	100.0
	20669015	CHEMBL4620274	Inhibition of biotinylated ligand binding to wild-type human full length IKKE (M1 to V716 residues) expressed in bacterial expression system at 50 nM measured after 1 hr by kinomescan assay relative to control	B	CN(C)[C@@H]1CC[C@@]2(C)[C@@H](CC[C@H]3[C@@H]4CC=C(c5cncc(Cl)c5)[C@@]4(C)CC[C@@H]32)C1		CHEMBL4648955	>	Inhibition	%	80.0	CHEMBL3529	Homo sapiens	INH	%	80.0
	22391695	CHEMBL4666971	Inhibition of recombinant human GST-tagged full length IKKepsilon expressed in baculovirus expression system using Ser/Thr 11 as substrate at 0.1 uM incubated for 60 mins by Z'-lyte assay relative to control	B	O=C(Nc1c[nH]nc1-c1cc(Cl)ccc1OC(F)F)c1cnn2cccnc12		CHEMBL4744172	=	Inhibition	%	8.0	CHEMBL3529	Homo sapiens	INH	%	8.0
	22391696	CHEMBL4666971	Inhibition of recombinant human GST-tagged full length IKKepsilon expressed in baculovirus expression system using Ser/Thr 11 as substrate at 0.1 uM incubated for 60 mins by Z'-lyte assay relative to control	B	Cn1cc(NC(=O)c2cnn3cccnc23)c(-c2cc(Cl)ccc2OC(F)F)n1		CHEMBL4777342	=	Inhibition	%	5.0	CHEMBL3529	Homo sapiens	INH	%	5.0
	22391697	CHEMBL4666971	Inhibition of recombinant human GST-tagged full length IKKepsilon expressed in baculovirus expression system using Ser/Thr 11 as substrate at 0.1 uM incubated for 60 mins by Z'-lyte assay relative to control	B	O=C(Nc1c[nH]nc1-c1cc2ccccc2cc1OC(F)F)c1cnn2cccnc12		CHEMBL4745474	=	Inhibition	%	3.0	CHEMBL3529	Homo sapiens	INH	%	3.0
	22392077	CHEMBL4667172	Inhibition of recombinant human GST-tagged full length IKKepsilon expressed in baculovirus expression system using Ser/Thr 11 as substrate at 10 uM incubated for 60 mins by Z'-lyte assay relative to control	B	CN1C(=O)[C@@H](NC(=O)c2n[nH]c3ncc(C(F)(F)C(F)(F)F)cc23)COc2ccccc21		CHEMBL4785812	=	Inhibition	%	1.5	CHEMBL3529	Homo sapiens	INH	%	1.5
	22423547	CHEMBL4674349	Inhibition of human IKKepsilon using casein as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OC1CCCCC1		CHEMBL4785602	=	Activity	%	100.49	CHEMBL3529	Homo sapiens	Activity	%	100.49
	22423548	CHEMBL4674349	Inhibition of human IKKepsilon using casein as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OCc1ccncc1		CHEMBL4749141	=	Activity	%	20.43	CHEMBL3529	Homo sapiens	Activity	%	20.43
	22759641	CHEMBL4701769	Inhibition of human IKBKE at 1 uM using fluorescently labeled peptide substrate measured after 3 hrs by microfluidic mobility shift assay relative to control	B	CN(C)C(=O)c1ccc(Oc2nc(-c3cnc(N)s3)nc(N3CCOCC3)n2)cc1		CHEMBL4782133	=	Inhibition	%	-1.0	CHEMBL3529	Homo sapiens	INH	%	-1.0
	22843714	CHEMBL4720700	Inhibition of human IKKepsilon using casein as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	0.199	CHEMBL3529	Homo sapiens	IC50	10^-10M	1.99
	22844064	CHEMBL4721050	Inhibition of human IKKepsilon assessed as residual activity using casein as substrate at 1 uM by [gamma-33P]-ATP assay relative to control	B	O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F		CHEMBL4750196	=	Activity	%	96.91	CHEMBL3529	Homo sapiens	Activity	%	96.91
	22844740	CHEMBL4721415	Inhibition of wild-type human full length IKK-epsilon (M1 to V716 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]ccc12		CHEMBL4794578	=	Activity	%	88.82	CHEMBL3529	Homo sapiens	Activity	%	88.82
	22952869	CHEMBL4766806	Inhibition of full length human IKKepsilon assessed as residual activity at 10 uM using peptide as substrate after 40 mins by [gamma-33ATP] radiometric assay relative to control	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4c3OCCCN4)cc2)no1		CHEMBL4793380	=	Activity	%	96.0	CHEMBL3529	Homo sapiens	Activity	%	96.0
	22955547	CHEMBL4767604	Inhibition of GST-tagged full length human IKK epsilon expressed in baculovirus expression system at 1 uM by Selectscreen kinase assay	B	COc1ccccc1-c1csc2cnc(Nc3ccc(C(=O)NC4CCNCC4)c(F)c3)nc12		CHEMBL4785582	=	Inhibition	%	66.0	CHEMBL3529	Homo sapiens	INH	%	66.0
	23120455	CHEMBL4804392	Inhibition of IKKE in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O	Outside typical range	CHEMBL4855542	=	IC50	nM	-9900.0	CHEMBL3529	Homo sapiens	IC50	uM	-9.9
	23120456	CHEMBL4804392	Inhibition of IKKE in human NCI-H929 cells by mass spectroscopic analysis	B	CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1	Outside typical range	CHEMBL4860979	=	IC50	nM	-14800.0	CHEMBL3529	Homo sapiens	IC50	uM	-14.8
	23120457	CHEMBL4804392	Inhibition of IKKE in human NCI-H929 cells by mass spectroscopic analysis	B	COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1	Outside typical range	CHEMBL4867931	=	IC50	nM	-18800.0	CHEMBL3529	Homo sapiens	IC50	uM	-18.8
	23120458	CHEMBL4804392	Inhibition of IKKE in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855730	=	IC50	nM	26700.0	CHEMBL3529	Homo sapiens	IC50	uM	26.7
	23120459	CHEMBL4804392	Inhibition of IKKE in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4868141	=	IC50	nM	81800.0	CHEMBL3529	Homo sapiens	IC50	uM	81.8
	23120460	CHEMBL4804392	Inhibition of IKKE in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4859660	=	IC50	nM	21200.0	CHEMBL3529	Homo sapiens	IC50	uM	21.2
	23121494	CHEMBL4804574	Inhibition of IKKE in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855542	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	INH	%	0.0
	23121495	CHEMBL4804574	Inhibition of IKKE in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1		CHEMBL4860979	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	INH	%	0.0
	23121496	CHEMBL4804574	Inhibition of IKKE in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1		CHEMBL4867931	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	INH	%	0.0
	23121497	CHEMBL4804574	Inhibition of IKKE in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855730	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	INH	%	0.0
	23121498	CHEMBL4804574	Inhibition of IKKE in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4868141	=	Inhibition	%	75.0	CHEMBL3529	Homo sapiens	INH	%	75.0
	23121499	CHEMBL4804574	Inhibition of IKKE in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4859660	=	Inhibition	%	0.0	CHEMBL3529	Homo sapiens	INH	%	0.0
	23122613	CHEMBL4804964	Inhibition of human IKK-epsilon assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN1CCN(C(=O)c2ccc3cc(CCNc4ccnc5ccc(C#N)cc45)ccc3c2)CC1		CHEMBL4878072	=	Activity	%	91.0	CHEMBL3529	Homo sapiens	Activity	%	91.0
	23123308	CHEMBL4805552	Inhibition of human IKK-epsilon assessed as percent of control at 1000 nM by KINOMEscan assay relative to control	B	COc1cc2nc(NC3CC3)nc(NC3CCN(C(C)C)CC3)c2cc1OC.O=C(O)C(F)(F)F		CHEMBL4870304	=	Activity	%	84.0	CHEMBL3529	Homo sapiens	Activity	%	84.0
	23123590	CHEMBL4805834	Inhibition of DNA-tagged human IKK-epsilon assessed as percent of control at 50000 nM by qPCR analysis relative to control	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Activity	%	100.0	CHEMBL3529	Homo sapiens	Activity	%	100.0
	23124706	CHEMBL4806569	Inhibition of human IKK-epsilon assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	100.0	CHEMBL3529	Homo sapiens	Activity	%	100.0
	23124707	CHEMBL4806569	Inhibition of human IKK-epsilon assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	100.0	CHEMBL3529	Homo sapiens	Activity	%	100.0
	23128182	CHEMBL4807869	Inhibition of IKKepsilon (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)csc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL4867844	=	Activity	%	50.0	CHEMBL3529	Homo sapiens	Activity	%	50.0
	23128183	CHEMBL4807869	Inhibition of IKKepsilon (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)ccnc3C)s2)cc(NN2CCN(CCO)CC2)n1		CHEMBL4855726	>	Activity	%	75.0	CHEMBL3529	Homo sapiens	Activity	%	75.0
	23128184	CHEMBL4807869	Inhibition of IKKepsilon (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Activity	%	75.0	CHEMBL3529	Homo sapiens	Activity	%	75.0
	23128923	CHEMBL4808099	Inhibition of IKK-epsilon (unknown origin) at 0.5 uM relative to control	B	CNC(=O)c1cc(Oc2ccc(NC(=O)c3nc(SC)n(CCN(C)C)c3-c3ccc(F)cc3)cc2)ccn1		CHEMBL4847460	=	Inhibition	%	34.0	CHEMBL3529	Homo sapiens	INH	%	34.0
Not Active	23317448	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CCC(=N\O)/C(C)=C/c1ccc(F)cc1		CHEMBL3697701		% Control	%	94.0	CHEMBL3529	Homo sapiens	% Control	%	94.0
Not Active	23317916	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CCC(=N\O)/C(C)=C/c1ccc(F)c(C)c1		CHEMBL3701197		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23318583	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	Cn1cncc1[C@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4586794		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23319066	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	Cn1cncc1[C@@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4526341		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23319703	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CCCCN(CCCC)C(=O)CN1C[C@H](c2cc(OC)c3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1CC(C)(C)CCC		CHEMBL111612		% Control	%	80.9	CHEMBL3529	Homo sapiens	% Control	%	80.9
Not Active	23320178	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC		CHEMBL4513786		% Control	%	89.7	CHEMBL3529	Homo sapiens	% Control	%	89.7
Not Active	23320856	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1		CHEMBL440687		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23321324	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CSc1cccnc1N1CCN(Cc2nc3ccccc3[nH]2)CC1		CHEMBL4630641		% Control	%	81.0	CHEMBL3529	Homo sapiens	% Control	%	81.0
Not Active	23321954	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CCCOc1ccc([C@H]2[C@H](C(=O)O)[C@@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL332794		% Control	%	68.0	CHEMBL3529	Homo sapiens	% Control	%	68.0
Not Active	23322422	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CCCOc1ccc([C@@H]2[C@@H](C(=O)O)[C@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL4533479		% Control	%	85.0	CHEMBL3529	Homo sapiens	% Control	%	85.0
Not Active	23323111	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	COc1ccc2c(c1)O[C@@H](c1ccc(OC)c(OC)c1)C[C@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4093612		% Control	%	70.0	CHEMBL3529	Homo sapiens	% Control	%	70.0
Not Active	23323579	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	COc1ccc2c(c1)O[C@H](c1ccc(OC)c(OC)c1)C[C@@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4066040		% Control	%	96.0	CHEMBL3529	Homo sapiens	% Control	%	96.0
Not Active	23324433	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CC1=C(C#N)[C@@H](c2ccc3[nH]nc(C)c3c2)C(C#N)=C(c2ccc(Cl)cc2)N1		CHEMBL4522773		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23325068	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@H]1CC[C@@H](Cn2nnc3ccccc3c2=O)[C@@H]1C(=O)O		CHEMBL4585243		% Control	%	90.0	CHEMBL3529	Homo sapiens	% Control	%	90.0
Not Active	23325536	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@@H]1CC[C@H](Cn2nnc3ccccc3c2=O)[C@H]1C(=O)O		CHEMBL4539943		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23326183	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1		CHEMBL4521594		% Control	%	69.0	CHEMBL3529	Homo sapiens	% Control	%	69.0
Not Active	23326651	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	NS(=O)(=O)c1cc(NC(=O)C2(c3ccccc3Cl)CC2)ccc1Oc1cccc(Cl)c1		CHEMBL4516843		% Control	%	70.0	CHEMBL3529	Homo sapiens	% Control	%	70.0
Not Active	23327351	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4537788		% Control	%	77.0	CHEMBL3529	Homo sapiens	% Control	%	77.0
Not Active	23327819	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4564312		% Control	%	82.0	CHEMBL3529	Homo sapiens	% Control	%	82.0
Not Active	23328406	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C#N)cc1		CHEMBL4448899		% Control	%	75.0	CHEMBL3529	Homo sapiens	% Control	%	75.0
Not Active	23328874	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C(C)(C)C)cc1		CHEMBL4552180		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23329377	CHEMBL4881084	IKKepsilon(h) Eurofins Kinase panel	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% residual kinase activity	%	107.0	CHEMBL3529	Homo sapiens	% residual kinase activity	%	107.0
Not Active	23329820	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% Control	%	98.0	CHEMBL3529	Homo sapiens	% Control	%	98.0
Not Active	23330288	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	Cc1nc(C2CCN(C(=O)c3ccc(OC(F)(F)F)cc3N)CC2)c2ncc(N3CCN(C)CC3)cc2n1		CHEMBL4455582		% Control	%	97.0	CHEMBL3529	Homo sapiens	% Control	%	97.0
Not Active	23331044	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	O=C(N1CCS(=O)(=O)CC1)N1C[C@H](c2ccc(OC(F)(F)F)cc2)C[C@H](c2nc(C3CC3)no2)C1		CHEMBL4630644		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23331512	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	Cc1noc([C@H]2C[C@@H](c3ccc(C(F)(F)F)cc3)CN(C(=O)N3CCS(=O)(=O)C3)C2)n1		CHEMBL4630643		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23332099	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1		CHEMBL3907057		% Control	%	59.9	CHEMBL3529	Homo sapiens	% Control	%	59.9
Not Active	23332565	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1		CHEMBL4526351		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23333283	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CC(=O)C1=C(C)N(c2cccc(C(F)(F)F)c2)C(=O)N[C@@H]1c1ccc(C#N)nc1		CHEMBL3617968		% Control	%	98.2	CHEMBL3529	Homo sapiens	% Control	%	98.2
Not Active	23333922	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4535474		% Control	%	71.0	CHEMBL3529	Homo sapiens	% Control	%	71.0
Not Active	23334390	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4520788		% Control	%	85.0	CHEMBL3529	Homo sapiens	% Control	%	85.0
Not Active	23335369	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		% Control	%	93.0	CHEMBL3529	Homo sapiens	% Control	%	93.0
Not Active	23335837	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	Cn1cc(Cl)c2c(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)ccnc21		CHEMBL4546802		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23336464	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	O=C(NC[C@H]1[C@@H]2CN(C(=O)OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C[C@H]12)c1ccc2[nH]nnc2c1		CHEMBL4165749		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23336932	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	Cc1nccc(COC(=O)N2C[C@H]3[C@H](CNC(=O)c4ccc5[nH]nnc5c4)[C@H]3C2)n1		CHEMBL4552354		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23337621	CHEMBL4881992	IKBKE Invitrogen selectivity data (BI)	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Ctrl	%	99.5	CHEMBL3529	Homo sapiens	% Ctrl	%	99.5
Not Active	23338013	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Control	%	86.0	CHEMBL3529	Homo sapiens	% Control	%	86.0
Not Active	23338481	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CN(C)C(=O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CC3)no2)cn1		CHEMBL4560241		% Control	%	57.0	CHEMBL3529	Homo sapiens	% Control	%	57.0
Not Active	23339093	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL3358954		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23339561	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CCS(=O)(=O)c1cc2cc(C[C@@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL4531220		% Control	%	83.0	CHEMBL3529	Homo sapiens	% Control	%	83.0
Not Active	23340198	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CS(=O)(=O)c1cc(C2(NC(=O)c3cncc4c3cnn4-c3ccc(F)cc3)CC2)ccn1		CHEMBL4456123		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23340666	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CS(=O)(=O)NCC[C@H](NC(=O)c1cncc2c1cnn2-c1ccc(F)cc1)c1ccnc(S(C)(=O)=O)c1		CHEMBL4539555		% Control	%	78.0	CHEMBL3529	Homo sapiens	% Control	%	78.0
Not Active	23341323	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1		CHEMBL2170610		% Control	%	70.0	CHEMBL3529	Homo sapiens	% Control	%	70.0
Not Active	23341791	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CC(=O)N1CCC(c2ccc(C(=O)NC3=NCCN3)cc2C(F)(F)F)CC1		CHEMBL4540759		% Control	%	71.0	CHEMBL3529	Homo sapiens	% Control	%	71.0
Not Active	23342407	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834184		% Control	%	52.0	CHEMBL3529	Homo sapiens	% Control	%	52.0
Not Active	23342875	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CCC(=O)N[C@@H]1CC[C@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834199		% Control	%	60.0	CHEMBL3529	Homo sapiens	% Control	%	60.0
Not Active	23343505	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Control	%	66.0	CHEMBL3529	Homo sapiens	% Control	%	66.0
Not Active	23343973	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	Cn1nc(C(=O)NCc2ccc(C(=O)O)cc2)cc1-c1ccc2[nH]ccc2c1		CHEMBL1939880		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23344611	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CCOCCn1cc(C(=O)Nc2ccc(-n3nc(-c4cccnc4)cc3C(F)(F)F)cn2)ccc1=O		CHEMBL4516982		% Control	%	79.0	CHEMBL3529	Homo sapiens	% Control	%	79.0
Not Active	23345184	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)CC5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(=O)C(C)C)n3)nc2c1C		CHEMBL4588900		% Control	%	82.0	CHEMBL3529	Homo sapiens	% Control	%	82.0
Not Active	23345652	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	O=C(N[C@H]1CCCCC/C=C\C2C[C@@]2(C(=O)O)NC(=O)[C@@H]2C[C@@H](Oc3ccncc3)CN2C1=O)OC1CCCC1		CHEMBL4516471		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23346229	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	Cc1cc(Nc2nccc(C)n2)cc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)c1		CHEMBL3685796		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23346698	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	Cc1ccc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)cc1Nc1cccc(C(F)(F)F)n1		CHEMBL4530401		% Control	%	73.8	CHEMBL3529	Homo sapiens	% Control	%	73.8
Not Active	23347300	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1		CHEMBL4538174		% Control	%	66.7	CHEMBL3529	Homo sapiens	% Control	%	66.7
Not Active	23347789	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	C[C@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccn1		CHEMBL4557026		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23348368	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12		CHEMBL204232		% Control	%	80.0	CHEMBL3529	Homo sapiens	% Control	%	80.0
Not Active	23348836	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CC(=O)c1c(NS(C)(=O)=O)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2n(C)c1=O		CHEMBL4578164		% Control	%	73.0	CHEMBL3529	Homo sapiens	% Control	%	73.0
Active	23349423	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	O=S(=O)(NC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F		CHEMBL1091513		% Control	%	0.0	CHEMBL3529	Homo sapiens	% Control	%	0.0
Not Active	23350041	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	COc1cc(-c2cn(C3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1		CHEMBL3609637		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23350509	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	COc1cc(-c2cn(C3CCc4ccccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1ccc(C)n1		CHEMBL4534005		% Control	%	68.0	CHEMBL3529	Homo sapiens	% Control	%	68.0
Not Active	23351114	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL561132		% Control	%	84.0	CHEMBL3529	Homo sapiens	% Control	%	84.0
Not Active	23351582	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CN([C@@H]1CCc2c(CC(=O)O)c3cc(S(C)(=O)=O)ccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL1643772		% Control	%	78.0	CHEMBL3529	Homo sapiens	% Control	%	78.0
Not Active	23352071	CHEMBL4882762	IKBKE (IKK epsilon) Kinase screen	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		Inhibition	%	1.77	CHEMBL3529	Homo sapiens	% Inhibition	%	1.7698
Not Active	23352606	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		% Control	%	74.0	CHEMBL3529	Homo sapiens	% Control	%	74.0
Not Active	23353074	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	C[C@H]1CN(c2cc(-c3nn(C)c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4560589		% Control	%	65.0	CHEMBL3529	Homo sapiens	% Control	%	65.0
Not Active	23353956	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1		CHEMBL1800685		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23354424	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	Cc1c(C(=O)O)cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc12		CHEMBL4566600		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23355156	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	COCCOc1nc(-c2ccc(Cl)nc2)nc2c1CN(C(=O)c1ncn3ccccc13)CC2		CHEMBL2204538		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23355624	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CC(C)CC(=O)N1CCc2nc(-c3ccc(Br)cc3)nc(N(C)Cc3ccccc3)c2C1		CHEMBL4518342		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23356260	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1		CHEMBL3582478		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23356728	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	FC(F)(F)c1ccc2c(c1)nc(-c1cccnc1)n2C1CC1		CHEMBL3582461		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23357337	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	C[C@H](c1ccc(F)cc1)N(Cc1cccc(C(=O)O)c1)C(=O)c1cnc2ccccc2c1		CHEMBL3577885		% Control	%	79.0	CHEMBL3529	Homo sapiens	% Control	%	79.0
Not Active	23357984	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1		CHEMBL1651534		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23358452	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	O=C(Nc1cccnn1)N1CC(C/C=C/c2cncc(Oc3ccc(C(F)(F)F)cn3)n2)C1		CHEMBL4780458		% Control	%	77.0	CHEMBL3529	Homo sapiens	% Control	%	77.0
Not Active	23359038	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	COc1cccc(CNC(=O)c2nc3scc(COCc4ccc(C(=O)O)cc4)c3c(=O)[nH]2)c1		CHEMBL3337894		% Control	%	83.9	CHEMBL3529	Homo sapiens	% Control	%	83.9
Not Active	23359636	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	C[C@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3799292		% Control	%	82.0	CHEMBL3529	Homo sapiens	% Control	%	82.0
Not Active	23360104	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	C[C@@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3797887		% Control	%	56.0	CHEMBL3529	Homo sapiens	% Control	%	56.0
Not Active	23360689	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	Cn1nc(C(F)(F)F)cc1-c1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4455357		% Control	%	94.0	CHEMBL3529	Homo sapiens	% Control	%	94.0
Not Active	23361157	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	Nc1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4585920		% Control	%	95.0	CHEMBL3529	Homo sapiens	% Control	%	95.0
Not Active	23361730	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	Cc1nc(N2CC[C@@H](O)C2)ncc1-c1cc(C(F)(F)F)cc2[nH]ncc12		CHEMBL3799512		% Control	%	89.0	CHEMBL3529	Homo sapiens	% Control	%	89.0
Not Active	23362266	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	Cc1cc(-n2nc(Cc3cc(F)cc(C(F)(F)F)c3)nc2C)ccc1C(N)=O		CHEMBL4082756		% Control	%	82.0	CHEMBL3529	Homo sapiens	% Control	%	82.0
Not Active	23362734	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	Cc1nc(Cc2cccc(C(F)(F)F)c2)sc1-c1ccc(C(N)=O)nc1		CHEMBL4100408		% Control	%	76.0	CHEMBL3529	Homo sapiens	% Control	%	76.0
Not Active	23364376	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1		CHEMBL4228713		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23364844	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1		CHEMBL4551344		% Control	%	65.0	CHEMBL3529	Homo sapiens	% Control	%	65.0
Not Active	23365583	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1		CHEMBL3342332		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23366126	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	Cc1c(Oc2c(F)cccc2F)c(OC(C)C)nn1-c1ncc(C2CC2)cc1F		CHEMBL3589752		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23366716	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	Nc1c(C(=O)NCc2ccc(C(=O)NCCCC3CCCCC3)cc2)cnn1-c1ccccc1		CHEMBL4436748		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23367184	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	O=C(NCCCC1CCCCC1)c1ccc(CNC(=O)c2cnn(-c3ccccc3)c2C(F)(F)F)cc1		CHEMBL4531775		% Control	%	78.0	CHEMBL3529	Homo sapiens	% Control	%	78.0
Not Active	23367600	CHEMBL4883953	IKK-epsilon ProQinase selectivity panel	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@H](O)CO)cc21		CHEMBL2152944		% Residual activity with Skepinone-L	%	103.0	CHEMBL3529	Homo sapiens	% Residual activity with Skepinone-L	%	103.0
Not Active	23368062	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1		CHEMBL4458424		% Control	%	98.0	CHEMBL3529	Homo sapiens	% Control	%	98.0
Not Active	23368530	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@H]1c1ccc(F)cc1		CHEMBL4592872		% Control	%	89.0	CHEMBL3529	Homo sapiens	% Control	%	89.0
Active	23368909	CHEMBL4884196	Biochemical assay (low ATP) with IKBKE	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		IC50	nM	2.0	CHEMBL3529	Homo sapiens	IC50	nM	2.0
Active	23368911	CHEMBL4884198	NanoBRET with IKBKE	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		IC50	nM	1725.0	CHEMBL3529	Homo sapiens	IC50	nM	1725.0
Active	23369129	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		% Control	%	9.9	CHEMBL3529	Homo sapiens	% Control	%	9.9
Active	23369597	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CN(C)c1ncnc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)c1Cl		CHEMBL4538591		% Control	%	13.0	CHEMBL3529	Homo sapiens	% Control	%	13.0
Not Active	23370099	CHEMBL4884343	IKKepsilon(h) Eurofins kinase panel	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% residual kinase activity	%	108.0	CHEMBL3529	Homo sapiens	% residual kinase activity	%	108.0
Not Active	23370565	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% Control	%	68.0	CHEMBL3529	Homo sapiens	% Control	%	68.0
Not Active	23371033	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CC1=C(C#N)C(c2ccc3c(c2)c(NC(=O)c2ccccc2C)nn3C)C(C#N)=C(C)N1		CHEMBL4630642		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23371842	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNC(=O)c3cnc4ccccn34)cc2)C1		CHEMBL4591082		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23372310	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNc3ncnc4c3nnn4-c3ccccc3)cc2)C1		CHEMBL4568183		% Control	%	73.0	CHEMBL3529	Homo sapiens	% Control	%	73.0
	23372765	CHEMBL4884730	IKKepsilon(IKBELGY1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(Cc4ccccc4)nc3C2=O)COc2ccccc21		CHEMBL4088216		IC50	nM	1000.0	CHEMBL3529	Homo sapiens	pIC50		6.0
	23373174	CHEMBL4885021	IKKepsilon(IKBELGY1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3c(nn(Cc4ccccc4)c3Br)C2=O)COc2ccccc21		CHEMBL4549667		IC50	nM	1000.0	CHEMBL3529	Homo sapiens	pIC50		6.0
	23373535	CHEMBL4885312	IKKepsilon(IKBELGY1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(CC4CCS(=O)(=O)CC4)nc3C2=O)COc2ccccc21		CHEMBL4097778		IC50	nM	1000.0	CHEMBL3529	Homo sapiens	pIC50		6.0
Not Active	23375001	CHEMBL4885994	IKK_epsilon Kinase panel	B	CC(C)(O)[C@H](F)CN1Cc2cc(NC(=O)c3cnn4cccnc34)c(N3CCOCC3)cc2C1=O		CHEMBL4475494		Inhibition	%	-0.5	CHEMBL3529	Homo sapiens	% Inhibition	%	-0.5
Not Active	23375737	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	O=C1CCc2cc(Nc3cc(OC4CCOCC4)c([N+](=O)[O-])cc3Cl)ccc2N1		CHEMBL4075278		% Control	%	90.0	CHEMBL3529	Homo sapiens	% Control	%	90.0
Not Active	23376205	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	N#Cc1ccc(Nc2ccc3[nH]c(=O)[nH]c3c2)c(Cl)c1		CHEMBL4063249		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23376782	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	O=c1nc(-c2ccccn2)sc2ccccc12		CHEMBL4516611		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23377250	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	O=C1NC(c2ccccn2)Sc2ccccc21		CHEMBL4561806		% Control	%	94.0	CHEMBL3529	Homo sapiens	% Control	%	94.0
Not Active	23378110	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4282264		% Control	%	51.0	CHEMBL3529	Homo sapiens	% Control	%	51.0
Not Active	23378578	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CNC(=O)Nc1ccc2c(c1)[C@@]1(CC2)OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4536197		% Control	%	75.0	CHEMBL3529	Homo sapiens	% Control	%	75.0
Not Active	23379745	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)O)c(=O)n3ccccc23)CC1		CHEMBL1800285		% Control	%	88.0	CHEMBL3529	Homo sapiens	% Control	%	88.0
Not Active	23380213	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)N3CCCC3)c(=O)n3ccccc23)CC1		CHEMBL2204283		% Control	%	94.0	CHEMBL3529	Homo sapiens	% Control	%	94.0
Not Active	23380907	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1		CHEMBL3286797		% Control	%	95.0	CHEMBL3529	Homo sapiens	% Control	%	95.0
Not Active	23381555	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	C[C@H](NC(=O)c1cnc2n1[C@](C)(Cc1ccc(C#N)cc1)C(=O)N2c1cc(Cl)c(F)c(Cl)c1)C(=O)NC1(c2ccccn2)CC1		CHEMBL4530740		% Control	%	89.0	CHEMBL3529	Homo sapiens	% Control	%	89.0
Not Active	23382023	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	C[C@@]1(Cc2ccc(C#N)cc2)C(=O)N(c2cc(Cl)cc(Cl)c2)c2ncc(C(=O)NC3(c4nc(C5CCC5)no4)CC3)n21		CHEMBL4577237		% Control	%	80.0	CHEMBL3529	Homo sapiens	% Control	%	80.0
Not Active	23382406	CHEMBL4887124	IKKi Invitrogen kinase activity assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		Inhibition	%	8.0	CHEMBL3529	Homo sapiens	% inhibition	%	8.0
Not Active	23382647	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		% Control	%	99.0	CHEMBL3529	Homo sapiens	% Control	%	99.0
Active	23383115	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CN(c1ccnc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)n1)S(C)(=O)=O		CHEMBL4518706		% Control	%	18.0	CHEMBL3529	Homo sapiens	% Control	%	18.0
Not Active	23383820	CHEMBL4887452	IKBKE Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	98.0	CHEMBL3529	Homo sapiens	% Ctrl	%	98.0
Not Active	23383821	CHEMBL4887452	IKBKE Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	98.0	CHEMBL3529	Homo sapiens	% Ctrl	%	98.0
Not Active	23384307	CHEMBL4887902	IKKepsilon(h Millipore kinase panel	B	CC[C@@H](Nc1c(C#N)c(-c2ccc(-c3cccc(C)c3F)cc2)nc2cnccc12)C(=O)O		CHEMBL4802045		Inhibition	%	10.23	CHEMBL3529	Homo sapiens	% inhibition	%	10.23
Not Active	23385030	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CO[C@@H](C)c1c(Nc2ccc([C@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4568735		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
Not Active	23385497	CHEMBL4879754	KinomeScan assay: inhibition of IKK-epsilon	B	CO[C@@H](C)c1c(Nc2ccc([C@@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4584981		% Control	%	100.0	CHEMBL3529	Homo sapiens	% Control	%	100.0
